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Studies Towards a Second-Generation Synthesis of the Aplyronines 
Nika Anžiček 
Summary 
The aplyronines are a family of 24-membered macrolides of polyketide origin, isolated from the Japanese 
sea hare Aplysia kurodai. They exhibit an exceptional biological activity profile, acting through an actin 
and tubulin dual-targeting mechanism, with subnanomolar growth inhibitory potency against a diverse 
range of cancer cell lines. These characteristics render the aplyronines ideal payloads for antibody-drug 
conjugates but their prohibitively low natural abundance calls for an efficient total synthesis to overcome 
the supply issue. This dissertation describes the efforts towards developing a second-generation Paterson 
synthesis of the macrocyclic core of the aplyronines, focused on improving the scalability and selectivity 
of key transformations. 
Chapter 1 details the isolation, biological background and previous synthetic efforts towards the 
aplyronines to illustrate their therapeutic potential and the challenges associated with material sourcing by 
chemical synthesis. Chapter 2 presents the existing body of work on the aplyronine project within the 
Paterson group, highlighting the lessons learned over the past two decades and shortcomings to be 
addressed. 
Chapter 3 discusses a revised protecting group strategy towards the C1-C27 macrocyclic alcohol 159 with 
fewer manipulation steps. A refined reaction sequence featuring titanium aldol methodology and an 
enzymatic desymmetrisation process delivered multigram stocks of the C15-C27 aldehyde 161 upon scale-
up, testifying to the robustness of the devised route. Synthesis of the C1-C14 northern fragment 253 
closely followed the existing boron aldol approach with optimisation of the C11-C12 alkylation step, 
geared towards enhancing the regioselectivity. 
Chapter 4 describes the coupling of the two major fragments using an Horner-Wadsworth-Emmons 
reaction to assemble the C1-C27 backbone of the cyclic aplyronine core and suitably adjusted endgame 
steps to enable a one-step oxidative unmasking of the macrolactonisation sites. The first-generation 
intermediate 159 was accessed via site-specific Yamaguchi esterification and orthogonal deprotection of 
the C27 allyl carbonate. Discussion in Chapter 5 includes the appendage of the C28-C34 side chain 118, 
prepared by the known sequence, and suggestions for the future direction of the second-generation route 
with the outlook of linker appendage for the purposes of antibody-drug conjugate development. 
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Nomenclature 
Double Bond Stereochemistry 
In accordance to the established convention, the two metal enolates A and B are referred to as (E)- and 
(Z)-enolates, respectively (Figure 1). The metal-oxygen substituent has a higher priority than the R1 
substituent designated in all cases. 
 
Figure 1 
Syn- and Anti-Diastereomers 
Assignments of relative configuration of vicinal stereocentres as syn or anti follows the convention 
introducted by Masamune.1 A syn relationship is defined by the two substituents (R1 and R2) both 
pointing into or out of a plane with the main chain drawn in a zig-zag conformation as shown in Figure 2. 
An anti relationship refers to the substituents on opposite sides of the plane. Hence, diastereomers C and 
D are regarded as syn and anti, respectively. 
 
Figure 2 
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x 
Aldol Adduct Stereochemistry 
Products of aldol reactions in which the stereochemical outcome is governed by the α-chiral centre of the 
ketone are referred to as shown in Figure 3. The pre-existing ketone stereocentre is assigned the label “1” 
as a point of reference for the relative configuration between substituents. 
 
Figure 3 
Compound and Atom Numbering 
The naming and numbering of compounds in this dissertation is done in accordance to the priorities set 
out by IUPAC. The numbering system adopted for aplyronine intermediates follows that proposed by 
Yamada and co-workers in their original publication on aplyronine isolation and characterisation.2 It is 
used in assignments of 1H NMR data and follows that shown in Figure 4. 
 
Figure 4 Atom numbering for the aplyronines 
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Chapter 1 
Introduction – Part I 
Marine Natural Products in Targeted Anticancer Therapy 
1.1. Natural Products and Chemical Synthesis in Drug Development 
1.1.1. Natural Products as Early Cures 
Natural products are secondary metabolites, produced by living organisms for functions not directly 
related to survival such as signalling, transport, excretion, chemical warfare or others.3 They are thought 
to confer a competitive advantage to the organism that produces them or to their host in case of a 
symbiotic relationship. The variety of processes they enable is linked to the vast array of intricate 
structures they display, each with their own specific purpose. If their primary intention is to immobolise 
prey or as a form of chemical defence against predators, they often exhibit exceptional potency against a 
well-defined molecular target. A combination of the two is a desirable trait with respect to increasing the 
species’ chance of survival and can thus be selected for in evolution. 
Owing to the same principles, natural products also play a central part in the history of medicine. Before 
the 20th century the only cures available to treat illnesses were crude or semi-pure extracts of plants, 
microbes and minerals. Scientific progress in pharmacology and other related fields has since enabled the 
isolation and characterisation of pure, active ingredients of many traditional remedies, e.g. artemisinin 
from Artemisia annua or morphine from Papaver somniferum. Eliciting a biological response in humans 
is merely a side effect of the inherent function of secondary metabolites in the organisms which produce 
them. However, having a better understanding of the relationship between their function, structure and 
molecular target can provide the tools to evaluate and harness their potential for the benefit of mankind. 
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The early harvesting of bioactive compounds was limited to specimens from terrestrial organisms. 
Advances in diving and submarine technologies have permitted sampling the underwater enviroment, 
opening the opportunity to explore the sea habitat as well. This marks a major step forward in natural 
product discovery as the oceans represent 95% of the biosphere with greater biodiversity due to harsh 
conditions which are encountered within the oceans.4,5 It is therefore unsurprising that metabolites 
isolated from marine organisms often display a wider structural variation and complexity than their 
terrestrial counterparts. In addition, many marine cytotoxins have been found to display exceptionally 
potent biological activity, possibly to offset the rapid dilution effect upon release into the environment. 
Further discoveries are ongoing in parallel with improving sampling and isolation techniques which may 
yield many more molecules of interest to modern medicine.6,7 
1.1.2. Sourcing and Supply of Bioactive Compounds 
Marine-derived natural products are often isolated from the source organism in minute amounts. In such 
cases, direct harvesting to obtain even very humble supplies of material would leave a devastating 
environmental impact.  Fortunately, the recent advances in bioengineering have made it possible to edit 
the genetic sequence of plants or certain strains of microbes to synthesise the desired compounds, which 
can then be extracted and purified as necessary. However, in many cases this process is not achievable as 
it is not trivial to pinpoint the exact biosynthetic origin of the natural product or it is difficult to create a 
suitable cultivation environment as these compounds are often produced under extreme conditions.8 
Another reason pertaining specifically to highly potent metabolites may be the fatal toxicity to the parent 
organism at the concentrations required for a practical production. 
A commercially more significant strategy is semi-synthesis, which involves the chemical modification of 
an appropriate advanced intermediate obtained from plant or bacterial sources.9 For example, paclitaxel 
(2) is a cytotoxic agent isolated from the bark of the Pacific yew tree and is currently used in the 
treatment of a variety of cancers. Large-scale commercial manufacture route currently employs plant 
tissue culture and fermentation,10 though the preceding process was a four-step synthetic transformation 
from 10-deacetylbaccatin (3) (Scheme 1).11  
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Scheme 1 Semi-synthesis of paclitaxel (2) from 10-deacetylbaccatin (3)11 
The ultimate option is de novo synthesis.12 While this seems like a daunting and laborious task for 
compounds with complex architectures, remarkable progress has been made by process chemists in 
translating research laboratory discoveries to natural product-derived commercial items.13 Several notable 
partnerships with the industry so far have made bold statements by demonstrating that with a 
collaborative approach total synthesis can indeed meet supply demands to facilitate clinical trials or even 
the market needs. 
An illustrative example is the story of discodermolide (4), a microtubule-stabilising agent originally 
isolated from a deep-sea sponge Discodermia dissolute (Figure 5). Drawing from the total syntheses of 
Smith14 and Paterson,15 Novartis devised a 33-step process chemistry route suitable for the pilot plant. 
Discodermolide was prepared in an overall yield of 0.65%, resulting in 60 g of material at the end of the 
scale-up campaign.16–20 Novartis’ commendable synthetic achievement enabled the Phase I clinical trials 
of discodermolide for treatment of pancreatic cancer. 
 
Figure 5 Structure of discodermolide (4) 
Another hallmark venture is the development of eribulin mesylate (5, Halaven®), a derivative of the 
natural product halichondrin B (Figure 6).21 The first total synthesis of this marine antiproliferative agent 
was completed by Kishi22 and served as a starting point for structure-activity-relationship (SAR) studies. 
Subsequent biological screening of numerous analogues revealed that the active pharmacophore of the 
natural product resides in the right-hand portion of the structure highlighted in red.23 The truncated 
skeleton retains the activity of the parent compound while the synthetic sequence is greatly simplified by 
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the omission of the seven polyether rings. It is marketed as a breast cancer drug and is produced by Eisai 
in a 37-step commercial manufacturing process.24  
 
Figure 6 Halichondrin B (6) and eribulin mesylate (5, HalavenÒ) with highlighted structural similarity 
Both projects are success stories of the combined efforts of academia and industry which resulted in a 
viable solution to the supply problem purely by synthesis. In addition, they provide a test of robustness 
(and selectivity, where applicable) for any chemical reaction performed on structurally complex late-stage 
intermediates in the sequence. If no suitable conditions are available, receptive organic chemists will seek 
inspiration in these challenges and devise novel methodologies or optimise existing ones to carry out the 
necessary steps. In the context of Halaven (5), the commercial synthesis underscored the power of the 
Nozaki-Hiyama-Kishi reaction,25,26 implementing this macrocycle formation step on more than a 
kilogram scale. Other related work contributes towards dispelling the prejudice against total synthesis in 
scale-up and creating a positive outlook for the field in future. 
1.1.3. Natural Products as Drug Leads 
Natural products represent the optimal starting point for drug development through chemical 
modifications. Design of mimics and analogues based on compounds which already interact with their 
biological targets in a highly selective manner offers the means of biological pathway determination and 
probing in vivo pharmacology. Ultimately, the results of these studies lead to a better understanding of 
what makes a good drug for the specific purpose and synthesis provides the tools to produce them. 
Unfortunately, over the past 20 years, the pharmaceutical industry has largely neglected natural products 
as lead molecules. This is partially due to expensive failures of numerous late-stage clinical candidates 
and comparatively long development timelines relative to other types of small molecule drugs. The rise of 
alternative compound screening tools such as high-throughput screening (HTS) for small molecule hits 
held great promise for the industry with the ability to rapidly produce and screen thousands of 
compounds. Once an active skeleton has been identified, the capacity of combinatorial chemistry for 
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structural optimisation is without par. However, this approach merely scratched the surface of available 
chemical space and after years of effort, only two approved drugs from this pipeline fall under the de 
novo category of discovery.27  
Despite the recent trends, natural products have clearly retained their dominant status in many areas of 
medicine. For example, chemotherapy still represents an essential pillar in the treatment of various forms 
of cancer. Of 136 small-molecule antineoplastic drugs which gained Food and Drug Administration 
(FDA) approval between 1940 and 2014 only 17% are fully synthetic candidates while others are derived 
from bioactive compounds isolated from nature (Figure 7).28  
Great promise comes from the search for secondary metabolites with novel cellular mechanisms of action 
to overcome the rising issue of drug resistance or development of targeted delivery systems. The latter 
would allow for previously abandoned projects, such as discodermolide, to be revisited and given a new 
chance at success with reduced toxicity.29 This is particularly relevant as the search for novel targets and 
natural product therapeutics is undeniably becoming increasingly difficult as demonstrated by the recent 
decline in FDA approval of new chemical entities.30  
 
Figure 7 Small-molecule anticancer drugs 1940-2014. N = unaltered natural product, NB = botanical drug, 
ND = natural product derivative, S = synthetic drug, S* = synthetic drug with a natural product pharmacophore, 
NM = natural product mimic28 
The above discussion aims to put the role of natural products and chemical synthesis in the context of 
pharmaceutical drug discovery. The groundwork for a greater impact of basic total synthesis research on 
future endeavours in the industry had been laid by establishing ambitious but ultimately fruitful 
collaborations. It is no longer a challenge to simply complete the synthesis of a complex target but to 
execute it in an elegant, concise, green, high yielding and scalable manner which provides a truly 
sustainable supply.31  
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1.2. The Aplyronines 
1.2.1. Isolation and Structural Determination 
The aplyronine natural products were first isolated in 1993 by Yamada and co-workers from the sea hare 
Aplysia kurodai, a mollusk collected off the coast of the Mie prefecture in Japan.2 This marine species has 
been an abundant source of biologically active natural products such as aplysin (7),32 aplaminal (8),33 
aplysiasecosterols (9-11)34,35 and others (Figure 8). Aplyronines A (1), B (12) and C (13) were 
characterised in an in vitro cytotoxicity-guided assay against HeLa-S3 cervical adenocarcinoma cells 
following extraction of natural specimens and laborious chromatographic separation. In 2000, the 
Yamada group developed a refined isolation protocol involving solvent partitioning and five-step 
chromatography which enabled the identification of five further minor congeners D-H (14-18).36,37 
While this had also facilitated a more efficient harvest of aplyronines A-C (1, 12-13), the yield remained 
extremely low (10-5 to 10-7 based on wet weight); 300 kg of the wet mollusk provided just 75 mg of the 
most abundant congener, aplyronine A and less than 1 mg of most others. 
 
Figure 8 Selected bioactive natural products isolated from Aplysia kurodai 
The gross structure of aplyronine A was determined through detailed 1D and 2D NMR analysis and 
degradation studies (Scheme 2), followed by enantioselective synthesis of the resulting fragments.2,38–41 
Yamada designed a flexible strategy to access all possible permutations of the stereocentres which 
asserted the structures of congeners A-C through total synthesis.41–43 
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Scheme 2 Degradation fragments from aplyronine A (1) 
Table 1 Structure of aplyronines A-H (1, 12-18) and their biological activity in HeLa-S3 cell line assay 
 
Aplyronine congener R1 R2 R3 IC50 / nM 
A (1) TMSer H DMAla 0.450 
B (12) H TMSer DMAla 2.89 
C (13) H H DMAla 22.4 
D (14) TMSer H DMGly 0.071 
E (15) = 22-methylaplyronine A 0.184 
F (16) TMSer H MMAla 0.189 
G (17) DMSer H DMAla 0.120 
H (18) H DMSer DMAla 9.80 
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The aplyronines are comprised of a highly decorated 34-carbon backbone. The two most prominent 
features are the 24-membered macrolactone and a polyketide side chain, terminating in an N-methyl-N-
vinylformamide moiety. Other notable structural elements are the three stereotetrads (C7-C10, C23-C26 
and C29-C32), three isolated chiral centres (C13, C17 and C19), an (E,E)-dienoate and two additional olefins. 
The variation between the congeners is seen in the identity and positioning of amino acid residues at the 
C7, C9 or C29 hydroxyls. This is true for the entire family except aplyronine E (15), which was deduced to 
be 22-methylaplyronine A (Table 1). Interestingly, the amino acids are present as scalemic mixtures of 
(R) and (S)-epimers, where the ratio is always in favour of the latter though not identical between 
different samples of Aplysia kurodai.2 This observation suggests that the naturally occurring (S)-
configuration may be subject to epimerisation in the aplyronines’ biosynthesis or the isolation process.36 
Aplyronine A obtained from the sea hare is thus a mixture of four diastereomers and the rotamers at the 
N-vinylformamide terminus (2:1 ratio) which further complicates the NMR spectra. 
The stereochemistry of aplyronines B-H (12-18) was determined by fast atom bombardment mass 
spectrometry (FABMS) and NMR comparison to the known structure of aplyronine A. The large 
discrepancies in their biological activities suggest that small variations in the amino acid structure play an 
important role in the binding to the cellular target which constitutes an early qualitative insight into the 
structure-activity relationships (SAR). A seemingly insignificant disparity of a single methyl group on the 
C29 amino acid between congeners A and D translates into a remarkable six-fold difference in potency 
(IC50 = 0.45 nM and 0.071 nM). Yamada’s investigations into this phenomenon as well as further 
biological studies are presented below. 
1.2.2. Biological Activity 
The prohibitively low availability of most congeners has prevented significant biological studies of the 
entire aplyronine family apart from the in vitro assay against the HeLa-S3 cells in the isolation process. 
However, even the limited data acquired so far shows that the anticancer activity is nothing short of 
exceptional with the IC50 values for all congeners in the low- to subnanomolar range) for that particular 
cell line (Table 1). 
O
NMe2
O
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NHMe
MeO
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The most abundant congener, aplyronine A, was also studied by Yamada on a selection of mouse cancer 
xenografts in vivo, which is arguably a better indicator of the true therapeutic potential. Mice receiving 
intraperitoneal treatment with the natural product showed a longer median survival rates against the 
control group over a period of 60 days with the highest success rate for the P388 leukaemia and Lewis 
lung carcinoma (Table 2).2,36,44  
Table 2 In vivo antitumour activity of aplyronine A in mouse cancer xenografts44 
Tumour Test group 
Dose / 
mg/kg/day 
Median survival 
time / days 
Survivors after 
60 days 
P388 leukaemia 
treatment 0.08 59.9 4/6 
control / 11.0 0/7 
colon C26 
carcinoma 
treatment 0.08 40.0 0/6 
control / 15.7 0/10 
Lewis lung 
carcinoma 
treatment 0.04 60.1 6/6 
control / 10.8 0/8 
B16 melanoma 
treatment 0.04 46.8 0/6 
control / 23.3 1/9 
Ehrlich carcinoma 
treatment 0.04 59.7 2/6 
control / 15.0 0/8 
Subsequently, Kigoshi reported revised IC50 values for aplyronine A, namely 10 pM for the activity in the 
HeLa-S3 cell line45 and 2.9 pM against HL60.46 There is clearly a degree of variation compared to 
Yamada’s data, which must be taken into account when trying to rationalise the discrepancy in activities 
between the congeners. Nevertheless, on testing in the US National Cancer Institute (NCI) primary 
screen,47 aplyronine A (NSC687160) displayed exquisite potency against 60 cancer cell lines where the 
GI50 values for the vast majority fell below the minimum measurement threshold (mean GI50 = 0.2 nM).48 
Interestingly, aplyronine A does not inhibit growth in a homogeneous manner and does not behave in 
vitro as a non-specific poisonous agent but rather displays some selectivity though not toward any given 
histopathological group. This data puts the aplyronines into serious contention for potential preclinical 
drug development, which is further supported by its unique mechanism of action and will be discussed in 
detail in Section 1.2.4. 
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1.2.3. Studies on Actin Binding 
In 1996, Karaki and co-workers identified actin as the target biomacromolecule of aplyronine A.49 Actin 
is a highly abundant protein, present in nearly all eukaryotic cells, structurally conserved among the 
organisms and it is one of the main classes of cytoskeletal proteins within the cytoplasm (Figure 9).50 It 
participates in a number of fundamental cell processes such as motility,51 division, signalling, cytokinesis 
and establishment of cell junctions.52 
 
Figure 9 Ribbon and space-filling models of ATP-bound actin with subdomains 1-4 indicated53 
These mechanisms are facilitated by the interconversion between the two distinct forms of the protein. 
The core constituent of the actin skeleton is the monomeric globular (G-) actin, which can polymerise 
into double-stranded helical microfilaments (F-actin) under physiological conditions, involving head-to-
tail interactions (Figure 10). Elongation primarily takes place at the barbed (+) end of the filament, 
starting with the incorporation of the adenosine triphosphate (ATP)-bound G-actin monomer. This event 
activates the ATPase which allows F-actin to carry out stoichiometric hydrolysis of ATP, causing a 
conformational change and weakening of the intermolecular interactions at the pointed (-) end. This leads 
to increased dissociation of the adenosine diphosphate (ADP)-bound G-actin, which is able to undergo 
phosphorylation to ATP and repolymerisation at the barbed end. The overall process is known as 
treadmilling and provides the means for unidirectional growth, which contributes to the spatial 
organisation of the actin cytoskeleton. 
Regulation of actin filament dynamics is affected by an array of actin-binding proteins through a variety 
of mechanisms. These include trapping free G-actin monomers to render them unavailable for addition to 
the barbed end (sequestering), binding to existing filaments to prevent further growth (capping),54 
stimulating polymerisation (nucleation),55 stabilising existing filaments56 and active breakdown of the 
filaments (severing).57,58 It is not surprising that many naturally occurring toxins interfere with these 
processes considering the key role of the actin equilibrium in healthy cell function.59 
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Figure 10 An illustration of the actin treadmilling process* 
Based on the effects exerted on the actin equilibrium, actin-binding natural products fall into either of the 
two main groups: compounds which prevent actin polymerisation and/or destabilise existing filaments, 
and those that stabilise them. Aplyronine A belongs to the former category by sequestering G-actin 
through formation of a 1:1 complex which reduces the free monomer presence below the critical 
concentration for treadmilling.49 Additionally, it can cap existing filaments at the barbed end, sever F-
actin and bind to proteins involved in forming branched actin polymer networks (Arp 2/3).45 There are at 
least six different natural product binding sites on actin, however, the majority of compounds appear to 
bind at the barbed end.60  
More than 80 known actin-binding natural products can be arranged into just eight major skeletal types.61 
Aplyronines belong to a specific class of structurally related compounds, which posess a hydrophobic 
macrocycle and an 11-carbon aliphatic chain.62 Several illustrative examples are shown in Figure 11. 
Studies by Rayment first confirmed the correlation between the actin-binding ability and the highly 
conserved groups along the tail of these macrolides.63 Ring architectures range from polyketide-type 
backbones of reidispongiolide A (19),64 tolytoxin (20)65 and the aplyronines to tris-oxazoles such as 
kabiramide C (21) and halichondramide (22)66,67 or even macrodiolides rhizopodin A (23)68,69 and 
luminaolide (24).61,70  
                                                
* Image by Dr James Sleigh, Scientific Research Correspondent for Spinal Muscular Atrophy Support UK. 
Reproduced with permission of the author. 
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Figure 11 Selected structurally related actin-binding natural products with a conserved side chain 
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A more detailed understanding of the underlying affinity for actin came from the synthesis and biological 
evaluation of a wide range of analogues based on the aplyronines or the structurally related 
reidispongiolide A (19) by the Yamada46,71,72 (Figure 12) and Paterson73,74 groups, respectively. Yamada 
found that the side chain is essential for actin binding as more than a 100-fold decrease in actin-binding 
activity is observed when the tail is heavily truncated (27) and when completely removed it renders 
macrocycle 28 inactive. Modifications to the ring are generally well tolerated, as exemplified by the 
mostly retained potency of a tetrahydro macrocycle lacking either the C2-C5 diene or the C13 methyl, 
aplyronine A without one or both amino acids (30 and 31) or an acyclic analogue with the full length of 
the carbon backbone. Replacing the N-vinylfomamide with another hydrophilic group such as an alcohol 
was reasonably well tolerated (29) and interestingly even small fragments such as 25 and 26 exhibited 
relatively strong activity considering their size and reduced complexicity compared to the parent 
compound. 
 
Figure 12 Representative aplyronine analogues from Yamada’s SAR studies their actin depolymerising activity 
values. IC50 indicates the concentration required to depolymerize F-actin (3.7 mM) to 50% of its control amplitude.  
The Paterson group prepared a library of reidispongiolide tail analogues to probe the role of various 
moieties on the backbone.74 The markedly different activities were attributed to the variation in the 
hydrogen bonding ability and flexibility of the chain, thus Paterson and Marriott postulated that the tail 
may be forced into a twisted conformation to fit the tight binding space.73  
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The overall results of these studies are in agreement with the crystal structure for the actin-bound 
aplyronine A, obtained by Takata in 2006 (Figure 13)75 as well those of related natural products.63,76,77 
The side chain intercalates into a narrow hydrophobic cleft of actin between subdomains 1 and 3 with the 
macrolide only making contacts at the small surface patch at the hydrophobic entrance. Depending on the 
stereochemistry at the junction of the ring and tail regions, the macrocycle is directed to either subdomain 
1 or subdomain 3 (as observed with aplyronine A) with the distal portion of the ring structure protruding 
into space. The N-vinylformamide terminus maintains critical interactions with two backbone amide 
residues on actin through bridging water molecules, which stabilise the complex.  
 
Figure 13 Crystal structure of actin-aplyronine A complex with the side chain inserted into the cleft between 
subdomains 1 and 3 and the macrolide making surface contacts at the entrance.45  
The mechanistic proposal for F-actin severing by barbed-end actin binders is based upon intercalation of 
the small molecule between two longitudinal monomers within the actin filament (Figure 14). Binding 
into the region of the DNAse-binding loop on one actin protomer and the aforementioned hydrophobic 
cleft on the adjacent subdomain outcompetes the protomer-protomer contacts in place and causes 
filament breakage at the point of intercalation.78 If binding occurs at the barbed end of a growing 
filament, the toxin prevents monomer addition by remaining attached, thereby capping the structure. 
 
Figure 14 Kabiramide C (21) in G-actin-bound conformation (red), superimposed onto the model for F-actin, 
showing steric clash between the natural product and the DNAse I-binding loop of the lower monomer (green).77 
The filament axis is vertical with the barbed end at the bottom. 
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1.2.4. Structure-Activity Relationship Studies and Cytotoxicity  
The exact origin of cytotoxicity to date remains unsolved, though there is an obvious disconnect between 
the observed IC50 values for actin depolymerising activity and cytotoxicity. Aplyronines A-C bind actin 
with equal affinity yet cytotoxicity data on HeLa-S3 cells acquired by Yamada reveals that aplyronine A 
is six times more potent than aplyronine B, which is in turn tenfold more active than aplyronine C. Minor 
congeners D-H are comparably cytotoxic with two notable exceptions: aplyronine H, in which the amino 
acid is appended at C9, and aplyronine D with a dimethylglycine (DMGly) residue in place of 
dimethylalanine (DMAla) at C29.  
Linking biological data to the structural discrepancies between the congeners reveals the paramount 
importance of the C7 trimethylserine (TMSer) residue in displaying strong cytotoxicity. More minor 
increases in activity are caused by N-demethylation of either the DMAla or TMSer, or presence of an 
additional methyl group at C22. However, Yamada did not specify whether the assays were repeated for 
the entire panel of aplyronines (A-H) or simply the newly isolated congeners (aplyronines D-H) two 
decades after the first isolation paper was published.2 Therefore, the exact IC50 values may have a degree 
of procedural error embedded in them and should notionally only be considered in the context of a 
general trend. 
Yamada also carried out extensive structure-activity relationship (SAR) studies on synthetic analogues to 
identify further features with an impact on cytotoxicity. The alterations within the side chain region were 
generally tolerated whereas changes to the macrocycle were more deleterious. The analogue 32 (Figure 
15) containing a primary alcohol in place of the N-vinylformamide and lacked the C14 methyl retained 
28% of the activity compared to aplyronine A (1). The further simplified analogue 33 where the 
dimethylalanine at C29 has also been removed resulted in a further drop in potency to less than 1% of the 
parent natural product. However, the greatest impact was observed upon altering the trimethylserine at 
C7. While aplyronine D with the C29 dimethylglycine is extremely active as mentioned above, the same 
cannot be said if this amino acid is attached in the C7 position as well in place of the trimethylserine (34). 
A highly relevant feature also appears to be the C2-C5 dienoate moiety, which is likely to influence the 
conformational rigidity of the ring in analogue 35. 
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Figure 15 Further analogues prepared by the Yamada group for SAR studies on cytotoxicity 
The influence of the structural elements near C23 can be observed from the bioactivity of a mycalolide 
B-aplyronine A hybrid 36 (Figure 16), synthesised by Kigoshi.79 The structure borrows from the side 
chain of the superior actin binder, mycalolide B, and the C1-C23 macrocyclic core of aplyronine A. Loss 
of the C24 methyl, inversion and methylation of C25 and alteration of the C29 ester result in a moderate 
increase in actin depolymerisation. On the other hand, cell growth inhibition is reduced by 1000-fold 
compared to aplyronine A, supporting the conclusion than the two activities are not directly correlated 
(Figure 17). 
 
Figure 16 Kigoshi's aplyronine A-mycacolide B hybrid 36 
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Figure 17 Summary of structure-activity relationship studies for the aplyronines 
More recently, the idea of a secondary biomolecule target for the aplyronines has emerged as a possible 
explanation for the observed phenomenon. To initiate investigations of this hypothesis, Kigoshi prepared 
a series of C34-modified aplyronine derivatives incorporating an aryl diaziridine tag (37),80 a 
polyethyleneglycol (PEG)-tethered biotin moiety (38)45 or a tetramethylrhodamine (TAMRA) conjugates 
(39-40) (Figure 18).81 Fluorescence experiments with these probes confirmed the specific interaction of 
aplyronines A and C with b-actin. 
 
Figure 18 Kigoshi’s aplyronine-derived probes for studies of binding to actin and their cytotoxicity IC50 values 
against the HeLa-S3 cells 
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A significant breakthrough in elucidating the mechanism of action of aplyronines was communicated in 
2013 when tubulin was identified as the second biomacromolecule target of aplyronine A.82 Kigoshi 
observed the formation of a 1:1:1 heterotrimeric structure which formed upon tubulin binding to a pre-
formed 1:1 complex of actin and aplyronine A (Figure 19). Considering the size and spatial proximity of 
both biomacromolecules the contacts formed must be carefully optimised when facilitated by a 
comparatively small molecule. This suggests that actin undergoes a conformational change upon binding 
to aplyronine A to create a tubulin binding site. Kigoshi later studied the kinetics of the proposed 
interactions with surface plasmon resonance (SPR), measuring Kd for each binding event.83 The ternary 
complex assembly was also found to be accelerated by a non-competitive actin depolymerising agent 
lantriculin A, presumably through increased effective actin monomer concentration.  
 
Figure 19 Kigoshi’s proposed 1:1:1 ternary complex of actin and tubulin82 
Cell permeability and accumulation levels for aplyronines A and C based on observed fluorescence were 
comparable,81 hence the discrepancy in cytotoxicity cannot stem simply from varying exposure levels of 
each toxin. Concentrations of the toxin required to inhibit microtubule assembly in living cells are much 
lower than those necessary for actin disassembly (0.1 nM compared to 100 nM, respectively). A possible 
explanation, consistent with the SPR studies, could be that high intracellular quantities of actin facilitate 
rapid formation of a 1:1 complex with aplyronine A which remains trapped within the cell. Binding to 
tubulin then exerts an enhanced cytotoxic effect due to localisation of the ternary complex in the tumour. 
However, exactly how the heterotrimeric complex induces cytotoxicity is still unknown. One likely mode 
of action might be disruption of spindle microtubule dynamics during mitosis. Similar antimitotic agents 
such as vinblastine or paclitaxel act by being embedded into the microtubule lattice or kinetically 
stabilising spindles, both of which lead to blocking mitosis and eventual cell death.84,85 The aplyronines 
may also be able to mimic proteins which mediate actin-tubulin interactions associated with the 
cytoskeleton dynamics like the mammalian diaphanous-related (mDia) formin proteins which regulates 
microtubule stabilisation.86  
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The challenge remains to identify the relevant binding site on tubulin and the residues involved. Tubulin-
targeting drugs are namely a successful area of anticancer therapy which heavily relies on highly potent 
natural products with known mode of action in certain types of tumours.87,88 While the aplyronines fit this 
category and are immensely potent, their true potential lies in the unique dual-targeting mechanism of 
action which holds tremendous promise in overcoming resistance in multi-drug resistant cancers as it is 
extremely rare.   
1.3. Antibody-Drug Conjugates 
Use of highly potent cytotoxic agents from nature in systemic cancer treatment relies on higher 
proliferation rates of tumour cells, targeting the mitosis cycle. For many seemingly promising candidates 
the maximum tolerated clinical dosage does not reach the therapeutic threshold or displays only a very 
narrow safety margin, leading to a high chance of failure in clinical trials. Actin-binding agents suffer 
from a similarly crippling limitation related to the abundance of actin and its importance in non-
neoplastic cells, making toxicity-related side effects unacceptable for direct clinical use.  
Cancer therapy has seen tremendous breakthroughs in the last few decades through the advent of 
monoclonal antibody (mAb) technology in the 1970s. Antibodies are large proteins produced by plasma 
cells with the task of eliciting an immune response upon binding to a pathogen. They exhibit exquisite 
specificity for the cognate target proteins (antigens) on the surface of a foreign body through non-
covalent interactions. mAbs embody ideal vehicles to deliver toxins directly to the sourse of the disease 
with specific genetic abnormalities. Attachment of cytotoxic warheads to amino acid functional handles 
on the antibody as the delivery vehicle has given rise to a new drug modality known as antibody-drug 
conjugates (ADCs). 
 
Figure 20 Schematic representation of the mechanism of ADC drug delivery. Dash line arrows represent antimitotic 
activity through extracellular payload release.89  
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The principal advantage of ADCs lies in the efficient shuttling of the payload to the intended target, 
binding to the surface antigen and subsequent internalisation through endocytosis (Figure 20). 
Intracellular trigger mechanisms within the lysosome facilitate the release of the drug of which maximises 
accumulation directly at the tumour site or in the nearby cells through trafficking.90 The balance between 
prolonged half-life of ADCs within the bloodstream yet sufficient lability near the malignant tissue 
reduces clearance rates and ensures that healthy tissue is bypassed during treatment. The crucial 
parameters regarding the complex process of design and production of ADCs have been extensively 
reviewed and selected publications on these topics form the basis of the discussion below.91–102 
1.3.1. The Antibody and Targets 
The highest degree of targeted delivery can be achieved if the mAb is able to select for an antigen which 
is known to be expressed exclusively at the surface of neoplastic cells but such discoveries are rare. ADC 
technology thus capitalises on accessible tumour-associated markers and proteins which are abundantly 
expressed at the site of the disease in a homogeneous manner and little expression in normal cells, often 
also limited to a given tissue type allowing for high levels of selectivity for cancer cells. The mAbs 
currently in use are three types of human immunoglobulin G (IgG) which display a prolonged half-life in 
blood and reduced immunogenicity issues compared to the murine and chimeric antibody sequences 
utilised previously.  
1.3.2. The Linker 
The linker represents a connecting piece between the antibody and the pendant warhead, fulfilling two 
key requirements: chemical stability in the bloodstream and efficient payload release at the intended site 
of action.94,99 The mode of drug liberation affects whether the payload can be freed and act in the vicinity 
of the tumour cell prior to endocytosis, exerting what is known as the bystander killing effect.103  
Examples of cleavable linkers with labile functional groups are hydrazones (e.g. 41, Figure 21), sensitive 
to hydrolysis at low pH following internalisation, or disulfides (e.g. 42), which are reductively cleaved by 
glutathione, present in a higher concentrations inside the cells. The third common type of linkage are 
peptide bonds (e.g. 43 or 44), often used in combination with a spacer unit such maleimide or as para-
aminobenzylcarbamate (PABC), which separates the drug from the site of enzymatic cleavage. Upon the 
action of lysosomal proteases (e.g. cathepsin B), the spacer undergoes self-immolation, releasing the 
toxin in a chemically unmodified, fully active form. 
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Figure 21 A representative selection of commonly utilised cleavable linkers in ADCs 
Non-cleavable linkers rely on proteolytic degradation of the whole antibody into amino acids in the 
lysosome, which liberates a modified version of the cytotoxin with attached remnants of the linker or the 
antibody. Structurally, they are typically alkyl, sulfonyl or polyethyleneglycol (PEG) chains with suitable 
functionality at the terminus to facilitate conjugation. 
1.3.3. The Payload 
Due to drug decomposition and metabolic processes in the body, only 0.01-0.1% of the injected dose of 
ADCs comes into action per gram of tumour mass, then further reduced by inefficient payload release, 
extracellular trafficking or poor permeability into the tumour.96 The number of drug molecules required 
for antimitotic activity should thus be substantially below the delivery threshold of an ADC and the 
required IC50 value of the unconjugated toxin in the subnanomolar range (100-1000 times more potent 
than regular chemotherapeutics). The therapeutic dose via this delivery route is merely a fraction of the 
quantity administered by traditional chemotherapy in comparison, which is favourable from the point of 
view of large-scale ADC manufacturing.  
At present, the majority of marketed ADCs or those in clinical research fall into two categories based on 
their mechanism:93 microtubule inhibitors (e.g. maytansines, tubulysins, auristatins) or DNA-damaging 
agents (e.g. duocarmycins). Further advances towards optimising the payload need not to be geared 
strictly towards increasing potency but also finding alternative mechanisms of action which set them apart 
from the ones currently dominating the field. One such successful example recently emerged are 
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benzodiazepines, natively potent DNA crosslinkers which were developed into DNA alkylating agents 
through purely chemical design.95  
1.3.4. Conjugation Methods 
To achieve predictable properties, the ADCs must be produced with a highly controlled drug to antibody 
ratio (DAR), which affects the drug’s efficacy and rate of aggregation.104 The ideal DAR is typically 2-4, 
though highly dependent on the nature of each ADC component and must be empirically determined. The 
majority of ADCs in development are prepared using the non-specific conjugation techniques via either 
the highly reactive, solvent-accessible lysines or the cysteine residues on the antibody. Lysine ligation 
almost always involves acylation chemistry and due to the uneven distribution of approximately 30 
available lysines on the mAb, non- specific linkage causes substantial heterogeneity in the ADC.105 
Conjugation through cysteine on the other hand is executed through thiol groups on the mAb which are 
tethered as four inter-chain disulfide bridges and liberated prior to conjugation by mild S -S bond 
reduction. Michael addition of the liberated thiol handles onto a maleimide group then produces non-
cleavable succinimide thioether linkages, which are featured in both currently marketed ADCs (vide 
infra). Additional control of the ligation can be achieved by engineering non-native cysteines on the mAb 
surface or linking both bridge thiols to a single moiety (e.g. PolyTherics’ ThioBridgeä technology, 
Scheme 3).99 Importantly, these alterations must not perturb the three-dimensional structure of the mAb. 
 
Scheme 3 Schematic of the ThioBridgeä disulfide conjugation technology99 
Other methods of site-specific linkage via sequence editing include introduction of serines for oxime 
ligation (pioneered by MedImmune and Immunogen),106 glycoconjugation with unnatural fucose 
derivatives or biorthogonal reactions of engineered unnatural amino acids (e.g. azide click chemistry). 
1.3.5. Challenges for Next-Generation ADC Development  
The expensive development process, combined with the low success rate in clinical trials makes ADCs 
not only a high-investement, but also a high-risk venture for pharmaceutical companies. Despite these 
drawbacks, the field has reached defined milestones following the FDA approval and launch of 
trastuzumab emtansine 45 (KadcylaÒ) and brentuximab vedotin 46 (AdcetrisÒ, Figure 22). Each 
subsequent generation of ADCs has a greater chance of success in clinical trials due to increased control 
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of factors in the manufacture process, widening the therapeutic window.91,92,107 In particular, this pertains 
to the diversification of linker strategies and recognition of new tumour-specific antigens.  
 
Figure 22 ADCs currently in clinical use. a) Trastuzumab emtansine contains a non-cleavable peptide linker 
conjugated via the pre-functionalised maleimide on the mAb. b) Brentiximab vedotin features a cleavable valine-
citrulline linker with maleimide conjugation to the mAb and a self-immolative spacer unit. 
ADCs are not immnue to resistance mechanisms, which are already beginning to emerge in the clinic.95 
Treatment with ADCs may induce downregulation of either tumour-associated antigen expression or 
slowing down of antigen-ADC internalisation as a mode of escape.91 Resistance to the payload itself may 
be overcome with the search for therapeutics with novel mechanisms of actions, though they are 
extremely rare. In the meantime, the ADC technology offers an ideal opportunity to examine the warhead 
potential of potent cytotoxins, which previously failed in clinical trials as standalone treatments.29,97  
1.3.6. The Aplyronines as Payload Candidates 
Despite the seemingly unattainable requirements for an ideal ADC payload, the aplyronines meet nearly 
all the fundamental ones. Their in vitro activity has been assessed against a vast range of cancer cell lines 
and even in vivo which ascertained an excellent potency across the board. Extensive SAR studies by 
Yamada have revealed the key binding regions within the molecule, leaving several possible functional 
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handles for linker attachment as well as chemical modifications through analogues to further boost the 
potency. The most promising feature of all is undisputedly the exciting, unprecedented mechanism of 
action, which while still not yet fully elucidated, holds tremendous promise with regards to battling 
resistance pathways. Conjugation to an antibody would both reduce the high likelihood of toxicity given 
the aplyronines’ biological targets but also bring down the amounts of these scarce compounds for 
therapeutic use. The currently supply, however, is minute and thus the potential advances towards the 
aplyronine ADCs are entirely reliant upon devising an efficient and scalable synthetic route. 
1.4. Previous Synthetic Efforts 
The aplyronines are evidently a formidable synthetic target with some truly impressive efforts published 
by a number of research groups. To date, three total syntheses have been disclosed beginning with the 
pioneering work by Yamada in 1994 which confirmed the structure and absolute configuration of 
aplyronines A38,42 and later congeners B and C.41 The Paterson group completed the synthesis of 
aplyronine C in 2013,108–110 and additionally aplyronines A and D in 2015.111 In early 2017, Kigoshi 
reported a second-generation route towards aplyronine A,112 building upon the strategy of an aplyronine 
A-mycalolide B hybrid previously targeted by the same group.79,113  
Marshall,114 Calter115,116 and Fuchs117–119 have also prepared several fragments, implementing the groups’ 
own methodologies for the construction of stereotetrads. On the whole, there is very little divergence 
from the major disconnections and fragment assembly strategies utilised in the Yamada and Paterson 
routes apart from Kigoshi’s unique approach to the macrocycle assembly. A brief comparison of the 
similarities in the overall retrosynthetic analysis is shown in Figure 23. The Paterson route is discussed in 
greater detail in Chapter 2. 
 
Figure 23 Common disconnections in the Marshall, Calter, Fuchs and Kigoshi approaches to the aplyronines 
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1.4.1. Yamada Synthesis of Aplyronines A, B and C 
A year after their first publication on the discovery of the aplyronines,2 Yamada and co-workers 
completed the total synthesis of aplyronine A.42 This work provided conclusive evidence of the absolute 
configuration of stereocentres through enantioselective synthesis following the initial elucidation of the 
gross structure.38–40 Retrosynthetic analysis of Yamada’s route is illustrated in Scheme 4. The pivotal 
disconnections break the molecule into the C5-C20 aldehyde 47 and the C21-C34 sulfone 48. Both can be 
further fragmented into five appropriately functionalised subunits (49-53), which largely mirror the 
segments obtained in the degradation studies.39 These segments were linked together by utilising sulfone 
chemistry, namely Julia olefinations and alkylations. Other key steps are the 
Horner-Wadsworth-Emmons (HWE) reaction to install the C1-C5 (E,E)-dienoate, regioselective 
Yamaguchi macrolactonisation with the complete C1-C34 carbon framework in place and a late-stage 
condensation to introduce the sensitive N-methyl-N-vinylformamide moiety.  
 
Scheme 4 Yamada's synthetic approach to aplyronine A (1) 
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The contiguous stereoclusters at C7-C10, C23-C26 and C29-C32 were conveniently segregated into three 
small subfragments. Each stereotetrad was introduced using a common eight-step protocol (Scheme 5) 
starting with a syn Evans aldol reaction120,121 between the required enantiomer of the chiral imide (54 or 
55) to induce stereocontrol and a suitable aldehyde electrophile. Protected aldol adducts underwent 
HWE122 olefination to introduce an allylic alcohol moiety for epoxidation under Sharpless conditions123 
and regioselective opening of the ensuing epoxide to afford 1,3-diols 56-58. All three fragments were 
further manipulated at the termini to provide the necessary functional handles for elongation of the carbon 
chain. 
 
Scheme 5 Enantioselective synthesis of the stereotetrads via the Evans aldol/Sharpless asymmetric epoxidation 
sequence by Yamada 
Iodide 50 was prepared in seven steps from acetonide 59, making C13 one of only two stereocentres 
sourced from the chiral pool (Scheme 6). Similarly, Yamada utilised the known furanone 60, which 
enabled the configuration of the remote C17 methyl by facially selective alkylation, reductive ring opening 
and functionalisation of the terminal carbon atoms.  
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Scheme 6 Yamada’s synthesis of the C12-C14 iodide 50 and C15-C20 sulfone 51 
Julia olefination124 forged the C20-C21 bond between sulfone 52 and aldehyde 53 (9:1 E/Z), which was 
subsequently subjected to hydrogenation. Concomitant double debenzylation enabled a protecting group 
change at C29 and sulfone installation at C21 to furnish C21-C34 fragment 48 in 24 steps longest linear 
sequence (LLS) and 22% yield (Scheme 7). 
 
Scheme 7 Union of 52 and 53 and elaboration to the C21-C34 sulfone 48 in the Yamada route 
The remaining three segments were coupled by alkylation of sulfone 49 with iodide 50 and derivatisation 
of the C14 terminus into a methyl ketone (54) set the scene for a Julia reaction with the C15-C20 sulfone 
51. Construction of the trisubstituted olefin transpired to be problematic as the product was isolated as a 
mixture of (E)-isomer 55 in 44% yield, along with 19% of the undesired (Z)-olefin 56 and 25% tertiary 
alcohol 57 as the two major side products. Next, the C20 terminus was engaged in another Julia coupling 
reaction with the C21-C34 fragment 48 with reasonable E/Z selectivity and good yield (9:1 E/Z, 88%). 
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Scheme 8 Coupling of the C5-C20 aldehyde 47 and C21-C34 sulfone 48 by Yamada 
The C5 position was unmasked prior to HWE attachment of the C1-C5 (E,E)-dienoate (15:1 E/Z), which 
was followed by hydrolysis of the methyl ether and the silyl ethers at C23 and C25 to reveal the 
macrolactonisation sites (Scheme 9). Under the modified Yamaguchi protocol,125 ring closure afforded a 
4:3 mixture of regioisomers with the preference for the smaller, 24-membered macrocycle 61 in 68% 
combined yield. The undesired 26-membered macrocyclic byproduct 60 was subjected to a Lewis acid-
mediated transesterification to further increase the yield of the desired macrolactone 61. This intermediate 
represents a common precursor to multiple aplyronine congeners by attaching the appropriate amino acids 
in the final steps, relying on an orthogonal protecting group strategy. 
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Scheme 9 Yamada's endgame and total synthesis of aplyronine A (1) 
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After silyl protection of the C25 hydroxyl, the terminal acetal was hydrolysed and condensed with N-
methylformamide under the Pattenden conditions126 (PPTS, hydroquinone) to install the N-
vinylformamide in a modest yield (48%). The C29 and C7 amino acids were appended by sequential 
removal of the 3,4-dimethoxybenzyl (DMB) and methylthiomethyl (MTM) ethers, then esterification 
with the DMAla or TMSer under the Keck variant of the Steglich conditions (DCC, DMAP, CSA).127 
Yamada observed that the amino acids partially epimerised in the activated form and thus a carefully 
chosen scalemic mixture of R/S enantiomers had to be added to the substrate for the ratio in the product to 
match that found in natural aplyronine. After a global deprotection, aplyronine A (1) was obtained in 
0.4% yield from the (S)-Evans imide 55 in 47 steps LLS and 98 steps in total. As noted above, Yamada 
was also able to use the late-stage intermediate 62 to complete the first total syntheses of aplyronines B 
(12) and C (13). 
Despite an impressive effort towards the total synthesis of the aplyronines the route does suffer from 
several drawbacks. At the time it was imperative to construct the stereocentres in a way that enabled a 
divergent route to all possible permutations of the 15 chiral centres present. Yamada’s approach was 
therefore designed with a high degree of flexibility in mind, which inevitably sacrificed conciseness on 
the account of numerous functional group manipulations and resulted in a synthesis consisting of nearly 
100 steps in total. The number may seem daunting but the average yield per step is impressively high 
when excluding several obvious weak points, e.g. the C14-C15 Julia coupling and formation of the 
terminal N-vinylformamide.  
Yamada was able to apply the strategy to carry out extensive structure-activity relationship studies, which 
provided a large body of knowledge on the activity of the aplyronines.71,72 However, in order to supply 
material for further biological studies, an entirely new synthesis would have to be devised to improve the 
overall process. 
1.4.2. Marshall, Calter and Fuchs’ Approach 
In 2000, Marshall reported the synthesis advanced fragments, C5-C20 (63) and C21-C34 (64) which 
contained all 15 stereocentres of the core aplyronine structure (Scheme 11). The retrosynthetic plan 
showcases Marshall’s diastereoselective propargylation,128 which can set up six new stereocentres in three 
separate stereotriads (C8-C10, C24-C26 and C30-C32). A highly distinct feature of Marshall’s synthetic plan 
is the construction of the trisubstituted C14-C15 double bond through acetylide addition and Suzuki 
coupling,129 starting from the (Z)-vinyl triflate.130 
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Scheme 11 Marshall's retrosynthetic strategy for the key fragments 63 and 64 
The foundation of Marshall’s approach lies in the in situ formation of allenylindium species from chiral 
secondary propargyl mesylates in the presence of an indium(I) salt, followed by reagent-controlled 
addition into an a-chiral aldehyde (Scheme 12). The resulting stereotriads are formed in comparable 
selectivity for both the Felkin and anti-Felkin attack.131 
 
Scheme 12 Marshall’s allenylindium methodology for constructing stereotriads128 
The C5-C14 fragment 63 was prepared by functionalisation of the anti, syn addition product 70 at the C7 
and C12 termini to install the C7 and C13 stereocentres, respectively (Scheme 13). This was achieved by a 
sequence involving chain homologation, Sharpless asymmetric epoxidation, iodination and epoxide 
opening (Scheme 13). The C15-C20 unit 66 was synthesised in six steps from the chiral lactone 60 via 
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facially selective alkylation and Seyferth-Gilbert homologation.132 After coupling of fragments 65 and 66 
via acetylide addition and construction of the trisubstituted olefin, the fully elaborated C5-C20 fragment 
63 was accessed in 24 steps LLS and 4% yield from TBS-protected aldehyde 71. 
 
Scheme 13 Synthesis of the C5-C20 fragment 63 by Marshall 
The C21-C34 fragment 64 was accessed from propargyl alcohols 69 and 72. Coupling of the appropriately 
functionalised units by lithium acetylide addition was followed by installation of the final C22 stereocentre 
via the familiar sequence based around Sharpless epoxidation (Scheme 14) to produce the C21-C34 
fragment 64 in 18 steps LLS from alcohol 72. Overall, Marshall’s route heavily relies on chiral pool 
starting materials and is unlikely to lead to the aplyronines without a revision of the protecting group 
strategy given the current lack of differentiation between the key hydroxyls. 
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Scheme 14 Marshall’s route towards the C21-C34 fragment 64 from propargyl alcohol 72 
Calter’s efforts towards the aplyronines culminated in the synthesis of the C21-C34 sulfone 74115 and an 
advanced C1-C27 intermediate 76 (Scheme 15).116 The skeleton assembly follows the disconnections of 
Yamada and Paterson whereas the stereocentres are introduced by Calter’s asymmetric dimerisation 
reactions133,134 and diastereoselective aldol reactions.135 
 
Scheme 15 Retrosynthetic analysis of fragments C1-C27 (75) and C21-C34 (74) by Calter 
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Calter’s methodology employs cinchona alkaloid catalysts (TMSQ or TMSQD) to induce 
enantioselectivity in dimerisation of in situ formed methylketene via formation of an ammonium enolate, 
followed by a formal Claisen condensation of the second ketene unit (Scheme 16).133,134 The resulting 
chiral b-lactones are then transformed into suitable enolate derivatives and used as aldol substrates to 
produce b-hydroxy ketone adducts 81 and 82 contain the required 1,4-syn-3,4-syn motifs. 
 
Scheme 16 Calter's organocatalytic asymmetric ketene dimerisation and stereoselective aldol reactions133,135 
The C21-C27 subunits 78 and 79, derived from the common intermediate 85, were elaborated to provide 
the suitably functionalised to furnish sulfone 79 and ylid 86 (Scheme 17).115 
 
Scheme 17 Calter’s synthesis of the C21-C27 fragments 79 and 86 from b-hydroxy ketone 81 
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b-Hydroxy ketone 82 was homologated at C33 in preparation for Wittig olefination with ylid 86, which 
led to the C21-C34 alcohol 74 in three further steps and an overall 13% yield from lactone 83 (Scheme 
18). 
 
Scheme 18 Preparation of the C28-C34 aldehyde 80 from aldol adduct 82 and fragment coupling to the C21-C34 
alcohol 74 by Calter 
The C7-C10 cluster required an alternative approach via a boron aldol with the a-chiral ethyl ketone 87. 
With the exception of the delayed C1-C5 dienoate installation, the sequence of steps to functionalise the 
fragment at the C11 terminus mirrors the Paterson strategy for that region of the macrocycle (Scheme 19), 
ending with the b-ketophosphonate moiety appendage.110 The C15-C20 aldehyde partner 77 for the HWE 
coupling was prepared in five steps from the furanone 88.  
 
Scheme 19 Construction of the C5-C14 phosphonate 76 from lactone 84 and aldehyde 77 from chiral 
furanone 88 
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The HWE olefination-CBS reduction-methylation sequence was followed by appendage of the dienoate 
(6:1 E/Z) at C5 and a Julia-Kocienski reaction (7:1 E/Z) to construct the C20-C21 double bond. The 
C1-C27 fragment 75 was accessed in 5% yield and 17 steps LLS from methylketene dimer 84. Strengths 
of Calter’s strategy are convergence and formation of chiral centres with a high degree of control. 
 
Scheme 20 HWE coupling of 76 and 77 and elaboration to the C1-C27 fragment 75 by Calter 
Fuchs achieved an enantioselective syntheses of the C1-C20 and C15-C27 segments 89 and 90119 and a 
C32-desmethyl analogue of the C28-C34 fragment 91.136 Chirality was introduced by Fuchs’ oxidative 
cleavage of cyclic vinyl sulfones, each containing one of the polypropionate clusters highlighted in 
Scheme 21 below.117 The envisaged major disconnections in the Fuchs route towards the aplyronines 
match those of Calter. 
Fuchs’ methodology is based on preparing termini-differentiated acyclic arrays of contiguous 
stereocentres starting by regioselective Jacobsen epoxidation137 of achiral, cross-conjugated dienyl 
sulfones.138 Further derivatisation exploits the reactivity of allylic or vinylic positions, diene transposition 
and facial bias of the 6- or 7-membered rings. In particular, Fuchs makes use of the double Lawton SN2’ 
addition139 to an allylic epoxide with 3,5-dimethylpyrazole nucleophile or direct opening of the epoxide 
with a methyl source, depending on the exact substitution pattern on the carbon chain. 
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Scheme 21 Retrosynthetic analysis of the aplyronine fragments 89 and 90 prepared by Fuchs 
  
Scheme 22 Fuchs' synthesis of the C5-C11 iodide 93 and C21-C27 sulfone 94 
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Scheme 22 shows how such a sequence of transformations led to the C5-C11 iodide 93 or the C21-C27 
sulfone 94 with the absolute stereochemistry dictated by the choice of the Mn N,N’-
ethylenebis(salicylideneiminato) (salen) ligand in the asymmetric epoxidation step. Fragment 94 was 
coupled to the C15-C20 aldehyde 96, derived from sulfone 92 (Scheme 23) and reduced to give the 
complete C15-C27 aldehyde 90.118 
 
Scheme 23 Preparation of the C15-C20 unit 96 and route to the C15-C27 aldehyde 90 by Fuchs 
 
Scheme 24 Fuchs’ synthesis of an alternative C15-C20 aldehyde 97 and fragment linkage via HWE coupling to 
afford the C1-C20 carboxylic acid 99 
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The alternative C15-C20 subfragment 97 was obtained from sulfone 92 (Scheme 24) and linked to the 
C12-C14 b-ketophosphonate 98 to furnish the C1-C20 carboxylic acid 99 in a similar sequence as 
previously detailed in Scheme 20. 
The C32-desmethyl analogue 91 was prepared as part of the studies towards the C28-C34 side chain via 
cleavage of the vinyl sulfone 100,136 followed by modified Upjohn dihydroxylation and Crigee oxidation 
(Scheme 25).  
 
Scheme 25 Fuchs' synthesis of a C32-desmethyl unit 91 
1.4.3. Kigoshi’s Synthesis of Apyronine A 
Kigoshi was involved in the first total synthesis of the aplyronine A as part of the Yamada group in 
199438,42 and later developed an entirely novel approach with the aim to address the drawbacks of the 
original route (Scheme 26).113 Poorly selective and low yielding olefination steps were to be superseded 
by the Nozaki-Hiyama-Kishi (NHK) fragment coupling25,26,140 on three occasions. Furthermore, the 
esterification at C1 was envisaged as an intermolecular step prior to macrocycle closure to prevent 
regioselectivity issues which had been observed in the previous synthesis. Using ths strategy, Kigoshi 
first prepared an aplyronine A-mycalolide B hybrid 36 (Section 1.2.4.)79 before completing second-
generation synthesis of aplyronine A itself.112 The endgame intersects a known common intermediate 62 
from Yamada’s route. 
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Scheme 26 Kigoshi's synthetic plan for aplyronine A (1) 
The C14-C19 vinyl iodide 104 was obtained from chiral alcohol 107 by homologation at C15 with the 
Ohira-Bestmann reagent 108,141 methylation of the alkyne and a silylcupration-iododesilylation. 
Fragment 104 was formed as a single geometric isomer (Scheme 27). 
  
Scheme 27 Kigoshi’s preparation of vinyl iodide 104 from alcohol 107 
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terminal diol to construct the aldehyde in preparation for the Ni/Cr coupling. Fragments 103 and 104 
were joined in an asymmetric variant of the NHK reaction140 with the bespoke sulfonamide ligand 109 to 
yield methyl ether 110 after methylation of the C13 hydroxyl in a much improved 7.3:1 dr compared to the 
result from the Yamada synthesis. 
  
Scheme 28 Preparation of the C5-C13 aldehyde 103 via the Evans aldol reaction and subsequent NHK coupling with 
the vinyl iodide 104 by Kigoshi 
The smaller subunit 106 was accessed in 10 steps from methyl (R)-3-carboxybutanoate 111142 where the 
anti, anti-stereotriad was forged in a Roush crotylation143 of the a-chiral aldehyde 112 (Scheme 29). The 
secondary alcohol 113 was obtained in 14:1 dr via the anti-Felkin transition state and three further 
transformations led to fragment 106.131 Vinyl iodide 105 was accessed from ethyl ketone 114 via a 1,3-
syn-3,4-syn tin-mediated aldol reaction,144 followed by Evans-Saksena 1,3-anti reduction145,146 to 
complete the stereotetrad and Takai olefination147 at C27 with excellent E/Z selectivity. 
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Scheme 29 Kigoshi's synthesis of the C21-C28 and C29-C34 fragments 105 and 106 
The second asymmetric Ni/Cr coupling between fragments 105 and 106 with the aforementioned chiral 
ligand 109 proceeded with complete control of stereochemistry at C29 (Scheme 30). After the necessary 
protecting group manipulations, Takai olefination at the C21 terminus gave a modest a 4.5:1 mixture of 
E/Z olefin isomers and selective cleavage of the C23 TES group exposed a single site for esterification. 
The synthesis of fragment 102 was completed in 20 steps LLS and 16% yield from ketone 114. 
 
Scheme 30 Fragment assembly and functionalisation to the C20-C34 vinyl iodide 102 by Kigoshi 
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The C5-C19 intermediate 110 was elaborated in preparation for the HWE olefination to append the key 
C1-C5 dienoate, followed by ester hydrolysis. Site-specific intermolecular esterification between 
carboxylic acid 115 and vinyl iodide 102 under modified Yamaguchi conditions125 and conversion of the 
C19 silyl ether into the aldehyde provided the appropriate precursor for the anticipated NHK 
macrocyclisation (Scheme 31). Ring closure could be achieved either in presence or absence of the chiral 
ligand 109 with the best result being 89% yield of the allylic alcohol as a 1.5:1 ratio of the (19R) and 
(19S) isomers. Methylation of the secondary hydroxyl generated the known intermediate 62 from which 
aplyronine A can be provided in eight further steps.42  
 
Scheme 31 Kigoshi's synthesis of aplyronine A (1) by intermolecular esterification and ring closure by Ni/Cr NHK 
coupling  
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Kigoshi’s synthesis consists of a total of 80 steps from commercially available materials, 38 steps LLS 
and 1.4% yield. The thoughtful application of the asymmetric NHK coupling bolstered the efficiency of 
the trisubstituted olefin construction and installation of the isolated C13 stereocentre, though the use of 
superstoichiometric chromium salts and poorly selective macrocyclisations left room for improvement. 
1.5. Summary 
The aplyronines are a highly attractive family of marine natural products and have garnered interest due 
to their complex structure as well as potent bioactivity. To date, the total syntheses of several congeners 
have been accomplished by Yamada, Paterson and Kigoshi. Other groups have reported the syntheses of 
smaller fragments, demonstrating that the stereotetrads on the carbon skeleton present an inspiration for 
development of new methodologies for their construction. Chemical synthesis has provided the tools to 
ascertain the aplyronines’ structure and to gain major insight into biological activity through extensive 
SAR studies and probe attachment for in vitro imaging. The latter established a strong the case for the 
aplyronines as ADC payloads due to their highly unique binding to actin and tubulin.  
However, limited supply from natural sources has precluded the development of aplyronine ADCs and 
thus any future efforts rely entirely upon synthesis to provide sufficient stocks of material. The next 
chapter details the story of the Paterson first-generation route to aplyronines A, C and D, which aimed to 
address this matter and strongly influenced other group’s work. 
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Chapter 2 
Introduction – Part II 
The Paterson Strategy Towards the Aplyronines 
2.1. Retrosynthetic Analysis and the Overall Strategy 
Shortly following Yamada’s first publication on the isolation of aplyronines A-C (1, 12-13)2 synthetic 
studies towards this family of natural products were also initiated in the Paterson group. The task of 
designing a retrosynthetic strategy was somewhat simplified as the stereochemistry had already been fully 
assigned by Yamada which allowed for a direct approach to the natural product.38,43 The primary focus of 
forward planning therefore revolved around shortening Yamada’s route, which is comprised of nearly 100 
individual transformation in total (47 steps LLS for aplyronine A and 0.4% overall yield). As an aside, it 
was hoped that the project would also provide opportunities to tackle the challenging steps by developing 
new synthetic methodologies. 
The means of achieving this goal relied on a highly stereocontrolled construction of the fragments, 
carefully designed to maximise convergency. A second consideration focused on a judicious selection of 
orthogonal protecting groups which could facilitate installation of highly diverse functionality of the 
carbon backbone. In addition, the presence of the three stereotetrads at C7-C10, C23-C26 and C29-C32 
offered the ideal opportunity to apply stereoselective aldol methodology developed by Paterson which 
would improve upon Yamada’s divergent but steppy protocol of Evans aldol reactions and Sharpless 
epoxidations. The exact choice of conditions for each aldol reaction dictates the pattern of the four 
stereocentres within the moiety and will be discussed in more detail in Section 2.2. 
Synthetic endeavours commenced with these directions in mind and in 1998, Paterson, Woodrow and 
Cowden reported a completed synthesis of the C1-C27 macrocycle 121,109,110 followed by a publication on 
the first-generation side chain studies with Blakey in 2002.148 After further revisions of the strategy for N
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vinylformamide installation, as well as a more substantial macrocycle scale-up campaign, the total 
synthesis of aplyronine C (1) was accomplished in 2012.108 
 
Scheme 32 Paterson first-generation total synthesis of aplyronines A (1), C (13) and D (14) 
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A unique feature of the strategy was the disconnection across the C27-C28 bond which splits the molecule 
into an appropriately functionalised macrolide core and side chain, containing the sensitive N-methyl-N-
vinylformamide (116-118 as the strategy evolved) as shown in Scheme 32. Its delicate nature raised the 
concern of not just how but also when to install it. Yamada introduced this moiety by condensation of a 
C34 aldehyde with N-methylformamide but the reaction was low-yielding. The decision was thus made to 
opt for a more adventurous approach and to implement it as part of the side chain fragment before linkage 
to the macrocycle. 
Another important consideration was attachment of the pendant amino acids which was vital for the 
purposes of accessing multiple congners. With the exception of aplyronines B, E and H, the variation in 
the number and identity of the amino acids occurs at the C7 and C29 hydroxyl groups. As they greatly 
increase the polarity of the ensuing compounds and affect the ease of compound handling, the synthetic 
plan must allow for esterification at a very late-stage, ideally via a common precursor which can readily 
be diversified. In principle, differentiation can be achieved by introducing orthogonal protecting groups 
and selectively unmasking each site as and when needed. However, at the onset of the studies, this option 
was to a certain extent sacrificed to instead exploit the stereoelectronic and conformational effects of 
carefully selected protecting groups to bias the outcome of key steps such as the macrolactonisation. 
The macrocycle was disconnected to the preceding seco-acid, which was anticipated to selectively cyclise 
onto the C23 hydroxyl of a free 1,3-diol at C23/C25. A very similar ring closure is featured in Yamada’s 
route, albeit the regioisomeric ratio is in favour of the undesired, 26-membered ring (as seen in Section 
1.4.1.). Woodrow’s supporting argument for proposing this step is hinged upon the idea that a utilising 
cyclic para-methoxyphenyl (PMP) protecting group would favour the formation of the smaller, 24-
membered ring owing to the rigidity imposed on the carbons in the immediate the proximity of the 
acetal.149 This effect would be reinforced by placing a bulky triisopropylsilyl (TIPS) protecting group at 
the C27 position, further discouraging side reactions through the C25 alcohol based on steric grounds.  
The assembly of the C1-C27 linear precursor would proceed via an expedient construction of the (14E)-
trisubstituted olefin using the Ba(OH)2-promoted HWE reaction.150 This step brings together four 
designated constituents of the macrocyclic backbone: the C1-C11 iodide 122, the C15-C20 phosphonate 
125, the C21-C27 aldehyde 124 and the C12-C14 linker unit 123 which is appended by regioselective 
alkylation151 at C11 ahead of the HWE coupling. The (E,E)-dienoate is formed by PPh3/PhOH-catalysed 
isomerisation of the C1-C3 ynoate ester,152 which is another efficient transformation, utilised exclusively 
in the Paterson strategy. The C13 and C19 stereocentres, which are not a part of the key stereotetrads, can 
be introduced by reagent-controlled Corey-Bakshi-Shibata (CBS) reduction of a,ß-unsaturated 
carbonyls153 resulting from HWE olefinations. In contrast, the remote C17 stereocentre was sourced from 
the chiral pool materials as proposed by Woodrow (noted in Section 3.4.1.). 
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2.2. Aldol Methodology 
The stereotetrads present in the aplyronines are common motifs in polyketide natural products which stem 
from iterative addition of malonyl CoA or methylmalonyl CoA to the growing carbon chain, orchestrated 
by the polyketide synthase enzymes. Each cycle can introduce up to two new stereocentres, depending on 
whether the condensations are of polyacetate or polypropionate type, producing a typical b-hydroxy 
ketone unit (Figure 24). This process is the origin of the ubiquitous 1,3-oxygenation patterns in 
polyketides, which can also be further derivatised to give 1,3-polyols through reduction or dehydration to 
produce a,b-unsaturated carbonyls.154 
 
Figure 24 Typical polyketide structural motif 
Such construction of stereogenic centres by means of chemical synthesis has been emulated using methyl 
or ethyl ketones in aldol reactions (Figure 25). Tremendous efforts in this field in the past decades have 
yielded arguably some of the most pivotal methodology for constructing C-C bonds from carbonyl 
compounds in a regio-, stereo- and enantioselective manner. Comprehensive understanding of how to 
generate aldol coupling partners with tuneable properties in combination with syn- or anti-selective 
reductions has provided access to every possible permutation of the stereotetrad pattern. The applicability 
of this approach spans from generating very small building blocks to stereoselective union of highly 
complex fragments in the assembly of polyoxygenated natural products.154 
 
Figure 25 Aldol reactions using methyl or ethyl ketones 
The relative topicity of aldol reactions with metal enolates can be predicted from the general mechanistic 
pathways. The reactions proceeds via a Zimmerman-Traxler transition state (TS)155 where the aldehyde 
carbonyl is coordinated to the enolate metal and the positioning of substituents in a chair-like 
conformation is governed by the minimisation of 1,3-diaxial interactions (Scheme 33).156 For this reason, 
(Z)-enolates generally proceed to give 1,2-syn aldol adducts whereas (E)-enolates produce a 1,2-anti 
relationship, thus it is vital to form the enolate with high stereochemical fidelity. 
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Scheme 33 Relative stereochemical outcome of aldol reactions with (Z)- or (E)- metal enolates 
While the enolate can impart relative configuration on the alpha methyl and beta hydroxyl groups in the 
the aldol adduct, the enantioselectivity must be conferred by one or more additional stereocontrolling 
elements. In particular, chiral ketones frequently furnish products with very high levels of induction and 
offer an attractive alternative to auxiliary-based methods. One of the most simple and efficient substrates 
for this purpose is methyl-3-hydoxy-2-methyl propionate ((S)- or (R)-Roche ester 126 and 127, vide 
infra), a dipropionate equivalent, which has been used in the syntheses of numerous polyketide natural 
products such as spirangien A157 and callipeltoside.158 The configurations of the three aplyronine 
stereotetrads lend themselves well to the aldol reactions of boron- and tin enolates of ketones 128 and 
129, developed by Paterson (Scheme 34). The basis for the selectivity in these key aldol reactions will be 
discussed in the following sections where appropriate. 
 
Scheme 34 Retrosynthetic analysis of the stereotetrads in aplyronines 
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2.3. First-Generation Total Synthesis of Aplyronines A, C and D 
2.3.1. Synthesis of C1-C11 Iodide 122 
Synthesis of the C1-C11 fragment 122, began with the 1,4-syn-3,4-anti-selective boron-mediated aldol 
reaction with ethyl ketone 128 and aldehyde 130 (Scheme 35), prepared in four steps from 5-hexyn-1-ol.  
 
Scheme 35 Boron-mediated aldol reaction in the Paterson synthesis of C1-C11 iodide 122 
Enolisation with dicyclohexylboron chloride (Cy2BCl) and triethylamine (Et3N) produced the (E)-boron 
enolate, which proceeded to react with aldehyde 130 to form aldol adduct 131 in 96% yield and >20:1 dr. 
High levels of stereoinduction in aldol reactions of b-alkoxy (E)-enol borinates have been rationalised by 
Paton and Goodman using density functional theory (DFT) studies. It was found that the transition state 
structure is boat-shaped, which is in agreement with a postulated stabilising interaction between the 
aldehyde proton and the lone pair electrons on the para-methoxybenzyl (PMB) group (Scheme 36).159,160 
The facial preference of enolate attack is thus dictated by the minimisation of 1,3-allylic strain (A1,3) 
around its double bond in TS 1 which is able to facilitate the formyl hydrogen bond. 
  
Scheme 36 Competing transition states TS 1 and TS 2 for the aldol reaction of ethyl ketone 128 with aldehyde 130 
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Scheme 37 Elaboration of aldol adduct 131 to iodide 122 
The directed 1,3-anti reduction was carried out under the Evans-Tishchenko protocol (SmI2, EtCHO),161 
which installed the final chiral centre in the C7-C10 tetrad (Scheme 37). Next, the conjugated alkyne was 
isomerised to the dienoate under Rychnovsky’s protocol (PPh3, PhOH),152 which afforded the product 
with complete selectivity for the thermodynamically favoured (E,E)-configuration. As discussed in 
Section 1.4., other group’s routes towards the aplyronine fragments feature an HWE reaction to construct 
the dienoate which results in mixtures of double bond isomers containing the undesired (Z)-olefins.  
The pendant propionate at C7 provided an opportunity for differentiation of the C7 and C9 hydroxyls 
which would simplify the diversification of late-stage intermediates towards multiple aplyronine 
congeners. Woodrow instead opted to cleave the ester with K2CO3 in MeOH to the corresponding 1,3-diol 
132 and inserted a rigid PMP acetal moiety. The resuting intermediate was further elaborated to the 
iodide at the C11 terminus to obtain a suitable leaving group for the envisaged alkylation. The PMB group 
was best cleaved with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in a mildly basic aqueous 
buffer (pH 9.2) to suppress the problematic migration of the PMP acetal or its overoxidation to the 
orthoester.162 The C11 alcohol was then subjected to Appel conditions (I2, PPh3, imidazole)163 to produce 
the primary iodide 133. 
To prevent the C1 ester interfering in the subsequent alkylation step, the carbonyl was reduced with 
diisobutylaluminium hydride (DIBALH) and protected with TBSOTf to give an allylic TBS ether. A 
fortuitous discovery made during this project was that this functionality can be directly transformed to an 
aldehyde149,164 which was subsequently incorporated as one of the cornerstones of the macrocycle 
synthesis and will be discussed in Section 3.2. Overall, the C1-C11 iodide 133 was synthesised in nine 
steps and 54% yield from ketone 128. 
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2.3.2. Synthesis of C15-C27 Aldehyde 134 
 
Scheme 38 Retrosynthesis of the C15-C27 aldehyde 134 
Lydia Lee assembled the C15-C27 aldehyde 134 from two smaller subfragments (Scheme 38). The 
C21-C27 segment 124 bears the C23-C26 stereotetrad and was installed using the Paterson tin(II)-mediated 
aldol methodology,144 which resulted in the required 1,4-syn-3,4-syn motif. The (S)-Roche ester-derived 
ketone 129 formed the (Z)-enolate upon treatment with tin(II) triflate and Et3N, then reacted with 
aldehyde 135 to produce aldol adduct 136 in 88% yield and 9:1 dr. The origin of stereoselectivity 
imparted by the chiral ketone can be deduced from either Zimmerman-Traxler transition states155 TS 3 
and TS 4.  
 
Scheme 39 The synthesis of C21-C27 aldehyde 124 
136 was subjected to an Evans-Tishchenko reaction, followed by methanolysis of the residual ester to 
furnish a 1,3-anti diol (94%, >20:1 dr). As before, the C23 and C25 hydroxyls could have been 
differentially protected at this stage. However, after careful deliberation the decision was made to protect 
the diol as a di-tert-butyl silylene protecting group with the aim of inducing a conformational bias to 
achieve the desired regioselectivity in the macrocyclisation step. The C21 aldehyde functionality for the 
planned HWE coupling was revealed by facile hydrogenation of the benzyl ether with Pd/C, followed by 
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Dess-Martin oxidation.165 The C21-C27 fragment was thus prepared in six steps and 65% yield from 
ketone 129. 
The C15-C20 phosphonate 125 bearing an isolated (17R) methyl stereocentre was obtained by 
functionalisation of commercially accessible methyl-(R)-3-methyl glutarate 137 (Scheme 40). The C15 
silyl ether was formed by chemoselective reduction of the carboxylic acid with BH3×SMe2.166 and the 
resulting primary alcohol was immediately protected with TBSCl to avoid spontaneous lactonisation onto 
the C19 carbonyl. The required b-ketophosphonate moiety was attached by homologation with lithiated 
dimethyl methylphosphonate,167 which concluded the synthesis of the C15-C20 fragment 125 in three steps 
and 85% yield from the chiral acid 137.  
 
Scheme 40 Synthesis of the C15-C20 phosphonate 125 from the chiral acid 137 
The Ba(OH)2-mediated HWE reaction150 of fragments 124 and 125 to forge the C20-C21 olefin proceeded 
in 91% yield and a 14:1 ratio of E/Z isomers (Scheme 41). The C19 stereocentre was installed in a 
catalyst-controlled enantioselective carbonyl reduction step by employing (S)-Me-CBS 138 and 
BH3×SMe2 as the source of hydride (91%, 15:1 dr).153,168 The ensuing secondary alcohol was methylated 
with NaH and MeI, followed by acidic hydrolysis of the TBS ether and Dess-Martin oxidation165 of the 
C15 terminus to produce the C15-C27 southern fragment 134 in 11 steps LLS and 49% yield from the (S)-
ethyl ketone 129. 
 
Scheme 41 Lee’s synthetic efforts towards the C15-C27 aldehyde 134 
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2.3.3. Synthesis of C1-C27 Macrocycle 120 
The Paterson strategy for macrocycle assembly was centred around the HWE reaction to forge the 
trisubstituted (14E) olefin in presence of a mild base as shown in Scheme 42. The phosphonate 
component for this step was appended to the C1-C11 iodide 122 by alkylation with the dianion of b-
ketophosphonate 123.151 The reaction is carried out under kinetic conditions to encourage the attack 
through the less hindered g-carbon. However, Lee identified a regioisomeric a-alkylation product in the 
mixture and efforts to suppress its formation only resulted in a modest improvement.162 The phosphonate 
product 139 was then subjected to deprotonation with Ba(OH)2 and reacted with aldehyde 134 to forge 
the enone in 91% yield and 14:1 mixture of E/Z double bond isomers. This impressive result greatly 
surpassed the 44% yield and 2.3:1 E/Z product ratio from Yamada’s Julia coupling and even to date 
remains the most efficient method of constructing the C14-C15 bond. Moreover, both components were 
prepared from the Roche ester-derived ethyl ketones 128 and 129 in ten and eleven steps, respectively, 
maximising the convergency of this synthetic plan. 
 
Scheme 42 Fragment coupling and macrolactonisation to the undesired regioisomer 142 by Woodrow and Cowden 
The remote C13 chiral centre was installed in a similar fashion to C19. Reduction with the enantiomeric 
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oxidised to the corresponding dienal when subjected DDQ.164 At this stage two additional transformations 
were necessary prior to macrocycle formation; oxidation of the aldehyde to the seco-acid and cleavage of 
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the di-tert-butyl silylene to expose the 1,3-diol for cyclisation. Due to high polarity of several late-stage 
intermediates, the best mass recovery was obtained when the silylene was first removed with HF×pyr, 
followed by chemoselective oxidation at C1 under Pinnick conditions.169  
Despite attempting to leverage the steric bulk of the TIPS group at C27 to favour the esterification of the 
C25 hydroxyl over C27, the approach failed and gave exclusively the undesired 26-membered lactone 142 
under the Yamaguchi-Yonemitsu protocol,125 albeit in good yield (79%). Lee and Atkinson trialled other 
conditions which resulted in little success with regards to regioselectivity but the Shiina protocol was 
found to be comparable in yield.162 
 
Scheme 43 Ti(iPrO)4-mediated transesterification and elaboration to the aldehyde at C27 by Blakey and Fink108 
Fortunately, translactonisation upon treatment with Ti(iPrO)4 returned a mixture of regioisomers in the 
varying range of 1:1 to 3:1 in favour of the thermodynamically preferred 24-membered ring 143. As the 
isomers were separable by column chromatography, resubmission of the undesired isomer 142 to 
isomerisation facilitated acceptable material throughput to the subsequent steps. Global deprotection with 
aqueous HF, followed by persilylation of the tetraol with TESOTf led to the key tetra-TES intermediate 
144. Over the course of the project, nearly 1 g of this precursor was prepared which enabled the pivotal 
studies of side chain attachment on advanced material. The delicate a-chiral aldehyde at C27 was accessed 
by hydrolysis of the most labile primary TES ether under mildly acidic conditions and careful Swern 
oxidation170 to avoid the risk of epimerisation. This concluded the synthesis of the C1-C27 macrocycle 
120 in 21 steps LLS and 14% yield. 
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2.3.4. Side Chain Attachment Studies 
The initial retrosynthetic plan envisaged a Masamune-Roush171 olefination to forge the C27-C28 bond 
between the macrocyclic aldehyde 120 and a suitable phosphonate 116. This fragment, which features the 
delicate N-vinylformamide, was prepared by Blakey and subsequently used in a model olefination with 
truncate aldehyde 145 to probe the feasibility of this approach. The initial studies were promising (146), 
though unfortunately this could not be replicated on the real system (Scheme 44). Despite the mild nature 
of the Masamune-Roush protocol,171 the reaction with aldehyde 120 returned solely the C25 TES 
elimination product 147. 
 
Scheme 44 Blakey’s model study and failed side chain attachment of the first-generation C28-C34 phosphonate 116 
to macrocycle 120172 
In light of this disappointing outcome, Blakey revised the strategy to retain macrocycle 120 and instead 
achieve the side chain union via a boron aldol/mesylation/elimination sequence with a new C28-C34 
methyl ketone fragment 117 as illustrated in Scheme 45. Early studies of subsequent steps showed 
promise, though an unsurmountable issue was faced upon installing the final stereocentre at C29 with the 
Evans-Tishchenko protocol. Even with increased loading of SmI2, high excesses of acetaldehyde were 
necessary to achieve good conversion, which often resulted in substantial amounts of the bis-acetylated 
byproduct 148 being formed.  
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Scheme 45 Attachment of the second-generation side chain fragment 117 and failed Evans-Tishchenko reaction by 
Blakey 
2.3.5. Endgame  
The strategy was refined once again to modify the precise structure of the ketone coupling partner after 
the boron aldol route had been successfully applied in the reaction with the macrocycle 120. The major 
changes were firstly the isomerisation of the (Z)- to (E)-vinylformamide prior to the coupling step and in 
the later iteration, earlier installation of the potentially sensitive C31 acetate. The new target was methyl 
ketone 118. 
Fink devised a 10-step synthesis of this fragment, mirroring the tin(II)aldol/ Evans-Tishchenko sequence 
as applied to the C23-C26 stereotetrad. Starting with the ethyl ketone 128 in the enantiomeric series of 
Roche ester, the (Z)-enolate was condensed with acetaldehyde to form the all-syn adduct 149 in 97% 
yield and 15:1 dr. This result may be attributed to the superior chelating ability of the PMB ether and the 
reaction proceeding through TS 5 (Scheme 46). 
(a) Cy2BCl, Et3N, Et2O; (b) MsCl, Et3N, DBU, CH2Cl2; (c) TBAF, AcOH, THF; (d) [CuH⋅PPh3]6, PhH; (d) SmI2, MeCHO, THF
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Scheme 46 Fink's synthesis of the third-generation side chain fragment 118 
After a directed 1,3-anti reduction of the C31 carbonyl (97%, >20:1 dr), the b-hydroxyl was masked as a 
TES ether. Protecting group removal and double Swern oxidation of diol 151 concomitantly formed the 
methyl ketone at C29 and aldehyde at C33. The latter then participated in a modified Wittig reaction to 
install the N-vinylformamide moiety with the ylid derived from the phosphonium salt 150.173 The C33-C34 
olefin was forged in an inconsequential 8:1 Z/E ratio. Fink found that the isomerisation to the 
thermodynamically favoured (E)-geometry failed with silyl ethers at the C31 hydroxyl and thus the 
protecting group was first replaced with the electron-withdrawing acetyl. Treatment of 152 with 
tetrabutylammonium fluoride (TBAF)/AcOH and esterification of the free hydroxyl with acetic anhydride 
yielded the suitable substrate for iodine-mediated isomerisation, which converted the olefin to the 
exclusively (E)-isomer. The C28-C34 fragment 118 was synthesised in 10 steps and 43% yield from ethyl 
ketone 128. 
With the two key fragments in hand the stage was set for the boron aldol coupling, followed by 
dehydration using Burgess’ reagent174 which reliably proceeded in 65% over two steps from the 
macrocyclic aldehyde 120 to return the corresponding enone (Scheme 47) with minimal elimination of 
the C31 acetate. A chemoselective reduction of the enone was cleanly achieved with Stryker’s reagent175 
with the yields consistently exceeding 80%. Williams implented Yun’s simplified procedure for the 
preparation of the reagent solution176 and hence ketone 153 was reliably accessible in an operationally 
undemanding manner. The final stereocentre was configured in a substrate-controlled reduction with 
freshly prepared Zn(BH4)2 which formed a 10:1 mixture in favour of the desired (29R) isomer 154, 
though the outcome was highly dependent on the quality of the reagent. 
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Scheme 47 Boron aldol side chain attachment and reduction of the C29 ketone by Fink177 
Fink completed the total synthesis of aplyronine C (13) by forming the ester on the C29 position using the 
Keck protocol127 with DMAla 156  then global deprotection of the three remaining silyl ethers. The 
overall yield of the sequence was 5% over 29 steps LLS from the Roche ester-derived ketone 129. 
Williams later demonstrated that that aplyronine C (13) is in fact a direct precursor to aplyronine A (1) 
without the need for differential protection of the hydroxyls at C7/C9. The free 1,3-diol undergoes 
regioselective esterification under Yamaguchi-Yonemitsu conditions125 with TMSer 158 when carefully 
monitored to prevent byproduct formation and pushed to 50-80% conversion before bis-acetylaton 
occurs. Aplyronine A (1) was obtained in 55% yield and 46% recovery of the precursor with a 2.2% 
overall yield over 30 steps LLS. By appending the DMGly 155 at C29 onto the tris-TES intermediate 154, 
the same route was able to provide aplyronine D (14, 61% yield with 25% recovered aplyronine C) in 
2.6% overall yield over the same number of steps in the LLS, which constituted the first completed total 
synthesis of this congener.  
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Scheme 48 Divergent endgame strategy and synthesis of aplyronines A, C and D by Williams111 
2.4. Summary 
At the onset of the work within the Paterson group, the main objective was to devise a shorter and more 
efficient route to the aplyronines as compared to the first reported synthesis by Yamada. A side-by-side 
overview of yields and step counts confirms that this goal had indeed been met (Table 3). A critical 
analysis of the existing total synthesis reveals several major advantages over other group’s strategies. For 
example, all three stereotetrads are set up using the Paterson aldol methodology/1,3-anti reduction 
sequence in high dr and 85% yield or better. Next, the (E,E)-dienoate is introduced with complete 
selectivity at an early stage in the C1-C11 iodide synthesis. Perhaps the most crucial advancement first 
seen in the Paterson approach is the convergent HWE olefination to assemble the C1-C27 carbon skeleton, 
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which brings together two fragments of similar size and complexity in a superb 91% yield and 14:1 ratio 
of E/Z isomers. Finally, the delicate N-vinylformamide is present in the side chain fragment 118 and is 
remarkably unaffected by any transformations following its appendage in the boron aldol reaction with 
the macrocycle 120. 
Table 3 Overview of the total synthesis routes to aplyronines A (1), C (13) and D (14) 
 Yamada Kigoshi Paterson 
Congener ApA ApC ApA ApA ApC ApD 
Steps LLS 47 46 38 30 29 30 
Steps total 98 97 80 48 47 48 
Yield (%) 0.39 0.14 1.4 2.6 3.6 2.2 
However, despite several advantages there remain a number of issues which must be addressed if this 
route is to be implemented on a large enough scale to deliver material for further biological studies. In 
particular, several steps remain capricious and appear to be greatly influenced by quality of starting 
materials or reagents in key stereoselective reactions. The majority of these pertain to the macrocyclic 
portion of the natural product and are undoubtedly the main areas to which attention should be turned in 
future refinements of the synthesis. 
Starting with the overall retrosynthetic analysis, the site-selective macrolactonisation plan had 
unfortunately failed and introduced an inefficient series of protecting group manipulations after the HWE 
coupling of the northern and sourthern fragments 139 and 134 (shown previously in Scheme 42). 
Furthermore, the translactonisation of macrolide 142 to the desired ring size (143) was found to be 
unreliable, giving mixtures of the two macrolactones which severely limits the throughput of these 
relatively late-stage intermediates.  
In the early fragment synthesis, yields for the tin aldol step on the C21-C27 aldehyde 124 were not be 
reproducible and the use of capricious Sn(OTf)2 was be cumbersome on large scale. Despite the studies 
on the side chain fragment 118 being more encouraging, the decision was made to investigate other 
suitable substitute for this methodology towards this fragment. With regards to the northern C1-C14 
phosphonate 139, the choice of the C7/C9 PMP acetal proved counterproductive and the appendage of the 
b-ketophosphonate was only recently identified as less regioselective than deemed by Woodrow and 
Blakey.  
In summary, the Paterson route to aplyronine A reduced the number of linear steps by more than 15 
compared to the first total synthesis by Yamada, accompanied by a dramatic increase in yield. 
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Nevertheless, there is plenty of scope for improvement. It is conceivable that this may be achieved by 
implementing more modern synthetic methodology developed after the early investigations in the late 
1990s and a more informed protecting group strategy. 
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Chapter 3 
Results and Discussion – Part I 
Synthesis of C1-C11 Iodide 160 and C15-C27 Aldehyde 161 
3.1. Project Aims 
Chapter 2 discussed the accomplishment of a divergent synthesis of multiple aplyronine congeners within 
the Paterson group. However, more recent findings on the mode of action of the aplyronines by 
Kigoshi75,81–83,178 gave the existing body of work an entirely new direction. Owing to the rare combination 
of picomolar potency and a novel mechanism of action the aplyronines have been identified as ideal 
candidates for ADC payloads. 
Detailed investigations into this potential application are currently limited by the prohibitively low 
isolation yields of aplyronines from natural sources. A successful campaign to develop them into serious 
ADC candidates will require a sustainable supply of stable late-stage precursors, which can only be 
achieved through chemical synthesis. This is an adventurous but realistic prospect for the future of this 
project based on the current concise endgame sequence following the assembly of the complete carbon 
skeleton. Williams also proved that the final steps of the strategy yield appropriate intermediates for 
diversification without the need for a strategy revision to include differential protection of amino acid-
bearing hydroxyls. 
To ultimately initiate investigations into the aplyronines as ADC payloads, multigram stocks of both the 
macrocycle 120 and the side chain 118 have to be replenished as the first priority to meet the demands. 
This goal calls for a large-scale synthesis of the C1-C27 alcohol 159 (vide supra), and offers the 
opportunity to develop an improved route drawing on the lessons learned en route to the first-generation 
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Paterson approach. Addressing the most pressing issues highlighted in Section 2.4 is expected to yield a 
more robust synthesis of individual fragments as well as a more convergent protecting group strategy in 
the ideal scenario. 
3.2. Second-Generation Protecting Group Strategy 
The major skeletal disconnections from the first-generation route had generally proved successful and so 
it was decided that these would be retained in developing a revised synthesis (Scheme 49). The challenge 
then became designing a streamlined protecting group strategy and improving upon the synthesis of the 
individual fragments. 
 
Scheme 49 Retrosynthetic analysis of macrocycle 159 and second-generation protecting group strategy 
The main goal of altering the protecting groups was to reduce the number of manipulations in the later 
stages of the synthesis of alcohol 159 and to provide a suitable substrate for site-specific 
macrolactonisation. The selection was largely inferred from the conclusions of the first-generation route 
combined with previous experience with the stability of individual moieties with regards to planned 
transformations. Firstly, alcohol 159 possesses TES ethers at the C7, C9 and C25 hydroxyls and it is 
favourable to introduce them at the earliest opportunity. C7 and C9 are differentiated by a pendant amino 
acid at C7 in the several aplyronine congeners. However, Williams has demonstrated that the required 
esterification can be achieved in a site-selective manner onto the C7 hydroxyl in presence of the C9 
alcohol. There is hence no need for distinction in the masking step and bis-TES silylation is a suitable 
option from the onset. By also introducing the required TES ether at C25, site-specific macrolactonisation 
O
14
1TESO
OTBS
O
15H
PMBO OTES
OAlloc
OMe
27
O P(OMe)2
O
+
TES
Yamaguchi
macrolactonisation
I
12
11
+
159
O OTES
OH
OMe
27
TESO O
TES 1
MeO
known intermediate
79
Ba(OH)2-mediated
HWE
23
alkylation
O
C1−C11 iodide 160
C12−C14 linker 123
C15−C27 aldehyde 161
Chapter 3: Results and Discussion – Part I 
 
65 
would be enabled by orthogonal protection and later unmasking of the C23 hydroxyl. It was proposed that 
a particularly attractive choice in this case would be a PMB group. It could be cleaved upon treatment 
with DDQ which coincides with the conditions used to convert the C1 allylic TBS ether into the 
corresponding aldehyde. Both macrolactonisation sites would effectively be unmasked in an efficient 
single operation. (Scheme 50).  
 
Scheme 50 One-step DDQ-mediated unmasking of C1 and C23 to facilitate site-specific macrolactonisation 
There is a certain risk that the steric bulk of the TES group would hinder or entirely preclude the 
cyclisation step. Evidence both for and against this argument can be found in syntheses of numerous other 
natural products with a 1,3-diol moiety as the macrolactonisaton site.179–183 However, the conclusion 
drawn from inspecting the literature is that it is not straightforward to predict how the structure of 
substrate will affect the ring closure and hence every system must be treated on an individual basis. 
The planned site-specific macrocyclisation was thus a particularly uncertain venture as its merit could 
only be tested at a relatively advanced stage. Williams’ attempts to break the tetra-TES lactone 144 by 
saponification in order to trial such a ring closure on material already in hand had been unsuccessful 
(Scheme 51).184 There was no surrogate path to acquiring the seco-acid 166 than through synthesis.  
 
Scheme 51 Failed attempt at hydrolysing the tetra-TES macrolactone 144184 
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Finally, alcohol 159 would be obtained by deprotection at C27 as the last step as had been demonstrated 
on a tetra-TES intermediate 144 where hydrolysis of the primary C27 silyl was possible, but not entirely 
selective.111,162,177 In order to avoid protecting group manipulations at a later stage, this moiety at C27 
would also have to be introduced very early on. The primary TES group was unlikely to withstand a long 
sequence of steps towards the macrolactone though identifying an alternative amongst conventional 
protecting groups was challenging. The deprotection step would need to take place in presence of silyl 
ethers, electron-rich and electron-poor olefins and the lactone. Eventually, the decision was made to opt 
for an orthogonal allyl carbonate (Alloc). Its cleavage can be affected by a source of palladium and an 
allyl scavenger, which was expected to leave any other functionality intact. The carbonate was anticipated 
to be stable to most conditions with the exception of strong nucleophiles or reducing agents185 and the use 
of these reagents was not anticipated after the fragment coupling. Williams trialled the Alloc 
protection/deprotection sequence at C27 on the available macrocyclic material which showed the 
feasibility of this method (Scheme 52).184  
 
Scheme 52 Williams' small-scale trial of Alloc protection and deprotection at C27 
This chapter will now describe the work done by the author towards a streamlined route to the C15-C27 
aldehyde 161 and synthesis of the C1-C11 iodide 160. All modifications were implemented with a large-
scale synthetic campaign in mind, carrying out as many transformations as possible on gram-quantities of 
substrates by devising highly scalable and robust protocols. 
3.3. Synthesis of C15–C27 Aldehyde 168 
3.3.1. Retrosynthesis of the C15–C27 Fragment 161 
The key disconnections from the initial retrosynthetic analysis for the C15-C27 fragment 134 envisioned 
by Woodrow and Cowden were maintained for the scale up campaign with the intention of adapting the 
route to the meet current needs of the project. A pivotal disconnection across the C14-C15 bond led to two 
key fragments, b–ketophosphonate 167 and aldehyde 168 which would be coupled in a mild, Ba(OH)2-
mediated HWE reaction (Scheme 53). Fragment 167 contains a remote C17 stereocentre, which can be 
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incorporated by functionalising (R)-methyl-3-methylglutarate 137, derived from an achiral precursor in an 
enzyme-mediated desymmetrisation reaction. Aldehyde 168 which carries a stereotetrad at C23-C26, 
which could be constructed through an aldol condensation. 
 
Scheme 53 Retrosynthetic analysis for the C15-C27 aldehyde 161 
3.3.2. Tin Aldol Approach to C23–C26 Stereotetrad 
One of the key motivations to revisit the synthesis of the C21-C27 aldehyde 168 beside adjusting the 
protecting groups was the requirement to produce a reliable and scalable protocol to generate the 1,3,4-
syn configuration embedded in the C23-C26 stereotetrad. This motif can be constructed in a Sn(OTf)2-
promoted aldol reaction using a chiral ketone to direct facial selectivity of the enolate. Early 
investigations on this methodology can be traced back to the work by Mukaiyama186 and Evans187 on the 
utility of Sn(OTf)2 in asymmetric aldol reactions of a-chiral ethyl ketones or b-ketoimides as propionate 
equivalents. 1,3-syn-3,4-syn aldol adducts can be obtained in excellent diastereoselectivity (90-95%) 
without the use of chiral auxiliaries which can be attributed to substrate control and highly selective 
formation of (Z)-enolates in the presence of a tertiary amine base. 
Paterson and Tillyer further expanded the substrate scope by exploring examples using Bn- and TIPS-
protected Roche ester-derived ethyl ketones 129 and 170 as enolates (Scheme 54).144 High levels of p-
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facial selectivity observed implied that in contrast to analogous boron and titanium enolates, tin enolates 
are likely to be conformationally more restricted. This proposal can be rationalised by considering a 
chelation interaction between the hydroxyl protecting group on the enolate and the Lewis acidic tin 
centre. In light of this stabilising effect, the favoured Zimmerman-Traxler155 transition state is one in 
which the methyl group points outwards to reduce axial steric congestion (TS 6). While the model is 
consistent for the electron-rich aryl or alkyl ethers on the ketone, it does not account for high dr observed 
with the triisopropylsilyl (TIPS) moiety as silyl groups have been shown to be poor chelating agents.188 
 
Scheme 54 Two contrasting transition state proposals for selectivity in Sn(OTf)2 propionate aldol reactions 
A more convincing argument may be drawn from the reactivity mode of analogous a-chiral olefins with 
electrophiles. In the ground state, allylic strain is preferentially minimised by having an eclipsing 
interaction between the hydrogen on the a-chiral stereocentre and the double bond. This forces the 
incoming electrophile to approach from the less sterically encumbered face (TS 7, Scheme 54). 
Conversely, certain have been known to react by having a methyl group eclipsing the olefin instead as the 
A1,3 interaction is not large.189 The activation energy of the system is hence lowered and the electrophile 
approaches past the hydrogen atom, which results in the same stereochemical outcome than the one 
predicted by the aforementioned chelation model (TS 6). In this case, greater bulk of the silyl ether is 
favourable and is expected to enhance the levels of selectivity. 
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Scheme 55 Lee’s synthesis of b-hydroxy ketone 136 
Woodrow initially obtained 9:1 dr and 88% yield for the aldol reaction between ketone 129 and aldehyde 
135, though Lee later struggled to reproduce this result (Scheme 55). The TIPS moiety was irreplaceable 
as part of the overall protecting group strategy thus efforts were focused on bolstering the yield instead. 
To probe the steric effect of different silyl group, the appropriate ethyl ketone bearing the tert-
butyldimethylsilyl (TBS) group was explored as the next option. 
Ketone 171 was synthesised by the controlled nucleophilic attack of ethylmagnesium bromide into 
Weinreb amide 172,† to form chelated intermediate 173 at low temperature before collapsing upon 
aqueous workup (Scheme 56). This stable intermediate precludes undesired further addition of the 
Grignard reagent to the more electrophilic carbonyl product. The amide precursor had previously been 
made by silyl protection of commercially available (S)-Roche ester 127 with TBSCl, followed by 
treatment with N,O-dimethylhydroxylamine hydrochloride in presence of isopropylmagnesium chloride. 
 
Scheme 56 Synthesis of ethyl ketone 171 
Aldehyde 169 was produced by reacting PMBCl with excess propane-1,3-diol to achieve mono-
protection, followed by Swern oxidation170 of the remaining primary alcohol. Aldol coupling partner 169 
was obtained in 82% yield over two steps from more than 20 mmol of PMBCl (Scheme 57). 
                                                
† Stocks of Weinreb amide 172 were available in the laboratory. 
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Scheme 57 Synthesis of aldehyde 169 
Ketone 171 was converted to the (Z)-enolate with Sn(OTf)2 and Et3N at -78 °C before slowly adding 
excess 169 to ensure complete consumption of the starting material. However, unreacted aldehyde 169 
proved difficult to separate from the reaction product and so the crude mixture was subjected to Pinnick 
oxidation to chemoselectively convert the aldehyde functionality into the corresponding carboxylic acid 
177.169 After purification by column chromatography, aldol adduct 175 and the minor diastereomer 176 
were isolated as an 8:1 dr mixture in 74% yield (Scheme 58). 
 
Scheme 58 Sn(OTf)2 aldol reaction of ketone 171 and aldehyde 169 
The changes in protecting groups at C21 and C27 were unlikely to overturn the expected all-syn 
stereochemical outcome of the aldol reaction and this could be verified by examining the characteristic 
coupling constants of protons at the newly formed chiral centres in the 1H NMR spectra. 
Conformationally unrestricted b-hydroxy ketones preferentially adopt a 6-membered half chair 
conformation when intramolecular hydrogen bonding between the hydroxyl group and the ketone exerts 
the dominant conformational bias in a non-hydrogen-bonding solvent (Figure 26).190  
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Figure 26 Favoured conformations of anti and syn aldol adducts governed by internal hydrogen bonding 
If the substituents at C23 and C24 in aldol adduct 175 indeed lie syn to each other, the dihedral angle 
between H23 and H24 is expected to be close to 60°, suggesting there should be a small vicinal coupling 
constant (3J = 2-4 Hz) observed between them as foreseen by the Karplus’ theory191,192 and reassured by 
empirical evidence. In contrast, 1,2-anti relationship would force a trans-diaxial arrangement of those 
protons, hence the large dihedral angle would give rise to coupling constants in the order of 7-10 Hz 
instead. The measured value for product 175 was 4.0 Hz, which supports the anticipated syn relationship 
between H23 and H24. 
The absolute configuration at the C23 carbinol centre was ascertained by Mosher ester analysis. This 
method is based on esterification of the chiral alcohol in question with both enantiomers of the a-
methoxy-a-trifluoromethyl-phenylacetic acid (MTPA-OH), followed by 1H NMR analysis of their 
diastereomeric derivatives.193 The MTPA esters adopt a thermodynamically favoured conformation in 
solution which places the highly electronegative CF3 group coplanar with the carbonyl and the methine 
proton. The phenyl ring exerts a through-space, time-weighted average shielding effect on the protons in 
its proximity, which causes an upfield shift in the 1H NMR compared to the same set of protons in the 
diastereomeric ester (Figure 27). The configuration is then deduced from the sign of the difference (Dd = 
dS – dR) in chemical shifts on each side of the chiral alcohol for as many protons as possible.194 
 
Figure 27 Mosher ester analysis model for a secondary alcohol193,194 
O
R2
OH
R1 O H
O
Ha
R1
R2
Me
Hb
O
R2
OH
R1 O H
O
Ha
R1
R2
Ha
Me
Ha
OR1
Hb
Me
R2
O
H
Ha
OR1
Me
Hb
R2
O
H
3,4-anti 3,4-syn
dihedral angle: ~60º
3J = 2−4 Hz
dihedral angle: ~180º
3J = 7−10 Hz
H
OHR
1
R2
(R) CF3HO2C
Ph OMe
(S) CF3HO2C
MeO PhH
OR
1
R2
O
(R) CF3
Ph OMe MeO Ph
F3C (S)
O
O
H
R2 protons shielded R1 protons shielded
R1
R2
(R)-MTPA ester (S)-MTPA ester
chiral alcohol
H
O
MTPA
Δδ < 0Δδ > 0R2 R1 Δδ = δS − δR
Chapter 3: Results and Discussion – Part I 
 
72 
 
Scheme 59 Preparation of Mosher esters of alcohol 175 
b-Hydroxy ketone 175 was esterified with (R)- and (S)-MTPA-OH in presence of N,N-
dicyclohexylcarbodiimide (DCC) and N,N-dimethylaminopyridine (DMAP) separately to provide the 
corresponding (R)- and (S)-MTPA esters 178 and 179 (Scheme 59). Analysis of 1H NMR spectra for both 
compounds showed that the DdS-R signs for protons in the vicinity of the carbinol centre corresponded to 
the pattern, in agreement with the (S)-configuration at C23. 
Unfortunately, the yield and dr of aldol adduct 175 were still deemed to be unsatisfactory, leading to a 
revision of the C27 protecting group. In the hope of reinforcing a chelation-controlled transition state, the 
C27 TBS was replaced by an electron-rich benzyl (Bn) ether. Scheme 60 depicts the possible rationale for 
enolisation outcome of ketone 170 based on tin chelation in the deprotonation step to give the (Z)-enolate. 
 
Scheme 60 Selective formation of the (Z)-enolate of ethyl ketone 170 with Sn(OTf)2 
Paterson had previously demonstrated this possibility with the enantiomeric (R)-ethyl ketone 180 which 
afforded the all-syn aldol adduct 181 in 92% yield and 15:1 dr (Scheme 61),144 which was highly 
promising. 
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Scheme 61 Paterson’s tin(II) aldol with ketone 180 and aldehyde 169 
(S)-Ethyl ketone 170 was prepared in the known manner from Weinreb amide 182. Disappointingly, the 
aldol step failed to give the sought degree of improvement as b-hydroxyketone 183 was isolated in 10:1 
dr and 61% yield after oxidation of the excess aldehyde (Scheme 62). 
 
Scheme 62 Sn(OTf)2 aldol reaction of ketone 170 and aldehyde 169 
Once again, Mosher ester analysis was carried out to reassure the (S)-configuration of the newly formed 
hydroxyl in a rigorous fashion as shown in Scheme 63. 
 
Scheme 63 Synthesis of Mosher esters of alcohol 183 
As this result compared poorly to the literature precedent, the quality of the Sn(OTf)2 used in the 
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drawbacks associated with the preparation and handling of Sn(OTf)2 combined with ambitious 
scale-up goals in this project led to the decision to seek an alternative avenue to forge the 
C23-C26 stereotetrad. 
3.3.3. Titanium Aldol Approach to C21-C27 Aldehyde 168 
In the search for a compatible method for constructing the vital 1,3-syn-3,4-syn propionate motif a survey 
of the literature revealed a suitable alternative in the form of aldol reactions using titanium enolates 
derived from unsymmetrical carbonyls. A seminal report in this area is Evans' protocol for soft, highly 
(Z)-selective enolisation of ketones with titanium(IV) Lewis acids in combination with tertiary amine 
bases,195 comparable to the analogous tin(II)-mediated process. The titanium enolates then proceed to 
react with aldehydes via a Zimmerman-Traxler transition state where the highly oxophilic titanium centre 
facilitates a chair-like conformation through tight Ti-O bonds. The stereoselectivity is imparted 
exclusively by one or more of the following elements: the stereogenic centres or chiral ligands on the 
enolate, chiral auxiliaries on the carbonyl, groups with chelating ability or Felkin-Anh control in 
reactions with a-chiral aldehydes.196 
Urpí and Roméa have made a substantial contribution to the applications of titanium enolates derived 
from a- and b-hydroxy ketones for the assembly of polypropionate-like natural products.197,198 Crucial 
insight into the peculiar behaviour of titanium complexes has been gathered through investigating 
enolisation conditions, particularly by tuning the acidity and steric demands of the metal centre. Starting 
from TiCl4, chloride ligands were systematically replaced for one or two isopropoxides (iPrO) to create 
softer Lewis acid species, tailored for each particular substrate for the case of a-hydroxy ketones.197–199 
The substrate scope was thus widely expanded as a greater variety of otherwise labile protecting groups 
on the aldol coupling partners was tolerated. 
The methodology was later extended to reactions of Roche ester-derived b-hydroxy ketones 170 and 187 
with the clear intention of providing alternatives to the Sn(OTf)2-promoted aldol reactions to forge the 
1,4-syn-3,4-syn pattern (Scheme 64).200 Its relevance has since been demonstrated in several syntheses of 
natural product fragments.201–203 
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Scheme 64 Urpí and Roméa’s (iPrO)TiCl3 aldol reations of Roche ester-derived ethyl ketones 170 and 187 with 
isobutyraldehyde 
With the above precedent as a starting point of investigations, a screen of titanium(IV) Lewis acids was 
carried out to establish the optimal choice for the aldol reaction of ketone 170 and aldehyde 169. The 
outcomes are summarised in Table 4.  
  
Table 4 Lewis acid (LA) screen for the titanium aldol of 170a and 169 
Entry Variations from the above  reaction conditions Isolated dr Yield
b / % 
1 none 8:1 75 
2 1.3 eq. (iPrO)TiCl3 LA 7:1 77 
3 -98 °C 4:1 70 
4 (iPrO)2TiCl2 LA 6:1 44 
5 TiCl4 (1 eq.) LA 3.5:1 62 
6 TiCl4 (2 eq.) LA  4.5:1 56 
7 200 mg 170 10:1 70 
aReactions performed on 50 mg ketone 170 bOverall isolated yield of the 
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The protocol developed by Urpí and Roméa200 gave a reasonably high yield, and acceptable 
stereoselectivity (entries 1-2) and the excess aldehyde was cleanly removed in the subsequent Pinnick 
oxidation step. Monitoring the progress by thin layer chromatography (TLC) was not always reliable and 
variable yields may be a reflection of the reactions being terminated prematurely. In an attempt to slow 
down the rapid conversion (<10 min) and to increase the selectivity, the temperature was lowered to 
 -98 °C (entry 3) though this did not boost the result due to inherent operational difficulty of maintaining 
that temperature constant whilst keeping strictly anhydrous conditions. Altering the Lewis acid also had a 
detrimental effect (entries 4-6). Unsurprisingly, the softer (iPrO)2TiCl2 resulted in very limited 
conversion and TiCl4 did not impart satisfactory selectivity. It was speculated that 2 eq. of TiCl4 may 
favour formation of a bimetallic enolate,204 though as Urpí and Roméa noted, any chelating groups on the 
aldehyde are likely to cause formation of other complexes and thus an erosion in stereocontrol. Finally, 
upon minor scale-up (entry 7) the selectivity and yield were comparable to the best result under the 
original conditions. 
Scale-up was thus performed under Urpí and Roméa’s original conditions as they offered the best 
compromise between conversion and selectivity. Gratifyingly, gram-scale experiments produced aldol 
adduct 183 in 85% yield and up to 15:1 dr and were reliably reproducible. Further scaling up to nearly 
10 g of the ketone 170 resulted in 82% yield and 12:1 dr for the isolated product 183, which affirmed the 
robustness of this methodology as well as its operational ease. Titanium Lewis acids are substantially 
easier to prepare than Sn(OTf)2 and the reaction work up is more straightforward as titanium does not 
cause emulsion formation to the same extent as tin. In this regard, investigations into the titanium aldol 
route were indeed a great success. Crucially, by inspection of 1H and 13C NMRs, b-hydroxy ketone 183 
was identical to the material obtained from the tin-mediated aldols. 
 
Scheme 65 Alternative sequences to PMP acetal 190 
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The final chiral centre of the C21-C27 fragment can be forged via a substrate-directed, 1,3-anti reduction 
where the stereochemical information is relayed from the existing hydroxyl. The strategy then requires 
transposition of the PMB group onto C23 which can be achieved via oxidative formation of a PMP acetal 
intermediate, followed by its regioselective opening. There are two possible methods to carry out the 
1,3-anti carbonyl reduction (Evans-Saksena or Evans-Tishchenko) as well as a different order of steps 
which leads to the required compound 190 (Scheme 65). 
Route B has one potential risk to associated with it. Due to steric hindrance around the secondary alcohol 
at C25, TES protection would almost certainly have to be done using a silyl triflate whose Lewis acidity 
may be able to facilitate undesired migration of the propionate ester onto C25. Therefore, route A in which 
the PMP acetal is formed before silyl protection was pursued as the first option. 
  
Scheme 66 Competing transition states in the Evans-Saksena reduction of ketone 183145,146 and observed byproduct 
from Evans-Saksena reduction of the 1,4-anti aldol adduct 184 
Diol 189 could be accessed directly by treatment of the b-hydroxy ketone 183 with Me4NBH(OAc)3 to 
afford the 1,3-anti product in 84% yield and excellent diastereoselectivity (>20:1) through intramolecular 
hydride delivery in a chair transition state (Scheme 66).145,146 Unfortunately, the desired product was 
isolated as an inseparable mixture with the reduced 1,4-anti minor diastereomer 184 carried forward from 
the earlier aldol step, which could not be removed by column chromatography. 
Fortunately, this was avoided by subjecting 183 to Evans-Tishchenko conditions161 instead, then cleaving 
off the residual ester. The initial mechanistic step of this reaction is thought to be SmI2-promoted 
reductive homocoupling of a sacrificial aldehyde. The ensuing samarium(III) pinacolate species acts as a 
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Lewis acid and enables the formation of a hemiacetal intermediate which undergoes hydride transfer via a 
highly organised, bicyclic, chair-like transition state (Scheme 67). The C23 hydroxy group remained 
masked as a propionate ester, which aided the chromatographic separation of the product derived from the 
minor aldol diastereomer 184 in the crude reaction mixture. 
 
Scheme 67 Proposed mechanism for the Evans-Tishchenko reduction of ketone 183161 
Methanolysis of the ester under mildly basic conditions (K2CO3, MeOH) revealed diol 189 as a single 
diastereomer in 86% yield from aldol adduct 183 (Scheme 68). This two-step sequence was reproducible 
on up to 10 g of substrate 183 though the reaction was reliant on the use of high purity SmI2. The catalytic 
loading could be reduced to as low as 5 mol% on larger scales which is attractive given the cost of the 
catalyst but required extended reaction times. The latter was found to be vital to achieve complete 
consumption of the starting material but it does not lead to deleterious side processes (e.g. retro-aldol).205 
 
Scheme 68 Comparison of both routes to diol 189 
The newly furnished 1,3-anti relationship of the hydroxyls was verified by the 13C NMR method of 
Rychnovsky.206 Empirical observations showed that acetonides originating from 1,3-diols form two 
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significantly different conformations controlled by the relationship between the parent hydroxyls (syn or 
anti). Anti-acetonides predominantly adopt a twist boat shape to avoid 1,3-diaxial clashes of non-
hydrogen groups whereas their syn counterparts exist in a more conventional chair conformation with 
equatorial placement of alkyl chains (Scheme 69). The latter puts the gem-dimethyl groups on the 
acetonide in two distinct environments, which can be identified by 13C NMR.  
 
Scheme 69 Acetonide 192 formation from the 1,3-diol 189 to confirm the anti stereochemistry at C23/C25. Structures 
193 and 194 show Rychnovsky’s reported values for the 1,3-anti and 1,3-syn diol relationships, respectively. 
Evans listed these characteristic resonances of acetonide carbons with 95% confidence limits which serve 
as reference values.207 NMR data for compound 192, prepared by treatment of diol 189 with 2,2-
dimethoxypropane and catalytic pyridinium p-toluenesulfonate (PPTS), was in good agreement with 
those predicted for the 1,3-anti product.  
As part of the planned protecting group strategy, the PMB group had to be migrated from the terminal 
position to the C23 hydroxyl. This could be accomplished by formation and later regioselective reductive 
opening of the ensuing PMP acetal. Subjecting diol 189 to oxidative conditions developed by Oikawa 
(DDQ) causes single-electron transfer (SET) oxidation of the benzylic position on the PMB ether and 
creates an electrophilic carbon, which is rapidly attacked by the nearby free hydroxyl in an anhydrous 
environment.208 However, there is a risk of acetal 195 overoxidation if excess DDQ is used which leads to 
an orthoester. Fink found such undesired side process to occur on a similar 1,3-diol substrate as part of 
the C28-C34 side chain synthesis.177  
A small (0.4 eq.) excess of the oxidant proved necessary to promote complete conversion of the starting 
material and did indeed facilitate the formation of significant amounts of byproduct 196 (Scheme 70). 
The yields of acetal 195 varied in the range of 59-67% and the material was isolated as an 
inconsequential mixture of epimers at the acetal stereocentre. Nuclear Overhauser effect (nOe) 
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correlations supported the conclusion that the ratio is in favour of the less axially congested (S)-195 in 
which the large groups are placed equatorially in a chair conformation. To circumvent the risk of 
overoxidation, DDQ was added in only substoichiometric amounts (0.9 eq.) in which case PMP acetal 
195 was isolated in 77% yield and any recovered starting material could be resubmitted.  
 
Scheme 70 Synthesis of PMP acetal 195 from diol 189 and nOe analysis 
Attempts to form the C25 TES ether by protecting the relatively hindered free hydroxyl with TESOTf 
were met with disappointment. The predominant component of the isolated mixture was bis-TES ether 
197, which may arise from Lewis acid-promoted PMP acetal opening as proposed in Scheme 71. 
Fortunately, the alcohol could be rapidly protected with the milder TESCl to afford the desired product in 
93% yield. 
 
Scheme 71 TES protection of the C25 hydroxyl  
Considering the difficulties encountered in the PMP acetal formation step, route B (Scheme 72) towards 
compound 190 was investigated as an alternative option. Despite the initial concerns regarding ester 
migration, TES protection of the C25 hydroxyl with TESOTf and reductive propionate cleavage with 
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suited to a site-specific cyclisation of the C23 PMB ether onto the nearby free alcohol and was thus 
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expected to be operationally more straightforward. Even though the yield was lower than anticipated 
(81%), one of the identified byproducts was PMP acetal which lacked the C25 TES group but this material 
could be easily recycled. Overall, the sequence from ester 188 to silyl ether 190 gave a 77% yield, which 
compares favourably to route A (66% over three steps) and was thus the preferred choice going forward. 
 
Scheme 72 Synthesis of TES ether 190 via route B 
The final step of the PMB migration was regioselective opening of the acetal 190 using DIBALH as the 
reducing agent. Mechanistically, steric bulk of the isobutyl groups favours coordination of the aluminium 
to the oxygen on the more exposed side of the acetal under kinetic control facilitating its opening to the 
oxocarbenium ion via an SN1 process (Scheme 73). The primary alcohol product 199 is then formed 
through intramolecular hydride delivery to the proximal electrophilic carbon centre.209 The undesired 
regioisomer 198 (ca. 10%) was also isolated but this material could be resubmitted to DDQ and the PMP 
acetal reformed to further increase the overall yield. Another side reaction observed in 5-10% yield was 
complete cleavage of the PMP acetal to reveal diol 200. This process is believed to arise from 
overreduction in presence of excess DIBALH which was required to achieve full conversion. Fortunately, 
diol 200 was easily recycled by bis-TES protection with TESOTf and hydrolysis of the labile primary 
silyl ether under mildly acidic conditions (90% over two steps). 
 
Scheme 73 Proposed mechanism of PMP acetal opening with DIBALH and recycling of byproduct 200 
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While all the byproducts could be identified and characterised, the crude mixture required laborious 
chromatographic separation of each component to retain good mass recovery. In an attempt to minimise 
the formation of byproducts, the reaction solvent, temperature and rate of DIBALH addition were varied 
to establish the optimal conditions for this step (Table 5). 
 
Table 5 Optimisation of PMP acetal 190 opening with DIBALHa 
Entry Reagent eq. Solvent Time / h Temperature Yield of 199 
1 3 CH2Cl2 1.5 0 °C 65%b 
2 2 + 1 CH2Cl2 2 0 °C 65% 
3 2.5 + 0.5 + 0.5 CH2Cl2 3 0 °C 73% 
4 3 CH2Cl2 2 -78 °C ® 0 °C 67% (75% BRSM) 
5 3 CH2Cl2 3 
-78 °C ® -30 °C 
® 0 °C 
79% 
6 3 TBME 1.5 0 °C 65%b 
7 2.5 + 0.5 TBME 2 0 °C 70% 
8c 3 TBME 3 0 °C ® rt no reaction  
a DIBALH used as a 1.0 M solution in hexanes. b Yield estimated by 1H NMR. c DIBALH used as a 1.0 
M solution in THF 
Invariably, a minimum of 3 eq. of the reducing agent were needed to push the reaction to completion 
every instance. Adjusting the rate of DIBALH addition (entries 1-3) caused no major changes, though 
gradual addition of the final aliquots generally gave a marginally higher yield. Despite the excess 
reductant in the mixture, the average reaction time at 0 °C was 2-3 hours, thus it came as no surprise that 
any substantial decreases in temperature precluded the reactivity altogether. Upon warming, slow onset of 
reaction was observed around -30 °C, which then proceeded to full conversion at 0 °C (entry 4). The 
observed increase in yield (entry 5) was attributed to suppressed PMB deprotection, which was a 
welcome improvement.  
Using a sterically congested ethereal solvent, e.g. tert-butyl methyl ether (TBME) can lead to a 
coordination cage being formed around aluminium. An effective increase in its size is expected to cause a 
stronger preference for attachment to the oxygen on the less hindered side of the acetal, increasing 
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regioselectivity. On the other hand, tighter coordination may also lower the reaction rate. Unexpectedly, 
this change made no difference to the overall outcome (entries 6-7) and using DIBALH solution in THF 
increased the bulk of both species to the extent that the reaction was suppressed entirely (entry 8). 
Finally, acetal opening was attempted with BH3×SMe2 as the source of hydride (Scheme 74). Unlike 
reductions with aluminium hydrides where cooling enables kinetic control, high temperatures are 
unavoidable to achieve good conversion rates. The reaction was slow at temperatures below 100 °C 
though any more substantial heating caused more rapid PMB cleavage. An initial yield of 73% on small 
scale (20 mg) was promising but could not be repeated on more than 100 mg of substrate 190. 
 
Scheme 74 Reductive acetal opening with BH3×SMe2 Lewis acid 
To this end, the transformation was best affected when DIBALH was added to the substrate at low 
temperature and then allowing the reaction mixture to gradually warm to 0 °C. Byproduct 201 lacking the 
C25 TES was observed very early on after warming from -78 °C and it was not possible to rationalise 
which factor caused its formation. Nevertheless, the protocol was easily scalable to up to 4 g of the PMP 
acetal 190 and enabled throughput with relatively minor losses of material. 
The synthesis of aldehyde 168 was completed by oxidation of the C21 hydroxyl. Unexpectedly, substrate 
199 was not tolerant of the standard Swern protocol170 which resulted in complete degradation of the 
alcohol. However, Dess-Martin periodinane (DMP)165 yielded the complete C21-C27 fragment in 92% 
yield with no observed b-alkoxy elimination even under prolonged storage. 
 
Scheme 75 Oxidation at C21 to complete the C21-C27 fragment 168 
One aim of the revised protecting group strategy requires an Alloc protecting group to be installed at C27. 
This would have to be introduced by removing the existing Bn ether once the complete carbon backbone 
of the C15-C27 southern fragment has been assembled. Due to the variety of functional groups present, 
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this may be a non-trivial step. If the debenzylation conditions were to prove too harsh for the C25 silyl 
group to be a TES, TBS is likely to be a more robust alternative. The synthesis of the TBS aldehyde 204 
from the known intermediate 195 very closely resembles the route to its TES counterpart 168 and is 
summarised in Scheme 76 below. 
 
Scheme 76 Synthesis of aldehyde 204 from PMP acetal 195 
3.3.4. Synthesis of C15-C20 b-Ketophosphonate 167 
Via Enzyme-Mediated Diester Desymmetrisation 
b-Ketophosphonate 167 can feasibly be accessed by a three-step procedure from the commercially 
available (R)-methyl-3-methylglutarate (137) (Scheme 77). 
  
Scheme 77 Retrosynthesis of the C15-C20 phosphonate 167 
As the C17 methyl stereocentre is fairly isolated, high enantiomeric excess (ee) of the C15-C20 fragment is 
imperative to prevent impurities arising from the minor C17 diasteromer from being carried through the 
steps after the HWE coupling with the C21-C27 aldehyde 168. Conveniently, Tamm has reported the 
synthesis of monoester 137 in estimated 90% ee by means of a pig liver esterase (PLE)-mediated 
desymmetrisation reaction of dimethyl 3-methylglutarate (205).210 Due to Woodrow’s reservations about 
the reproducibility of an enzyme-catalysed reaction the ultimate decision was to source chiral acid 137 for 
this project from a commercial supplier in the early stages of the aplyronine project. However, benign 
reaction conditions and readily available racemic starting material make a compelling argument for 
exploring a biocatalysed transformation as an alternative. 
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Woodrow’s concerns are to a certain extent founded. Relatively inexpensive crude porcine liver extract as 
a source of PLE is not only a mixture of isozymes in itself but it also consists of a multitude of other ester 
hydrolysing enzymes. This can induce considerable discrepancies in batches and unpredictable responses 
to variations in reaction parameters, which directly affects the product quality. On the other hand, the 
minimum guaranteed enantiomeric excess of the acid 137 from commercial sources (>80% ee) is also less 
than ideal.  
Fortunately, Lam and co-workers have optimised the protocol for the PLE-mediated hydrolysis of diester 
205 by observing the effects of temperature, organic co-solvent, concentration and pH.211 Due to high 
substrate specificity of the enzyme binding site (Scheme 78), common for biocatalysed transformations, 
the reaction terminates itself after one ester equivalent has been consumed. Enantiomeric purity has been 
shown to diminish when approaching complete conversion,212 though the excess of the desired isomer can 
be boosted by reacting the chiral acid with cinhonidine, recrystallisation of the resulting salt and cleavage 
of the amine to recover enantioenriched material.213 Recently, Fürstner has established that this protocol 
is practically achievable on large scale (>20 g of substrate 205 in a single batch) in good yield and 
excellent ee, carried out in a conventional organic chemistry laboratory setting.214 This was decided to be 
the most viable way to access multi-gram quantities of an otherwise expensive chiral building block. 
 
Scheme 78 Substrate scope of PLE in reactions of glutarate diesters 
Preparation of the substrate for the desymmetrisation reaction commenced with esterification of 3-
methylglutaric acid with acetyl chloride and methanol (89%). The following enzymatic transformation 
was carried out by incubating the enzyme and diester 205 in a pH 7 phosphate buffer with MeOH as the 
co-solvent (4:1). The reaction temperature was maintained at -10 °C and the rate of NaOH addition such 
that the pH was kept between 6.0 and 7.5 when monitored using a pH-stat. Gratifyingly, the reaction gave 
gradual, clean conversion to the enantioenriched monoester 137 in near quantitative yield (97%, 92% ee). 
The enantiomeric excess of 137 was analysed by chiral gas chromatography (GC) in comparison with the 
racemic sample, prepared by diester 205 hydrolysis with 1 eq. of KOH. It should be noted that due to the 
carboxylic acid moiety in the molecule, chromatographic separation without further derivatisation was 
found to be tricky and hence the ee value should be considered an estimate (>90%). 
To enhance the optical purity by kinetic resolution, crude product 137 was crystallised with (-)-
cinchonidine by heating in acetone at 40 °C, then left to precipitate overnight. The resulting co-crystals, 
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enriched in the (R)-isomer of the chiral acid, were collected by filtration and cinchonidine was cleaved 
using HCl to afford 137 in 96% ee by GC analysis. Owing to the scalability of the process, more than 25 
g of the chiral acid was produced over the course of the project. 
 
Scheme 79 PLE approach to the monoester 137 
The carboxylic acid was chemoselectively reduced using BH3·SMe2 (Scheme 80).215 Trace acid 
contaminants or generation of boronic acid upon MeOH workup can facilitate rapid intramolecular 
cyclisation of the hydroxyl onto the C19 carbonyl to form the volatile lactone byproduct 207. Switching to 
a mildly basic aqueous quench almost entirely suppressed this pathway and the reduction was 
successfully performed on up to 8 g of substrate 137. 
 
Scheme 80 Chemoselective reduction of the C15 carboxylic acid 137 
The C15-C20 fragment synthesis was completed by protection of the C15 terminus (TESCl, imidazole) and 
homologation of the C19 ester in a Corey-Kwiatkowski condensation (Scheme 81).167 Deprotonation of 
dimethyl methylphosphonate with nBuLi at -78 °C generated a lithium anion which underwent a single 
addition into the ester, attaching the phosphonate functionality for the HWE coupling to aldehyde 168. 
 
Scheme 81 TES protection of the C15 alcohol and homologation to the b-ketophosphonate 167 
As mentioned previously, the removal of the C27 benzyl group was forseen to be problematic due to the 
delicate protecting groups in place on the planned C15-C27 fragment. It was envisioned that should the C15 
TES-protected material fail to withstand the debenzylation, the more robust TBS protected intermediate 
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125 should provide a means to perform the deprotection without unnecessary protecting group 
manipulations. Its synthesis closely follows that for phosphonate 167. 
 
Scheme 82 Synthesis of the TBS-protected b-ketophosphonate 125 
Via Enantioselective Hetero-Diels-Alder Reaction 
While the investigations on the desymmetrisation route were underway, synthesis of the required 
fragment by enantioselective catalysis was explored as an alternative means to access phosphonate 167 
from achiral starting material. Lactone 207 was identified as a precursor to fragment 167 and could be 
obtained via a hetero-Diels-Alder (HDA) reaction of crotonaldehyde 211 and ethyl vinyl ether (212) 
(Scheme 83). Enantioselectivity is induced by a chiral catalyst which activates the aldehyde and imposes 
a facial constraint in the transition state. 
 
Scheme 83 Retrosynthesis of phosphonate 167 via the enantioselective hetero Diels-Alder reaction 
The methodology in question is based upon the tridentate Schiff base chromium(III) complex 213, 
introduced by Jacobsen216 which catalyses the inverse-electron-demand HDA reaction between the 
aforementioned aldehyde 211 and dienophile 212 (Scheme 84).217 
  
Scheme 84 Jacobsen’s synthesis of lactone 207 via HDA using chromium(III) catalyst 213 
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Despite acting solely through a single-point binding interaction to the carbonyl, impressive levels of both 
endo/exo- and enantioselectivity can be generated. Using a large excess (10 eq.) of the vinyl ether and 
addition of 4 Å molecular sieves (MS) affords dihydropyran 214 in 75% yield and 94% ee. Jacobsen 
showed that three further derivatisation steps lead can to the sought lactone 207.  
Insight into the basis for stereoinduction can be gained by inspecting the crystal structure of the 
catalyst,217 whose stable form is as a water-bridged dimer 215 with one terminal water ligand on each 
chromium. Kinetic studies imply that this dimeric structure is maintained throughout the catalytic cycle 
and the crucial role of molecular sieves is likely to involve abstraction of a water molecule to open a 
coordination site on the metal. By linking the absolute stereochemistry of the catalyst and product, a 
tentative transition state structure can be postulated as illustrated in Scheme 85. 
 
Scheme 85 Transition state proposal for the HDA reaction of ethyl vinyl ether and crotonaldehyde, catalysed by 213 
This seemed like an attractive way to accumulate large stocks of enantioenriched lactone 207, ready for 
later homologation to attach the phosphonate at C19. As has been mentioned in Section 3.4.1, this lactone 
had been previously considered an undesired byproduct of a the PLE route but was difficult to isolate 
after column chromatography of the crude mixture due to its volatility. 
Jacobsen reported a practical synthesis of the catalyst 213 starting from para-cresol.217 Friedel-Crafts 
alkylation of the phenol with 1-adamantanol and conc. H2SO4 to promote formation of the alkyl 
carbocation which attaches a single adamantanyl group in the ortho position (Scheme 86). Next, 
condensation of the phenol product 216 with formaldehyde and SnCl4 catalyst218 gives salicylaldehyde 
derivative 217 in 71% over two steps. This proceeds via an ortho-specific Friedel-Crafts step, followed 
by an Oppenauer-type oxidation after binding of a second equivalent of formaldehyde to the tin(IV) 
centre as depicted in Scheme 86.  
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Scheme 86 Synthesis of aldehyde 217 via Friedel-Crafts alkylation/acylation and Oppenauer oxidation 
The chiral portion of the ligand is incorporated in a condensation step between aldehyde 217 and 
(1S,2R)-aminoindanol 218 to form the crystaline imine 219 in 78% yield. Complexation of the metal ion 
with CrCl2 forms the air-stable Cr(III) complex 213 in near-quantitative yield.216 
 
Scheme 87 Formation of the Schiff base ligand (1S,2R)-213 and complexation with Cr(II) 
With the catalyst in hand, studies began to investigate the feasibility of the HDA. The sequence was first 
tested on a small scale (ca. 35 mmol of crotonaldehyde 211) with 5% catalyst loading and moderate 
excess (5 eq.) of ethyl vinyl ether (212, Scheme 88). After 3 days the product was distilled off under 
reduced pressure, though the catalyst was unfortunately not recoverable. This has been been attributed to 
the presence of 4 Å molecular sieves as even polymer-supported chromium(III) catalysts of similar 
structure have degraded in the reaction of the aforementioned starting materials.219  
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Scheme 88 Small-scale test synthesis of lactone 207 
The obtained material contained some residual aldehyde 211 beside the dihydropyran 214 and was 
subjected to hydrogenation with catalytic Pd/C. After stirring for 2 days to ensure complete reduction the 
solvent was once again removed from the reaction mixture by distillation, which also separated out the 
butanal byproduct 219. Next, hydrolysis of the mixed acetal was conducted in aqueous acetone and 
catalytic p-toluenesulfonic acid (TsOH) to afford a lactol which was oxidised to the corresponding 
lactone 207 with pyridinium chlorochromate (PCC). The overall yield of the four-step sequence was 47% 
and the optical rotation value was in excellent agreement with the literature,220 which was a testament to 
the superior enantioselectivity of the HDA. 
The remaining two steps to the C15-C20 phosphonate 167 were homologation at C19 and protection of the 
C15 hydroxyl. Addition of 2 eq. of lithiated dimethyl methylphosphonate produced exclusively lactol 221 
(Scheme 89). While it may be reasonable to expect formation of the open-chain alcohol 222 with an 
excess of the basic enolate in solution, stable lactol products are commonly observed in similar types of 
reactions.221 
  
Scheme 89 Homologation of the C15-C19 lactone 207 
The lactol can be opened by a strong, non-nucleophilic base (e.g. KH, KtBuO) under kinetic control 
which enables protection of the free hydroxyl in the same step. To this end, deprotonation with NaH, 
followed by addition of TESCl afforded the known phosphonate 167 in 85% yield (Scheme 90). 
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Scheme 90 Opening of the lactol 221 and silyl protection of the C15 hydroxyl 
The route appeared highly amenable to producing large quantities of material in a single batch. After 
preparing a fresh supply of the catalyst, the HDA was repeated on 0.5 mol of crotonaldehyde 211. 
Disappointingly, even after 14 days of reaction time, 1H NMR analysis still showed about 50% residual 
aldehyde. It is conceivable that the catalyst decomposed during this time as Jacobsen had concluded that 
the uncatalysed background reaction does not take place unless the mixture is heated under pressure.217 
Subsequent steps as per Scheme 88 (b-d) took several days’ reaction time in order for the starting 
materials to diminish to an acceptably low level. Even then, trace amounts made purification by 
distillation more cumbersome. Resubmission of unreacted substrates reduced throughput and major losses 
were incurred, making scale-up substantially less productive and more labour-intensive than foreseen. In 
hindsight, there are other downsides to this route, the most conspicuous one being the use of an expensive 
chromium(II) salt to form the catalyst which cannot be recovered as well as effectively six steps needed 
to form a single stereocentre at C17 although it does give the advantage of using achiral starting material 
(Scheme 91). After careful consideration and given the success of the PLE approach, the quest of 
building the C15-C20 fragment via enantioselective catalysis was abandoned. 
 
Scheme 91 Comparison of two investigated routes to phosphonates 125 and 167 
3.5. Fragment Coupling Towards the C15-C27 Aldehyde 161 
3.5.1. Synthesis of the C19 Methyl Ethers via HWE Olefination 
The next important advancement towards the southern fragment 161 was the HWE olefination between 
aldehyde 168 and the phosphonate coupling partner 167 under very mildly basic conditions.150 Studies 
previously carried out in our group provided ample precedent for use of a Ba(OH)2-mediated HWE 
reaction to yield complex enone structures in a highly (E)-selective manner on delicate substrates.  
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Deprotonation of the b-ketophosphonate 167 with Ba(OH)2 in anhydrous solvent, followed by the 
addition of aldehyde in 40:1 THF/H2O forged enone 223 in 85% yield and excellent trans-selectivity 
(>20:1 E/Z, 3JH20-H21 = 15.8 Hz), as none of the undesired (Z)-olefin was detected in the crude mixture by 
1H NMR (Scheme 92). 
 
Scheme 92 HWE olefination to form enone 233  
The C19 stereocentre was configured in a reagent-controlled 1,2-asymmetric reduction using the (S)-2-
Me-CBS catalyst 138 and BH3×SMe2 as the hydride source.168 The lack of stereochemical elements in the 
vicinity of the enone dictates that there should be very little inherent substrate bias towards either 
diastereomer in reactions with achiral reducing agents. CBS reduction can bypass this issue by employing 
a chiral catalyst which forms different steric interactions with the re and si faces of the carbonyl, 
favouring either one depending on the choice of catalyst. The mechanism153 commences with the 
coordination of the BH3×SMe2 to the nitrogen lone pair on the proline-derived oxazaborolidine to form a 
stable 1:1 adduct. This step activates the reducing agent and increases the Lewis acidity of the endocyclic 
boron. As a consequence, the catalyst coordinates to the carbonyl in a manner which minimises 
unfavourable steric interactions between the oxazaborolidine and the substrate (Scheme 93).  
 
Scheme 93 Transition state model for ketone reduction with (S)-CBS catalyst 138 
In the case of a,b-unsaturated ketones, the olefinic portion adopts the position of the large group (RL) in a 
boat-like transition state. This arrangement prevents the energetically unfavourable steric clash between 
the fully conjugated, coplanar C=C-C=O arrangement of the enone and the methyl group on boron 
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during hydride transfer. The absolute stereochemistry of the newly formed carbinol can thus be predicted 
from the transition state structure TS 8. 
Enone 223 was subjected to a catalytic amount of the (S)-2-Me-CBS catalyst 138 (10 mol%) and 
BH3×SMe2 at -20 °C before gradually increasing the temperature to -10 °C for 2 h (Scheme 94). Allylic 
alcohol 224 was isolated in 13:1 dr and near-quantitative yield (99%). Careful chromatography ensured 
that minimal quantities of the undesired (19S)-isomer were carried through to the next step. 
 
 
Scheme 94 CBS reduction of enone 223 to the allylic alcohol 224 
The fidelity of the stereochemical model was verified by the Mosher method (outlined in Section 3.3.2.). 
The corresponding (R)- and (S)-Mosher esters of alcohol 224 were synthesised by esterification with 
MTPA in presence of DCC and catalytic DMAP (Scheme 95). Finally, the C19 hydroxyl was methylated 
with NaH and MeI to yield methyl ether 227 (89%). 
 
Scheme 95 Mosher ester analysis and methylation of the C19 alcohol 224 
The same sequence of steps (HWE/CBS reduction/methylation) was used to prepare two more 
permutations of the C15-C27 fragment methyl ether. By replacing either component (or both) of the HWE 
reaction with their TBS analogues 125 and 204, giving three systems of different stability which can be 
investigated for the subsequent deprotection steps and therefore maximising the chance of success.  
Scheme 96 depicts the steps to methyl ethers 232 and 233. 
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Scheme 96 Synthesis of methyl ethers 232 and 233 
3.5.2. Studies of C15 and C27 Protecting Group Removal 
The success of the revised overall strategy heavily relies on selective removal of protecting groups at the 
C15 and C27 termini of the southern fragment in presence of potentially labile moieties, which is a non-
trivial undertaking. Deprotection at each end was tested separately to determine the optimal combination 
of the silyl ethers to provide the needed required stability in the debenzylation step and sufficient lability 
to selectively expose C15 later on. 
Arguably, Bn cleavage was the greater challenge of the two. The most commonly utilised methods for 
this transformation are cleavage with catalytic hydrogenation, Lewis acids, or single electron reductive 
methods. It is however vital to acknowledge the threat each one of them poses to one or more of the 
groups on the carbon backbone, highlighted in Figure 28.185 
 
Figure 28 Lability of protecting groups in 227, 232 and 233 under different deprotection conditions 
(a) Ba(OH)2, THF, rt, 1 h, then 168 or 204, THF/H2O (40:1), rt, 16 h; (b) (S)-138 (10 mol%), BH3⋅SMe2, THF, −20 ºC → −10 ºC,
2 h; (c) NaH, THF, 0 ºC, 1 h, then MeI, rt, 18 h
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The logical starting point for investigations was the bis-TBS ether 232 (Scheme 97) with the most robust 
combination of silyl groups out of the three prepared substrates shown above. Minimising the likelihood 
of concomitant silyl removal was expected to simplify the investigations into the selectivity for Bn over 
PMB ether. Raney Ni shows a degree of selectivity for Bn deprotection over olefin reduction in 
hydrogenation reactions compared to other common metal catalysts such as Pd/C. In addition, there is 
precedent for Raney Ni-catalysed Bn removal on a substrate containing a trisubstituted olefin.222 To probe 
the kinetic preference for this process over the C20-C21 double bond reduction on 232, the reaction with 
Raney Ni under an atmosphere of H2 performed and the presence of each functional group was monitored 
by 1H NMR. Unfortunately, reduction of the double bond occurred in preference to debenzylation, thus 
this was not a feasible option. 
 
Scheme 97 Failed attempts at C27 benzyl deprotection of 232 
Subjecting the substrate to trihaloborane Lewis acids at low temperatures presents another alternative 
method for debenzylation but poses the problem of potential side reactions arising from demethylation of 
the C19 methyl ether as well as cleavage of the silyl groups under the acidic conditions. Treatment of 232 
with either BBr3×SMe2 or BCl3×SMe2 resulted in a complex mixture showing primarily the loss of the C25 
TBS as well as the C19 methyl ether and even possible cyclised byproducts (Figure 29). This is a rather 
surprising result given the relative hindrance of this position compared to the seemingly more exposed 
primary TBS ether. The underlying argument may be the involvement of electron-rich aryl groups nearby 
through their coordinating ability that delivers the Lewis acid closer to the more hindered silyl ether. 
Therefore, substrate 233 with the C25 TES is likely to be even less suitable for this experiment. 
 
Figure 29 Observed or speculated debenzylation byproducts  
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Next, attention was turned to reducing methods using radicals, generated from sodium or lithium metal. 
One of the more common reagents for this application in even fairly complex systems is lithium 4,4’-di-
tert-butylbiphenylide (LiDBB), which a less powerful reducing agent than lithium metal itself.223 The 
moiety at risk in this case would be the electron-rich secondary PMB ether. Crimmins’ synthesis of 
brevetoxin A showcases a step where a very similar challenge was overcome using mild excess of LiDBB 
which cleaved the pendant Bn group on 234 in impressive 95% yield (Scheme 98).224 This example gave 
further evidence to support the deprotection of the benzyl group under these conditions. 
 
Scheme 98 LiDBB-mediated debenzylation step in the synthesis of brevetoxin A224 
Gratifyingly, treating substrate 233 with an excess of freshly prepared LiDBB solution in THF at -78 °C 
preferentially deprotected the C27 hydroxyl without any loss of the methyl ether or silyl groups and gave 
an 83% yield of 235 on small scale (Scheme 99). Crucially, no TES migration from C25 to the less 
congested primary hydroxyl occurred in the process.  
 
 
Scheme 99 Formation of LiDBB radical anion and trial Bn cleavage on 233 
With conditions for the C27 deprotection in hand, attention now turned to ascertaining the optimal 
protecting group at the C15 position that could be cleaved selectively while leaving the C25 TES group 
intact. The reasonable methods to choose from were fluoride-based nucleophilic reagents or hydrolysis in 
mild acid. The reaction in buffered HF×pyr proceeded with both silyl groups being cleaved at a similar 
rate from the onset of the reaction, returning predominantly the diol product 237. Catalytic para-
toluenesulfonic acid (PPTS) in CH2Cl2/MeOH resulted in very slow conversion and surprisingly, 
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preferential removal of the C25 protecting group, which is identical to what had occurred with boron 
Lewis acids. This result is in agreement with previous bases where the C25 TES appeared to be more 
labile upon treatment with Lewis acids such as BBr3. The use of buffered TBAF solution on the other 
hand removed the primary TBS first though the rate was very slow and led to appearance of other 
byproducts, possibly due to extended reaction time.  
 
Scheme 100 Unsuccessful TBS deprotection attempts on substrate 233 
As none of these options seemed feasible, let alone scalable, substrate 227 which features a more labile 
primary TES group became the last resort. With the silyl groups now exactly matched, it was anticipated 
that selective deprotection would be more facile and subject to purely the difference in sterics on each 
end. Using Fink’s conditions for hydrolysis of a primary TES group in presence of a secondary one,177 the 
C15 silyl ether was removed with mild acid (THF/AcOH/H2O, 5:2:1) to generate alcohol 236 in 95% yield 
(Scheme 101).  
 
Scheme 101 Successful C15 deprotection of the primary silyl ether on bis-TES ether 227 
With alcohol 238 in hand, a viable route to the C15-C27 aldehyde 161 was in sight. Small-scale 
debenzylation experiments with the bis-TES substrate 232 indicated no lability of either silyl group when 
treated with LiDBB. The insight gained in these deprotection studies was valuable and further studies 
focused on optimisating the process to ensure it was reproducible on scale to deliver the multi-gram of 
alcohol 239 required for the project (Figure 30). 
 
Figure 30 Desired product from LiDBB debenzylation of substrate 227 
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Starting with the LiDBB debenzylation, reaction parameters were varied to obtain a reproducible protocol 
for a multi-gram debenzylation of 227. The important factors given the rapid kinetics of the reaction even 
at low temperature were following: 
1. Reaction time 
This must be sufficiently long to account for the margin of error in run time due to addition of reagent at 
the beginning and to keep the window of preferential Bn over PMB cleavage as wide as possible. It 
should be noted that the reaction time is measured as the period immediately after complete addition of 
the reductant solution until the moment the mixture is quenched and exposed to air.   
2. Quantity of reductant used 
Many protocols involving LiDBB call for a gradual addition of aliquots as the substrate is consumed and 
the radical colour dissipates. However, the reagent is extremely air-sensitive and preparation using a 
literature protocol224 immediately before use may cause discrepancies in LiDBB concentration. Addition 
of an excess in a single portion ensures there is a sufficient amount of the reducing agent present to 
complete the transformation while also trying to avoid using excess quantities unnecessarily, especially 
on large scale. 
3. Concentration of reagent and substrate 
LiDBB must be prepared at reasonably low concentration to avoid precipitation and prevent addition hot 
spots when adding into a significantly cooler reaction mixture (-78 °C). However, running large scale 
experiements at high dilution is impractical and requires efficient stirring for uniform heat transfer. 
The first two factors are mutually beneficial in this process; the greater the excess of reagent, the faster 
the conversion rate. It is important to note that monitoring by TLC gives only a rough indication of 
reaction progression, thus it is not uncommon to overestimate the conversion and terminate the 
experiment prematurely. Table 6 shows the results of varying the amount of LiDBB. 
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Table 6 Small-scale studies of C27 deprotection on benzyl ether 227 
 
Entry 
Amount of 
LiDBB / eq. 
Reaction 
time / min 
Yield of 238 / % 
 
 1 5 15 80a  
 2 5 20 71b  
 3 10 5 83b  
 4c 20 5 71b  
 5c 45 10 64b  
a Yield determined by 1H NMR. b Isolated yield. c Run at 0.003 M concentration of 227 
(Reactions performed on 20-50 mg of substrate 227 at standard concentration 0.03 M) 
Entries 1 and 2 represent an acceptable reaction time frame with regards to accuracy of time measurement 
following reagent addition. The decrease in yield was attributed to the deprotection of the PMB group to 
give the undesired diol 239 which cannot be easily recycled. Entries 3-5 on the other hand, with a larger 
excess of LiDBB, reflect an impractically fast process albeit with respectable outcomes. To follow up on 
promising entries 1-2, the next parameter to investigate was the reaction time (Table 7). To minimise the 
reagent addition time at the start and thereby reduce the error in time measurement, the concentration of 
LiDBB was increased to 1 M with no detrimental effect. 
Table 7 Optimisation of reaction time 
Entry 
Reaction 
time / min 
Ratio of 227 : 238 : 239 / %a 
1 5 60 : 40 : 0 
2 10 50 : 50 : 0 
3 12 40 : 60 : 0 
4 14 33 : 64 : 3 
5 15 19 : 76 : 6 
6 17 10 : 70 : 20 
7 20 0 : 85 : 15 
8 25 0 : 77 : 23 
a Ratios determined by 1H NMR. 
There is a clear trend of gradual conversion over time, with the best results being obtained after around 
the 15-minutes mark (entry 5). The real test came with gram-scale experiments under the optimised 
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conditions. The results of the fruitful scale-up campaign, which produced more than 10 g of alcohol 238 
on up to 3 g of substrate (Scheme 102) are summarised in Table 8. 
Table 8 Results for gram-scale reactions 
 Entry Scale / g Reaction time / min Yield of 238 / %  
 1 1.00 15 67 (99% BRSM)  
 2 1.00 17 69 (94% BRSM)  
 3 3.00 18 77 (96% BRSM)  
 4 7.13 20 69 (89% BRSM)  
(Reactions performed at substrate concentration 0.03 M with 5 eq. LiDBB (1.0 M in THF) at -78 °C) 
 
Scheme 102 LiDBB debenzylation on 3 g of benzyl ether 227 
3.5.3. Completion of the C15-C27 Aldehyde 161 
With generous stocks of alcohol 238 in hand, the C27 terminus was now due to be protected with an 
orthogonal Alloc group. As mentioned before, this moiety is not stable in presence of strong 
nucleophiles.185 This is a potential concern since the union of the C15-C27 fragment to the northern portion 
of the macrocycle was planned to be carried out in a Ba(OH)2-mediated HWE reaction. 
To gain some insight into the stability of the allyl carbonate, model substrate 240 (Scheme 103) was 
prepared with the intention of subjecting it to the above HWE conditions. Fortunately, no Alloc cleavage 
was seen during prolonged treatment with Ba(OH)2 in aqueous THF. 
 
Scheme 103 Test of Alloc stability under Ba(OH)2 HWE conditions on a model substrate 240 
Allyl carbonate was then attached at the C15 terminus by subjecting primary alcohol 238 to excess allyl 
chloroformate in a mixture of CH2Cl2/pyr (1:1), which encourages precipitation of the formed pyr×HCl 
salt and precludes cleavage of the especially sensitive primary TES ether. The reaction was very rapid at 
LiDBB (1 M in THF)
THF, −78 ºC, 18 minTESO
15
PMBO OTES
OBn
227
27
OMe TESO
15
PMBO OTES
OH
238
27
OMe
(77%, 96% BRSM)
BnO OH
a
BnO OAlloc
no 
reaction(69%)
(a) allylOC(O)Cl, CH2Cl2/pyr (1:1), 0 ºC → rt, 18 h; (b) Ba(OH)2, THF/H2O (40:1), rt, 24 h
b
240
Chapter 3: Results and Discussion – Part I 
 
101 
temperatures above -20 °C and despite buffered conditions produced two major undesired byproducts 
(Scheme 104), which can be rationally accounted for. 
 
Scheme 104 Synthesis of allyl carbonate 241 and observed byproducts 242 and 243 
Primary alcohol 242 is a result of C15 deprotection of the desired product 241 which leaves the free 
hydroxyl prone to second carbonate formation. This pathway is alarming since excess allyl chloroformate 
can react at that terminus to yielding bis-Alloc material 243, which is not synthetically useful in the 
current route. Fortunately, after screening a variety of conditions it was observed that performing the 
reaction at lower temperature (-30 °C compared to 0 °C) both undesired side reactions were largely 
suppressed. Product 241 was formed cleanly in high yield (88%, 94% BRSM) on multi-gram scale of 
starting material 238. 
The remaining transformations required to complete the fragment were TES hydrolysis at the C15 
hydroxyl, followed by oxidation. Attempts to carry out this sequence as an efficient one-pot procedure 
under Swern conditions225 were met with disappointment and resulted in material degradation (Scheme 
105). Since the analogous experiment with Bn ether 227 directly afforded aldehyde 244 in 90% yield 
without difficulty it is assumed that the underlying issue is the lability of the Alloc moiety.  
 
Scheme 105 Attempted one-pot oxidation of the C15 TES to aldehyde 
Conditions for TES removal at C15 which had been investigated for substrate 227 (Section 3.5.2.) were 
revisited with the assumption that the Alloc group would be stable in presence of buffered TBAF or mild 
acid. The use of AcOH on large scale poses a practical issue as neutralising a large amount of acid with 
NaHCO3 is a slow process during which further deprotection with residual AcOH may still occur. If 
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NaHCO3 is added too late after the desired TES has been removed, overdeprotection can lead to the 
C15/C25 diol byproduct. For this reason, TBAF was tested as the first choice to probe the stability of the 
C25 TES under buffered conditions. Table 9 presents the outcomes of optimisation efforts, focused on 
controlling the rate while minimising the formation of byproduct 245.  
  
Table 9 Optimisation of C15 TES deprotection on substrate 241 
Entry Conditions Notes Reaction time Result 
1 TBAF/AcOH (1:1), rt 1.2 eq. TBAF 3 h 55% 242 + 20% 241 + 25% 245a 
2 
TBAF/AcOH (1:1) 
 0 °C ® rt 
1.1 + 0.5 + 0.5 eq. 
TBAF 5 h 64% 242
b 
3 
THF/AcOH/H2O 
(5:2:1), rt 
slow conversion 8 h 85% 242 b 
4 
THF/AcOH/H2O 
(2:2:1), rt 
 1 h 79% 242 + 11% 241b 
5 
THF/AcOH/H2O 
(2:2:1), rt 
2 x more 
concentrated 1 h 
49% 242 + 5% 241 
+ 24% 245b 
6 
THF/AcOH/H2O 
(2:2:1), rt 
undistilled (wet) 
AcOH 20 min mainly 245
a 
a Yield determined by 1H NMR. b Isolated yield. 
Entries 1-2 do not support the viability of TBAF in this process. The reaction is slow at temperatures 
below 0 °C and before the starting material is fully consumed, diol 245 starts appearing. Returning to 
hydrolysis with THF/AcOH/H2O required some tweaking of the solvent mixture before an acceptable 
ratio was found. Entry 3 mirrors the exact conditions from the early studies and as the proportion of THF 
was decreased (entry 4), the reaction time became shorter as well. Higher concentration increased the rate 
of bis-deprotection (entry 5) as did use of undistilled AcOH which in itself contains a non-negligible 
amount of H2O (entry 6). 
Testing the best conditions (0.1 M substrate in 2:2:1 THF/AcOH/H2O) on 5 g of TES ether 241 gave 81% 
yield (89% BRSM) after 3-4 h of reaction. Although undesirable, the resulting diol 245 can be 
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reprotected to give the bis-TES 241 which can then be resubmitted to the deprotection, further increasing 
the yield of product 242 (Scheme 106). 
  
Scheme 106 TES deprotection under optimised conditions and oxidation to aldehyde 161 
Finally, in light of the previous failed attempts at subjecting TES ether 241 to Swern conditions, 
oxidation of 242 at C15 was performed using Dess-Martin periodinane, which provided aldehyde 161 in 
85% yield. In summary, more than 7 g of the C15-C27 southern fragment 161 was synthesised in 14 steps 
and 15% yield from ethyl ketone 170 over the course of this project (Scheme 107). 
 
Scheme 107 Summary of the C15-C27 aldehyde 161 synthesis 
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3.6. Synthesis of the C1–C11 Iodide 160 
3.6.1. Retrosynthesis 
Synthesis of the C1-C11 iodide 160 follows a well-established synthetic route by Woodrow (Scheme 
108). The stereotetrad is constructed in a boron aldol/1,3-anti reduction sequence using a Roche ester-
derived ethyl ketone 128 and aldehyde 130. The diene moiety is formed in an alkyne-diene isomerisation 
with PPh3/PhOH and the ester group at C1 is masked as an allylic TBS ether. 
 
Scheme 108 Retrosynthetic analysis of the C1-C11 iodide 160 
3.6.2. Synthesis of Iodide 160 from Intermediate 247 
Stocks of the known diol intermediate 132 were prepared by Dr Mike Housden in 4 steps from (R)-Roche 
ester 126 (Scheme 109). A bis-TES protection was then carried out with excess TESOTf to afford 247 in 
80% yield. The work detailed from this point onwards is that of the author. 
 
Scheme 109 Summary of Housden's synthesis of bis-TES ether 247 
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The C11 alcohol could be selectively revealed by oxidative cleavage of the PMB group using DDQ. 
Mechanistically, this step proceeds via a series of single electron transfer (SET) steps to form a transient 
charge-transfer complex between the electron-donating aromatic ring on the substrate and the electron-
poor ring on the oxidant, followed by benzylic dehydrogenation (Scheme 110). 
 
Scheme 110 Proposed mechanism of DDQ-mediated PMB cleavage226 
Replacing the C7/C9 PMP acetal from the first-generation synthesis helped alleviate the issue of acetal 
migration or overoxidation in this step. PMB deprotection of the analogous bis-TES compound 247 with 
1.5 eq. DDQ in neutral (pH 7) conditions formed no detectable byproducts and smoothly furnished 
alcohol 248 (Scheme 111). The silyl ethers were not expected to be labile and pleasingly, no migration to 
the less hindered C11 position was observed. Alcohol 248 was formed in 92% yield, which was an 
improvement in material retention in comparison to the result on the analogous PMP acetal observed by 
Woodrow (81%, Section 2.3.1). 
 
Scheme 111 Elaboration of the C11 terminus on PMB ether 247 into alkyl iodide 249 
The alkyl iodide was installed under Appel-like conditions by stirring the primary alcohol with molecular 
iodine, PPh3 and imidazole.163 Next, the ester moiety at C1 was masked as an allylic TBS ether to prevent 
interference of the carbonyl in the following alkylation reaction with lithiated phosphonate 123. 
Reduction of the ester with excess DIBALH, followed by protection with TBSCl and imidazole forged 
160 in 95% yield over two steps (Scheme 112). Worryingly, iodide 160 was found to degrade upon 
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prolonged storage even at -20 °C, thus major stocks of material were held at the more stable preceding 
stage as alcohol 248. 
 
Scheme 112 Reduction of the C1 ester moiety and TBS protection of allylic alcohol 250 
3.7. Summary 
This chapter details the endeavours towards an improved synthesis of the C15-C27 southern fragment 161 
with efforts focused on refining the assembly of the C23-C26 stereotetrad and implementing the second-
generation protecting group strategy for macrocyclic core of the aplyronines (Scheme 113). These key 
aims had been reached owing to the power of titanium aldol methodology and perseverance with several 
iterations of protecting group alterations which taught us valuable lessons regarding their stability and 
compatibility. Additionally, two different methods of installing the C17 chiral centre were explored, which 
culminated in a viable supply strategy for the C15-C20 phosphonate 167. This new approach utilises 
racemic starting materials and is carried out via enzyme catalysis. Overall, the new route ultimately 
provided more than 7 g of the C15-C27 aldehyde 161 in 14 steps LLS (19 steps total) and 15% yield from 
ketone 170.  
 
Scheme 113 Summary of steps towards the C15-C27 sourthern fragment 161 
In addition, stocks of the C1-C11 iodide 160 were synthesised from the known intermediate 247 in 4 steps 
and 68% yield, harnessing the efficiency and exquisite stereocontrol of the boron aldol reaction which 
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forges the C7-C10 chiral centres (Scheme 114). Alignment of the protecting groups at C7/C9 with the 
newly designed macrocycle endgame ahead was predominantly straightforward, though observing 
degradation of iodide 160 upon prolonged storage was a crucial realisation prior to its scale-up and the 
following HWE reaction with aldehyde 161. This highly anticipated event and further steps truly put to 
the test the merits of our ideas and are presented in the next chapter. 
 
Scheme 114 Summary of steps to the C1-C11 iodide 160  
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Chapter 4 
Results and Discussion – Part II 
Synthesis of the C1-C27 Macrocycle 159  
4.1. Synthesis of C1-C27 Allylic TBS Ether 162 
4.1.1. Coupling of C12-C14 b-Ketophosphonate 123 with C15-C27 Aldehyde 161 
The challenging task of forging the C14-C15 trisubstituted olefin was intended to be carried out using 
Ba(OH)2-mediated HWE methodology as this had previously served well in the first-generation 
aplyronine synthesis (Scheme 115). As the southern C15-C27 fragment 161 was designed as the aldehyde 
coupling partner, the phosphonate moiety had to be appended to the C1-C11 iodide 160. This step must 
concomitantly homologate the carbon chain, which can be achieved in a single transformation by 
alkylation with the C12-C14 b-ketophosphonate 123 under the conditions developed by Grieco and 
Pogonowski.151 
 
Scheme 115 Linkage of the northern and southern fragments 160 and 161 via the C12-C14 123 b-ketophosphonate 
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Synthesis of the C12-C14 linker 123 entails the alkylation of the lithium anion of diethyl ethylphosphonate 
with ethyl acetate to attach the acetyl group. Deprotonation with nBuLi forms the lithiated species, which 
undergoes a single addition into the ester (Scheme 116). The product was isolated in 61% yield by 
distillation under reduced pressure and the process was highly amenable to scale-up, producing in excess 
of 15 g of fragment 123 in a single batch. 
 
Scheme 116 Synthesis of the C12-C14 fragment 123 by acetylation 
Alkylation at C11 requires the b-ketophosphonate 123 to act as a nucleophile at the less hindered g-
terminus. Due to negative charge stabilisation at C14, g-deprotonation can only be achieved once the most 
acidic proton has been removed first. Treatment of 123 with sodium hydride in THF produces an 
insoluble monoanion, which is subsequently metallated with nBuLi at -78 °C to generate a pale yellow 
solution of the dianion (Scheme 117), ready to react with the iodide. 
 
Scheme 117 Formation of the dianion of 123 by double deprotonation 
The reaction was expected to proceed with virtually no stereoselectivity at C14 to produce a 1:1 mixture of 
diastereomers 253 at that position. However, a regioisomeric alkylation product 254 (Scheme 118) 
constituted a significant component (20-30%) of the isolated product mixture and the selectivity had 
previously been found to be highly dependent on the nature of the electrophile (Scheme 118).162 The 
branched regioisomer 254 is inseparable by chromatography, though it does not interfere with the 
subsequent HWE step due to the lack of a-protons on the phosphonate and can thus be carried through 
the olefination step. Nevertheless, the unproductive pathway causes unnecessary loss of advanced 
material and every effort must be made to prevent it. 
 
Scheme 118 Observed mixture of products in the alkylation reaction of iodide 160 
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Housden’s preliminary work towards the alkylation of the bis-TES iodide 160 indicated that no reaction 
occurs below 0 °C. The addition of hexamethylphosphoramide (HMPA) with the intention of 
deaggregating the dianion did not affect the outcome. The product distributions of regioisomers 253 and 
254 (Scheme 119) varied in the range of 2:1 up to 4:1 by 1H NMR analysis. The highest yield (85%, 3:1 
253:254) was obtained with 50-fold excess of the dianion. This was clearly not a practicable solution on 
scale but it could be replicated by reverse addition of the iodide 160 into a solution of the anion. 
 
Scheme 119 Alkylation of iodide 160 with phosphonate 123 
Optimisation efforts by the author are presented in Table 10. Standard conditions were taken to be 50 mg 
160, 6 eq. 123, 7 eq. NaH, 6 eq. nBuLi, THF, 0 °C (entries 1-3) where full conversion as judged by TLC 
was achieved after 1.5-2 h reaction time. It became immediately apparent that the reaction yields and 
selectivities drop progressively with increasing scale. Reducing the speed of addition, either adding the 
iodide into the dianion (entry 4) or vice versa (entry 5) produced similar yields and it was not possible to 
account for the remaining mass balance.  
One potentially important parameter was the reaction solvent. Replacing THF with a different ethereal 
solvent could change the aggregation and hence the reactivity of the dianion. By this logic, a larger 
solvation cage around the metallated species should encourage reaction through the less hindered g-
terminus, though it may also preclude any alkylation entirely. This was indeed the case when using 
TBME (entry 6), and, more surprisingly, 1,2-dimethoxyethane (DME, entry 7), which was expected to 
more strongly bind the lithium cation and increase the dianion nucleophilicity. Even warming both 
reactions to room temperature and adding HMPA only returned recovered substrate. Conducting the 
experiments in Et2O (entries 8-11) was met with slight success, though there was no noteworthy 
improvement. Increasing the equivalents of HMPA (entries 9-10) gave a more favourable isomer ratio 
but also diminished the yield.  
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Table 10 Screening of conditions for alkylation of iodide 160 
Entry Variation from standard conditions Solvent Ratioa (253:254) Combined yield 
1 / THF 4.6:1 86% 
2 400 mg 160 THF 3.0:1 75% 
3 1.00 g 160 THF 2.7:1 68% 
4 syringe pump addition over 30 min THF 3.4:1 70% 
5 dianion added to 160 by syringe pump over 30 min THF 5.5:1 66% 
6 0 ° C ® rt, 100 µL HMPA TBME no reaction 
7 0 ° C ® rt, 100 µL HMPA DME no reaction 
8 / Et2O no reaction 
9 2 eq. HMPA, -78 ° C ® -30 ° C Et2O 1.5:1 66% 
10 6 eq. HMPA, -78 ° C ® -30 ° C Et2O 2.2:1 56% 
11 300 mg 160, 50 eq. HMPA Et2O 3.3:1 54% 
a Determined by 1H NMR analysis of the isolated product mixture. 
One final attempt at upgrading the selectivity was to perform a modified alkylation. Instead of forming 
the b-ketophosphonate 253, the iodide can be homologated with EtOAc, followed by a single addition of 
the lithiated diethyl ethylphosphonate into the resulting ester 255 (Scheme 120). This would add a step to 
the longest linear sequence but on the other hand completely prevent the formation of the undesired 
regioisomer 254 by virtue of the mechanism. 
 
Scheme 120 Alternative sequence from iodide 160 to phosphonate 253 and the observed byproduct 250 
What seemed like a relatively straightforward transformation ultimately lead to none of the desired ester 
255. No conversion was observed below 0 °C even with HMPA additive and at room temperature. In 
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each case the TBS-deprotected material was the only recovered product. This option was not pursued 
further and instead the attention was turned on the more pressing C1-C14 phosphonate 253 linkage to the 
C15-C27 aldehyde 161 with the intention of removing the undesired regioisomers at this stage. 
The mechanism of a HWE olefination is illustrated in Scheme 121. Construction of a trisubstituted olefin 
in an HWE reaction is generally more challenging but the Ba(OH)2 variant of this methodology has been 
applied to highly functionalised substrates in the syntheses of numerous natural products. Due to the 
similar complexity of both components, the aldehyde to phosphonate ratio was kept as close to 1:1 as 
possible, also taking into account the presence of the unreactive regioisomer 254. 
 
Scheme 121 The origin of selectivity in the Horner-Wadsworth-Emmons olefination with aldehyde 161 and b-
ketophosphonate 253 
b-Ketophosphonate 253 (1.05 eq. of 253, used as a mixture with 254‡) was deprotonated with Ba(OH)2 in 
anhydrous THF followed by the addition of aldehyde 161 in aqueous THF (THF/H2O, 40:1) which forged 
enone 251 in 96% yield. No undesired (Z)-isomer was detected in the 1H NMR of the crude product, 
indicating superb E/Z selectivity (>20:1). The aldehyde was largely consumed in the first 24 h 
(determined by TLC analysis) and although the progress was slower on larger scales (up to 1 g of 
aldehyde 161), extended reaction times did not negatively impact the outcome. Any unreacted southern 
fragment 161 was easily separated from the product 251 by chromatography on silica and recovered. 
Pleasingly, no loss of the allylic carbonate functionality at C27 occurred.  
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This result constitutes the most efficient and selective method of constructing the C14-C15 trisubstituted 
double bond to date. Kigoshi’s publication on a second-generation route to aplyronine A112 presents an 
improvement in the NHK coupling step as part of their overall strategy, yet the need to simultaneously 
introduce the C13 chiral centre reduces the overall yield due to the more challenging nature of the 
asymmetric reaction variant. 
 
Scheme 122 HWE reaction between the northern and southern fragments 161 and 253 
4.1.2. Elaboration of Enone 251 
The final, C13 allylic stereocentre was installed in an analogous manner to C19 on the southern fragment, 
using the enantiomeric (R)-Me-CBS oxazaborolidine 140 in stoichiometric quantities to ensure complete 
conversion and prevent unwanted hydroboration of the alkenes in the molecule. Alcohol 256 was 
generated in an excellent 93% yield and 15:1 dr. 
 
Scheme 123 CBS reduction of the C13 carbonyl and synthesis of Mosher esters 257 and 258 
Mosher ester derivatives 257 and 258 were synthesised to confirm the absolute configuration, however, a 
lack of distinct signals near the C13 oxymethine gave an inconsistent result in the analysis. Due to the 
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structural similarity to the analogous allylic alcohol from the first-generation route (Figure 31), the new 
stereocentre was assumed to be (13S) without further investigation. 
 
Figure 31 CBS reduction substrate from the first-generation Paterson synthesis of the aplyronine 
Methylation of the newly formed allylic alcohol under previously established conditions (NaH, MeI) was 
predicted to proceed without difficulties. Employing sodium hydride as a strong, non-nucleophilic base 
should facilitate irreversible deprotonation of the free hydroxyl at C13, which can then be alkylated by 
excess electrophile to produce the methyl ether.  
This was unfortunately not the case as the starting material was converted into unexpected new products 
by TLC analysis, of which four main components were isolated (Scheme 124). Beside the desired methyl 
ether 162 the compounds can be attributed to the cleavage of Alloc group which first yields alcohol 259, 
followed by either methylation at C27 or migration of the C25 TES group onto the less hindered primary 
hydroxyl.  
 
Scheme 124 Multiple byproduct formation in the methylation of alcohol 256 with NaH and MeI 
Upon prolonged storage, sodium hydride reacts with atmospheric moisture and is hydrolysed into 
nucleophilic sodium hydroxide, which is a threat to the allyl carbonate group. Despite employing strictly 
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anhydrous conditions and using a new bottle of sodium hydride the byproduct formation could not be 
prevented. It became apparent that a screen of alternative methylation conditions would be required in 
order to complete this transformation in a high yielding and reproducible manner. 
Model substrate 240 was revisited as a suitable substrate to first establish which combination of bases and 
methylating agents would leave the Alloc intact before optimising for higher yields (Table 11). Lee’s 
conditions (NaH, MeI, 0 °C ® rt) in entry 1 served as a reference for the rate of deprotection and 
lowering the temperature (entry 2) gave a similar outcome. Changing the solvent to N,N-
dimethylformamide (DMF) (entries 3 and 4) still facilitated carbonate removal and also promoted rapid 
methylation of the resulting alcohol, possibly as a consequence of poor oxyanion solvation and greater 
nucleophilicity towards MeI. Gratifyingly, prolonged treatment with either Meerwein salt (Me3O×BF4) or 
methyl triflate (MeOTf) (entries 5-8) returned only recovered starting material suggesting that using a 
milder base may prove beneficial. 
 
Table 11 Screen of methylation conditions on model substrate 240 
Entry Base and methylating agent Solvent Temperature Major product 
1 NaH, MeI THF rt 262 
2 NaH, MeI THF 0 °C 262 
3 NaH, MeI DMF rt 263 
4 NaH, MeI DMF 0 °C 263 
5 
Meerwein salt, 
Proton-spongeÒ 
CH2Cl2 rt 240 
6 
Meerwein salt, 
Proton-spongeÒ 
CH2Cl2 0 °C 240 
7 MeOTf, di-tBu-pyr CH2Cl2 rt 240 
8 MeOTf, di-tBu-pyr CH2Cl2 0 °C 240 
(Reactions performed on 5 mg of substrate 240 at 16-24 h reaction time) 
To lend further confidence to the new conditions a second model system was investigated which would 
match the more sterically congested stereocentre at C13. 265 was synthesised in an analogous manner to 
the C1-C27 substrate 256 using a simple Alloc-protected aldehyde 264 (derived from octane-1,8-diol in 
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two steps) and b-ketophosphonate 123, which underwent an HWE reaction and subsequent CBS 
reduction (Scheme 125). Note that all yields are unoptimised. 
 
Scheme 125 Synthesis of a model methylation substrate 265 
With allylic alcohol 265 in hand, methylation experiments were carried out on small scale to monitor 
progression and any additional side reactions over time (Scheme 126). 10 eq. of both Meerwein salt and 
Proton-spongeÒ gave clean and rapid conversion within the first few hours. Unfortunately, it proved 
difficult to push the reaction to completion. Despite the addition extra portions of the Meerwein reagent, 
the crude mixture consisted of 40% recovered alcohol 265 after 2 days at room temperature, judging by 
1H NMR analysis. Alternatively, using 10 eq. of MeOTf as the electrophile in presence of di-tBu-pyridine 
base gave near-quantitative conversion but with a significantly longer reaction time (3 days). 
  
Scheme 126 Methylation studies on model alcohol 265 
MeOTf was a highly promising option on the model system, yet gave somewhat disappointing results on 
the C1-C27 substrate 256 (Table 12, entries 1-3). Conversion stalled even at mildly elevated temperature 
(30 °C) or prolonged reaction times and appearance of unidentified byproducts was clearly seen by TLC. 
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Table 12 Methylation of the C1-C27 allylic alcohol  
Entry Base and methylating agent Temperature Reaction time Isolated yield 
1a 
MeOTf (10 eq.), 
di-tBu-pyr (20 eq.) 
rt 24 h 58% (95% BRSM) 
2a 
MeOTf (15 eq.), 
di-tBu-pyr (20 eq.) 
30 °C 24 h 70% 
3a 
MeOTf (15 eq.), 
di-tBu-pyr (20 eq.) 
30 °C 3 days 69% 
4a Meerwein salt (20 eq.), Proton-spongeÒ (20 eq.) rt 24 h 72% (100% BRSM) 
5 Meerwein salt (5 eq.), Proton-spongeÒ (5 eq.) rt 7 h 69% (77% BRSM) 
6 Meerwein salt (5 eq.), Proton-spongeÒ (5 eq.) rt 16 h 78% (85% BRSM) 
7b Meerwein salt (10 eq.), Proton-spongeÒ (10 eq.) rt 16 h 74% 
8b Meerwein salt (7 eq.), Proton-spongeÒ (7 eq.) rt 16 h 76% 
a Reactions performed on more than 50 mg 256. b Reactions performed on more than 1 g 256. 
Meerwein methylation proved to be the safer option and produced more consistent results. Using a large 
excess of reagent on small scale (entry 4) indicated that the majority of 162 was produced in the first 1-2 
hours and the substrate was never fully consumed. Other optimisation experiments were aimed towards 
reducing the excess of the electrophile and finding the optimal reaction time (entries 5 and 6) Despite 
investigating several conditions the yields remained uniform across a range of scales up to more than a 
gram of alcohol 256 (entries 7 and 8). Over the course of this project, more than 3 g of compound 162 
were prepared.  
With plentiful stocks of the C1-C27 methyl ether 162 in hand, the planned sequence continued by 
revealing the macrolactonisation sites in a single oxidative step. Firstly, PMB cleavage at the C23 
hydroxyl was anticipated to occur without difficulty. The second transformation, perhaps one of the most 
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elegant features of the Paterson strategy, was the conversion of the allylic TBS moiety into the 
corresponding aldehyde in a DDQ-mediated oxidation. 
This serendipitous discovery in the early stages of the aplyronine project was later identified to be a more 
general transformation for electron-rich silyl ethers.164 The mechanism commences with substrate 
oxidation at the allylic position and hydrogen radical transfer to the quinone. The resulting intermediate is 
stabilised by the silyloxy group, which leaves the Si-O bond weakened and subject to facile cleavage to 
reveal the carbonyl (Scheme 127). As with other oxidative processes in presence of DDQ, the mechanism 
likely involves SET steps, indicated by the distinctly coloured charge-transfer complex. 
 
Scheme 127 Mechanism of allylic TBS ether oxidation to aldehyde with DDQ 
Methyl ether 162 was treated with DDQ in CH2Cl2/pH 7 buffer (1:1) at 0 °C and gradual oxidation of 
initially the allylic, followed by the benzylic methylene was observed to afford aldehyde 163 in 82% 
yield as illustrated in Scheme 128. The preferentially allylic oxidation was confirmed by the isolation of 
the intermediate enal 267 with with the PMB group still intact. 267 could be separated from the crude 
mixture and subjected to further deprotection to yield the desired aldehyde 163 though it was generally 
carried out as a one-step double transformation. The reaction is rapid, often complete within 10 min. 
 
Scheme 128 One-step DDQ-mediated double deprotection and C1 oxidation to yield dienal 163 
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Adding further portions of DDQ (0.5-1 eq.) to achieve full double deprotection must be done with great 
care to avoid the formation of overoxidation byproduct, tentatively assigned to be 268. The supporting 
argument for it is the loss of the C19 OMe signal in the 1H NMR and a downfield shift of the H20/H21 
olefinic peaks, which can be attributed to the undesired oxidation of the allylic methyl ether to the 
corresponding enone (Figure 32). No such occurence was observed for the C13 methyl ether. 
 
Figure 32 Enone overoxidation byproduct 268 
Another unexpected event was occasional diminishing of signals for the H2-H5 protons in comparison to 
other olefinic peaks (Figure 33). 
 
Figure 33 Olefinic region of the 1H NMR spectrum of a mixture of aldehyde 163 an an unidentified byproduct, 
lacking H2-H5 protons 
This observation was particularly puzzling as no other distinct additional protons appeared and this was 
not observed in the spectrum of the preceding compound 162. The byproduct was to some extent 
separable by column chromatography, though it was not possible to isolate it as a single compound and 
was thus never fully characterised. One hypothesis is that the electron-poor nature of the dienal may 
cause the moiety to become light-sensitive or susceptible to reaction with radicals. PMB removal with 
DDQ undergoes two SET steps and may inadvertently facilitate other radical-mediated processes. Similar 
issues have been encountered in the Paterson synthetic efforts towards the total synthesis of hemicalide.227 
Light sensitivity was probed by exposing the solution of compound 163 in CDCl3 to sunlight and 
monitoring the presence of the peaks in question by 1H NMR over time. The rate of diene signal 
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disappearance was slow over several days and it was not clear whether this was due to UV exposure or 
storage at room temperature. Ultimately, the most effective method of avoiding this unwanted side 
process was carrying out the transformation in the absence of light, the addition of DDQ in sub-
stoichiometric portions and with minimal excess, keeping the reaction time as short as possible and the 
temperature at 0 °C. 
The seco-acid for the macrolactonisation can be furnished by chemoselective oxidation of the C1 
aldehyde precursor under Pinnick conditions.169 A general mechanism for this process is depicted in 
Scheme 129. In the mildly acidic, dihydrogenphosphate-buffered reaction medium, sodium chlorite 
(NaClO2) is converted into chlorous acid (HClO2). This species is thought to be the active oxidant, which 
forms an adduct with the aldehyde and facilitates hydride abstraction in a pericyclic transition state. 
Products of this step are the corresponding carboxylic acid and hypochlorous acid (HOCl). The latter is a 
highly electrophilic byproduct, which can either react with free chlorite ions (ClO2-) or with any olefins 
to give a halohydrin. For this purpose, 2-methyl-2-butene is added in excess as a HOCl scavenger. 
 
Scheme 129 Mechanism of the Pinnick oxidation 
When aldehyde 163 was subjected to the mixture of Pinnick reagents at room temperature, gradual 
conversion into the ensuing seco-acid 164 occurred in excellent yield (96%) as shown in Scheme 130. 
The reaction often stalled and additional oxidant was needed before all starting material was consumed. 
An important caveat to mention is that more 2-methyl-2-butene must also be added before further 
portions of NaClO2 to prevent the formation of byproducts. As was the case with the aldehyde formation 
step, the H2-H5 proton signals were seen to diminish if this protocol was not followed.  
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Scheme 130 Pinnick oxidation of dienal 163 to produce seco-acid 164 
While it may seem convenient to attribute the changes in the diene to the reactive nature of the HOCl 
byproduct, there are other more electron-rich olefins present, which should in theory attack HOCl 
preferentially, though they seemingly remained unaffected (as judged bt 1H NMR analysis). The seco-
acid 164 was generally found to be suitably pure after a simple aqueous work up and could be used in the 
macrolactonisation without further purification. Due to the high solubility of the carboxylic acid in the 
aqueous phase it proved tricky to fully wash out the residual tBuOH. Column chromatography enabled 
clean separation of any unwanted residues and byproducts, though this incurred some loss of material, 
which is likely a consequence of the polar acid being partially retained on the silica. 
4.2. Macrolactonisation and Formal Second-Generation Total Synthesis 
With the required seco-acid 164 in hand, the pivotal site-specific macrolactonisation could be attempted. 
There is still a lack of extensive methodological studies investigating the optimal conditions to apply to a 
particular substrate due to precious nature of the intermediates which are usually subjected to 
macrocyclisation.228 The initial method of choice here was the Yamaguchi protocol as this previously 
gave the best result in forming the C1-C27 macrocycle 121 (Section 2.3.3.).  
Substrate 164 was first activated at the carboxylic acid through formation of a mixed anhydride with 
superstoichiometric 2,4,6-trichlorobenzoyl chloride (TCBC, 10 eq.) and Et3N (20 eq.) in THF in the 
absence of light (Scheme 131). The latter was a precautionary measure to minimise further disappearance 
of the H2-H5 protons in the delicate dienoate. The resulting anhydride 269 was diluted with PhMe and 
added to a solution of DMAP in PhMe. By keeping the addition rate low and dilution high, the risk of 
unproductive oligomerisation occurring instead of intramolecular attack was kept at a minimum.  
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Scheme 131 Activation of the C1 carbonyl towards nucleophilic attack through the mixed anhydride 269 
Beside the expected macrolactone 165, several unidentified byproducts were isolated from the crude 
mixture. Their predominant distinguishing features by 1H NMR were substantial loss of the H2-H5, H7 
and H9 protons. In addition, some of the mass balance was thought to consist of unwanted oligomeric 
species. This conclusion is based on the characteristic shift of the C23 hydroxyl to the ester methine region 
in the 1H NMR whereas other peaks, particularly in the olefinic range, remained aligned with the 
spectrum of the open-chain seco-acid substrate 164. The lack of more obvious shifts in that region is very 
much unlike the major spectral changes observed for cyclic product 165. The loss of H7 and H9 signals is 
more difficult to rationalise, particularly as both TES groups in those positions remained intact. This 
occurred particularly frequently at temperatures upwards of 50 °C and prolonged reaction times. Gentle 
heating just above ambient temperature (30 °C) was tolerated but did not greatly improve the outcome, 
yielding around 40% of product 165 at best. 
In an attempt to suppress oligomerisation, for Shiina macrolactonisation229 using 2-methyl-6-nitrobenzoic 
anhydride (MNBA, Figure 34) to activate the carboxylic acid was tested as an alternative, albeit without 
much success. Starting material was being consumed but only trace product was detected amongst a 
complex mixture of byproducts. This was clearly not a satisfying solution either and attention was turned 
back to improving the Yamaguchi conditions as this had shown initial promise. 
 
Figure 34 Structure of MNBA 
A relevant factor was found to be the purity of seco-acid 164. In most cases, the crude product of Pinnick 
oxidation appeared sufficiently pure to be carried through the next step. Pleasingly, when the carboxylic 
acid was purified by column chromatography prior to the Yamaguchi step, the yield increased to 65-70% 
for the macrolactonisation step alone (Scheme 132). In this particular case, addition of the anhydride to 
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DMAP in PhMe could be performed either fairly rapidly (< 1 h) or over an extended period of time (12 h) 
and produced a very similar outcome.  
 
Scheme 132 Macrolactonisation of seco-acid 164 under Yamaguchi conditions 
The very last step towards the known macrocyclic intermediate 159 was the Alloc deprotection at C27 
with a source of Pd(0). Mechanistically, this proceeds via a oxidative addition of Pd(0) into the allylic 
carbonate to form a Pd(II) p-allyl complex (Scheme 133). In the process, the carbonate anion is liberated 
and can undergo spontaneous decarboxylation to reveal the primary alcohol. Pd(II) can be reduced by the 
attack of dimedone on the p-allyl species, which regenerates Pd(0) and closes the catalytic cycle. 
  
Scheme 133 Mechanism for Pd(0)-catalysed Alloc deprotection 
Protected macrolactone 165 was treated with catalytic tetrakis(triphenylphosphine)-palladium(0) 
(Pd(PPh3)4) in THF in the absence of light and with dimedone as the allyl scavenger (Scheme 134). The 
reaction was complete after stirring at room temperature for 1 h and alcohol 159 was isolated in excellent 
yield (99%). Gratifyingly, NMR spectra of 159 were in complete agreement with those previously 
reported.108 This achievement marks the finish line of the second-generation formal total synthesis of the 
aplyronines by meeting one of the key goals set out at the beginning of this work. 
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Scheme 134 C27 Alloc deprotection of macrolactone 165 with catalytic Pd(0) 
4.3. Summary 
Chapter 4 concludes the final, most challenging part of the campaign towards a sustainable supply of the 
aplyronine macrocycle. The strategic features of the revised strategy introduced new hurdles to overcome 
and while not every step could be perfected in the given time frame, none of the difficulties proved to be 
unsurmountable.  
The Paterson strategy for the assembly of the C1-C27 backbone once again served well to unite two 
complex fragments in an excellent yield and selectivity, thereby paving the way towards the planned 
endgame (Scheme 135). Several late-stage intermediates containing the C1-C5 dienal were unexpectedly 
delicate and it was difficult to ascertain the underlying reasons for this. Perhaps the most pleasant surprise 
during this study was the largely dormant behaviour of the Alloc protecting group, which had been 
introduced with much scepticism as there are very limited examples of its use in a multi-step synthesis of 
a complex natural product. The only unexpected difficulty pertaining to this decision was observed in the 
C13 methyl ether formation, a generally trivial transformation. 
After significant efforts to synthesise the seco-acid 164 for the site-specific macrolactonisation and the 
orthogonal unmasking of the C27 position, these reaction indeed proceeded as planned. The first-
generation route was hence intercepted at intermediate 159, thereby eliminating several time-consuming 
steps after macrocycle closure. Following the new sequence, alcohol 159 was prepared in 21 steps and 
6% yield from (S)-ethyl ketone 170.  
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Scheme 135 Summary of the fragment coupling and steps towards the C1-C27 macrocycle 159
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Chapter 5 
Results and Discussion – Part III 
C28-C34 Side Chain Synthesis and Linkage to the Macrocycle 
5.1. Synthesis of C28-C34 Side Chain 118 
5.1.1. Retrosynthesis 
Synthesis of the third-generation ketone coupling partner 118 had been devised by Fink (as presented in 
Section 2.3.4). In the process of replenishing stocks of 118 for the purposes of the aplyronine campaign, 
the 1,3-syn-3,4-syn C29-C32 stereotetrad was constructed by utilising titanium aldol reaction as the only 
deviation from the original sequence. This alteration was inspired by the success of this methodology in 
the earlier stages of this project (as seen in Section 3.3.3.). The carbon atom bearing the N-
vinylformamide functionality was appended under modified Wittig conditions, followed by isomerisation 
to the (E)-olefin.  
 
Scheme 136 Retrosynthetic analysis of the C28-C34 ketone 118 
5.1.2. Preparation of the N-Vinylformamide from PMB Ether 274 
Side chain scale-up, undertaken by the author, commenced from stocks of material which had been kindly 
provided by another Paterson group member working on the aplyronine project, Talia Pettigrew. For 
completeness, her contribution is summarised below. 
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Chiral ketone 128 was prepared via the familiar sequence (seen in Section 3.3.2.), this time starting from 
the (R)- enantiomer of commercially available Roche ester 126 (Scheme 137). The hydroxyl was 
protected with PMBTCA and catalytic acid (PPTS) before the ester functionality was converted into the 
corresponding Weinreb amide with N,O-dimethylhydroxylamine hydrochloride and iPrMgCl. Carefully 
controlled single addition of ethylmagnesium bromide to amide 272 affored ethyl ketone 128 in 72% 
yield over three steps, ready for the following aldol condensation. 
 
Scheme 137 Synthesis of the (R)-Roche ester ethyl ketone 128 by Pettigrew 
The pre-existing stereocentre on ketone 128 exerted good levels of enantioselectivity in the aldol reaction 
with excess acetaldehyde in presence of (iPrO)TiCl3 Lewis acid, forging b-hydroxyketone 149 with an 
all-syn stereotriad in an isolated yield of 85% yield and 11:1 dr. As expected, the electron-rich PMB 
group aids the stereoinduction by imposing a chelated transition state (TS 9), facilitated by the oxophilic 
titanium centre (Scheme 138). This reaction represents further exploration of the titanium aldol 
methodology as part of the aplyronine project and has now superseded Fink’s original protocol with 
Sn(OTf)2 as the preferred method for constructing the C29-C30 bond. Pettigrew noted that under optimal 
conditions, dr values up to 15:1 can be obtained. 
 
Scheme 138 Pettigrew's titanium aldol to form the C28-C33 b-hydroxyketone 149 
Reduction of the remaining C31 carbonyl occurred smoothly under the Evans-Tishchenko conditions 
(Scheme 139), relaying the stereochemical information from the existing C29 hydroxyl to forge a 1,3-anti 
motif in 273 with excellent control (96%, >20:1 dr). Finally, differential protection of the C31 secondary 
alcohol as TES ether was achieved with TESOTf and 2,6-lutidine to provide 274 in 94% yield. 
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Scheme 139 Elaboration of the aldol adduct 149 to the PMB ether 274 
Synthetic efforts described hereupon had been undertaken solely by the author. The PMB ether was 
oxidatively cleaved with DDQ in CH2Cl2/pH 7 buffer (4:1) biphasic solvent mixture as indicated in 
Scheme 140. Careful purification by column chromatography in toluene/EtOAc enabled removal of any 
remaining minor isomers from the aldol and Evans-Tishchenko reactions as insufficient polarity 
difference rendered them inseparable in the previous stages. Diastereomerically pure alcohol 275 was 
isolated in 92% yield and was reacted further with DIBALH to rapidly cleave the residual propionate 
ester and provide diol 151 (94%).  
 
Scheme 140 Sequential deprotection of the C29 and C33 hydroxyls 
Adjusting the C29 oxidation level could be carried out in the same step as converting the C33 terminus into 
the aldehyde, ready for a Wittig reaction to append the delicate N-vinylformamide. Kinetically, oxidation 
of C33 is likely to be more rapid, which would leave the newly formed carbonyl susceptible to the attack 
of the C29 hydroxyl and formation of a cyclic byproduct 276 (Scheme 141).  
 
Scheme 141 Formation of a cyclic byproduct as a result of kinetically favoured oxidation of the C33 alcohol 
The method which can circumvent this issue by virtue of its mechanism is Swern oxidation (Scheme 
142). Addition of the triethylamine base, which triggers the carbonyl formation, is done only after both 
alcohols had been activated as the alkoxysulfonium salt and can no longer act as nucleophiles at the 
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oxygen atom. The sensitive keto aldehyde 277 was formed with no detectable epimerisation of the a-
stereocentres (Scheme 143) and to prevent this occurring during chromatography on silica, crude material 
was used in the next step without further purification. 
 
Scheme 142 Proposed mechanism of the Swern oxidation 
 
Scheme 143 Double Swern oxidation of diol 151 and modified Wittig reaction to install the (Z)-vinylformamide 
The C33-C34 double bond was forged following a modified Wittig protocol developed in the Paterson 
group in the earlier stages of the aplyronine project173 and used with great success in a previous synthesis 
of the reidispongiolide A side chain containing this exact functionality.230,231 Phosphonium salt 150 
(prepared in two steps from N-methylformamide and paraformaldehyde by Pettigrew) was deprotonated 
with lithium hexamethyldisilazane (LiHMDS) to form the corresponding ylid and reacted at the more 
electrophilic aldehyde terminus of 277. N-Vinylformamide 152 was isolated as a 4.3:1 mixture of Z/E 
isomers in 70% yield over two steps on more than 1.5 g of crude aldehyde. 
Next, TES ether 152 was first treated with AcOH-buffered TBAF to reveal the secondary alcohol under 
neutral conditions (Scheme 144), followed by acetylation with acetic anhydride, triethylamine and 
catalytic DMAP. Minimising acetate loss via E1cb was achieved by strictly keeping the reaction 
temperature below 0 °C and only a small amount (< 5%) of enone elimination byproduct was observed 
even after purification on silica. Regardless, the crude acetate 279 was typically subjected to the 
isomerisation without the need for chromatography beforehand. 
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Scheme 144 Deprotection/acetylation sequence on the C31 hydroxyl and isomerisation of the N-vinylformamide 
Finally, the Z/E olefin mixture at the N-vinylformamide 279 was fully converted into the 
thermodynamically favoured (E)-isomer with molecular iodine in CH2Cl2. In the absence of light, the 
reaction is thought to proceed via an ionic mechanism (Scheme 145). Theoretically, iodine should only 
be required in catalytic quantities as it is regenerated in the final elimination step. However, in order to 
obtain satisfactory reaction rates, a stoichiometric amount was added instead. Williams also observed that 
the success of the isomerisation is dependant upon the concentration of substrate. The C28-C34 side chain 
118 was thus isolated in excellent yield (95%) over two steps from alcohol 278. 
 
Scheme 145 Iodine-mediated ionic mechanism for the (Z)- to (E)- isomerisation of the vinylformamide 
In summary, nearly 1 g of ketone 118 was prepared in seven steps and 63% yield from the stocks of 
intermediate 274, confirming once again that Fink had devised a reliable route to the aplyronine side 
chain. 
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5.2. Boron Aldol Coupling to the C1-C27 Macrocyclic Aldehyde 120 
With a replenished supply of the macrocycle 159 and side chain 118 in hand, the synthesis could be 
advanced towards the full aplyronine skeleton. A Swern oxidation at C27 successfully delivered the C27 
aldehyde 120 and the risk of epimerisation at the a-stereocentre was mitigated by avoiding aldehyde 120 
purification by flash chromatography. Triethylamine hydrochloride salts were removed in the mildly 
acidic workup and and the crude material was used immediately in the subsequent boron aldol reaction to 
complete the carbon backbone of the aplyronines. 
  
Scheme 146 Swern oxidation of the macrocyclic alcohol 159 and side chain attachment through aldol reaction of 
118 and 120 
The less precious side chain 118, relatively speaking, is used in excess to ensure complete consumption of 
the valuable aldehyde 120. Ketone 118 was enolised with Cy2BCl Lewis acid and Et3N at 0 °C, making 
(a) (COCl)2, DMSO, CH2Cl2, −78 ºC, 30 min, then 159, 30 min, then Et3N, 0 ºC → rt, 45 min; (b) 118, Cy2BCl, Et3N, Et2O, 0 ºC, 
30 min, then 120, −78 ºC, 1 h, then −40 ºC, 1 h, then −10 ºC, 1 h; (c) Burgess' reagent, THF, rt, 17 h
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every effort to rigorously exclude moisture. After addition of aldehyde 120 at -78 °C, the reaction was 
gradually warmed up to -40 °C then -10 °C over 2 h until complete. No substantial byproducts were 
observed in the crude 1H NMR and the aldehyde was consumed entirely within a relatively short reaction 
time. The typical boron-mediated aldol oxidative workup with hydrogen peroxide232 was avoided due to 
the potentially sensitive nature of this advanced fragment and was replaced by MeOH/pH 7 buffer.  
At this stage, excess unreacted side chain 118 was carried forward as a mixture with the aldol adduct 281 
as chromatographic separation proved to be very difficult. Dehydration to the enone 282 was achieved by 
using Burgess’ reagent174 (N-(triethylammoniumsulfonyl)carbamate), avoiding the risk of elimination of 
the delicate C31 acetate. This reaction proceeds via an initial attack of the C27 hydroxyl on the 
electrophilic sulfur which enables an intramolecular syn elimination via a 6-membered transition state as 
illustrated in Scheme 146. Use of fresh reagent was crucial in order to reach full conversion, though 
unreacted material can be easily resubjected if the reaction stalls. 
5.3. Summary 
The Paterson second-generation route to the known macrocyclic alcohol 159 constitutes a total of 53 
steps and 20 steps in the longest linear sequence (Scheme 147). The cornerstone of fragment assembly 
remained the efficient Ba(OH)2-mediated olefination to forge the C14-C15 and C20-C21 (E)-olefins and the 
stereotetrads were constructed in a series of highly stereocontrolled aldol reaction, followed by 1,3-anti 
reductions, showcasing the impressive selectivity of these transformations. 
The most pivotal strategic revision was the alteration of the overall protecting group strategy to 
accommodate the planned site-specific macrocyclisation. To facilitate this goal, the synthesis of the 
C21-C27 168 was revisited to introduce the necessary orthogonal protecting groups as well as produce a 
more scalable and robust synthesis of the C23-C26 stereotetrad. Replacing the capricious Sn(OTf)2 aldol 
methodology with a titanium variant produced excellent results and is one of the most impactful 
improvements in this project. A similarly fruitful venture was the investigation into the synthesis of chiral 
acid 137 from achiral starting materials. Pig liver esterase-mediated desymmetrisation has been 
established as the protocol of choice to reliably afford the C15-C20 phosphonate fragment 167 in more 
than 95% ee of the isolated (17R) methyl stereocentre with high material throughput. Adjustments of silyl 
groups in the C15-C27 region were introduced stepwise with great caution, though some of the initial 
reservations regarding their stability transpired to be unnecessary. Overall, the C15-C27 aldehyde 161 was 
prepared in a total of 20 steps (14 steps LLS). As every step of the sequence was carried out on multi-
grams of substrate, the route can be relied upon to deliver the necessary quantities of material for a 
substantial scale-up of the macrocycle. 
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Scheme 147 Summary of the second-generation synthesis of the aplyronines 
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The C1-C11 part of the macrocyclic skeleton was aligned with the new protecting group strategy to place 
a bis-TES moiety on the 1,3-anti diol early on. Alkylation at C11 to form the b-ketophosphonate 253 
remained somewhat of a bottleneck as brief optimisation studies did not yield the desired increase in 
regioselectivity for that step. Nevertheless, union of the northern and southern fragments assembled the 
C1-C27 framework with great efficiency (96%) and paved the way towards the advanced intermediates. In 
the later stages, the concise one-step allylic TBS oxidation/PMB deprotection, site-specific macrolide 
formation and palladium-catalysed Alloc deprotection replaced a rather laborious sequence of protecting 
group manipulations. This had been one of the major goals set out at the beginning and it was pleasing to 
see that the adventurous plan lead to a reduced overall step count. 
Finally, stocks of the C28-C34 ketone 118 were also replenished for the purposes of late-stage intermediate 
scale-up. The troublesome tin aldol step to construct the C29-C32 stereotetrad has now been superseded, 
which has improved the scalability of the otherwise efficient route. Shortly after coupling of the 
macrocycle 120 to the side chain 118, studies by the author were concluded. 
5.4. Future Work 
Notionally, this project was devised to address the issues in the original Paterson synthesis of the 
aplyronine core and to start afresh with the existing experience as a guideline. While many improvements 
have been made, there remains several steps which could be further optimised. The most pressing matters 
to be examined in the future endeavours are summarised below.   
5.4.1. Improvements to the C1-C27 Macrocycle Synthesis 
The route towards the C1-C14 northern fragment 253 has been highly optimised at all stages except for the 
alkylation of iodide 160. In the event, at least 25% of material half way through the LLS of the aplyronine 
synthesis is lost in a single operation on a medium scale (a few hundred mg). This remains a highly 
frustrating bottleneck and stems from the lack of understanding of the nature of the dianion in solution 
with regards to the complex electrophile. Experiments carried out in different ethereal solvents (Et2O, 
TBME, DME) gave a preliminary indication that perhaps the phosphonate solvation plays a key role in 
the reactivity profile. There is scope to probethis hypothesis further, including using additives to de-
aggregate the species other than HMPA such as DMPU or tetraalkylureas. 
The peculiar loss of proton signals observed at a late stage in the synthesis prior to forming the 
macrolactone must be further investigated before the precious late-stage material is brought to a point 
where these issues seem to appear. By considering the case of the C1-C11 iodide 160, where storage even 
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at low temperatures over prolonged time periods causes degradation, the suspected problematic 
intermediates could be put to the test by altering either storage conditions or rigorously excluding light 
when carrying out the DDQ allylic TBS oxidation/PMB removal or the Pinnick oxidation of 162 and 163, 
respectively. With the supply of material in excess of 2 g currently stored at the methyl ether 162 stage, 
approximately 1 g of the macrocycle should still be accessible if the reactions are carefully performed on 
small scale even before further optimisation is undertaken.  
The macrocyclisation of 164 has not yet been explored in great detail. Blakey and Lee found the 
Yamaguchi-Yonemitsu and Keck macrolactonisation procedures to be inferior in comparison to the 
Yamaguchi and Shiina variant. That being said, due to the unique behaviour of each cyclisation substrate, 
results and speculations based on merely structurally similar examples should not be taken as conclusive. 
This is especially relevant for examples where particular protecting groups assert major conformational 
bias of the compound in solution. The extensive choice of esterification methodology available nowadays 
which has been applied to macrolacronisations in particular233 provides plenty of scope to experiment 
beyond the select few fallback options.  
The Yamaguchi protocol could be altered by variation of solvent (e.g. CHCl3 or THF) as well as higher 
temperatures at reduced reaction times to prevent substrate degradation upon heating. On the other hand, 
use of the highly basic DMAP, especially in large excess, is one of the main drawbacks of the Yamaguchi 
procedure as it has been shown to sometimes lead to isomerisation of double bonds out of conjugation at 
the mixed anhydride stage (Scheme 148). This occurrence has not been confirmed for seco-acid 164 
specifically but closer inspection of the residues isolated from column chromatography may indicate 
whether this is a potentially problematic event. Such isomerisations were observed by Evans during the 
synthesis of oasomycin A234 and addition of iPrNEt2 to the macrolactonisation substrate was vital to the 
successful ring formation when treating with TCBC. 
 
Scheme 148 Speculative deconjugation of the C2-C5 diene after formation of the mixed anhydride 283 
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5.4.2. Synthesis of Linker-Modified Derivatives for ADC Development 
Williams had devised a route towards the enantiopure isomers of N,N,O-trimethylserine but did not 
manage to prepare any natural aplyronine congeners with each of them attached. These highly interesting 
targets for biological testing should be accessible with further stocks of aplyronine C prepared by the 
established endgame following a scale-up of the macrocycle 159. Each of the diastereomers is expected to 
have a unique biological profile due to subtle differences in the key pharmacophore on the northern 
portion of the macrocycle with regards to tubulin binding, which has to date not been fully elucidated. It 
is likely that one of the serine enantiomers forms stronger interactions than the other and the observed 
binding affinity is the average of the two as the natural material was collected as a scalemic mixture. If 
this theory is proven correct, there may be scope to increase potency by simply appending enantiopure 
amino acids at C7. Williams has already demonstrated that under Yonemitsu conditions, no racemisation 
of the stereocentre is seen in reaction with a linker-modified alcohol 284 (Scheme 149), hence it is 
predicted that this would not occur upon reaction with any structurally similar intermediates either. 
 
Scheme 149 Williams' esterification studies with enantiopure (R)- or (S)-N,N,O-trimethylserine 156  
In the context of the aplyronines as ADC payloads, the pendant amino acids may be compatible with the 
recent linkage technology developed by Genentech (Scheme 150).235 Starting with a commercially 
available valine-citrulline linker 285 with a maleimide handle and a PABC spacer, the benzylic alcohol is 
converted the chloride, then reacted with a tertiary amine on the payload to form a quaternary ammonium 
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linkage by an SN2 displacement of the halide (286). Conjugation through a cysteine on the mAb affords 
the ADC in a highly efficient three-step sequence without the use of protecting groups. Release of the 
toxin is triggered by the action of lysosome proteases to cleave the linker peptide bond, followed by a 
traceless elimination of the spacer. Genentech have achieved successful preparation of ADCs with a 
variety of tertiary amine-containing drugs as warheads and an additional disulfide-based linker which 
operates by the same basic principle.  
 
Scheme 150 Application of Genentech's quaternary ammonium linkage technology in the context of aplyronines as 
ADC payloads  
The major advantage of this technology is the formation of charged species, which decreases the risk of 
ADC aggregation as well as freeing the drug without any remnants of the linker which could impede 
target binding. The latter is especially relevant for the aplyronines when binding to two large 
biomolecules (actin and tubulin) at the same time. As the amino acids in aplyronines are appended late-
stage and have a profound effect of binding, a number of ADC variations could easily be prepared from a 
late-stage precursor.  
The future goal of combining the apylronines with ADCs to develop anticancer agents which are highly 
specific for cancer cells could lead to a huge breakthrough in modern medicine for the treatment of a 
variety of different cancers. The development of a scalable synthesis towards these natural products 
represents one step to this prospect becoming a reality. 
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Chapter 6 
Experimental 
6.1. General Prodecures 
Except where stated otherwise, all reactions were performed under anhydrous conditions under an 
atmosphere of argon at room temperature, using oven-dried glassware and standard techniques for 
handling air-sensitive materials.  
Purification of reagents and solvents was carried out by standard means.§ Benzene (PhH), toluene 
(PhMe), dichloromethane (CH2Cl2) and dimethyl sulfoxide (DMSO) were distilled from calcium hydride 
(CaH2) and stored under an atmosphere of argon. THF and Et2O were distilled from benzophenone ketyl 
radical / potassium or sodium wire, respectively, and stored under an atmosphere of argon. Solvents used 
for chromatography and extraction were distilled. 
Et3N, pyridine (pyr), 2,6-lutidine, dimethyl methylphosphonate and diethyl ethylphosphonate were 
distilled from and stored over CaH2 under an argon atmosphere. iPr2NEt was first distilled from 
ninhydrin, then from KOH and stored over CaH2 under an atmosphere of argon. EtOAc, 1,2-
dimethoxyethane (DME), crotonaldehyde and methyl vinyl ether were distilled from CaH2. TCBC, TiCl4 
and oxalyl chloride were distilled and stored under an argon atmosphere. Propionaldehyde was distilled 
from anhydrous CaCl2 and used immediately. AcOH was distilled from chromium trioxide and stored 
under an atmosphere of argon. 4 Å molecular sieves were activated by heating in a microwave oven and 
dried under vacuum. DDQ was recrystallised from distilled CHCl3. Proton-Spongeâ was recrystallized 
from MeOH. Anhydrous barium hydroxide (Ba(OH)2) was generated by drying barium hydroxide 
                                                
§ W.L.F. Armarego and D.D. Perrin, Purification of Laboratory Chemicals, 4th edition, Butterworth-Heinemann, 
1996 
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octahydrate (Ba(OH)2·8H2O) at 130 ºC under vacuum overnight and stored in the glove box. Unless 
stated otherwise, all other chemicals were used as received.  
Solutions of ammonium chloride (NH4Cl), sodium hydrogencarbonate (NaHCO3), sodium/potassium 
(Na+/K+) tartrate, brine (NaCl) and sodium thiosulfate (Na2S2O3) were saturated and aqueous. Buffer 
solutions were prepared from stock tablets as directed. 
Flash column chromatography was conducted on Merck Kieselgel 60 (230-400 mesh) silica gel under a 
positive pressure. Preparative thin layer chromatography was carried out using Merck Kieselgel 60 F254 
plates. All solvent mixtures are reported as volume ratios. 
6.2. Analytical Procedures 
Analytical thin layer chromatography (TLC) was carried out on Merck Kieselgel 60 F254 plates, coated 
with 0.25 mm of silica gel, using phosphomolybdic acid/cerium (IV) sulphate dip, potassium 
permanganate dip, bromocresol green dip and/or ultraviolet light (254 nm) for visualisation. 
Spectra were recorded on the following machines: Bruker Avance 500 BB (500 MHz) and Bruker 
Avance TCI Cryoprobe (500 MHz) and Bruker Avance DRX 400 (400 MHz).  
1H nuclear magnetic resonance (NMR) spectra were recorded at ambient probe temperature (298 K) using 
an internal deuterium lock for CDCl3 (δH = 7.26 ppm). 1H NMR data are presented as: chemical shift (in 
ppm, δ scale relative to tetramethylsilane, δTMS = 0 ppm), integration, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quin = quintet, sext = sextet, m = multiplet, br = broad, obs = obscured), 
coupling constants (J in Hz). Assignments of protons were based on unambiguous chemical shifts and 
coupling patterns with the aid of 2D spectra, and by analogy to fully interpreted spectra for structurally 
related compounds. Proton-decoupled 13C NMR spectra were recorded at at ambient probe temperature 
(298 K) and an internal deuterium lock for CDCl3 (δC = 77.14 ppm). Data are listed by chemical shift (in 
ppm, δ scale relative to tetramethylsilane, δTMS = 0 ppm). 
Fourier transform infrared (FT-IR) spectra were recorded as a thin film using a Perkin-Elmer Spectrum 
One spectrometer. Maximum absorbance frequencies (νmax) are reported in wavenumbers (cm-1). 
Optical rotation measurements were performed on the Perkin-Elmer 343 polarimeter at the sodium D-line 
(589 nm) and reported in the following format: [α] !"# , concentration of solution (c in g / 100 mL) and 
solvent.  
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High resolution mass spectrometry (HRMS) spectra were recorded by the EPRSC National Mass 
Spectrometry facility (Swansea, UK) or the departmental Mass spectrometry service (University 
Chemical Laboratories, Cambridge) using the electrospray ionisation (ESI) or the atmospheric solids 
analysis (ASAP) technique. The parent ion is quoted with the indicated ion: [M+H]+, [M+Na]+, 
[M+NH4]+ or [M-H2O]. 
GC analysis was performed using a 6890N Network GC system (Agilent Technologies Inc., Palo Alto, 
CA, USA), equipped with a Varian CP7502, CHIRASIL DEX CB (25.0 m x 250 µm x 0.25 µL nominal) 
capillary column. 
Melting points are uncorrected. 
6.3. Preparation of Reagents 
Tin(II) Triflate (Sn(OTf)2)162 
Tin granules (2.64 g, 22.2 mmol) were stirred in vacuo for 3 days with occasional heating to melt. Triflic 
acid (10.0 g, 66.6 mmol) was added dropwise under an argon atmosphere and the mixture was heated to 
85 °C for 3 days. After cooling to room temperature, the light grey foam was broken up by washing with 
anhydrous Et2O without exposure to air until the filtrate appeared colourless. The residue was dried in 
vacuo with vigorous stirring for 16 hours. Tin triflate (6.75 g, 16.2 mmol, 73%) was obtained as a white-
grey powder and stored under a strictly anhydrous argon atmosphere. 
Samarium Diiodide (SmI2) 
Method A:236 THF (23.7 mL) was added to a mixture of samarium metal (745 mg, 4.95 mmol) and iodine 
(697 mg, 2.47 mmol) under Ar, rigorously excluding oxygen. The resulting suspension was sonicated at rt 
for 45 min and the resulting deep blue solution of SmI2 (ca. 0.1 M in THF) was used immediately. 
Method B:237 Samarium metal (448 mg, 2.98 mmol) and iodine (684 mg, 2.69 mmol) were suspended in 
anhydrous THF (27 mL) under Ar and refluxed for 3 h, taking care to exclude oxygen. The resulting deep 
blue solution of SmI2 (ca. 0.1 M in THF) was cooled to rt and used immediately.  
Raney Nickel238 
Ni/Al alloy powder (15.0 g) was added portion-wise to a solution of NaOH (19.0 g) in H2O (75 mL) at 0 
°C, controlling the exotherm by maintaining the reaction temperature below 20 °C. The mixture was then 
let to warm to rt at which point evolution of hydrogen gas and a temperature rise to 30 °C were observed. 
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Once effervescence became slow, the reaction was warmed to 80 °C and stirred at this temperature for 4 
h. The mixture was then cooled to rt and the liquid phase decanted away. The residual slurry was 
transferred to a beaker and stirred with 10% NaOH solution (125 mL). The liquid phase was then 
decanted and the washing repeated with H2O (20 x 50 mL) until the pH of the decanted solution became 
pH 7. The black solid was finally washed with EtOH (5 x 50 mL) and stored under EtOH in an airtight 
container. 
Lithium di-tert-Butylbiphenyl (LiDBB)223 
Freshly cut Li wire (320 mg, 46.1 mmol) was rinsed with hexane, cut into 1 cm strips and added to a 
solution of di-tert-butylbiphenyl (13.7 g, 51.3 mmol) in THF (48 mL), rigorously excluding oxygen. The 
resulting mixture was sonicated for 4 h at 0 °C to give a dark green solution of LiDBB (1 M in THF), 
which was used immediately. 
2-Iodoxybenzoic Acid (IBX)239 
2-Iodobenzoic acid (50.0 g, 202 mmol) was added in one portion to a stirred solution of Oxone™ (181 g, 
689 mmol) in H2O (650 mL) and the resulting suspension heated to 80 °C for 3.5 h during which a white 
foam had formed. The mixture was cooled to rt and left to stand for 16 h. The precipitate was collected by 
filtration, washed with H2O (6 x 100 mL) and acetone (2 x 100 mL), then dried in vacuo to give IBX 
(45.8 g, 164 mmol, 81%) as a white powder. 
Dess-Martin Periodinane (DMP)239 
A mixture of IBX (44.2 g, 158 mmol) and TsOH×H2O (311 mg, 1.58 mmol) in acetic anhydride (220 mL) 
was heated to 85 °C for 1.5 h, then at 90 °C for a further 2 h. The resulting yellow solution was cooled to 
rt then to 0 °C for 2 h to give a precipitate. The mixture was filtered and the solids washed with Et2O (5 x 
50 mL), then dried under vacuum to give DMP (62.7 g, 148 mmol, 94%) as a white solid. 
Lithium hexamethyldisilazane (LiHMDS)240 
nBuLi (4.43 mL, 1.6 M in hexanes, 7.00 mmol) was added dropwise over 10 min to a stirred solution of 
hexamethyldisilazane (1.61 mL, 7.69 mmol) in THF (2.56 mL) at 0 °C and stirred at this temperature for 
an additional 1 h. The resulting solution of LiHMDS (1.0 M in THF) was used immediately. 
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6.4. Experimental Procedures for Chapter 3 
Ethyl ketone 171 
 
EtMgBr (12.8 mL, 3.0 M in Et2O, 38.2 mmol) was added dropwise to a solution of Weinreb amide 172 
(4.98 g, 19.1 mmol) in Et2O (75 mL) at 0 °C. The mixture was stirred at this temperature for 2 h then 
warmed to rt for a further 13 h. After cooling to 0 °C, the reaction was quenched by careful addition of 
NH4Cl solution (45 mL). The phases were separated and the aqueous layer was extracted with Et2O (3 × 
75 mL). Combined organic phases were washed with brine (75 mL), dried (MgSO4) and concentrated in 
vacuo. Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:10 → 1:5) 
afforded ketone 171 (3.80 g, 16.5 mmol, 86%) as a colourless oil. 
Rf 0.72 (EtOAc/40-60 PE, 1:5); 1H NMR (400 MHz, CDCl3): δH 3.73-3.69 (1H, m, H27a), 3.59 (1H, dd, 
J = 9.6, 5.6 Hz, H27b), 2.76 (1H, m, H26), 2.56-2.44 (2H, m, H24 × 2), 1.05-0.99 (6H, m, Me24, Me26), 
0.85 (9H, s, SiC(CH3)3), 0.02 (3H, s, SiCH3), 0.00 (3H, s, SiCH3).  
The data is in accordance with that reported by Denmark.241 
3-((4-Methoxybenzyl)oxy)propan-1-ol (174) 
 
Powdered KOH (1.27 g, 22.6 mmol) was added portion-wise to a cold slurry of propane-1,3-diol (16.7 g, 
21.9 mmol) in DMSO (80 mL), carefully cooled using an ice bath. On warming to rt, a clear solution 
formed. The mixture was cooled to 0 °C and PMBCl (2.98 mL, 22.0 mmol) was added dropwise. The 
reaction was warmed to rt and stirred for 3.5 h until complete, then cooled to 0 °C and quenched with 3 M 
HCl (40 mL). The quenching mixture was stirred for 30 min while warming to rt, then diluted with 
EtOAc (100 mL). The phases were separated and the aqueous layer was extracted with EtOAc (5 × 50 
mL). Combined organic phases were washed with H2O (50 mL) and brine (50 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 
1:4 → 1:0) yielded alcohol 174 (3.62 g, 18.5 mmol, 84%) as a pale yellow oil. 
Rf 0.10 (EtOAc/40-60 PE, 1:3); 1H NMR (500 MHz, CDCl3): δH 7.28 (2H, d, J = 8.7 Hz, ArH), 6.91 
(2H, d, J = 8.7 Hz, ArH), 4.48 (2H, s, ArCH2O), 3.83 (3H, s, ArOCH3), 3.80 (2H, t, J = 5.6 Hz, H23 × 2), 
O
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3.67 (2H, t, J = 5.6 Hz, H21 × 2), 2.24 (1H, br s, OH), 1.88 (2H, quin, J = 5.6 Hz, H22 x 2). 
The data is in accordance with that reported by Menche.242 
3-((4-Methoxybenzyl)oxy)propanal (169) 
 
DMSO (3.83 mL, 54.0 mmol) was added dropwise to a solution of oxalyl chloride (3.48 mL, 40.5 mmol) 
in CH2Cl2 (60 mL) at −78 °C and stirred for 1 h. A solution of alcohol 174 (5.30 g, 27.0 mmol) in CH2Cl2 
(40 mL) was added via cannula and the mixture was stirred for 30 min before addition of Et3N (11.3 mL, 
81.0 mmol). The resulting bright yellow reaction mixture was warmed to rt and stirred for 15 h, then 
quenched with H2O (40 mL). The phases were separated and the aqueous layer was extracted with 
CH2Cl2 (3 × 200 mL). The combined organic phases were washed with NaHCO3 solution (3 × 200 mL) 
and brine (200 mL), dried (MgSO4) and concentrated in vacuo. Aldehyde 169 (5.16 g, 26.6 mmol, 98%) 
was obtained as a pungent yellow oil and used without further purification.  
Rf 0.38 (EtOAc/40-60 PE, 1:3); 1H NMR (500 MHz, CDCl3): δH 9.81 (1H, t, J = 1.9 Hz, H23), 7.27 (2H, 
d, J = 8.7 Hz, ArH), 6.90 (2H, d, J = 8.7 Hz, ArH), 4.48 (2H, s, ArCH2O), 3.83 (3H, s, ArOCH3), 3.81 
(2H, t, J = 6.2 Hz, H21 × 2), 2.70 (2H, td, J = 6.2, 1.8 Hz, H22 × 2). 
The data is in accordance with that reported by Menche.243  
Aldol adduct 175 
  
Et3N (180 µL, 1.29 mmol) was added dropwise to a suspension of Sn(OTf)2 (479 mg, 1.15 mmol) in 
CH2Cl2 (1 mL) at −78 °C to form a bright yellow mixture. A solution of ketone 171 (204 mg, 0.885 
mmol, dried azeotropically from PhH and stirred over CaH2 immediately prior to use) in CH2Cl2 (1.5 mL) 
was added via cannula and the reaction mixture was stirred at −78 °C for 2 h. Aldehyde 169 (255 mg, 
1.31 mmol, dried azeotropically from PhH and stirred over CaH2 immediately prior to use) in CH2Cl2 (1 
mL) was added slowly via cannula. The reaction was stirred at −78 °C for 15 h and quenched with pH 7 
buffer (2.5 mL) and Na+/K+ tartrate solution (2.5 mL). The resulting emulsion was vigorously stirred for 2 
h while warming to rt. The organic phase was separated and filtered through Celite® and the aqueous 
layer was extracted with Et2O (3 × 20 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. The crude material was subjected to a Pinnick oxidation to remove unreacted 
alkylation
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aldehyde 169: 
A solution of NaClO2 (354 mg, 3.91 mmol) and NaH2PO42H2O (809 mg, 5.19 mmol) in H2O (3.0 mL) 
was added to the solution of the crude mixture in 2-methyl-2-butene (0.3 mL) and t-BuOH (3 mL) at 0 
°C. The reaction was warmed to rt and stirred for 16 h. The mixture was diluted with brine (3 mL) and 
extracted with Et2O (3 × 3 mL). The combined organic extracts were dried (MgSO4) and concentrated in 
vacuo. Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:30 → 1:10) 
yielded aldol adduct 175 (273 mg, 0.643 mmol, 74% over 2 steps, 8:1 dr) as a pale yellow oil. 
Rf 0.59 (EtOAc/40-60 PE, 1:3); [α] !"# = +15.6 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3483, 2930, 
2858, 1702, 1613, 1513, 1463, 1362, 1302, 1248, 1173, 1091, 1035, 105, 835, 777; 1H NMR (500 MHz, 
CDCl3): δH 7.27 (2H, d, J = 8.8 Hz, ArH), 6.90 (2H, d, J = 8.8 Hz, ArH), 4.47 (1H, d, J = 11.5 Hz, 
ArCHaHbO), 4.45 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.19 (1H, m, H23), 3.83 (3H, s, ArOCH3), 3.80 (1H, 
dd, J = 9.4, 8.6 Hz, H27a), 3.64 (2H, app q, J = 6.1 Hz, H21 x 2), 3.59 (1H, dd, J = 9.4, 5.1 Hz, H27b), 3.27 
(1H, d, J = 2.8 Hz, OH), 3.09-3.00 (1H, m, H26), 2.76 (1H, dq, J = 7.0, 3.9 Hz, H24), 1.83-1.76 (1H, m, 
H22a), 1.71-1.65 (1H, m, H22b), 1.15 (3H, d, J = 7.0 Hz, Me24), 1.01 (3H, d, J = 7.1 Hz, Me26), 0.89 (9H, s, 
SiC(CH3)3), 0.06 (3H, s, SiCH3), 0.05 (3H, s, SiCH3); 13C NMR (125 MHz, CDCl3): δC 218.3, 159.2, 
130.3, 129.3, 113.9, 72.9, 69.4, 68.1, 66.1, 55.3, 51.2, 47.3, 34.0, 25.9, 18.4, 13.6, 10.1, −5.5, −5.6; 
HRMS calculated for C23H44O5NSi [M+NH4]+ 442.2983, found 442.2981.  
(R)-Mosher ester 178 
 
DCC (60 µL, 1.0 M in CH2Cl2, 60.0 µmol) and DMAP (8.2 mg, 67.1 µmol) were added sequentially to a 
solution of β-hydroxy ketone 175 (6.2 mg, 14.6 µmol) and (R)-(+)-α-methoxy-α-(trifluoromethyl)-
phenylacetic acid (14.9 mg, 63.6 µmol) in CH2Cl2 (1 mL) and the mixture was stirred at rt for 17 h. The 
white suspension was concentrated in vacuo and the residue was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:20 → 1:10) to afford (R)-Mosher ester 178 as an 
inseparable mixture with DCC (11.1 mg, ca. 70%). 
Rf 0.62 (EtOAc/40-60 PE, 1:3); 1H NMR (500 MHz, CDCl3): δH 7.62-7.54 (2H, m, PhH), 7.47-7.37 
(3H, m, PhH), 7.25 (2H, d, J = 8.5 Hz, ArH), 6.88 (2H, d, J  = 8.5 Hz, ArH), 5.60-5.57 (1H, m, H23), 4.37 
(1H, d, J = 11.6 Hz, ArCHaHbO), 4.33 (1H, d, J = 11.6 Hz, ArCHaHbO), 3.82 (3H, s, ArOCH3), 3.74 (1H, 
O
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dd, J = 9.8, 7.5 Hz, H27a), 3.53 (3H, s, OCH3), 3.52 (1H, dd, J = 9.7, 6.0 Hz, H27b), 3.49-3.40 (2H, m, H21 
x 2), 2.96 (1H, qd, J = 7.1, 5.6 Hz, H24), 2.83 (1H, m, H26), 1.95 (1H, obs m, H22a), 1.89 (1H, obs m, H22b), 
1.06 (3H, d, J = 7.1 Hz, Me24), 0.97 (3H, d, J = 7.0 Hz, Me26), 0.88 (9H, s, SiC(CH3)3), 0.05 (3H, s, 
SiCH3), 0.03 (3H, s, SiCH3). 
(S)-Mosher ester 179 
 
DCC (60 µL, 1.0 M in CH2Cl2, 60.0 µmol) and DMAP (7.4 mg, 60.6 µmol) were added sequentially to a 
solution of β-hydroxy ketone 175 (5.3 mg, 11.8 µmol) and (S)-(−)-α-methoxy-α-(trifluoromethyl)-
phenylacetic acid (15.0 mg, 64.0 µmol) in CH2Cl2 (1 mL) and the mixture was stirred at rt for 17 h. Upon 
completion, the mixture was quenched with NaHCO3 solution (2 mL) and diluted with CH2Cl2 (2 mL). 
Phases were separated and the aqueous layer was extracted with CH2Cl2 (3 × 1 mL). The combined 
organic layers were washed with NaHCO3 solution (2 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 
1:20) to yield (S)-Mosher ester 179 (6.9 mg, 10.8 µmol, 86%) as a colourless oil. 
Rf 0.72 (EtOAc/40-60 PE, 1:3); 1H NMR (400 MHz, CDCl3): δH 7.59-7.53 (2H, m, PhH), 7.45-7.35 
(3H, m, PhH), 7.23 (2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J  = 8.6 Hz, ArH), 5.63-5.59 (1H, m, H23), 4.35 
(1H, d, J = 11.6 Hz, ArCHaHbO), 4.33 (1H, d, J = 11.6 Hz, ArCHaHbO), 3.81 (3H, s, ArOCH3), 3.75 (1H, 
dd, J = 9.7, 7.2 Hz, H27a), 3.54 (1H, dd, J = 9.7, 6.2 Hz, H27b), 3.50 (3H, s, OCH3), 3.39-3.28 (2H, m, H21 
× 2), 2.99 (1H, qd, J = 7.1, 4.7 Hz, H24), 2.97-2.89 (1H, m, H26), 1.91 (1H, obs m, H22a), 1.88 (1H, obs m, 
H22b), 1.14 (3H, d, J = 7.2 Hz, Me24), 1.03 (3H, d, J = 7.0 Hz, Me26), 0.88 (9H, s, SiC(CH3)3), 0.05 (3H, s, 
SiCH3), 0.04 (3H, s, SiCH3). 
Ethyl ketone 170 
 
EtMgBr (60.0 mL, 3.0 M in Et2O, 180 mmol) was added over 1.5 h to a solution of Weinreb amide 182 
(14.1 g, 60.0 mmol) in Et2O (150 mL) at 0 °C. The grey suspension was stirred at this temperature for 18 
h then quenched by careful addition of NH4Cl solution (150 mL). The mixture was warmed to rt and the 
aqueous layer was extracted with Et2O (3 × 100 mL). Combined organic phases were dried (MgSO4), 
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concentrated in vacuo and purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 
1:20 → 1:2). Ketone 170 (7.28 g, 35.3 mmol, 59%, 83% BRSM) was obtained as a colourless oil.  
Rf 0.43 (EtOAc/40-60 PE, 1:10); 1H NMR (500 MHz, CDCl3): δH 7.38-7.35 (2H, m, PhH), 7.32-7.30 
(3H, m, PhH), 4.53 (1H, d, J = 12.1 Hz, PhCHaHbO), 4.49 (1H, d, J = 12.1 Hz, PhCHaHbO), 3.66 (1H, dd, 
J = 9.0, 7.9 Hz, H27a), 3.49 (1H, dd, J = 9.0, 5.5 Hz, H27b), 2.95-2.88 (1H, m, H26), 2.54 (2H, q, J = 7.2 
Hz, H24 × 2), 1.10 (3H, d, J = 7.2 Hz, Me26), 1.07 (3H, d, J = 7.2 Hz, Me24). 
The data is in accordance with that reported by Paterson.244 
Aldol adduct 183 
 
Ti(iPrO)4 (4.10 mL, 13.9 mmol) was added dropwise to a solution of TiCl4 (4.55 mL, 41.4 mmol) in 
CH2Cl2 (100 mL) at 0 °C. The mixture was stirred for 10 min, then warmed to rt and stirred for a further 
20 min. The resulting colourless solution was added dropwise to a solution of ketone 170 (9.51 g, 46.1 
mmol, dried azeotropically from PhH and stirred over CaH2 immediately prior to use) in CH2Cl2 (210 
mL) at −78 °C and a gradual colour change from colourless through yellow and finally bright orange was 
observed as well as evolution of gas. The mixture was stirred for 10 min before iPr2NEt (8.83 mL, 50.7 
mmol) was added dropwise and a colour change to dark red was observed. Aldehyde 169 (12.1 g, 62.1 
mmol, dried azeotropically from PhH and stirred over CaH2 immediately prior to use) in CH2Cl2 (210 
mL) was then added dropwise via syringe down the side of the reaction flask over 30 min. The mixture 
was stirred at −78 °C for a further 16 h before being quenched with MeOH (2 mL), warmed to rt and 
Na+/K+ tartrate solution (25 mL) added. The biphasic mixture was stirred at rt for a further 2 h before 
extracting with CH2Cl2 (3 x 250 mL). The combined organic phases were dried (MgSO4) and 
concentrated in vacuo. 
The crude product was dissolved in tBuOH/2-Me-but-2-ene (88 mL, 10:1) at 0 °C. A solution of NaClO2 
(4.65 g, 51.5 mmol) and NaH2PO4×2H2O (16.2 g, 103 mmol) in H2O (80 mL) was added portionwise and 
a colour change to bright yellow was observed. The mixture was warmed to rt and stirred for 64 h during 
which the colour had dissipated. The reaction was diluted with brine (100 mL), extracted with Et2O (6 x 
100 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:8 ® 1:4) to yield aldol adduct 183 (15.1 g, 37.7 
mmol, 82%, 12:1 dr) as a colourless oil.  
O
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The title compound can also be accessed via the following protocol: 
Et3N (190 µL, 1.36 mmol) was added dropwise to a suspension of Sn(OTf)2 (525 mg, 1.26 mmol) in 
CH2Cl2 (1.5 mL) at −78 °C to form a bright yellow mixture. A solution of ketone 170 (200 mg, 0.969 
mmol, dried azeotropically from PhH and stirred over CaH2 immediately prior to use) in CH2Cl2 (1.5 mL) 
was added via cannula and the reaction mixture was stirred at −78 °C for 2 h. Aldehyde 169 (270 mg, 
1.39 mmol, dried azeotropically from PhH and stirred over CaH2 immediately prior to use) in CH2Cl2 (1 
mL) was added via cannula. The reaction mixture was stirred at −78 °C for 75 min and quenched by the 
addition of pH 7 buffer solution (5 mL) The resulting emulsion was filtered through Celite®, washing 
with CH2Cl2. Phases were separated and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The 
combined organic extracts were dried (MgSO4) and concentrated in vacuo. 1H NMR analysis of the crude 
product mixture indicated an 8:1 diastereomeric ratio.  
The crude material was subjected to Pinnick oxidation to remove unreacted aldehyde. A solution of 
NaClO2 (62.9 mg, 0.684 mmol) and NaH2PO42H2O (213 mg, 1.37 mmol) in H2O (2 mL) was added to 
the solution of the crude reaction product in 2-methyl-2-butene (0.2 mL) and tBuOH (2 mL) at 0 °C. The 
reaction was warmed to rt and stirred for 16 h. The mixture was diluted with brine (3 mL) and extracted 
with Et2O (3 × 3 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. 
Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:15 → 1:5) yielded 
aldol adduct 183 (227 mg, 0.591 mmol, 61%, 9:1 dr) as a colourless oil. 
Rf 0.29 (EtOAc/40-60 PE, 1:3); [α] !"#	 = −2.9 (c 1.0, CHCl3); IR (thin film, νmax / cm-1): 3495, 2935, 2861, 
1709, 1613, 1513, 1455, 1363, 1302, 1247, 1174, 1094, 1032, 821, 739, 699; 1H NMR (400 MHz, 
CDCl3): δH 7.35-7.22 (7H, m, PhH, ArH), 6.87 (2H, d, J = 8.7 Hz, ArH), 4.48 (2H, d, J = 11.8 Hz, 
ArCHaHbO), 4.45 (2H, d, J = 11.8 Hz, ArCHaHbO), 4.42 (2H, s, PhCH2O), 4.19-4.15 (1H, m, H23) 3.80 
(3H, s, ArOCH3), 3.66 (1H, t, J = 8.8 Hz, H21a), 3.59-3.52 (2H, m, H27 × 2), 3.45 (1H, dd, J = 8.8, 5.0 Hz, 
H21b), 3.21 (1H, d, J = 3.2 Hz, OH), 3.17 (1H, obs qt, J = 7.0, 1.9 Hz, H26), 2.77 (1H, qd, J = 6.9, 4.0 Hz, 
H24), 1.78-1.61 (2H, m, H22 × 2), 1.11 (3H, d, J = 7.0 Hz, Me26), 1.03 (3H, d, J = 7.0 Hz, Me24); 13C 
NMR (125 MHz, CDCl3): δC 217.2, 159.2, 137.8, 130.3, 129.3, 128.5, 127.8, 127.7, 113.8, 73.4, 73.0, 
72.8, 69.7, 68.0, 55.3, 51.3, 45.2, 33.8, 13.7, 10.2; HRMS calculated for C24H36O5N [M+NH4]+ 418.2588, 
found 418.2588. 
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(R)-Mosher ester 185 
 
DCC (62 µL, 1.0 M in CH2Cl2, 62.0 µmol) and DMAP (8.0 mg, 65.5 µmol) were added sequentially to a 
solution of β-hydroxy ketone 183 (5.4 mg, 13.5 µmol) and (R)-(+)-α-methoxy-α-(trifluoromethyl)-
phenylacetic acid (14.0 mg, 59.8 µmol) in CH2Cl2 (1 mL). The mixture was stirred at rt for 17 h, then 
quenched by the addition of NaHCO3 solution (2 mL). Layers were separated and the aqueous phase was 
extracted with CH2Cl2 (2 × 2 mL). The combined organic phases were dried (MgSO4) and concentrated in 
vacuo. The crude product was purified by flash column chromatography (gradient elution: EtOAc/40-60 
PE, 1:25 → 1:15) to yield (S)-Mosher ester 185 as an inseparable mixture with DCC (5.0 mg, ca. 50% 
yield). 
Rf 0.71 (EtOAc/40-60 PE, 1:3); 1H NMR (500 MHz, CDCl3): δH 7.66-7.62 (2H, m, PhH), 7.59-7.54 
(3H, m, PhH), 7.42-7.30 (5H, m, PhH), 7.23 (2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J  = 8.6 Hz, ArH), 
5.61-5.57 (1H, m, H23), 4.46 (1H, d, J = 11.9 Hz, ArCHaCHbO), 4.41 (1H, d, J = 11.8 Hz, ArCHaCHbO), 
4.35 (2H, s, PhCH2O), 3.81 (3H, s, ArOCH3), 3.59 (1H, dd, J = 8.9, 8.2 Hz, H27a), 3.52 (3H, s, OCH3), 
3.39 (1H, dd, J = 8.9, 5.8 Hz, H27b), 3.40 (1H, obs m, H21a), 3.38 (1H, obs m, H21b), 2.98 (1H, obs m, H26), 
2.95 (1H, obs m, H24), 1.98-1.90 (2H, m, H22 × 2), 1.05 (3H, d, J = 7.1 Hz, Me26), 0.98 (3H, d, J = 7.1 
Hz, Me24). 
(S)-Mosher ester 186 
 
DCC (62 µL, 1.0 M in CH2Cl2, 62.0 µmol) and DMAP (8.0 mg, 65.5 µmol) were added sequentially to a 
solution of β-hydroxy ketone 183 (5.5 mg, 13.7 µmol) and (S)-(−)-α-methoxy-α-(trifluoromethyl)-
phenylacetic acid (15.6 mg, 66.6 µmol) in CH2Cl2 (1 mL) and the mixture was stirred at rt for 17 h. The 
reaction was quenched with NaHCO3 solution (2 mL) and diluted with CH2Cl2 (2 mL). The phases were 
separated and the aqueous layer was extracted with CH2Cl2 (2 × 2 mL). The combined organic phases 
were dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:25 → 1:15) to yield (S)-Mosher ester 186 (8.4 mg, 
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13.6 µmol, 98%) as a colourless oil. 
Rf 0.72 (EtOAc/40-60 PE, 1:3); 1H NMR (500 MHz, CDCl3): δH 7.58-7.55 (2H, m, PhH), 7.42-7.37 
(3H, m, PhH), 7.34-7.26 (5H, m, PhH), 7.26 (2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J  = 8.7 Hz, ArH), 
5.66-5.62 (1H, m, H23), 4.48 (1H, d, J = 12.0 Hz, ArCHaCHbO), 4.41 (1H, d, J = 12.0 Hz, ArCHaCHbO), 
4.32 (2H, ABq, J = 11.4 Hz, PhCH2O), 3.81 (3H, s, ArOCH3), 3.62 (1H, dd, J = 9.0, 7.9 Hz, H27a), 3.51 
(3H, s, OCH3), 3.43 (1H, dd, J = 9.0, 5.9 Hz, H27b), 3.36 (1H, dt, J = 9.7, 5.9 Hz, H21a), 3.31 (1H, dt, J = 
9.7, 6.8 Hz, H21b), 3.12-3.04 (1H, m, H26), 3.04 (1H, qd, J = 7.1, 4.8 Hz, H24), 1.92-1.85 (2H, m, H22 × 
2), 1.13 (3H, d, J = 7.1 Hz, Me24), 1.05 (3H, d, J = 7.1 Hz, Me26). 
Propionate 188 
 
Freshly prepared SmI2 (25.6 mL, 0.1 M in THF, 2.56 mmol) was added dropwise to a solution of 
propionaldehyde (freshly distilled from CaCl2, 8.36 mL, 116 mmol) in THF (200 mL) at 0 °C. The 
mixture was stirred for 5 min until the dark blue colour no longer persisted and cooled to −20 °C. A 
solution of aldol adduct 183 (10.2 g, 25.6 mmol) in THF (70 mL) was added via cannula and the 
green/yellow reaction mixture was stirred at −20 °C for 16 h. The reaction was then warmed up to −10 °C 
and stirred for a further 65 h before quenching with NaHCO3 solution (200 mL) and warming to rt. The 
mixture was extracted with EtOAc (3 × 150 mL) and the combined organic extracts were washed with 
brine (10 mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash 
column chromatography (gradient elution: EtOAc/40-60 PE, 1:12 ® 1:8) to afford ester 188 (11.0 g, 
23.9 mmol, 93%, >20:1 dr) as a colourless oil. 
Rf 0.66 (EtOAc/40-60 PE, 1:2); [α] !"# = −13.2 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3513, 2859, 
1712, 1612, 1513, 1455, 1363, 1247, 1200, 1083, 1034, 1002, 820, 737, 698; 1H NMR (500 MHz, 
CDCl3): δH 7.36-7.26 (5H, m, PhH), 7.25 (2H, d, J = 8.7 Hz, ArH), 6.87 (2H, d, J = 8.7 Hz, ArH), 5.46 
(1H, ddd, J = 9.3, 4.0, 1.7 Hz, H23), 4.48 (2H, s, PhCH2O), 4.41 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39 
(1H, d, J = 11.5 Hz, ArCHaHbO), 3.80 (3H, s, ArOCH3), 3.58 (1H, dd, J = 9.2, 5.2 Hz, H27a), 3.49-3.42 
(3H, m, H21 × 2, H27b), 3.39 (1H, d, J = 5.7 Hz, OH), 3.12 (1H, ddd, J = 9.1, 5.7, 3.4 Hz, H25), 2.30 (1H, 
dq, J = 15.9, 7.8 Hz, H2a'), 2.29 (1H, dq, J = 15.9, 7.5 Hz, H2b'), 2.10-1.96 (2H, m, H22a, H26), 1.85-1.72 
(2H, m, H22b, H24), 1.12 (2H, t, J = 7.6 Hz, H3' × 3), 1.08 (3H, d, J = 7.1 Hz, Me26), 0.90 (3H, d, J = 7.0 
Hz, Me24); 13C NMR (125 MHz, CDCl3): δC 175.2, 159.2, 138.4, 130.4, 129.3, 128.4, 127.6, 127.5, 113.8, 
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76.3, 73.3, 72.8, 72.1, 71.2, 67.0, 55.3, 40.8, 34.8, 33.2, 27.8, 16.4, 10.3, 9.3; HRMS calculated for 
C27H39O6 [M+NH4]+ 459.2741, found 459.2738. 
TES ether 191 
 
TESOTf (6.48 mL, 28.7 mmol) was added dropwise to a solution of alcohol 188 (11.0 g, 23.9 mmol) and 
2,6-lutidine (5.53 mL, 47.8 mmol) in CH2Cl2 (500 mL) at -78 °C. The reaction mixture was stirred for 2 
h, then quenched by the addition of NaHCO3 solution (300 mL) and warmed to rt. The phases were 
separated and the organic layer was extracted with CH2Cl2 (2 x 300 mL). The combined organic phases 
were dried (MgSO4), concentrated in vacuo and purified by flash column chromatography (gradient 
elution: EtOAc/40-60 PE, 1:50 → 1:15) to afford TES ether 191 (13.2 g, 22.9 mmol, 96%) as a 
colourless oil. 
Rf 0.59 (EtOAc/40-60 PE, 1:5); [α] !"# = −14.0 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2956, 2873, 
1728, 1609, 1510, 1459, 1362, 1302, 1251, 1189, 1096, 1038, 1005, 820, 737, 700; 1H NMR (500 MHz, 
CDCl3): δH 7.38-7.34 (4H, m, PhH), 7.31-7.29 (1H, m, PhH), 7.28 (2H, d, J = 8.8 Hz, ArH), 6.89 (2H, d, 
J = 8.8 Hz, ArH), 5.22 (1H, ddd, J = 7.6, 5.5, 3.1, H23), 4.50 (2H, s, PhCH2O), 4.43 (1H, d, J = 11.3 Hz, 
ArCHaHbO), 4.40 (1H, d, J = 11.3 Hz, ArCHaHbO), 3.82 (3H, s, ArOCH3), 3.59 (1H, dd, J = 9.3, 4.6 Hz, 
H27a), 3.57 (1H, dd, J = 7.0, 3.9 Hz, H25), 3.51-3.44 (2H, m, H21 × 2), 3.33 (1H, dd, J = 9.2, 7.9 Hz, H27b), 
2.30 (2H, q, J = 7.5 Hz, H2' x 2), 2.12-2.07 (1H, m, H26), 2.00-1.93 (1H, m, H22a), 1.90-1.83 (2H, m, 
H22b, H24), 1.14 (3H, t, J = 7.5 Hz, H3' x 3), 1.05 (3H, d, J = 7.1 Hz, Me26), 0.96 (9H, t, J = 8.0 Hz, 
SiCH2CH3 x 3), 0.96 (3H, d, J = 7.0 Hz, Me24), 0.63 (6H, q, J = 8.0 Hz, SiCH2CH3 x 3); 13C NMR (125 
MHz, CDCl3): δC 174.0, 159.1, 138.8, 130.5, 129.3, 128.3, 127.5, 127.4, 113.7, 76.9, 73.0, 72.7, 72.1, 
71.9 67.2, 55.3, 41.1, 36.9, 33.5, 27.9, 15.9, 11.1, 9.2, 7.1, 5.4; HRMS calculated for C33H53O6Si [M+H]+ 
573.3606, found 573.3609. 
Alcohol 198 
 
DIBALH (29.8 mL, 1.0 M in hexanes, 29.8 mmol) was added dropwise to a solution of TES ether 191 
(13.2 g, 22.9 mmol) in CH2Cl2 (350 mL) at -78 °C and the mixture was stirred at this temperature for 2 h. 
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An additional portion of DIBALH (4.58 mL, 4.58 mmol) was added and the reaction stirred for a further 
30 min. Upon completion, the mixture was quenched by the addition of Na+/K+ tartrate solution (500 
mL), warmed to rt and stirred vigorously for 16 h. The layers were separated and the aqueous phase 
extracted with EtOAc (5 x 200 mL). Combined organic extracts were dried (Na2SO4) and concentrated in 
vacuo to give alcohol 198 (11.8 g, 22.9 mmol, 99%) as a colourless oil which was used without further 
purification.  
Rf 0.50 (EtOAc/40-60 PE, 1:4); [α] !"# = −10.7 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2952, 2881, 
1617, 1514, 1455, 1413, 1368, 1300, 1247, 1169, 1094, 1037, 1001, 819, 737, 696; 1H NMR (500 MHz, 
CDCl3): δH 7.39-7.34 (4H, m, PhH), 7.32-7.29 (1H, m, PhH), 7.27 (2H, d, J = 8.6 Hz, ArH), 6.89 (2H, d, 
J = 8.6 Hz, ArH), 4.54 (1H, d, J = 12.0 Hz, ArCHaHbO), 4.48 (1H, d, J = 12.0 Hz, ArCHaHbO), 4.46 (1H, 
d, J = 11.5 Hz, PhCHaHbO), 4.44 (1H, d, J = 11.5 Hz, PhCHaHbO), 4.22 (1H, dd, J = 8.9, 3.9, H23), 3.82 
(3H, s, ArOCH3), 3.76 (1H, dd, J = 7.4, 3.2 Hz, H25), 3.59 (2H, t, J = 6.4 Hz, H21 x 2), 3.52 (1H, dd, J = 
9.0, 4.4 Hz, H27a), 3.41 (1H, dd, J = 8.8, 6.4 Hz, H27b), 2.12 (1H, ddd, J = 11.5, 6.8, 4.7 Hz, H26), 
1.91-1.84 (1H, m, H22a), 1.70-1.64 (1H, m, H24), 1.61-1.55 (1H, m, H22b), 1.02 (3H, d, J = 7.0 Hz, Me24), 
1.00 (3H, d, J = 7.0 Hz, Me26), 0.97 (9H, t, J = 8.0 Hz, SiCH2CH3 x 3), 0.66 (6H, q, J = 7.8 Hz, 
SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): δC 159.1, 138.6, 130.6, 129.3, 128.3, 127.6, 127.5, 113.8, 
80.1, 73.1, 72.8, 72.6, 68.5, 68.0, 55.3, 38.1, 38.1, 35.1, 14.8, 11.6, 7.0, 5.3; HRMS calculated for 
C30H49O5Si [M+H]+ 517.3344, found 517.3333. 
Diol 189 
 
Me4NBH(OAc)3 (1.79 g, 6.82 mmol) was dissolved in MeCN/AcOH (2:1, 9 mL) and the cloudy solution 
was stirred at rt for 1 h before being cooled to −30 °C. A solution of aldol adduct 183 (275 mg, 0.687 
mmol, 9:1 dr) in MeCN (2 mL) was added via cannula. The mixture was stirred for 24 h before being 
quenched by pouring into Na+/K+ tartrate / NaHCO3 solution (1:1, 15 mL) at 0 °C. The solution was 
stirred for 3 h whilst being warmed to rt. The phases were separated and the aqueous layer was extracted 
with CH2Cl2 (3 × 10 mL). The combined organics were washed with brine (10 mL), dried (MgSO4) and 
concentrated in vacuo. The crude product was purified by flash column chromatography (gradient elution: 
EtOAc/40-60 PE, 1:4 → 1:3) to afford diol 189 as a colourless oil (232 mg, 0.576 mmol, 84%, 18:1 dr). 
The title compound can also be accessed via the following protocol from ester 188: 
OH
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Potassium carbonate (2.00 g, 14.4 mmol) was added to a solution of ester 188 (3.31 g, 7.22 mmol) in 
MeOH (72 mL) and stirred at rt for 20 h. Upon completion, the reaction mixture was poured into brine 
(40 mL) and extracted with EtOAc (3 × 100 mL). The combined organic extracts were dried (MgSO4) 
and concentrated in vacuo to afford diol 189 (2.66 g, 6.61 mmol, 92%), which was used without further 
purification.  
Rf 0.31 (EtOAc/40-60 PE, 1:2); [α] !"# = +0.85 (c 2.0, CHCl3); IR (thin film, νmax / cm−1): 3417, 2863, 
1613, 1586, 1514, 1455, 1363, 1303, 1248, 1174, 1093, 1034, 975, 820, 739, 699; 1H NMR (500 MHz, 
CDCl3): δH 7.40-7.30 (5H, m, PhH), 7.27 (2H, d, J = 8.7 Hz, ArH), 6.89 (2H, d, J = 8.7 Hz, ArH), 4.55 
(2H, s, PhCH2O), 4.47 (2H, s, ArCH2O), 4.28 (2H, d, J = 3.5 Hz, OH25), 4.20-4.16 (1H, m, H23), 3.87 
(1H, d, J = 1.6 Hz, OH23), 3.82 (3H, s, ArOCH3), 3.69-3.61 (3H, m, H27a, H25, H21a), 3.59-3.54 (2H, m, 
H27b, H21b), 2.14 (1H, app qd, J = 6.8, 4.7 Hz, H26), 1.97-1.89 (1H, m, H24), 1.79-1.73 (1H, m, H22a), 
1.64-1.58 (1H, m, H22b), 1.04 (3H, d, J = 7.2 Hz, Me24), 0.90 (3H, d, J = 6.8 Hz, Me26); 13C NMR (125 
MHz, CDCl3): δC 159.3, 137.8, 130.5, 129.4, 128.4, 127.8, 127.6, 113.9, 81.1, 75.1, 73.6, 73.0, 70.2, 68.3, 
55.2, 38.5, 36.0, 34.2, 14.4, 11.6; HRMS calculated for C24H35O5 [M+H]+ 403.2479, found 403.2480. 
Acetonide 192 
 
PPTS (1 crystal) was added to a solution of diol 189 (22.0 mg, 54.7 µmol) in 2,2-dimethoxypropane (1 
mL) at rt. The reaction mixture was stirred at rt for 17 h then concentrated in vacuo. The crude product 
was purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:20 → 1:1) to yield 
acetonide 192 (21.0 mg, 47.4 µmol, 87%) as a colourless oil.  
Rf 0.73 (EtOAc/40-60 PE, 1:3); [α] !"# = −8.6 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2858, 1613, 1587, 
1513, 1455, 1379, 1302, 1247, 1224, 1174, 1143, 1098, 1037, 989, 820, 736, 698; 1H NMR (500 MHz, 
CDCl3): δH 7.36 (4H, m, PhH), 7.32-7.27 (3H, m, PhH, ArH), 6.90 (2H, d, J = 8.7 Hz, ArH), 4.46 (1H, 
ABq, J = 12.0 Hz, PhCHaHb), 4.44 (1H, ABq, J = 12.0 Hz, PhCHaHb), 4.45 (2H, ABq, J = 11.6 Hz, 
ArCH2O), 4.00 (1H, dt, J = 10.2, 4.0 Hz, H23), 3.83 (3H, s, ArOCH3), 3.61 (1H, dd, 9.2, 4.6 Hz, H27a), 
3.57-3.50 (2H, m, H21 × 2), 3.38 (1H, dd, J = 9.2, 6.9 Hz, H27b), 3.27 (1H, dd, J = 7.3, 5.5 Hz, H25), 
2.01-1.93 (1H, m, H26), 1.86-1.80 (1H, m, H24), 1.75-1.61 (2H, m, H22 × 2), 1.32 (3H, s, 
C(CH3)a(CH3)b), 1.30 (3H, s, C(CH3)a(CH3)b), 1.05 (3H, d, J = 6.9 Hz, Me26), 0.88 (3H, d, J = 6.9 Hz, 
Me24); 13C NMR (125 MHz, CDCl3): δC 159.2, 138.8, 130.6, 129.4, 128.3, 127.6, 127.4, 113.8, 100.3, 
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76.6, 73.1, 72.9, 72.3, 66.9, 66.0, 55.3, 37.8, 36.9, 31.1, 25.3, 23.5, 14.4, 12.6; HRMS calculated for 
C27H38O5Na [M+Na]+ 465.2600, found 465.2611. 
PMP acetal 195 
 
A mixture of activated 4 Å molecular sieves (388 mg) and PMB ether 189 (302 mg, 0.750 mmol, dried 
azeotropically from PhH) in CH2Cl2 (5 mL) was cooled to 0 °C. A solution of DDQ (157 mg, 0.692 
mmol) in CH2Cl2 (10 mL) was added slowly via syringe and immediate colour change to dark green/blue 
was observed. The mixture was stirred at this temperature for a further 2 h before being warmed to rt and 
quenched by filtering through a pad of Celite® onto NaHCO3 solution (15 mL). The layers were separated 
and the aqueous phase extracted with CH2Cl2 (3 × 10 mL). The combined organic extracts were washed 
with brine (30 mL), dried (MgSO4) and concentrated in vacuo. The residue was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:7 → 1:0) to yield PMP acetal 195 (211 mg, 0.527 
mmol, 77%) as a colourless oil. 
Rf 0.52 (EtOAc/40-60 PE, 1:2); [α] !"# = −20.5 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3507, 2963, 
2857, 1615, 1517, 1362, 1303, 1247, 1100, 981, 827, 749, 697, 595 ; 1H NMR (400 MHz, CDCl3): δH 
7.38 (2H, d, J = 8.7 Hz, ArH), 7.36-7.28 (5H, m, PhH), 6.88 (2H, d, J = 8.7 Hz, ArH), 5.48 (1H, s, 
ArCHO2), 5.12 (1H, d, J = 12.0 Hz, PhCHaHb), 5.10 (1H, d, J = 12.0 Hz, PhCHaHb), 4.31-4.25 (2H, m, 
H21a, H23), 3.98 (1H, td, J = 12.0, 2.6 Hz, H21b), 3.80 (3H, s, ArOCH3), 3.66 (1H, dd, J = 9.0, 4.0 Hz, H27a), 
3.54 (1H, dd, J = 9.1, 5.7 Hz, H27b), 3.50 (1H, dd, J = 7.0, 5.2 Hz, H25), 3.23 (1H, d, J = 6.9 Hz, OH), 2.12 
(1H, dddd, J = 12.5, 12.2, 5.0, 4.8 Hz, H22a), 2.04-1.94 (1H, m, H26), 1.82 (1H, ddq, J = 7.2, 2.5 Hz, H24), 
1.35-1.30 (1H, m, H22b), 1.11 (3H, d, J = 6.9 Hz, Me26), 1.02 (3H, d, J = 7.0 Hz, Me24); 13C NMR (125 
MHz, CDCl3): δC 156.0, 138.4, 131.2, 128.4, 128.4, 127.6, 127.4, 113.6, 101.3, 78.1, 76.8, 73.5, 72.5, 
67.3, 55.3, 40.0, 36.0, 27.7, 15.7, 11.9; HRMS calculated for C24H33O5 [M+H]+ 401.2325, found 
401.2323. 
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PMP acetal 190 
 
DDQ (7.80 g, 34.3 mmol) was added in one portion to a stirred slurry of alcohol 198 (11.8 g, 22.9 mmol) 
and activated 4 Å molecular sieves (~20 g) in CH2Cl2 (500 mL) at 0 °C. The resulting dark blue mixture 
was stirred at this temperature for 30 min before being warmed to rt and stirred for a further 1.5 h during 
which the colour had gradually changed to brown. The mixture was filtered through a plug of Celite® 
onto NaHCO3 solution (300 mL) and rinsed with CH2Cl2 (200 mL). The aqueous phase was extracted 
with CH2Cl2 (3 x 300 mL), the combined organic extracts were dried (MgSO4) and the crude product was 
purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:30 ® 1:20) to afford 
PMP acetal 190 (9.54 g, 18.5 mmol, 81%) as a colourless oil. 
Rf 0.69 (EtOAc/40-60 PE, 1:4); [α] !"# = +19.6 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2957, 2876, 
1616, 1518, 1456, 1393, 1302, 1249, 1171, 1093, 1038, 1011, 827, 735, 698; 1H NMR (400 MHz, 
CDCl3): δH 7.40 (2H, d, J = 8.6 Hz, ArH), 7.35-7.27 (5H, m, PhH), 6.88 (2H, d, J = 8.6 Hz, ArH), 5.46 
(1H, s, ArCHO2), 4.51 (1H, d, J = 12.4 Hz, PhCHaHbO), 4.47 (1H, d, J = 12.4 Hz, PhCHaHbO), 4.27 (1H, 
dd, J = 11.2, 4.7, Hz, H21a), 4.10-4.07 (1H, m, H23), 3.94 (1H, br t, J = 11.2 Hz, H21b), 3.80 (3H, s, 
ArOCH3), 3.72 (1H, dd, J = 10.3, 8.3 Hz, H25), 3.64 (1H, dd, J = 9.2, 4.9 Hz, H27a), 3.29 (1H, dd, J = 9.2 
Hz, H27b), 2.13-1.98 (2H, m, H22a, H26), 1.73-1.66 (1H, m, H24), 1.31-1.27 (1H, m, H22b), 1.05 (3H, d, J = 
7.0 Hz, Me26), 0.99 (3H, d, J = 7.0 Hz, Me24), 0.94 (9H, t, J = 7.8 Hz, SiCH2CH3 x 3), 0.63 (6H, q, J = 7.8 
Hz, SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): δC 159.8, 138.9, 131.8, 128.3, 127.5, 127.4, 127.3, 
113.5, 101.0, 76.6, 76.2, 73.0, 71.8, 67.3, 55.3, 42.7, 36.5, 29.2, 16.3, 11.0, 7.2, 5.6; HRMS calculated 
for C30H47O5Si [M+H]+ 515.3187, found 515.3182. 
PMP acetal 202 
 
TBSOTf (106 µL, 0.460 mmol) was added dropwise to a stirred solution of alcohol 195 (123 mg, 0.307 
mmol) and 2,6-lutidine (71 µL, 0.614 mmol) in CH2Cl2 (0.5 mL) at −78 °C. The reaction was stirred at 
this temperature for 2 h, then quenched with MeOH (0.5 mL) and NaHCO3 solution (2 mL). The mixture 
was warmed to rt and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 × 2 
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mL) and the combined organic extracts dried (MgSO4) and concentrated in vacuo. The residue was 
purified by flash column chromatography (EtOAc/40-60 PE, 1:20) to yield TBS ether 202 (150 mg, 
0.291 mmol, 95%) as a colourless oil.  
Rf 0.80 (EtOAc/40-60 PE, 1:3); [α] !"# = +14.8 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2955, 2857, 
1615, 1518, 1463, 1390, 1361, 1302, 1249, 1170, 1094, 1037, 832, 774, 698; 1H NMR (400 MHz, 
CDCl3): δH 7.41 (2H, d, J = 8.7 Hz, ArH), 7.35-7.27 (5H, m, PhH), 6.88 (2H, d, J = 8.7 Hz, ArH), 5.46 
(1H, s, ArCHO2), 4.50 (1H, d, J = 12.4 Hz, PhCHaHb), 4.46 (1H, d, J = 12.4 Hz, PhCHaHb), 4.26 (1H, 
ddd, J = 11.4, 4.9, 1.2 Hz, H21a), 4.04 (1H, ddd, J = 11.4, 3.8, 2.5 Hz, H23), 3.93 (1H, ddd, J = 12.0, 11.4, 
2.4 Hz, H21b), 3.80 (3H, s, ArOCH3), 3.71 (1H, dd, J = 7.0, 3.1 Hz, H25), 3.64 (1H, dd, J = 9.3, 4.8 Hz, 
H27a), 3.30 (1H, dd, J = 9.3, 8.2 Hz, H27b), 2.14-2.05 (1H, m, H26), 1.99 (1H, dddd, J = 12.0, 12.0, 5.0, 4.9 
Hz, H22a), 1.73 (1H, qdd, J = 7.0, 7.9, 3.8 Hz, H24), 1.35 (1H, m, H22b), 1.04 (3H, d, J = 7.0 Hz, Me26), 
1.01 (3H, d, J = 7.0 Hz, Me24), 0.90 (9H, s, SiC(CH3)3) 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3); 13C 
NMR (100 MHz, CDCl3): δC 159.5, 138.4, 131.4, 128.0, 127.1, 127.0, 126.9, 113.2, 100.5, 76.0, 75.5, 
72.6, 71.9, 66.8, 54.9, 42.8, 36.7, 29.1, 25.8, 18.1, 15.8, 10.8, −4.0, −4.5; calculated for C30H47O5Si 
[M+H]+ 515.3187, found 515.3182. 
Alcohol 199 
 
DIBALH (12.2 mL, 1.0 M in hexanes, 12.2 mmol) was added dropwise over 30 min to a solution of PMP 
acetal 190 (2.11 g, 4.10 mmol) in CH2Cl2 (40 mL) at -78 °C and stirred at this temperature for 1 h. The 
reaction mixture was warmed to -30 °C for 1 h, during which a yellow colour gradually appeared. The 
solution was allowed to warm to 0 °C and stirred for a further 1 h before quenching with Na+/K+ tartrate 
solution (100 mL). The biphasic mixture was stirred vigorously for 16 h, then extracted with CH2Cl2 (3 x 
100 mL). The combined organic phases were dried (Na2SO4) and concentrated in vacuo. The crude 
product was purified by flash column chromatography (gradient elution: PhMe/CH2Cl2, 1:1 ® 0:1, then 
EtOAc/40-60 PE, 1:4) to give alcohol 199 (1.67 g, 3.23 mmol, 79%) as a colourless oil. 
The title compound can also be accessed via the following protocol: 
TESOTf (264 µL, 1.23 mmol) was added dropwise to a solution of bis-alcohol 200 (165 mg, 0.410 mmol) 
and 2,6-lutidine (286 µL, 2.46 mmol) in CH2Cl2 (10 mL) at -78 °C. The reaction was stirred for 1 h 
before quenching with NaHCO3 solution (10 mL). Phases were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL). Combined organic extracts were dried (Na2SO4), concentrated in 
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vacuo and the crude product was purified by flash column chromatography (gradient elution, 
EtOAc/40-60, 1:50 ® 1:40).  
The Bis-TES ether product (253 mg, 0.401 mmol) was dissolved in THF/H2O/AcOH (5:2:1, 5 mL) and 
stirred at rt for 5 h before being cooled to 0 °C and quenched with NaHCO3 solution (10 mL) and stirred 
for 15 min until bubbling had ceased. The phases were separated and the aqueous layer was extracted 
with EtOAc (3 x 10 mL). The combined organic phases were dried (Na2SO4) and alcohol 199 (191 mg, 
0.369 mmol, 90% over 2 steps) was obtained as a colourless oil. 
Rf 0.15 (EtOAc/40-60 PE, 1:5); [α] !"# = −12.6 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3428, 2955, 
2876, 1613, 1514, 1455, 1413, 1301, 1247, 1173, 1039, 1011, 821, 735, 698; 1H NMR (400 MHz, 
CDCl3): δH 7.35-7.33 (4H, m, PhH), 7.31-7.28 (1H, m, PhH), 7.26 (2H, d, J = 8.7 Hz, ArH), 6.87 (2H, d, 
J = 8.7 Hz, ArH), 4.51 (2H, s, PhCH2O), 4.49 (2H, s, ArCH2O), 3.80 (3H, s, ArOCH3), 3.79-3.69 (4H, m, 
H21 x 2, H23, H25), 3.62 (1H, dd, J = 9.2, 4.6 Hz, H27a), 3.30 (1H, dd, J = 9.2, 8.0 Hz, H27b), 2.11-2.01 (2H, 
m, H26, OH), 1.90-1.76 (3H, m, H22 x 2, H24), 1.03 (3H, d, J = 7.0 Hz, Me26), 1.00 (3H, d, J = 7.2 Hz, 
Me24), 0.95 (9H, t, J = 7.9 Hz, SiCH2CH3 x 3), 0.62 (6H, q, J = 7.9 Hz, SiCH2CH3 x 3); 13C NMR (125 
MHz, CDCl3): δC 159.0, 138.7, 130.8, 129.1, 128.2, 127.4, 127.3, 113.7, 78.2, 77.1, 73.0, 72.3, 71.8, 60.7, 
55.2, 42.2, 37.1, 35.5, 15.9, 11.7, 7.0, 5.4; HRMS calculated for C30H49O5Si [M+H]+ 517.3344, found 
517.3335. 
Aldehyde 168 
 
Dess-Martin periodinane (6.16 g, 14.5 mmol) was added portion-wise to a stirred slurry of alcohol 199 
(5.00 g, 9.68 mmol) and NaHCO3 (2.44 g, 29.0 mmol) in CH2Cl2 (150 ml) at 0 °C. The reaction mixture 
was stirred at this temperature for 1 h, then warmed to rt and stirred for a further 75 min until complete. 
The suspension was quenched with Na2S2O3 solution (300 mL) and stirred for 45 min before extracting 
with CH2Cl2 (2 x 200 mL). The combined organic extracts were dried (MgSO4), concentrated in vacuo 
and purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 0:1 ® 1:5) to afford 
aldehyde 168 (4.57 g, 8.88 mmol, 92%) as a colourless oil. 
Rf 0.49 (EtOAc/40-60 PE, 1:5); [α] !"# = −5.2 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2956, 2876, 1725, 
1613, 1514, 1455, 1302, 1248, 1173, 1087, 1039, 1011, 821, 736, 698; 1H NMR (400 MHz, CDCl3): δH 
9.79 (1H, br t, J = 2.2 Hz, CHO), 7.35-7.32 (4H, m, PhH), 7.30-7.27 (1H, m, PhH), 7.23 (2H, d, J = 8.6 
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Hz, ArH), 6.87 (2H, d, J = 8.6 Hz, ArH), 4.49 (2H, s, ArCH2O), 4.46 (2H, s, PhCH2O), 4.23−4.19 (1H, 
m, H23), 3.80 (3H, s, ArOCH3), 3.75 (1H, dd, J = 6.7, 3.8 Hz, H25), 3.59 (1H, dd, J = 9.2, 4.9 Hz, H27a), 
3.30 (1H, dd, J = 9.2, 7.8 Hz, H27b), 2.78 (1H, ddd, J = 16.4, 6.9, 2.4 Hz, H22a), 2.61 (1H, ddd, J = 16.4, 
5.0, 1.9 Hz, H22b), 2.12-2.06 (1H, m, H26), 1.78 (1H, qdd, J = 7.0, 4.3, 3.7 Hz, H24), 1.04 (3H, d, J = 6.9 
Hz, Me26), 0.99-0.94 (12H, m, Me24, SiCH2CH3 x 3), 0.64 (6H, q, J = 7.9 Hz, SiCH2CH3 x 3); 13C NMR 
(100 MHz, CDCl3): δC 201.1, 158.7, 138.4, 130.3, 128.6, 127.9, 127.1, 127.0, 113.4, 76.8, 74.0, 72.7, 
71.7, 71.2, 54.9, 47.8, 42.3, 36.9, 15.4, 11.5, 6.8, 5.2; HRMS calculated for C30H47O5Si [M+H]+ 
515.3187, found 515.3180. 
Alcohol 203 
 
DIBALH (790 µL, 1.0 M in hexanes, 0.787 mmol) was added dropwise to a solution of PMP acetal 202 
(135 mg, 0.262 mmol) in CH2Cl2 (3 mL) at −78 °C. The mixture was stirred at this temperature for 30 
min and warmed to rt for a further 3.5 h. The reaction was quenched with Na+/K+ tartrate solution (3 mL) 
and stirred vigorously for 18 h. The layers were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 5 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. The 
crude product was purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:8 → 
1:5) to yield alcohol 203 (104 mg, 0.201 mmol, 77%) as a colourless oil.  
Rf 0.35 (EtOAc/40-60 PE, 1:3); [α] !"# = −16.5 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3390, 2928, 
1612, 1513, 1462, 1360, 1301, 1247, 1173, 1035, 833, 772, 735, 697; 1H NMR (500 MHz, CDCl3): δH 
7.38-7.34 (4H, m, PhH), 7.32-7.28 (3H, m, PhH, ArH × 2), 6.89 (2H, d, J = 8.6 Hz, ArH), 4.52 (2H, s, 
ArCH2O), 4.50 (2H, s, PhCH2O), 3.82 (3H, s, ArOCH3), 3.81-3.71 (4H, m, H21 × 2, H23, H25), 3.67 (1H, 
dd, J = 9.3, 4.5 Hz, H27a), 3.31 (1H, dd, J = 9.3, 8.3 Hz, H27b), 2.16-2.12 (1H, m, OH), 2.09-2.02 (1H, m, 
H26), 1.93-1.87 (2H, m, H22a, H24), 1.83-1.77 (1H, m, H22b), 1.06 (3H, d, J = 7.0 Hz, Me26), 1.06 (3H, d, J 
= 7.0 Hz, Me24), 0.90 (9H, s, SiC(CH3)3) 0.09 (3H, s, SiCH3), 0.07 (3H, s, SiCH3); 13C NMR (125 MHz, 
CDCl3): δC 159.2, 138.8, 130.8, 129.4, 128.3, 127.6, 127.5, 113.9, 79.2, 76.5, 73.0, 73.6, 72.2, 60.0, 55.3, 
43.2, 37.1, 35.1, 26.1, 18.4, 16.4, 11.8, −3.8, −4.3; HRMS calculated for C30H49O5Si [M+H]+ 517.3344, 
found 517.3338. 
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Aldehyde 204 
 
DMSO (14 µL, 0.193 mmol) was added dropwise to a solution of oxalyl chloride (12 µL, 0.145 mol) in 
CH2Cl2 (1 mL) at −78 °C and the mixture was stirred for 1 h. A solution of alcohol 203 (51.0 mg, 98.7 
µmol) in CH2Cl2 (0.5 mL) was added via cannula and stirred for a further 45 min. Et3N (41 µL, 0.30 
mmol) was added and the cloudy mixture was warmed to rt for 2 h. The reaction was quenched by the 
addition of NH4Cl solution (2 mL). The phases were separated and the aqueous layer was extracted with 
CH2Cl2 (3 × 3 mL). The combined organic phases were dried (MgSO4) and concentrated in vacuo. The 
residue was purified by flash column chromatography (EtOAc/40-60 PE, 1:10) to afford aldehyde 204 
(48.0 mg, 93.2 µmol, 95%) as a colourless oil.  
Rf 0.39 (EtOAc/40-60 PE, 1:5); [α] !"# = −8.4 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2929, 1724, 1613, 
1514, 1463, 1249, 1038, 835, 774, 698; 1H NMR (500 MHz, CDCl3): δH 9.83 (1H, m, CHO), 7.39-7.29 
(5H, m, PhH), 7.25 (2H, d, J = 8.6 Hz, ArH), 6.89 (2H, d, J = 8.6 Hz, ArH), 4.50 (2H, s, ArCH2O), 4.50 
(1H, d, J = 11.1 Hz, PhCHaHbO), 4.48 (1H, d, J = 11.1 Hz, PhCHaHbO), 4.15 (1H, dd, J = 5.1, 4.9 Hz, 
H23), 3.82 (3H, s, ArOCH3), 3.77 (1H, dd, J = 5.9, 3.7 Hz, H25), 3.64 (1H, dd, J = 9.2, 4.9 Hz, H27a), 3.32 
(1H, dd, J = 9.2, 8.0 Hz, H27b), 2.76 (1H, ddd, J = 16.4, 6.8, 2.6 Hz, H22a), 2.68 (1H, ddd, J = 16.4, 5.0, 1.8 
Hz, H22b), 2.15-2.06 (1H, m, H26), 1.88-1.82 (1H, m, H24), 1.06 (3H, d, J = 7.0 Hz, Me26), 1.04 (3H, d, J 
= 7.0 Hz, Me24), 0.92 (9H, s, SiC(CH3)3) 0.10 (3H, s, SiCH3), 0.09 (3H, s, SiCH3); 13C NMR (125 MHz, 
CDCl3): δC 201.5, 159.2, 138.7, 130.5, 129.1, 128.3, 127.5, 127.4, 113.8, 76.5, 74.9, 73.0, 72.4, 71.7, 
55.3, 47.9, 43.3, 37.4, 26.2, 18.4, 15.8, 11.9, −3.8, −4.1; HRMS calculated for C30H47O5Si [M+H]+ 
515.3187, found 515.3181. 
Dimethyl 3-methylglutarate (205) 
 
Acetyl chloride (29.3 mL, 411 mmol) was added dropwise to a solution of 3-methylglutaric acid (15.0 g, 
103 mmol) in MeOH (200 mL) at 0 °C. The mixture was heated at reflux for 16 h, then cooled to rt. The 
solvent was removed under reduced pressure and the residue was neutralised by careful addition of 
NaHCO3 solution (200 mL). Once gas evolution had ceased, the residue was extracted with CH2Cl2 (3 × 
50 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford diester 
205 (15.9 g, 90.7 mmol, 89% yield) as a yellow oil, which was used without further purification. 
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Rf 0.61 (EtOAc/40-60 PE, 1:2); 1H NMR (400 MHz, CDCl3): δH 3.68 (6H, s, OCH3 x 2), 2.52-2.42 (1H, 
m, H1), 2.40 (2H, dd, J = 15.0, 6.0 Hz, H2a × 2), 2.25 (2H, dd, J = 15.0, 7.3 Hz, H2b × 2), 1.03 (3H, d, J = 
6.5 Hz, Me3).  
Data in agreement with that presented by Jones.211  
 (R)-Methyl-3-methylglutarate (137) 
 
Dimethyl 3-methylglutarate (205) (17.8 g, 102 mmol) was dissolved in KH2PO4/Na2PO4 buffer solution 
(480 mL, 0.1 M, pH 7) and MeOH (120 mL). The solution was cooled to −10 °C and pig liver esterase 
(370 mg, 6660 U) was added. Aqueous NaOH (1.0 M, 102 mL, 102 mmol) was added dropwise at such a 
rate as to maintain the pH between 6.0 and 7.5. After 10 hours the addition was complete, the light brown 
suspension was filtered through a pad of Celite® and the residue was rinsed with H2O (200 mL). The pH 
of the combined filtrates was adjusted to 3 with 3 N HCl solution and the mixture extracted with Et2O (8 
× 400 mL). The combined organic phases were dried (Na2SO4) and concentrated in vacuo to give 
monoester 137 (15.9 g, 99.0 mmol, 97%) as a colourless liquid. 
(-)-Cinchonidine (29.1 g, 99.0 mmol) was added to a solution of enantioenriched monoester 137 in 
acetone (280 mL). The white suspension was heated to 40 °C. H2O (35 mL) was added dropwise to the 
rapidly stirring mixture until a clear pale yellow solution formed. The solution was cooled to rt, then left 
to stand at -5 °C for 16 h to give off-white, needle-like crystals. The solid was collected by filtration, 
washed with ice-cold acetone (50 mL) and dried in vacuo. An additional crop of product was obtained 
from the mother liquor by leaving it to stand at -10 °C for 16 h, filtering and washing the solids with 
acetone (20 mL). The combined collected solids were dissolved 2 N HCl solution (200 mL), then 
extracted with Et2O (5 × 200 mL). The organic extracts were dried (Na2SO4) and concentrated in vacuo to 
yield monoester 137 as a colourless oil (9.90 g, 61.8 mmol, 62%, 96% ee). 
The GC analyses were carried out in split mode (ratio 50:1) using helium as a carrier gas at a flow rate of 
134 mL min-1 25.00 psi. The injection port temperature was 250 °C and the oven was maintained at 97 
°C. The FID detector was at 250 °C, using H2 flow at 40.00 mL min-1, air at 450 mL min-1
 and helium 
makeup flow at 45.0 mL min-1. RT (R) 165.6 min, RT (S) 172.0 min, total run time 240 min.  
Rf 0.24 (EtOAc/40-60 PE, 1:1); 1H NMR (500 MHz, CDCl3): δH 3.70 (3H, s, OCH3), 2.53-2.42 (3H, m, 
H16a, H17, H18a), 2.35-2.27 (2H, m, H16b, H18b), 1.08 (3H, d, J = 6.5 Hz, Me17).  
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Data in agreement with that presented by Fürstner.214 
Methyl (R)-5-hydroxy-3-methylpentanoate (206) 
 
Borane-dimethylsulfide complex (3.41 mL, 35.9 mmol) was added dropwise to a solution of (R)-methyl-
3-methylglutarate 137 (4.79 g, 29.9 mmol) in THF (200 mL) at 0 °C. The solution was stirred at 0 °C for 
1 h, then warmed to rt and stirred for a further 2 h. Upon completion, the reaction mixture was cooled to 0 
°C and quenched by the dropwise addition of NaHCO3 solution (10 mL). The mixture was diluted with 
H2O (50 mL) and extracted with Et2O (6 x 200 mL). The combined organic phases were dried (Na2SO4), 
concentrated in vacuo and the residue was purified by flash column chromatography (gradient elution: 
EtOAc/40-60 PE, 1:4 ® 1:1). Alcohol 206 (4.28 g, 29.3 mmol, 98%) was obtained as a colourless oil. 
Rf 0.31 (EtOAc/40-60 PE, 1:3); 1H NMR (400 MHz, CDCl3): δH 3.70-3.65 (2H, m, H15 x 2), 3.68 (3H, 
s, OCH3), 2.35 (1H, dd, J = 14.9, 6.5 Hz, H18a), 2.21 (1H, dd, J = 14.9, 7.1 Hz, H18b), 2.20-2.11 (1H, m, 
H17), 1.66 (1H, br s, OH), 1.63−1.47 (2H, m, H16 x 2), 0.99 (3H, d, J = 6.6 Hz, Me17).  
Data in agreement with that presented by Tamm.166 
TES ester 208 
 
TESCl (2.45 mL, 14.6 mmol) was added dropwise to a solution of alcohol 206 (1.78 g, 12.2 mmol) and 
imidazole (1.24 g, 18.2 mmol) in CH2Cl2 (100 mL) at 0 °C. The reaction mixture was warmed to rt and 
stirred for 1 h before being cooled to 0 °C, then quenched by addition of NaHCO3 solution (100 mL). The 
mixture was warmed to rt and diluted with H2O (50 mL). The phases were separated and the aqueous 
layer extracted with CH2Cl2 (2 x 100 mL). The combined organic phases were dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 
1:50 ® 1:20) yielded ester 208 (2.99 g, 11.5 mmol, 94%) as a colourless oil. 
Rf 0.76 (EtOAc/40-60 PE, 1:4); 1H NMR (500 MHz, CDCl3): δH 3.70-3.64 (2H, m, H15 × 2), 3.69 (3H, 
s, OCH3), 2.38 (1H, dd, J = 14.1, 5.2 Hz, H18a), 2.17-2.09 (1H, m, H17), 2.16 (1H, dd, J = 14.1, 8.2 Hz, 
H18b), 1.64-1.57 (1H, m, H16a), 1.50-1.43 (1H, m, H16b), 0.98 (9H, t, J = 8.0 Hz, SiCH2CH3 x 3), 0.98 
(3H, d, J = 6.5 Hz, Me17), 0.62 (6H, q, J = 8.0 Hz, SiCH2CH3 x 3).  
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Data in agreement with that presented by Lee.245 
TES phosphonate 167 
 
nBuLi (58.4 mL, 1.6 M in hexanes, 93.4 mmol) was added to a solution of dimethyl methylphosphonate 
(13.9 g, 112 mmol) in THF (350 mL) at -78 °C and the mixture was stirred for 45 min. A solution of 
ester 208 (9.72 g, 37.3 mmol) in THF (50 mL) was added via cannula and the reaction mixture was stirred 
for 2.5 h. Upon completion, the mixture was quenched with NH4Cl solution (200 mL), warmed to rt and 
diluted with water (200 mL). The aqueous phase was extracted with EtOAc (4 x 300 mL), the combined 
organic layers dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:4 ® 3:1) to yield phosphonate 167 (12.4 g, 35.1 
mmol, 94%) as a colourless oil. 
The title compound can also be accessed via the following protocol: 
NaH (251 mg, 60% in mineral oil, 6.30 mmol) was suspended in THF (15 mL) at 0 °C. Lactol 221 (500 
mg, 2.10 mmol) was dissolved in THF (10 mL) and added via cannula. The reaction mixture was stirred 
at this temperature for 1 h, followed by the dropwise addition of TESCl (0.704 mL, 4.20 mmol). The 
resulting mixture was warmed to rt and stirred for a further 45 min before being cooled to 0 °C and 
quenched with NH4Cl solution (20 mL). Layers were separated and the aqueous phase was extracted with 
EtOAc (5 x 15 mL). Combined organic phases were dried (MgSO4) and condentrated in vacuo. 
Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:4 ® 3:2) afforded 
phosphonate 167 (632 mg, 1.79 mmol, 85%) as a colourless oil. 
Rf 0.31 (EtOAc/40-60 PE, 1:1); [α] !"# = +4.5 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2956, 2873, 1713, 
1457, 1261, 1185, 1088, 1033, 807, 741; 1H NMR (500 MHz, CDCl3): δH 3.76 (6H, d, J = 11.2 Hz, 
P(OCH3) x 2), 3.64-3.56 (2H, m, H15 x 2), 3.06 (1H, dd, J = 18.2, 13.6 Hz, H20a), 3.02 (1H, dd, J = 18.2, 
13.6 Hz, H20b), 2.60 (1H, dd, J = 17.0, 5.4 Hz, H18a), 2.44 (1H, dd, J = 17.0, 8.0 Hz, H18b), 2.18-2.09 (1H, 
m, H17), 1.54-1.47 (1H, m, H16a), 1.41-1.34 (1H, m, H16b), 0.93-0.89 (12H, SiCH2CH3 x 3, Me17), 0.55 
(6H, q, J = 8.1 Hz, SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): δC 201.4, 77.3, 60.6, 51.4, 41.0, 39.3, 
25.9, 19.7, 6.7, 4.3; HRMS calculated for C15H34O5PSi3 [M+H]+ 353.1908, found 353.1910. 
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TBS ester 209 
 
TBSCl (262 mg, 1.74 mmol) was added to a solution of alcohol 206 (182 mg, 1.24 mmol) and imidazole 
(127 mg, 1.87 mmol) in CH2Cl2 (20 mL). A white precipitate formed gradually and the resulting 
suspension was stirred at rt for 16 h. Upon completion, the reaction was cooled to 0 °C and quenched 
with NH4Cl solution (10 mL). The mixture was warmed to rt and stirred for 20 min. The organic phase 
was separated and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined organic 
extracts were dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash column 
chromatography (EtOAc/40-60 PE, 1:50) to yield ester 209 (233 mg, 89.5 µmol, 72%) as a colourless oil. 
Rf 0.81 (EtOAc/40-60 PE, 1:4); 1H NMR (500 MHz, CDCl3): δH 3.70-3.65 (2H, m, H15 x 2), 3.69 (3H, 
s, OCH3), 2.38 (1H, dd, J = 14.1, 5.1 Hz, H18a), 2.17 (1H, dd, J = 14.1, 8.2 Hz, H18b), 2.16-2.09 (1H, m, 
H17), 1.62-1.56 (1H, m, H16a), 1.45 (1H, ddd, J = 13.5, 7.0, 6.5 Hz, H16b), 0.98 (3H, d, J = 6.5 Hz, Me17), 
0.91 (9H, s, SiC(CH3)3), 0.07 (6H, s, Si(CH3)2).  
Data in agreement with that presented by Lee.162  
TBS phosphonate 210 
 
nBuLi (480 µL, 1.6 M in hexanes, 0.768 mmol) was added dropwise to a solution of distilled dimethyl 
methylphosphonate (100 µL, 0.921 mmol) in THF (3 mL) at −78 °C and the mixture was stirred for 1 h. 
A solution of ester 209 (79.0 mg, 0.303 mmol) in THF (1 mL) was added via cannula and the reaction 
was stirred at this temperature for 3 h. Upon completion, the mixture was quenched with NH4Cl solution 
(3 mL). Layers were separated and the aqueous phase was extracted with CH2Cl2 (3 × 3 mL). The 
combined organic extracts were washed with brine (5 mL), dried (MgSO4) and concentrated in vacuo. 
The crude product was purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:6 
→ 1:0) to afford phosphonate 210 (91.0 mg, 25.8 µmol, 85% yield) as a colourless oil. 
Rf 0.24 (EtOAc/40-60 PE, 1:3); 1H NMR (400 MHz, CDCl3): δH 3.79 (6H, d, J = 11.2 Hz, P(OCH3) x 2), 
3.69-3.58 (2H, m, H15 x 2), 3.10 (1H, dd, J = 16.1, 13.8 Hz, H20a), 3.04 (1H, dd, J = 16.1, 13.8 Hz, H20b), 
2.63 (1H, dd, J = 17.0, 5.4 Hz, H18a), 2.47 (1H, dd, J = 17.0, 8.0 Hz, H18b), 2.23-2.12 (1H, m, H17), 
1.58-1.49 (1H, m, H16a), 1.45-1.36 (1H, m, H16b), 0.93 (3H, d, J = 6.7 Hz, Me17), 0.89 (9H, s, 
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SiC(CH3)3), 0.05 (6H, s, SiCH3 x 2).  
Data in agreement with that presented by Lee.162  
2-(1-Adamantanyl)-4-methylphenol (216) 
 
Adamantan-1-ol (5.00 g, 3.28 mmol) was added to a solution of p-cresol (3.38 g, 31.3 mmol) in CH2Cl2 
(30 mL), followed by addition of conc. H2SO4 (1.83 mL) over 20 min. The resulting cloudy mixture was 
stirred for 20 min then diluted with H2O and slowly neutralised to pH 10 by addition of 10% aqueous 
NaOH solution (30 mL). The mixture was extracted with CH2Cl2 (3 x 100 mL), the combined organic 
phases dried (Na2SO4) and concentrated in vacuo. Crude material was triturated with MeOH (30 mL), 
heated to reflux then cooled to rt and filtered. The solid was washed with MeOH (2 x 50 mL) and the 
filtrate concentrated in vacuo to yield phenol 216 (5.44 g, 22.4 mmol, 72%) as white crystals. 
Rf 0.46 (EtOAc/40-60 PE, 1:5); 1H NMR (500 MHz, CDCl3): δH 7.02 (1H, d, J = 1.9 Hz, ArH), 6.87 
(1H, dd, J = 8.0, 1.9 Hz, ArH), 6.55 (1H, dd, J = 8.0 Hz, ArH), 4.53 (1H, s, OH), 2.28 (3H, s, ArCH3), 
2.14-2.12 (6H, m, CH2 x 3), 2.08-2.06 (3H, m, CH x 3), 1.78 (6H, t, J = 3.1 Hz, CH2 x 3). 
Data in agreement with that presented by Jacobsen.217  
3-(1-Adamantanyl)-2-hydroxy-5-methylbenzaldehyde (217) 
 
SnCl4 (97 µL, 82.6 µmol) was added dropwise to a stirred solution of phenol 216 (1.00 g, 4.13 mmol) and 
2,6-lutidine (382 µL, 3.30 mmol) in PhMe (13 mL) and a yellow precipitate was observed. The bright 
yellow mixture was stirred at rt for 1.5 h before paraformaldehyde (701 mg, 23.4 mmol) was added in one 
portion. The reaction was heated to reflux for 4 h, then cooled to rt and filtered through a short pad of 
silica gel, eluting with EtOAc (50 mL). The filtrate was washed with H2O (30 mL), 1 N HCl solution (30 
mL) and brine (30 mL) and dried (Na2SO4). The organic phase was concentrated in vacuo to afford 
aldehyde 217 (1.05 g, 3.88 mmol, 94%) as a yellow solid. 
Rf 0.71 (EtOAc/40-60 PE, 1:5); 1H NMR (400 MHz, CDCl3): δH 11.65 (1H, s, CHO), 9.83 (1H, s, OH), 
7.28 (1H, d, J = 2.1 Hz, ArH), 7.17 (1H, d, J = 2.1 Hz, ArH), 2.33 (3H, s, ArCH3), 2.16-2.12 (6H, m, 
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CH2 x 3) 2.11-2.08 (3H, m, CH x 3), 1.79 (6H, t, J = 2.9 Hz, CH2 x 3).  
Data in agreement with that presented by Jacobsen.217 
Imine 219 
 
Aldehyde 217 (5.05 g, 18.7 mmol) was suspended in EtOH (200 proof, 75 mL) and the mixture heated to 
80 °C until a clear solution was obtained. (1S,2R)-Aminoindanol (2.93 g, 19.6 mmol) was added and the 
reaction heated to reflux for 1 h during which a bright yellow precipitate had formed. The mixture was 
then cooled to rt and left to stand for 16 h. The solid was collected by filtration, washed with cold EtOH 
(200 proof, 150 mL) and dried in vacuo to obtain imine 219 (5.83 g, 14.5 mmol, 78%) as yellow crystals. 
Rf 0.49 (EtOAc/40-60 PE, 1:5); 1H NMR (500 MHz, CDCl3): δH 13.07 (1H, s, ArOH), 8.57 (1H, s, 
CH=N), 7.34-7.17 (4H, m, ArH), 7.12 (1H, d, J = 2.1 Hz, ArH), 6.99 (1H, d, J = 2.1 Hz, ArH), 4.80 (1H, 
d, J = 5.4 Hz, H1), 4.70 (1H, dq, J = 7.0, 5.4 Hz, H2), 3.26 (1H, dd, J = 16.2, 6.0 Hz, H3a), 3.14 (1H, dd, J 
= 16.2, 5.1 Hz, H3b), 2.31 (3H, s, ArCH3), 2.16-2.12 (6H, m, CH2 x 3), 2.10-2.03 (3H, m, CH x 3), 1.77 
(6H, br s, CH2 x 3). 
Data in agreement with that presented by Jacobsen.217 
(1S,2R)-Jacobsen catalyst 213 
 
Chromium(II) chloride (2.02 g, 17.4 mmol) was added to imine 219 (5.83 g, 14.5 mmol)  in the glove 
box. The solids were suspended in THF (200 mL) under Ar and stirred at rt for 3 h, then exposed to air 
and stirred for a further 14 h. The flask was put under an Ar atmosphere followed by addition of 2,6-
lutidine (4.04 mL, 34.9 mmol) and the reaction stirred at rt for 3 h during which a colour change to brown 
was observed. The mixture was diluted with Et2O (150 mL) and washed with NH4Cl solution (2 x 200 
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mL) and brine (2 x 200 mL). The organic phase was dried (Na2SO4) and concentrated in vacuo to yield 
catalyst 213 (7.05 g, 14.4 mmol, 99%) as a brown powder. 
IR (νmax / cm−1): 2900, 2846, 1615,1536, 1432, 1339, 1308, 1228, 1169, 1081. 
Dihydropyran 214 
 
Crotonaldehyde (2.83 mL, 34.2 mmol) and ethyl vinyl ether (16.4 mL, 171 mmol) were added to a flask 
containing (1S,2R)-catalyst 213 (416 mg, 0.855 mmol) and activated powdered 4 Å molecular sieves 
(2.50 g). The resulting brown suspension was stirred for 3 days at rt, then diluted with 30-40 PE (20 mL) 
and filtered through Celite®, eluting with 30-40 PE (2 x 10 mL). The solvent was removed under reduced 
pressure (400 mmHg) and the residue was fractionally distilled under reduced pressure (15 mmHg) into a 
cooled flask (-78 °C). Dihydropyran 214 was obtained as a mixture with crotonaldehyde and was 
transferred into the next step without further purification. 
Rf 0.87 (EtOAc/40-60 PE, 1:4); 1H NMR (400 MHz, CDCl3): δH 6.24 (1H, dd, J = 6.2, 2.2 Hz, H15), 4.92 
(1H, dd, J = 8.8, 2.2 Hz, H19), 4.65 (1H, ddd, J = 6.1, 2.2, 1.4 Hz, H16), 3.93 (1H, dq, J = 9.6 Hz, 7.0 Hz, 
OCHaHbCH3), 3.58 (1H, dq, J = 9.6, 7.0 Hz, OCHaHbCH3), 2.47-2.37 (1H, m, H17), 2.02 (1H, dddd, J  = 
13.0, 6.2, 2.1, 1.4 Hz, H18a), 1.50 (1H, ddd, J = 13.1, 10.0, 8.8 Hz, H18b), 1.25 (3H, t, J = 7.1 Hz, 
OCHaHbCH3), 1.04 (3H, d, J = 7.0 Hz, Me17).  
Data in agreement with that presented by Jacobsen.217  
Mixed acetal 220 
 
A mixture of dihydropyran 214 and crotonaldehyde was dissolved in Et2O (30 mL) and Pd/C (1.60 g, 
1.50 mmol, 10 wt%) was added. The reaction mixture was placed under an atmosphere of hydrogen 
(balloon pressure) and stirred for 2 days at rt. Upon completion, the catalyst was removed by filtration 
through Celite®, eluting with Et2O (2 x 5 mL). The solvent was removed under reduced pressure (400 
mmHg) to give mixed acetal 220 (3.16 g, 21.9 mmol, 74% over 2 steps) as a colourless oil.  
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Rf 0.82 (EtOAc/40-60 PE, 1:4); 1H NMR (500 MHz, CDCl3): δH 4.35 (1H, dd, J = 9.4, 2.2 Hz, H19), 4.00 
(1H, ddd, J = 11.6, 4.6, 1.7 Hz, H15a), 3.92 (1H, dq, J = 9.5, 7.2 Hz, OCHaHbCH3), 3.53 (1H, dq, J = 9.5, 
7.0 Hz, OCHaHbCH3), 3.43 (1H, app td, J = 12.0, 2.4 Hz, H15b), 1.82-1.79 (1H, m, J = 12.7 Hz, H18a), 
1.72-1.59 (1H, m, H17), 1.51-1.48 (1H, m, J = 13.2 Hz, H16a), 1.23 (3H, t, J = 7.1 Hz, OCHaHbCH3), 
1.23-1.17 (1H, m, H18b), 1.11 (1H, ddd, J = 12.7, 12.1, 9.5 Hz, H16b), 0.97 (3H, d, J = 6.6 Hz, Me17). 
Data in agreement with that presented by Jacobsen for the enantiomer of mixed acetal 220.217  
Lactone 207 
 
Mixed acetal 220 was dissolved in H2O/acetone (1:1, 30 mL) and TsOH×H2O (300 mg, 1.58 mmol) was 
added. The reaction mixture was stirred at rt for 24 h before being quenched with NaHCO3 solution. The 
layers were separated and the aqueous phase was extracted with Et2O (3 x 80 mL). Combined organic 
extracts were dried (Na2SO4) and carefully concentrated under reduced pressure (200 torr). 
The residue was dissolved in CH2Cl2 (450 mL) at rt and PCC (31.9 g, 148 mmol) was added portion-
wise. A colour change from orange to dark brown was observed and the reaction mixture was stirred at rt 
for 20 h. The mixture was diluted with 30-40 PE (50 mL) and filtered through Celite®, eluting with 
30-40 PE (2 x 15 mL). The solvent was removed under reduced pressure (430 mmHg) and the residue 
was purified by flash column chromatography (gradient elution: Et2O/30-40 PE, 1:5 ® 1:0) and fractions 
containing product 207 were combined. The solvent was removed by careful fractional distillation at 
ambient pressure to yield lactone 207 as a colourless oil (1.83 g, 16.0 mmol, 64% yield over 2 steps). 
Rf 0.22 (EtOAc/40-60 PE, 1:4); [α] !"# = +20.0 (c 1.0, CHCl3);  1H NMR (500 MHz, CDCl3): δH 4.44 (1H, 
ddd, J = 11.3, 4.7, 4.0 Hz, H15a), 4.29 (1H, ddd, J = 11.3, 10.8, 3.8 Hz, H15b), 2.74-2.67 (1H, m, H18a), 
2.17-2.07 (2H, m, H16a, H18b), 1.94 (1H, dqd, J = 14.2, 4.0, 1.7 Hz, H16b), 1.59-1.51 (1H, m H17), 1.09 
(3H, d, J = 6.3 Hz, Me17). 
Data in agreement with that presented by Evans.220  
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Lactol 221 
 
nBuLi (9.86 mL, 1.6 M in hexanes, 6.16 mmol) was added dropwise to a solution of dimethyl 
methylphosphonate (2.18 g, 17.5 mmol) in THF (30 mL) at -78 °C and the bright yellow mixture was 
stirred at this temperature for 45 min. Lactone 207 (1.00 g, 8.76 mmol) was dissolved in THF (10 mL) 
and added to the solution of the anion via cannula. The reaction mixture was stirred at -78 °C for 1.5 h 
until complete, then quenched by the addition of NH4Cl solution (30 mL) while warming to rt. The 
phases were separated and the aqueous layer was extracted with EtOAc (3 x 50 mL). Combined organic 
phases were dried (Na2SO4) and the crude product was purified by flash column chromatography 
(gradient elution: EtOAc/40-60 PE, 1:4 ® 1:0). Lactol 221 (1.83 g, 7.68 mmol, 87%) was obtained as a 
colourless oil which crystallised to a white solid upon standing. 
Rf 0.26 (EtOAc); m.p. 32-34 °C; IR (thin film, νmax / cm−1): 3383, 2953, 1442, 1218, 1183, 1091, 1024, 
986, 929, 905, 859, 845, 820, 801, 771, 728; 1H NMR (500 MHz, CDCl3): δH 5.16 (1H, br s, OH), 3.86 
(1H, dd, J = 12.7, 11.3 Hz, H15a), 3.74 (3H, d, J = 11.4 Hz, P(OCH3)), 3.66 (3H, d, J = 11.4 Hz, 
P(OCH3)), 3.61 (1H, dd, J = 11.3, 4.7 Hz, H15b), 2.11 (1H, br s, H20a), 2.07 (1H, br s, H20b), 2.03-1.94 
(1H, m, H17), 1.79-1.76 (1H, m, H18a), 1.51-1.47 (1H, m, H16a), 1.13 (1H, dddd, J = 12.7, 12.7, 12.7, 4.7 
Hz, H16b), 1.00 (1H, dd, J = 12.9, 12.3 Hz, H18b), 0.84 (3H, d, J = 7.1 Hz, Me17); 13C NMR (125 MHz, 
CDCl3): δC 94.6, [94.5], 60.9, 53.3, 51.6, 44.6, 38.2, [37.2], 33.5, 25.1, [25.0], 22.0; HRMS calculated for 
C9H18O4P [M-H2O] 221.0943, found 221.0947. 
Distinguishable resonances of the diastereomers in the 13C NMR spectrum are given in brackets. 
Enone 223 
 
A solution of phosphonate 167 (7.26 g, 20.6 mmol) in THF (80 mL) was added via cannula to a 
suspension of Ba(OH)2 (4.71 g, 27.4 mmol) in THF (60 mL) and the mixture stirred at rt for 1 h. A 
solution of aldehyde 168 (10.1 g, 19.6 mmol) in THF/H2O (40:1, 120 mL) was added via cannula and the 
reaction stirred for 16 h. Upon completion, the mixture was quenched with NH4Cl solution (200 mL) and 
diluted with H2O (150 mL). The aqueous phase was extracted with EtOAc (3 x 300 mL), dried (MgSO4) 
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and concentrated in vacuo. Crude material was purified by flash column chromatography (gradient 
elution: EtOAc/40-60 PE, 1:30 ® 1:20) to yield enone 223 (12.2 g, 16.5 mmol, 85%, > 20:1 E/Z) as a 
colourless oil. 
Rf 0.54 (EtOAc/40-60 PE, 1:10); [α] !"# = −14.4 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2948, 2913, 
2877, 1669, 1613, 1514, 1457, 1415, 1376, 1298, 1243, 1169, 1092, 1041, 1009, 973, 822, 737, 694; 1H 
NMR (500 MHz, CDCl3): δH 7.38-7.34 (4H, m, PhH), 7.32-7.28 (1H, m, PhH), 7.26 (2H, d, J = 8.5 Hz, 
ArH), 6.88 (2H, d, J = 8.5 Hz, ArH), 6.82 (1H, dt, J = 15.8, 7.3 Hz, H21), 6.17 (1H, d, J = 15.8 Hz, H20), 
4.53 (1H, d, J = 11.1 Hz, ArCHaHbO), 4.50 (2H, ABq, J = 12.2 Hz, PhCH2O), 4.44 (1H, d, J = 11.1 Hz, 
ArCHaHbO), 3.82 (3H, s, ArOCH3), 3.78-3.71 (2H, m, H23, H25), 3.70-3.61 (3H, m, H15 x 2, H27a), 3.31 
(1H, app t, J = 8.6 Hz, H27b), 2.60-2.51 (2H, m, H18a, H22a), 2.49-2.44 (1H, m, H22b), 2.36 (1H, dd, J = 
15.4, 8.5 Hz, H18b), 2.22-2.16 (1H, m, H17), 2.11-2.05 (1H, m, H26) 1.79-1.72 (1H, m, H24), 1.62-1.56 
(1H, m, H16a), 1.49-1.42 (1H, m, H16b), 1.05 (3H, d, J = 7.0 Hz, Me26), 1.00-0.93 (24H, m, Me17, Me24, 
SiCH2CH3 x 6), 0.66-0.60 (12H, m, SiCH2CH3 x 6); 13C NMR (125 MHz, CDCl3): δC 199.9, 159.1, 
143.7, 138.8, 132.5, 130.9, 128.9, 128.3, 127.5, 127.4, 113.8, 78.3, 77.1, 73.0, 72.2, 71.5, 60.9, 55.3, 
47.6, 42.1, 39.9, 37.0, 36.0, 26.7, 20.0, 16.1, 11.1, 7.2, 6.8, 5.6, 4.4; HRMS calculated for C43H73O6Si2 
[M+H]+ 741.4940, found 741.4935. 
Allylic alcohol 224 
 
(S)-Me-CBS catalyst 138 (673 µL, 1.0 M in PhMe, 0.673 mmol) was added to a solution of enone 223 
(4.99 g, 6.73 mmol) in THF (100 mL) at -20 °C and stirred for 10 min. BH3×SMe2 (761 µL, 15.4 mmol) 
was added dropwise, the reaction warmed to -10 °C and stirred for 1.5 h before being carefully quenched 
with MeOH (20 mL). The mixture was warmed to rt and stirred for a further 15 min before concentrating 
in vacuo. The residue was redissolved in MeOH (20 mL), then concentrated in vacuo and the procedure 
repeated three times. Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 
1:30 ® 1:10) afforded allylic alcohol 224 (4.97 g, 6.69 mmol, 99%, 13:1 dr) as a colourless oil. 
Rf 0.44 (EtOAc/40-60 PE, 1:5); [α] !"# = −5.2 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2956, 2869, 1616, 
1518, 1454, 1378, 1301, 1244, 1171, 1082, 1033, 996, 963, 820, 808, 729, 696; 1H NMR (500 MHz, 
CDCl3): δH 7.34-7.35 (4H, m, PhH), 7.32-7.28 (1H, m, PhH), 7.27 (2H, d, J = 8.4 Hz, ArH), 6.88 (2H, d, 
J = 8.4 Hz, ArH), 5.64 (1H, ddd, J = 15.2, 8.0, 7.0 Hz, H21), 5.54 (1H, dd, J = 15.2, 6.8 Hz, H20), 4.57 
(1H, d, J = 11.1 Hz, ArCHaHbO), 4.52 (1H, d, J = 12.2 Hz, PhCHaHbO), 4.49 (1H, d, J = 12.2 Hz, 
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PhCHaHbO), 4.41 (1H, d, J = 11.1 Hz, ArCHaHbO), 4.21-4.14 (1H, m, H19) 3.82 (3H, s, ArOCH3), 3.74 
(1H, dd, J = 7.0, 3.2 Hz, H25), 3.72-3.63 (4H, m, H15 x 2, H23, H27b), 3.32 (1H, dd, J = 8.8, 8.8 Hz, H27b), 
2.44 (1H, ddd, J = 14.2, 7.3, 6.0 Hz, H22a), 2.29 (1H, ddd, J = 14.2, 7.2, 7.2 Hz, H22b), 2.13-2.05 (1H, m, 
H26), 1.83-1.63 (4H, m, H16a, H17, H24, OH) 1.50-1.37 (3H, m, H16b, H18 x 2), 1.06 (3H, d, J = 7.0 Hz, 
Me26), 1.01-0.94 (24H, m, Me17, Me24, SiCH2CH3 x 6), 0.63 (12H, J = 7.9 Hz, SiCH2CH3 x 6); 13C NMR 
(125 MHz, CDCl3): δC 158.8, 138.8, 135.4, 131.3, 128.7, 128.2, 128.0, 127.3, 127.2, 113.5, 78.6, 77.1, 
72.9, 72.1, 70.9, 70.7, 60.9, 55.2, 44.4, 41.4, 39.4, 36.7, 35.1, 26.3, 20.3, 16.1, 10.6, 7.1, 6.7, 5.5, 4.3; 
HRMS calculated for C43H78O6Si2N [M+NH4]+ 760.5362, found 760.5360. 
(R)-Mosher ester 225 
 
DCC (67 µL, 1.0 M in CH2Cl2, 67.0 µmol) and DMAP (8.0 mg, 67.0 µmol) were added sequentially to a 
solution of allylic alcohol 224 (10.4 mg, 14.0 µmol) and (R)-(+)-α-methoxy-α-(trifluoromethyl)-
phenylacetic acid (16.0 mg, 68.3 µmol) in CH2Cl2 (2 mL) and the mixture was stirred at rt for 17 h. The 
white suspension was concentrated in vacuo and the residue was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 0:1 → 1:30) to afford (R)-Mosher ester 225 as a 
colourless oil (10.2 mg, 10.6 µmol, 76%). 
Rf 0.66 (EtOAc/40-60 PE, 1:8); 1H NMR (400 MHz, CDCl3): δH 7.53-7.48 (2H, m, PhH), 7.40-7.35 
(3H, m, PhH), 7.34-7.29 (4H, m, PhH), 7.29-7.27 (1H, m, PhH), 7.24 (2H, d, J = 8.6 Hz, ArH), 6.85 
(2H, d, J = 8.6 Hz, ArH), 5.80 (1H, dt, J = 15.2, 7.0 Hz, H21), 5.55-5.48 (1H, m, H19), 5.39 (1H, dd, J = 
15.2, 7.9 Hz, H20), 4.50 (1H, d, J = 11.0 Hz, ArCHaHbO), 4.48 (1H, d, J = 12.0 Hz, PhCHaHbO), 4.44 
(1H, d, J = 12.0 Hz, PhCHaHbO), 4.37 (1H, dd, J = 11.0 Hz, ArCHaHbO), 3.80 (3H, s, ArOCH3), 3.70 
(1H, dd, J = 7.1, 3.3 Hz, H25), 3.65-3.57 (4H, m, H15 x 2, H23, H27a), 3.53 (3H, s, OCH3), 3.29 (1H, dd, J 
= 8.9, 8.5 Hz, H27b), 2.39 (1H, dt, J = 14.2, 6.5 Hz, H22a), 2.25 (1H, dt, J = 14.2, 7.1 Hz, H22b), 2.11-2.08 
(1H, m, H26), 1.75-1.60 (4H, m, H16a, H17, H18a, H24), 1.42-1.28 (2H, m, H16b, H18b), 1.02 (3H, d, J = 6.8 
Hz, Me26), 0.97-0.91 (24H, m, Me17, Me24, SiCH2CH3 x 6), 0.62-0.55 (12H, m, SiCH2CH3 x 6). 
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(S)-Mosher ester 226 
 
DCC (67 µL, 1.0 M in CH2Cl2, 67.0 µmol) and DMAP (8.0 mg, 67.0 µmol) were added sequentially to a 
solution of allylic alcohol 224 (9.8 mg, 13.2 µmol) and (S)-(+)-α-methoxy-α-(trifluoromethyl)-
phenylacetic acid (16.0 mg, 68.3 µmol) in CH2Cl2 (2 mL) and the mixture was stirred at rt for 17 h. The 
white suspension was concentrated in vacuo and the residue was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 0:1 → 1:30) to afford (R)-Mosher ester 226 as a 
colourless oil (6.2 mg, 6.5 µmol, 49%). 
Rf 0.64 (EtOAc/40-60 PE, 1:8); 1H NMR (400 MHz, CDCl3): δH 7.55-7.50 (2H, m, PhH), 7.39-7.35 
(3H, m, PhH), 7.34-7.31 (4H, m, PhH), 7.29-7.27 (1H, m, PhH), 7.24 (2H, d, J = 8.5 Hz, ArH), 6.85 
(2H, d, J = 8.5 Hz, ArH), 5.86 (1H, dt, J = 14.2, 7.0 Hz, H21), 5.56-5.47 (2H, m, H19, H20), 4.51 (1H, d, J 
= 11.0 Hz, PhCHaHbO), 4.48 (1H, d, J = 12.1 Hz, ArCHaHbO), 4.43 (1H, d, J = 12.1 Hz, ArCHaHbO), 
4.38 (1H, d, J = 11.0 Hz, PhCHaHbO), 3.80 (3H, s, ArOCH3), 3.71 (1H, dd, J = 6.9, 3.3 Hz, H25), 
3.65-3.57 (4H, m, H12 x 2, H23, H27a), 3.52 (3H, s, OCH3), 3.28 (1H, dd, J = 8.7, 8.7 Hz, H27b), 2.43 (1H, 
dt, J = 14.3, 6.3 Hz, H22a), 2.28 (1H, dt, J = 14.3, 6.9 Hz, H22b), 2.09-2.00 (1H, m, H26), 1.74-1.65 (1H, 
m, H24), 1.63-1.51 (3H, m, H16a, H17, H18a), 1.37-1.27 (2H, m, H16b, H18b), 1.02 (3H, d, J = 6.9 Hz, Me26), 
0.97-0.90 (21H, m, Me24, SiCH2CH3 x 6), 0.85 (3H, d, J = 6.2 Hz, Me17), 0.63-0.56 (12H, m, SiCH2CH3 
x 6). 
Methyl ether 227 
 
Sodium hydride (3.99 g, 60% dispersion in mineral oil) was washed with hexane (2 x 20 mL) and dried in 
vacuo before adding THF (50 mL). The suspension was cooled to 0 °C and a solution of allylic alcohol 
224 (10.6 g, 14.2 mmol) in THF (70 mL) was added via cannula. The mixture was left to stir for 1 h 
before adding MeI (7.09 mL, 114 mmol) and warming to rt. The reaction was stirred for 4 h until 
complete and carefully quenched with MeOH (50 mL) at 0 °C. The mixture was warmed to rt, poured 
into brine (200 mL), diluted with H2O (100 mL) and extracted with EtOAc (2 x 250 mL). Combined 
organic phases were dried (MgSO4), concentrated in vacuo and purified by flash column chromatography 
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(gradient elution: EtOAc/40-60 PE, 0:1 ® 1:22) to give methyl ether 227 (9.57 g, 12.6 mmol, 89%) as a 
colourless oil. 
Rf 0.79 (EtOAc/40-60 PE, 1:8); [α] !"# = +3.6 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2956, 2875, 1613, 
1514, 1455, 1248, 1091, 1041, 1011, 971, 818, 738; 1H NMR (400 MHz, CDCl3): δH 7.35-7.33 (4H, m, 
PhH), 7.31-7.27 (1H, m, PhH), 7.26 (2H, d, J = 8.3 Hz, ArH), 6.87 (2H, d, J = 8.3 Hz, ArH), 5.58 (1H, 
dt, J = 15.2, 7.4 Hz, H21), 5.29 (1H, dd, J = 15.2, 8.6 Hz, H20), 4.58 (1H, d, J = 11.1 Hz, ArCHaHbO), 4.51 
(1H, d, J = 12.2 Hz, PhCHaHbO), 4.46 (1H, d, J = 12.2 Hz, PhCHaHbO), 4.40 (1H, J = 11.1 Hz, 
ArCHaHbO), 3.81 (3H, s, ArOCH3), 3.74 (1H, dd, J = 7.8, 2.4 Hz, H25), 3.72-3.59 (4H, m, H15 × 2, H23, 
H27a), 3.56 (1H, app q, J = 7.4 Hz, H19), 3.29 (1H, app t, J = 8.9 Hz, H27b), 3.22 (3H, s, OMe), 2.48 (1H, 
dt, J = 14.2, 5.4 Hz, H22a), 2.29 (1H, dt, J = 14.2, 7.8 Hz, H22b), 2.13-2.06 (1H, m, H26), 1.83-1.75 (1H, 
m, H24), 1.72-1.58 (2H, m, H16a, H17), 1.51-1.33 (3H, m, H16b, H18 x 2), 1.05 (3H, d, J = 6.9 Hz, Me26), 
0.99-0.93 (21H, m, Me24, SiCH2CH3 x 6), 0.89 (3H, d, J = 6.7 Hz, Me17), 0.65-0.58 (12H, m, SiCH2CH3 
x 6); 13C NMR (100 MHz, CDCl3): δC 158.6, 138.5, 132.7, 131.0, 130.3, 128.3, 127.9, 127.1, 127.0, 
113.3, 80.4, 78.1, 76.8, 72.7, 71.7, 70.6, 60.6, 55.4, 54.9, 42.7, 40.8, 39.7, 36.5, 34.8, 25.8, 19.6, 15.7, 
10.0, 6.8, 6.5, 5.3, 4.1; HRMS calculated for C44H76O6Si2Na [M+Na]+ 779.5073, found 779.5057.  
Alcohol 238 
 
A solution of LiDBB (20.0 mL, 1.0 M in THF, 20.0 mmol) was added to a solution of methyl ether 227 
(3.03 g, 4.00 mmol) in degassed THF (145 mL) at -78 °C. The reaction was stirred for 20 min before 
being quenched by addition of NH4Cl solution and warming to rt. The phases were separated and the 
aqueous layer extracted with EtOAc (3 x 100 mL). Combined organic extracts were dried (Na2SO4), 
concentrated in vacuo and purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 
1:50 ® 1:8) to yield alcohol 238 (2.04 g, 3.20 mmol, 77%, 96% BRSM) as a colourless oil. 
Rf 0.51 (EtOAc/40-60 PE, 1:3); [α] !"# = +11.0 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3452, 2960, 
2877, 1615, 1514, 1459, 1417, 1378, 1302, 1251, 1169, 1088, 1038, 1011, 969, 820, 747; 1H NMR (400 
MHz, CDCl3): δH 7.24 (2H, d, J = 8.6 Hz, ArH), 6.88 (2H, d, J = 8.6 Hz, ArH), 5.59 (1H, dt, J = 15.2, 6.6 
Hz, H21), 5.33 (1H, dd, J = 15.2, 8.2 Hz, H20), 4.59 (1H, d, J = 11.1 Hz, ArCHaHbO), 4.50, (1H, J = 11.1 
Hz, ArCHaHbO), 3.81 (3H, s, ArOCH3), 3.82-3.77 (2H, m, H25, H27a), 3.69-3.52 (5H, m, H15 × 2, H19, 
H23, H27b), 3.24 (3H, s, OCH3), 2.66 (1H, dd, J = 7.3, 4.0 Hz, OH), 2.51 (1H, dt, J = 14.1, 5.4 Hz, H22a), 
2.38 (1H, dt, J = 14.1, 7.9 Hz, H22b), 1.91-1.85 (2H, m, H24, H26), 1.71-1.55 (2H, m, H16a, H18a), 
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1.52-1.33 (3H, m, H16b, H17, H18b), 1.07 (3H, d, J = 6.9 Hz, Me26), 0.99-0.94 (21H, m, Me24, SiCH2CH3 x 
6), 0.89 (3H, d, J = 6.5 Hz, Me17), 0.69-0.57 (12H, m, SiCH2CH3 x 6); 13C NMR (125 MHz, CDCl3): δC 
159.0, 133.5, 131.1, 130.0, 128.6, 113.7, 80.7, 79.8, 78.4, 70.7, 65.3, 61.0, 55.9, 55.3, 43.1, 42.0, 40.0, 
36.2, 34.9, 26.2, 20.0, 16.6, 9.9, 7.0, 6.8, 5.4, 4.5; HRMS calculated for C37H74O6Si2N [M+NH4]+ 
684.5049, found 684.5048.  
Allyl carbonate 241 
 
Allyl chloroformate (5.00 mL, 47.2 mmol) was added dropwise to a solution of alcohol 238 (3.16 g, 4.72 
mmol) in CH2Cl2/pyr (1:1, 60 mL) at -60 °C and a white precipitate was observed. The resulting 
suspension was let to gradually warm to -20 °C and stirred at this temperature for 3 h before being 
quenched with NaHCO3 solution (30 mL) and stirred until bubbling had ceased. The aqueous phase was 
extracted with CH2Cl2 (3 x 100 mL) and the combined organic extracts dried (Na2SO4), concentrated in 
vacuo and purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:50 ® 1:15). 
Allyl carbonate 241 (3.12 g, 4.15 mmol, 88%) was obtained as a colourless oil. 
Rf 0.45 (EtOAc/40-60 PE, 1:10); [α] !"# = +5.0 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2960, 2877, 
1746, 1514, 1461, 1294, 1253, 1090, 1037, 1009, 969, 737, 727; 1H NMR (500 MHz, CDCl3): δH 7.26 
(2H, d, J = 8.5 Hz, ArH), 6.89 (2H, d, J = 8.5 Hz, ArH), 6.00-5.92 (1H, m, CH=CH2), 5.62-5.56 (1H, m, 
H21), 5.38 (1H dd, J = 17.1, 1.2 Hz, CH=CHaHb), 5.34 (1H, dd, J = 15.5, 7.1 Hz, H20), 5.29 (1H, dd, J = 
10.3, 1.2 Hz, CH=CHaHb), 4.64 (2H, d, J = 5.7 Hz, OCH2), 4.60 (1H, d, J = 11.1 Hz, ArCHaHbO), 4.40 
(1H, J = 11.1 Hz, ArCHaHbO), 4.32 (1H, dd, J = 10.6, 4.1 Hz, H27a), 3.97 (1H, dd, J = 10.6, 9.3 Hz, H27b), 
3.82 (3H, s, ArOCH3), 3.74 (1H, dd, J = 7.4, 2.6 Hz, H25), 3.70-3.62 (3H, m, H15 × 2, H23), 3.60-3.55 
(1H, m, H19), 3.25 (3H, s, OCH3), 2.51 (1H, dt, J = 14.0, 5.5 Hz, H22a), 2.31 (1H, dt, J = 14.0, 7.9 Hz, 
H22b), 2.16-2.11 (1H, m, H26), 1.84-1.77 (1H, m, H24), 1.71-1.60 (2H, m, H17, H18a), 1.51-1.36 (2H, m, 
H16a x 2, H18b), 1.06 (3H, d, J = 6.9 Hz, Me26), 1.00-0.96 (21H, m, Me24, SiCH2CH3 x 6), 0.91 (3H, d, J = 
6.9 Hz, Me17), 0.67-0.59 (12H, m, SiCH2CH3 x 6); 13C NMR (125 MHz, CDCl3): δC 158.9, 155.2, 133.3, 
131.8, 131.3, 130.3, 128.7, 118.8, 113.7, 80.8, 78.4, 77.0, 70.9, 69.9, 68.3, 61.0, 55.8, 55.3, 43.1, 41.3, 
40.0, 35.7, 35.0, 26.2, 20.0, 16.0, 10.1, 7.1, 6.8, 5.6, 4.5; HRMS calculated for C41H78O8Si2N [M+NH4]+ 
768.5260, found 768.5253.  
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Alcohol 242 
 
Acetic acid (10 mL) was added dropwise to a solution of TES ether 241 (4.95 g, 6.58 mmol) in THF/H2O 
(3:1, 10 mL) at 0 °C. The mixture was warmed to rt and stirred for 3.5 h. Upon completion, the reaction 
mixture was cannulated into NaHCO3 solution (250 mL) at 0 °C and stirred until bubbling had ceased. 
The layers were separated and the aqueous phase extracted with EtOAc (3 x 300 mL). The combined 
organic extracts were dried (Na2SO4), concentrated in vacuo and purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:8 ® 1:3) to afford alcohol 242 (3.41 g, 5.35 
mmol, 81%, 89% BRSM) as a colourless oil. 
Rf 0.24 (EtOAc/40-60 PE, 1:2); [α] !"# = +2.0 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3464, 2956, 2877, 
1742, 1512, 1457, 1395, 1376, 1292, 1253, 1167, 1092, 1041, 1009, 969, 822, 791, 735; 1H NMR (500 
MHz, CDCl3): δH 7.26 (2H, d, J = 8.6 Hz, ArH), 6.89 (2H, d, J = 8.6 Hz, ArH), 6.00-5.92 (1H, m, 
CH=CH2), 5.64-5.58 (1H, m, H21), 5.38 (1H, dd, J = 17.1, 1.4 Hz, CH=CHaHb), 5.34 (1H, dd, J = 15.4, 
8.3 Hz, H20), 5.29 (1H, dd, J = 10.4, 1.4 Hz, CH=CHaHb), 4.64 (2H, d, J = 5.7 Hz, OCH2), 4.59 (1H, d, J 
= 11.1 Hz, ArCHaHbO), 4.40 (1H, J = 11.1 Hz, ArCHaHbO), 4.32 (1H, dd, J = 10.6, 4.1 Hz, H27a), 3.96 
(1H, dd, J = 10.5, 8.9 Hz, H27b), 3.83 (3H, s, ArOCH3), 3.74 (1H, dd, J = 7.5, 2.6 Hz, H25), 3.72-3.64 
(3H, m, H15 x 2, H23), 3.62-3.58 (1H, m, H19), 3.26 (3H, s, OCH3), 2.52 (1H, dt, J = 14.1, 7.0 Hz, H22a), 
2.32 (1H, dt, J = 14.1, 7.8 Hz, H22b), 2.17-2.10 (1H, m, H26), 1.82-1.77 (1H, m, H24), 1.75-1.69 (1H, m, 
H17), 1.67-1.61 (1H, m, H18a), 1.56-1.49 (1H, m, H16a), 1.47-1.40 (2H, m, H16b, H18b), 1.06 (3H, d, J = 6.8 
Hz, Me26), 0.97 (9H, t, J = 8.0 Hz, SiCH2CH3 x 3), 0.97 (3H, d, J = 7.0 Hz, Me24), 0.94 (3H, d, J = 6.7 
Hz, Me17), 0.65 (6H, q, J = 8.0 Hz, SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): δC 158.9, 155.3, 133.1, 
131.7, 131.2, 130.4, 128.6, 118.8, 113.7, 80.7, 78.3, 77.0, 70.8, 69.8, 68.3, 61.0, 55.8, 55.3, 42.8, 41.2, 
39.8, 35.6, 34.9, 26.2, 20.2, 16.1, 10.2, 7.1, 5.6; HRMS calculated for C35H64O8SiN [M+NH4]+ 654.4396, 
found 654.4393.  
Aldehyde 161 
 
Dess-Martin periodinane (3.19 g, 7.52 mmol) was added portion-wise to a stirred mixture of alcohol 242 
(3.99 g, 6.27 mmol) and NaHCO3 (2.11 g, 25.1 mmol) in CH2Cl2 (130 mL) at 0 °C. The bright yellow 
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reaction slurry was stirred at this temperature for 1 h until complete. The mixture was quenched with 
Na2S2O3 solution (150 mL) and stirred for 45 min until the yellow colour had dissipated. After diluting 
with H2O (100 mL), the phases were separated and the aqueous layer was extracted with CH2Cl2 (5 x 100 
mL). Combined organic phases were dried (MgSO4), concentrated in vacuo and purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:20 ® 1:4) to yield aldehyde 161 (3.39 g, 5.34 
mmol, 85%) as a colourless oil. 
Rf 0.58 (EtOAc/40-60 PE, 1:2); [α] !"# = +1.1 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2956, 2873, 1750, 
1726, 1609, 1510, 1463, 1399, 1378, 1294, 1247, 1175, 1098, 1037, 1013, 969, 822, 791, 739; 1H NMR 
(500 MHz, CDCl3): δH 9.74 (1H, t, J = 2.0 Hz, CHO), 7.26 (2H, d, J = 8.6 Hz, ArH), 6.89 (2H, d, J = 8.6 
Hz, ArH), 6.00-5.92 (1H, m, CH=CH2), 5.65-5.59 (1H, m, H21), 5.38 (1H, dd, J = 17.2, 1.2, Hz, 
CH=CHaHb), 5.34 (1H, dd, J = 15.5, 7.1 Hz, H20), 5.29 (1H, dd, J = 10.4, 1.2 Hz, CH=CHaHb), 4.64 (2H, 
d, J = 5.7 Hz, OCH2), 4.59 (1H, d, J = 10.9 Hz, ArCHaHbO), 4.41 (1H, J = 10.9 Hz, ArCHaHbO), 4.32 
(1H, dd, J = 10.6, 4.2 Hz, H27a), 3.96 (1H, dd, J = 10.6, 9.1 Hz, H27b), 3.82 (3H, s, ArOCH3), 3.74 (1H, 
dd, J = 7.6, 2.6 Hz, H25), 3.70-3.67 (1H, m, H23), 3.57-3.53 (1H, m, H19), 3.24 (3H, s, OCH3), 2.54-2.42 
(2H, m, H16a, H22a), 2.35-2.22 (3H, m, H16b, H17, H22b), 2.17-2.10 (1H, m, H26), 1.83-1.76 (1H, m, H24), 
1.63-1.57 (1H, m, H18a), 1.42 (1H, dt, J = 13.9, 6.1 Hz, H18b), 1.06 (3H, d, J = 6.9 Hz, Me26), 1.00-0.96 
(15H, m, Me17, Me24, SiCH2CH3 x 3), 0.67-0.62 (6H, m, SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): 
δC 202.8, 159.0, 155.2, 132.8, 131.8, 131.2, 130.8, 128.6, 118.8, 113.7, 80.2, 78.3, 77.1, 70.8, 69.8, 68.3, 
55.7, 55.3, 50.8, 42.7, 41.4, 35.6, 35.0, 24.8, 20.5, 16.0, 10.2, 7.1, 5.6; HRMS calculated for 
C35H58O8SiNa [M+Na]+ 657.3793, found 657.3774.  
Enone 229 
 
THF (0.8 mL) was added to a flask containing Ba(OH)2 (34.8 mg, 0.203 mmol) and sonicated for 5 min. 
A solution of phosphonate 210 (58.0 mg, 0.165 mmol) in THF (1.2 mL) was added via cannula to the 
resulting white suspension and the mixture stirred at rt for 45 min. A solution of aldehyde 168 (81.0 mg, 
0.157 mmol) in THF/H2O (40:1, 2 mL) was added via cannula and the reaction stirred for 16 h. Upon 
completion, the mixture was diluted with THF (2 mL) and quenched with NH4Cl solution (3 mL). The 
aqueous phase was extracted with Et2O (3 x 5 mL), dried (MgSO4) and concentrated in vacuo. Crude 
material was purified by flash column chromatography (EtOAc/40-60 PE, 1:10) to yield enone 229 (110 
mg, 0.148 mmol, 94%, > 20:1 E/Z) as a pale yellow oil. 
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Rf 0.69 (EtOAc/40-60 PE, 1:5); [α] !"# = −13.2 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2952, 2929, 
2877, 2849, 1699, 1675, 1627, 1615, 1516, 1459, 1365, 1296, 1250, 1172, 1092, 1037, 1009, 977, 830, 
778, 737, 699; 1H NMR (500 MHz, CDCl3): δH 7.34-7.33 (4H, m, PhH), 7.30-7.26 (1H, m, PhH), 7.24 
(2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J = 8.6 Hz, ArH), 6.80 (1H, dt, J = 15.8, 7.4 Hz, H21), 6.15 (1H, d, 
J = 15.8 Hz, H20), 4.51 (1H, d, J = 11.0 Hz, PhCHaHbO), 4.50 (1H, d, J = 12.2 Hz, ArCHaHb), 4.46 (1H, d, 
J = 12.2 Hz, ArCHaHb), 4.42 (1H, d, J = 11.0 Hz, PhCHaHbO), 3.80 (3H, s, ArOCH3), 3.76-3.70 (2H, m, 
H23, H25), 3.68-3.59 (3H, m, H15 x 2, H27a), 3.29 (1H, dd, J = 8.6, 7.8 Hz, H27b), 2.59-2.41 (3H, m, H18a, 
H22 × 2), 2.33 (1H, dd, J = 15.5, 8.3 Hz, H18b), 2.22-2.13 (1H, m, H17), 2.09-2.03 (1H, m, H26), 1.76-1.71 
(1H, m, H24), 1.60-1.51 (1H, m, H16a), 1.45-1.37 (1H, m, H16b), 1.03 (3H, d, J = 6.9 Hz, Me26), 0.97-0.90 
(24H, m, Me17, Me24, SiC(CH3)3, SiCH2CH3 x 3), 0.61 (6H, q, J = 8.0 Hz, SiCH2CH3 x 3), 0.05 (6H, s, 
SiCH3 x 2); 13C NMR (125 MHz, CDCl3): δC 199.5, 158.7, 143.3, 138.4, 132.1, 130.5, 128.5, 127.9, 
127.1, 127.0, 113.4, 77.9, 76.7, 72.7, 71.8, 71.1, 60.8, 54.9, 47.2, 41.7, 39.4, 36.7, 35.6, 26.3, 25.6, 19.6, 
17.9, 15.7, 10.7, 6.8, 5.2, −5.6 x 2; HRMS calculated for C43H76O6NSi2 [M+NH4]+ 758.5206, found 
758.5194. 
Allylic alcohol 231 
 
(S)-Me-CBS catalyst (209 µL, 1.0 M in PhMe, 0.209 mmol) and BH3×SMe2 (198 µL, 2.09 mol) were 
added sequentially to a solution of enone 229 (776 mg, 1.05 mmol) in THF (35 mL) at -20 °C. The 
reaction was stirred at this temperature for 2.5 h, then quenched with MeOH (30 mL). After warming to 
rt, solvent was removed under reduced pressure. The residue was dissolved in MeOH (15 mL), then 
concentrated in vacuo and the procedure repeated three times. Crude product was purified by flash 
column chromatography (gradient elution: EtOAc/40-60 PE, 1:15 ® 1:5) afforded allylic alcohol 231 
(700 mg, 0.942 mmol, 90%, 10:1 dr) as a colourless oil. 
Rf 0.48 (EtOAc/40-60 PE, 1:4); [α] !"# = −3.8 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3404, 2956, 2931, 
2876, 1613, 1514, 1462, 1361, 1302, 1249, 1172, 1092, 1039, 1008, 970, 836, 776, 736, 697; 1H NMR 
(500 MHz, CDCl3): δH 7.36-7.35 (4H, m, PhH), 7.32-7.28 (1H, m, PhH), 7.27 (2H, d, J = 8.2 Hz, ArH), 
6.88 (2H, d, J = 8.2 Hz, ArH), 5.64 (1H, dt, J = 15.2, 7.2 Hz, H21), 5.53 (1H, dd, J = 15.2, 6.8 Hz, H20), 
4.56 (1H, d, J = 11.2 Hz, ArCHaHbO), 4.52 (1H, d, J = 11.9 Hz, PhCHaHbO), 4.49 (1H, d, J = 11.9 Hz, 
PhCHaHbO), 4.41 (1H, d, J = 11.2 Hz, ArCHaHbO), 4.20-4.14 (1H, m, H19) 3.82 (3H, s, ArOCH3), 
3.74-3.62 (5H, m, H15 × 2, H23, H25, H27a), 3.31 (1H, dd, J = 8.7, 8.7 Hz, H27b), 2.44 (1H, dt, J = 7.5, 6.5 
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Hz, H22a), 2.31-2.25 (1H, m, H22b), 2.11-2.06 (1H, m, H26), 1.81-1.76 (1H, m, H17), 1.75-1.70 (1H, m, 
H24), 1.67-1.62 (2H, m, H16a, OH), 1.45 (2H, t, J = 6.8 Hz, H18 x 2), 1.42-1.35 (1H, m, H16b), 1.05 (3H, d, 
J = 6.8 Hz, Me26), 0.98-0.92 (15H, m, SiCH2CH3 x 3, Me17, Me24), 0.92 (9H, s, SiC(CH3)3), 0.63 (6H, q, 
J = 8.0 Hz, SiCH2CH3 x 3), 0.08 (6H, s, SiCH3 x 2); 13C NMR (125 MHz, CDCl3): δC 158.8, 135.5, 
131.2, 128.7, 128.2, 128.0, 127.4, 127.3, 113.6, 78.6, 77.1, 76.9, 72.9, 72.1, 71.0, 70.9, 61.3, 55.2, 44.4, 
41.4, 39.4, 36.7, 35.2, 26.2, 25.9, 20.3, 18.2, 16.2, 10.6, 7.1, 5.5, −5.4 x 2; HRMS calculated for 
C43H78O6NSi2 [M+NH4]+ 760.5362, found 760.5356. 
Methyl ether 233 
 
Sodium hydride (377 mg, 60% dispersion in mineral oil, 9.42 mmol) was washed with hexane (3 x 5 
mL), dried in vacuo and suspended in THF (10 mL) at 0 °C. A solution of allylic alcohol 231 (700 mg, 
0.942 mmol) in THF (10 mL) was added via cannula and the white suspension was stirred at this 
temperature for 1 h. MeI (754 µl, 11.3 mmol) was added dropwise and the reaction was warmed to rt and 
stirred for 20 h. The mixture was quenched with MeOH (15 mL), then poured into brine (20 mL) and 
extracted with Et2O (3 x 20 mL). Combined organic phases were dried (MgSO4), concentrated in vacuo 
and purified by flash column chromatography (gradient elution: EtOAc/40-60, 1:25 ® 1:18) to afford 
methyl ether 233 (639 mg, 0.844 mmol, 90%) as a colourless oil. 
Rf 0.52 (EtOAc/40-60 PE, 1:8); [α] !"# = +4.2 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2952, 2929, 2877, 
1613, 1512, 1463, 1360, 1298, 1251, 1173, 1094, 1044, 1007, 969, 836, 777, 731, 696; 1H NMR (500 
MHz, CDCl3): δH 7.36-7.35 (4H, m, PhH), 7.31-7.29 (1H, m, PhH), 7.27 (2H, d, J = 8.2 Hz, ArH), 6.88 
(2H, d, J = 8.2 Hz, ArH), 5.62-5.56 (1H, m, H21), 5.30 (1H, dd, J = 15.4, 8.4 Hz, H20), 4.58 (1H, d, J = 
11.0 Hz, ArCHaHbO), 4.49 (2H, ABq, J = 11.9 Hz, PhCH2O), 4.41 (1H, J = 11.0 Hz, ArCHaHbO), 3.82 
(3H, s, ArOCH3), 3.76-3.74 (1H, m, H23), 3.71-3.60 (4H, m, H15 × 2, H25, H27a), 3.56 (1H, app q, J = 7.4 
Hz, H19), 3.30 (1H, app t, J = 8.8 Hz, H27b), 3.23 (3H, s, OCH3), 2.49 (1H, dt, J = 14.0, 5.3 Hz, H22a), 2.30 
(1H, dt, J = 14.0, 7.9 Hz, H22b), 2.13-2.07 (1H, m, H26), 1.82-1.76 (1H, m, H24), 1.70 (1H, app sext, J = 
6.7 Hz, H17), 1.63-1.57 (1H, m, H16a), 1.50-1.33 (3H, m, H16b, H18 x 2), 1.06 (3H, d, J = 6.9 Hz, Me26), 
0.98-0.90 (24H, m, Me17, Me24, SiC(CH3)3, SiCH2CH3 x 3), 0.63 (6H, q, J = 7.8 Hz, SiCH2CH3 x 3), 0.07 
(6H, s, SiCH3 x 2); 13C NMR (125 MHz, CDCl3): δC 158.8, 138.7, 132.9, 131.3, 130.5, 128.5, 128.2, 
127.4, 127.3, 113.6, 80.7, 78.4, 77.0, 72.9, 71.9, 70.8, 61.1, 55.7, 55.2, 42.9, 41.0, 40.0, 36.8, 35.1, 26.0, 
25.9, 19.9, 18.2, 16.0, 10.3, 7.0, 5.5 −5.3, −5.4; HRMS calculated for C44H80O6NSi2 [M+NH4]+ 774.5519, 
found 774.5518.  
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Enone 228 
 
Anhydrous Ba(OH)2 (9.6 mg, 56.0 µmol) in THF (0.8 mL) was sonicated for 5 min to form a white 
suspension. A solution of phosphonate 210 (35.2 mg, 99.7 µmol) in THF (1.2 mL) was added via 
cannula. The reaction mixture was stirred at rt for 1 h before a solution of aldehyde 204 (47.9 mg, 93.2 
µmol) in THF/H2O (40:1, 2 mL) was added. The cloudy mixture was stirred for a further 16 h, diluted 
with THF (2 mL) and poured into NH4Cl solution (5 mL). The phases were separated and the aqueous 
layer was extracted with Et2O (3 × 5 mL). The combined organic phases were washed with brine (5 mL), 
dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash column 
chromatography (EtOAc/40-60 PE, 1:20) to give enone 228 (48.0 mg, 64.8 µmol, 69%) as a colourless 
oil.  
Rf 0.61 (EtOAc/40-60 PE, 1:5); [α] !"# = −15.5 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2927, 2855, 
1696, 1614, 1514, 1462, 1361, 1248, 1173, 1091, 1037, 834, 774, 698; 1H NMR (500 MHz, CDCl3): δH 
7.38-7.29 (5H, m, PhH), 7.26 (2H, d, J = 8.5 Hz, ArH), 6.88 (2H, d, J = 8.5 Hz, ArH), 6.84 (1H, dt, J = 
15.8, 7.9 Hz, H21), 6.17 (1H, d, J = 15.8 Hz, H20), 4.51 (1H, d, J = 10.9 Hz, PhCHaHbO), 4.50 (1H, d, J = 
12.1 Hz, ArCHaHbO), 4.48 (1H, d, J = 12.1 Hz, ArCHaHbO), 4.43 (1H, d, J = 10.9 Hz, PhCHaHbO), 3.81 
(3H, s, ArOCH3), 3.73-3.63 (5H, m, H15 × 2, H23, H25, H27a), 3.30 (1H, app t, J = 8.7 Hz, H27b), 2.57-2.49 
(3H, m, H18a, H22 × 2), 2.36 (1H, dd, J = 15.2, 8.4 Hz, H18b), 2.23-2.15 (1H, m, H17), 2.10-2.03 (1H, m, 
H26) 1.83-1.76 (1H, m, H24), 1.60-1.54 (1H, m, H16a), 1.47-1.40 (1H, m, H16b), 1.05 (3H, d, J = 7.0 Hz, 
Me26), 1.01 (3H, d, J = 7.0 Hz, Me24), 0.93 (3H, d, J = 7.0 Hz, Me17), 0.92 (9H, s, SiC(CH3)3), 0.89 (9H, 
s, SiC(CH3)3), 0.07 (6H, s, SiCH3), 0.06 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13C NMR (125 MHz, 
CDCl3): δC 199.8, 159.1, 143.3, 138.7, 132.6, 130.6, 129.0, 128.2, 127.4, 127.3, 113.7, 78.7, 76.3, 72.9, 
72.4, 71.5, 61.1, 55.1, 47.3, 42.7, 39.7, 37.0, 35.6, 26.6, 26.0, 25.9, 19.9, 18.2, 18.2, 16.2, 11.1, −4.0, 
−4.3, −5.4, −5.4; HRMS calculated for C43H76O6NSi2 [M+NH4]+ 758.5206, found 758.5227. 
Allylic alcohol 230 
 
(S)-Me-CBS catalyst (3 µL, 1.0 M in PhMe, 3.0 µmol) was added to a solution of enone 228 (22.0 mg, 
29.7 mmol) in THF (0.5 mL) at -20 °C, followed by BH3×SMe2 (2 µL, 19.3 mmol). The reaction was 
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warmed to -10 °C and stirred for 1.5 h before being carefully quenched with MeOH (1 mL). The mixture 
was warmed to rt and stirred for a further 30 min before concentrating in vacuo. The residue was 
redissolved in MeOH (1 mL), then concentrated in vacuo and the procedure repeated three times. 
Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:15 ® 1:10) afforded 
allylic alcohol 230 (18.0 mg, 24.2 mmol, 82%, 15:1 dr) as a colourless oil. 
Rf 0.40 (EtOAc/40-60 PE, 1:5); [α] !"# = −6.7 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 3465, 2953, 2927, 
2854, 1514, 1463, 1361, 1302, 1248, 1172, 1090, 1037, 1005, 969, 939, 899, 834, 773, 734, 698; 1H 
NMR (500 MHz, CDCl3): δH 7.35-7.33 (4H, m, PhH), 7.30-7.27 (1H, m, PhH), 7.26 (2H, d, J = 8.7 Hz, 
ArH), 6.86 (2H, d, J = 8.7 Hz, ArH), 5.66 (1H, dt, J = 15.4, 7.0 Hz, H21), 5.54 (1H, dd, J = 15.4, 6.9 Hz, 
H20), 4.53 (1H, d, J = 11.0 Hz, ArCHaHbO), 4.49 (1H, d, J = 12.0 Hz, PhCHaHbO), 4.45 (1H, d, J = 12.0 
Hz, PhCHaHbO), 4.39 (1H, d, J = 11.0 Hz, ArCHaHbO), 4.19−4.14 (1H, m, H19), 3.80 (3H, s, ArOCH3), 
3.72-3.61 (4H, m, H15 × 2, H25, H27a), 3.58-3.55 (1H, m, H23), 3.30 (1H, dd, J = 8.9, 8.6 Hz, H27b), 
2.39-2.30 (2H, m, H22 × 2), 2.10-2.02 (1H, m, H26) 1.85-1.78 (1H, m, H24), 1.75-1.69 (1H, m, H17), 
1.65-1.58 (2H, m, OH, H16a), 1.44 (2H, t, J = 6.9 Hz, H18 x 2), 1.40-1.33 (1H, m, H16b), 1.04 (3H, d, J = 
6.9 Hz, Me26), 0.98 (3H, d, J = 7.1 Hz, Me24), 0.92 (3H, d, J = 6.7 Hz, Me17), 0.91 (9H, s, SiC(CH3)3), 
0.88 (9H, s, SiC(CH3)3), 0.06 (6H, s, SiCH3 x 2), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13C NMR 
(125 MHz, CDCl3): δC 159.0, 138.9, 135.7, 131.2, 129.0, 128.3, 127.8, 127.5, 127.4, 113.7, 79.3, 76.7, 
73.0, 72.6, 71.2, 70.9, 61.4, 55.3, 44.6, 42.4, 39.5, 36.9, 35.1, 29.7, 26.1, 26.0, 20.4, 18.4, 18.4, 16.5, 
10.8, −3.8, −4.2, −5.3, −5.3; HRMS calculated for C43H78O6NSi2 [M+NH4]+ 760.5362, found 760.5361. 
Methyl ether 232 
 
Sodium hydride (11.0 mg, 60% dispersion in mineral oil, 275 µmol) was washed with hexane (3 x 1 mL) 
and dried in vacuo. THF (0.2 mL) was added and the suspension was cooled to 0 °C. A solution of allylic 
alcohol 230 (9.1 mg, 12.2 mmol) in THF (0.35 mL) was added via cannula and the pale yellow mixture 
was stirred at this temperature for 30 min before addition of MeI (15 µl, 245 µmol). The reaction was 
warmed to rt and stirred for 18 h before being quenched with MeOH (0.5 mL). The quenched mixture 
was poured into brine (2 mL) and extracted with Et2O (3 x 2 mL). Combined organic phases were dried 
(MgSO4), concentrated in vacuo and purified by flash column chromatography (gradient elution: 
EtOAc/40-60, 1:20 ® 1:10) to afford methyl ether 232 (9.5 mg, 12.5 µmol, 94%) as a colourless oil. 
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Rf 0.65 (EtOAc/40-60 PE, 1:5); [α] !"# = −2.5 (c 0.53, CHCl3); IR (thin film, νmax / cm−1): 2926, 2855, 
1514, 1462, 1249, 1093, 835, 773, 698; 1H NMR (500 MHz, CDCl3): δH 7.37-7.33 (4H, m, PhH), 
7.30-7.28 (1H, m, PhH), 7.26 (2H, d, J = 8.5 Hz, ArH), 6.87 (2H, d, J = 8.5 Hz, ArH), 5.64-5.58 (1H, m, 
H21), 5.31 (1H, dd, J = 15.4, 8.3 Hz, H20), 4.56 (1H, d, J = 11.1 Hz, ArCHaHbO), 4.50 (1H, ABq, J = 11.7 
Hz, PhCHaHbO), 4.46 (1H, ABq, J = 11.7 Hz, PhCHaHbO), 4.41 (1H, J = 11.1 Hz, ArCHaHbO), 3.81 (3H, 
s, ArOCH3), 3.75 (1H, dd, J = 6.4, 2.5 Hz, H25), 3.69-3.61 (4H, m, H15 × 2, H23, H27a), 3.58-3.54 (1H, m, 
H19), 3.31 (1H, app t, J = 9.0 Hz, H27b), 3.23 (3H, s, OCH3), 2.46-2.41 (1H, m, H22a), 2.37-2.30 (1H, m, 
H22b), 2.14-2.07 (1H, m, H26), 1.86-1.80 (1H, m, H24), 1.75-1.67 (1H, m, H17), 1.63-1.57 (1H, m, H16a), 
1.50-1.22 (3H, m, H16b, H18 x 2), 1.05 (3H, d, J = 6.8 Hz, Me26), 0.97 (3H, d, J = 6.9 Hz, Me24), 
0.91-0.89 (21H, m, Me17, SiC(CH3)3 x 2), 0.07 (12H, s, SiCH3 x 4); 13C NMR (125 MHz, CDCl3): δC 
158.9, 138.8, 133.1, 131.3, 130.3, 128.8, 128.3, 127.5, 127.4, 113.7, 80.8, 79.0, 76.6, 73.0, 72.5, 71.1, 
61.3, 55.8, 55.3, 43.1, 41.9, 39.9, 37.1, 35.1, 29.7, 26.2, 26.0, 20.0, 18.4, 18.3, 16.1, 10.6, −3.8, −4.0, 
−5.2, −5.3; HRMS calculated for C44H80O6NSi2 [M+NH4]+ 774.5519, found 774.5518. 
Bis-TES alcohol 248 
 
DDQ (5.48 g, 24.2 mmol) was added in one portion to a solution of PMB ether 247 (10.0 g, 16.1 mmol) 
in CH2Cl2/pH 7 buffer (2:1, 300 ml) at 0 °C. The resulting dark green mixture was warmed to rt and 
stirred for 1 h until completion before quenching with NaHCO3 solution (300 mL) and diluting with 
CH2Cl2 (200 mL). The emulsion was stirred for a further 1 h before being diluted with H2O (600 mL). 
The layers were separated and the aqueous phase was extracted with EtOAc (3 x 500 mL). Combined 
organic extracts were dried (Na2SO4), concentrated in vacuo and purified by flash column 
chromatography (PhMe, then gradient elution: EtOAc/40-60 PE, 1:7 ® 1:5) to yield alcohol 248 (7.27 g, 
14.5 mmol, 90%) as a pale yellow oil. 
Rf 0.31 (EtOAc/40-60 PE, 1:10); [α] !"# = -11.1 (c 1.6, CHCl3); IR (thin film, νmax / cm−1): 3456, 2953, 
2912, 2877, 1722, 1703, 1644, 1617, 1458, 1436, 1415, 1303, 1240, 1174, 1139, 1063, 1003, 867, 804, 
725; 1H NMR (500 MHz, CDCl3): δH 7.29 (1H, dd, J = 15.4, 10.0 Hz, H3), 6.23 (1H, dd, J = 15.4, 10.0 
Hz, H4), 6.17 (1H, ddd, J = 15.4, 6.9, 6.0 Hz, H5), 5.83 (1H, d, J = 15.3 Hz, H2), 3.80-3.76 (2H, m, H9, 
H11a), 3.77 (3H, s, CO2CH3), 3.74 (1H, ddd, J = 6.4, 3.7 Hz, H7), 3.59-3.55 (1H, m, H11b), 2.65 (1H, t, J = 
5.1 Hz, OH), 2.37-2.32 (1H, m, H6a), 2.28 (1H, ddd, J = 14.7, 6.2, 3.9 Hz, H6b), 1.88-1.81 (1H, m, H8), 
1.81-1.75 (1H, m, H10), 1.03 (3H, d, J = 7.1 Hz, Me10), 1.00 (9H, t, J = 7.9 Hz, SiCH2CH3 x 3), 0.98 (9H, 
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t, J = 7.9 Hz, SiCH2CH3 x 3), 0.91 (3H, d, J = 6.9 Hz, Me8), 0.68 (6H, t, J = 7.9 Hz, SiCH2CH3 x 3), 0.62 
(6H, t, J = 7.9 Hz, SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): δC 167.7, 144.8, 140.6, 130.5, 119.3, 
77.6, 73.4, 65.3, 51.5, 42.5, 39.2, 36.7, 14.7, 11.0, 7.1, 7.0, 5.5, 5.3; HRMS calculated for C26H53O5Si2 
[M+H]+ 501.3426, found 501.3418. 
Iodide 249 
 
PPh3 (4.22 g, 16.1 mmol) and imidazole (1.34 g, 19.6 mmol) were added sequentially to a solution of 
alcohol 248 (4.47 g, 8.93 mmol) in Et2O/MeCN (1:1, 100 mL) at 0 °C, followed by portion-wise addition 
of I2 (4.07 g, 16.1 mmol). The reaction mixture was warmed up to rt and stirred for 2 h before being 
quenched by addition of NaHCO3 solution (100 mL). The mixture was extracted with Et2O (3 x 100 mL), 
the combined organic phases dried (MgSO4) and concentrated in vacuo. Purification by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:50 ® 1:10) yielded iodide 249 (4.18 g, 6.84 
mmol, 77%, 92% BRSM) as a colourless oil. 
Rf 0.58 (EtOAc/40-60 PE, 1:10); [α] !"# = -10.0 (c 2.0, CHCl3); IR (thin film, νmax / cm−1): 2955, 2911, 
2877, 1722, 1645, 1617, 1458, 1434, 1415, 1300, 1264, 1241, 1140, 1102, 1064, 1003, 739, 723; 1H 
NMR (500 MHz, CDCl3): δH 7.27 (1H, dd, J = 15.4, 10.0 Hz, H3), 6.21 (1H, dd, J = 15.0, 9.9 Hz, H4), 
6.15 (1H, ddd, J = 15.0, 6.9, 6.4 Hz, H5), 5.81 (1H, d, J = 15.4 Hz, H2), 3.74 (3H, s, CO2CH3), 3.69 (1H, 
ddd, J = 6.7, 5.3, 4.1 Hz, H7), 3.66 (1H, dd, J = 4.2, 3.8 Hz, H9), 3.29 (1H, dd, J = 9.9, 4.2 Hz, H11a), 2.99 
(1H, dd, J = 9.9, 9.0 Hz, H11b), 2.32-2.25 (2H, m, H6 x 2), 1.86-1.79 (1H, m, H10), 1.72-1.66 (1H, m, 
H8), 1.05 (3H, d, J = 6.8 Hz, Me10), 0.96 (9H, t, J = 7.8 Hz, SiCH2CH3 x 3), 0.95 (9H, t, J = 7.8 Hz, 
SiCH2CH3 x 3), 0.85 (3H, d, J = 6.8 Hz, Me8), 0.68 (6H, t, J = 7.8 Hz, SiCH2CH3 x 3), 0.59 (6H, t, J = 7.8 
Hz, SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): δC 167.6, 144.8, 141.0, 130.3, 119.2, 76.1, 73.7, 51.4, 
42.1, 41.6, 36.7, 17.7, 11.5, 10.2, 7.0, 6.9, 5.5, 5.2; HRMS calculated for C26H52O4ISi2 [M+H]+ 611.2443, 
found 611.2435. 
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Alcohol 250 
 
DIBALH (38.7 mL, 1.0 M in hexanes, 38.7 mmol) was added dropwise to a solution of ester 249 (7.87 g, 
12.9 mmol) in CH2Cl2 (250 mL) at -78 °C and the mixture stirred for 1.5 h. Upon completion, the 
mixture was quenched by addition of Na+/K+ tartrate solution (300 mL) and water (100 mL), then 
warmed to rt and stirred vigorously for 1.5 h. The phases were separated and the aqueous layer extracted 
with CH2Cl2 (3 x 200 mL). The combined organic extracts were dried (Na2SO4), concentrated in vacuo 
and purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:20 ® 1:15) to give 
alcohol 250 (7.31 g, 12.5 mmol, 97%) as a colourless oil. 
Rf 0.33 (EtOAc/40-60 PE, 1:5); [α] !"# = -10.6 (c 0.8, CHCl3); IR (thin film, νmax / cm−1): 3357, 2956, 
2909, 2881, 1461, 1415, 1378, 1237, 1140, 1102, 1068, 1009, 993, 741, 727; 1H NMR (500 MHz, 
CDCl3): δH 6.23 (1H, dd, J = 15.3, 10.7 Hz, H3), 6.08 (1H, dd, J = 15.3, 10.7 Hz, H4), 5.77-5.69 (2H, m, 
H2, H5), 4.18 (2H, br d, J = 4.9 Hz, H1 x 2), 3.67-3.64 (2H, m, H7, H9), 3.32 (1H, dd, J = 9.9, 3.7 Hz, 
H11a), 2.98 (1H, dd, J = 9.9, 9.1 Hz, H11b), 2.22-2.20 (2H, m, H6 x 2), 1.87-1.79 (1H, m, H10), 1.72-1.65 
(1H, m, H8), 1.33 (1H, t, J = 5.3 Hz, OH), 1.05 (3H, d, J = 6.9 Hz, Me10), 0.96 (18H, t, J = 7.8 Hz, 
SiCH2CH3 x 6), 0.84 (3H, d, J = 6.8 Hz, Me8), 0.63 (6H, q, J = 7.8 Hz, SiCH2CH3 x 3), 0.60 (6H, q, J = 
7.8 Hz, SiCH2CH3 x 3); 13C NMR (125 MHz, CDCl3): δC 132.0, 131.6, 131.4, 129.8, 76.2, 73.9, 63.4, 
42.0, 41.6, 36.3, 17.8, 11.8, 10.5, 7.0, 6.9, 5.5, 5.2; HRMS calculated for C25H52O3ISi2 [M+H]+ 583.2494, 
found 583.2486. 
TBS ether 160 
 
Imidazole (1.71 g, 25.1 mmol) and TBSCl (2.84 g, 18.8 mmol) were added sequentially to a solution of 
alcohol 250 (7.31 g, 12.5 mmol) in CH2Cl2 (250 mL) and the resulting mixture stirred for 30 min until 
completion. The reaction was quenched with NH4Cl solution (200 mL), the phases separated and the 
aqueous layer extracted with CH2Cl2 (2 x 200 mL). The combined organic extracts were dried (MgSO4), 
concentrated in vacuo and the residue purified by flash column chromatography (EtOAc/40-60 PE, 1:50). 
TBS ether 160 (8.63 g, 12.4 mmol, 99% yield) was obtained as a colourless oil.  
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Rf 0.72 (40-60 PE); [α] !"# = -6.0 (c 1.2, CHCl3); IR (thin film, νmax / cm−1): 2952, 2873, 1459, 1413, 
1378, 1260, 1255, 1241, 1104, 1062, 1007, 963, 836, 777, 737, 727; 1H NMR (500 MHz, CDCl3): δH 
6.19 (1H, dd, J = 15.1, 10.4 Hz, H3), 6.06 (1H, dd, J = 15.1, 10.9 Hz, H4), 5.69-5.63 (2H, m, H2, H5), 
4.21 (2H, d, J = 5.6 Hz, H1 x 2), 3.66-3.64 (2H, m, H7, H9), 3.32 (1H, dd, J = 9.7, 3.7 Hz, H11a), 2.98 (1H, 
dd, J = 9.7, 9.1 Hz, H11b), 2.21-2.18 (2H, m, H6 x 2), 1.88-1.81 (1H, m, H10), 1.73-1.66 (1H, m, H8), 
1.05 (3H, d, J = 6.8 Hz, Me10), 0.96 (18H, t, J = 7.8 Hz, SiCH2CH3 x 6), 0.91 (9H, s, SiC(CH3)3), 0.85 
(3H, d, J = 6.9 Hz, Me8), 0.62 (6H, q, J = 7.8 Hz, SiCH2CH3 x 3), 0.61 (6H, q, J = 7.8 Hz, SiCH2CH3 x 
3), 0.07 (SiCH3 x 2); 13C NMR (125 MHz, CDCl3): δC 131.7, 131.5 x 2, 130.0, 76.3, 74.0, 63.5, 42.1, 
41.5, 36.3, 25.9, 18.3, 17.9, 11.7, 10.5, 7.0, 6.9, 5.5, 5.2, -5.3; HRMS calculated for C31H66O3ISi3 
[M+H]+ 697.3359, found 697.3357. 
6.5. Experimental Procedures for Chapter 4 
Phosphonate 123 
 
nBuLi (100 mL, 1.6M in hexanes, 160 mmol) was added to a solution of diethyl ethylphosphonate (23.6 
mL, 146 mmol) in THF (200 mL) at -78 °C and stirred for 1 h. EtOAc (14.3 mL, 146 mmol) was added 
dropwise and the reaction stirred at this temperature for a further 30 min before being quenched with 
NH4Cl solution (100 mL) and warmed to rt. Phases were separated and the aqueous layer extracted with 
EtOAc (5 x 250 mL). Combined organic extracts were dried (MgSO4), concentrated in vacuo and the 
residue purified by distillation under reduced pressure (95 °C, 0.5 mm Hg). Phosphonate 123 (18.5 g, 
88.7 mmol, 61%) was obtained as a colourless oil. 
Rf 0.24 (EtOAc); 1H NMR (500 MHz, CDCl3): δH 4.19-4.13 (4H, m, P(OCH2CH3) x 2), 3.23 (1H, dq, J 
= 25.5, 7.1 Hz, H14), 2.36 (3H, s, Me12), 1.38 (3H, dd, J = 16.5, 7.1 Hz, Me14), 1.35 (6H, td, J = 7.1, 2.1 
Hz, P(OCH2CH3) x 2).  
Data in agreement with that presented by Lee.162  
  
P(OEt)2
OO
14
12
Chapter 6: Experimental 
 
183 
Phosphonate 253 
 
Phosphonate 123 (715 mg, 3.44 mmol) was added to a suspension of NaH (160 mg, 60% dispersion in 
mineral oil, 4.02 mmol) in THF (10 mL) at 0 °C and stirred at this temperature for 30 min, followed by 
dropwise addition of nBuLi (2.15 mL, 1.6 M in hexanes, 3.44 mmol). After stirring for a further 30 min, 
during which a clear pale yellow solution of the dianion was formed, the mixture was cooled to -10 °C 
and a solution of iodide 160 (400 mg, 0.574 mmol) in THF (5 mL) was added via cannula over 10 min. 
The reaction mixture was stirred for 2 h, gradually developing a bright yellow colour, then quenched by 
addition of NH4Cl solution (100 mL) and warmed to rt. The aqueous phase was extracted with EtOAc (3 
x 20 mL), dried (MgSO4) and the crude product purified by flash column chromatography (gradient 
elution: EtOAc/40-60 PE, 1:20 ® 1:3). Phosphonate 253 was obtained as an inseparable mixture with 
the undesired regioisomer 254 (336 mg, 0.432 mmol, 75%, 88% BRSM) in a 3:1 ratio. 
Rf 0.23 (EtOAc/40-60 PE, 1:2); 1H NMR (500 MHz, CDCl3): δH 6.19 (1H, dd, J = 15.1, 10.6 Hz, H3), 
6.05 (1H, dd, J = 15.1, 10.6 Hz, H4), 5.72-5.62 (2H, m, H2, H5), 4.21 (2H, d, J = 5.5 Hz, H1 x 2), 
4.17-4.08 (4H, m, P(OCH2CH3) x 2), 3.67-3.57 (1H, m, H7), 3.55-3.52 (1H, m, H9), 3.23 (0.80H, dq, J = 
25.1, 7.2 Hz, H14), 2.88 (0.40H, ddd, J = 17.5, 9.9, 4.9 Hz, H12a), 2.77-2.60 (0.80H, m, H12a, H12b), 2.47 
(0.40H, ddd, J = 17.5, 9.5, 6.1 Hz, H12b), [2.36] (0.75H, s, Me14*), [1.89-1.81] (0.25H, m, H11b*), 
1.78-1.63 (2H, m, H8, H11a, H11b), 1.55-1.48 (1H, m, H10), 1.42-1.31 (10H, m, H11a, H11b, Me14, 
P(OCH2CH3) x 2), 1.00-0.85 (33H, m, Me8, Me10, Me14*, SiCH2CH3 x 6, C(CH3)3), [0.72] (0.75H, d, J = 
6.7 Hz, Me8*), 0.64-0.55 (12H, m, SiCH2CH3 x 6), 0.08 (6H, s, SiCH3 x 2); HRMS calculated for 
C39H85NO7PSi3 [M+NH4]+ 794.5366, found 794.5362.  
Distinguishable resonances of the minor regioisomer are given in brackets and marked with an asterisk. 
Note that the diastereomeric ratio of 253 at C14 is approximately 1:1. 
Allyl (4-(benzyloxy)butyl) carbonate (240) 
 
Allyl chloroformate (176 µL, 1.81 mmol) was added to a solution of alcohol 262 (100 mg, 0.555 mmol) 
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in CH2Cl2/pyr (1:1, 6 mL) at 0 °C. The reaction was warmed to rt and stirred for 16 h before being 
recooled to 0 °C and quenched with NaHCO3 solution (5 mL). Phases were separated and the aqueous 
layer extracted with EtOAc (3 x 10 mL). Combined organic extracts were dried (Na2SO4), concentrated in 
vacuo and purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:50 ® 1:20) to 
give allyl carbonate 240 (101 mg, 0.382 mmol, 69%) as a coulourless oil. 
Rf 0.73 (EtOAc/40-60 PE, 1:3); IR (thin film, νmax / cm−1): 2952, 2853, 1744, 1450, 1393, 1362, 1247, 
1094, 1025, 991, 949, 931, 789, 737, 694; 1H NMR (400 MHz, CDCl3): δH 7.37-7.27 (5H, m, PhH), 5.94 
(1H, ddt, J = 17.1, 10.4, 5.7 Hz, CH=CH2), 5.36 (1H, dq, J = 17.1, 1.4 Hz, CH=CHaCHb), 5.27 (1H, dq, J 
= 10.4, 1.4 Hz, CH=CHaHb), 4.62 (2H, dt, J = 5.7, 1.4 Hz, OCH2), 4.50 (2H, s, PhCH2O), 4.18 (2H, t, J = 
6.5 Hz, H1 x 2), 3.50 (2H, t, J = 6.2 Hz, H4 x 2), 1.83-1.76 (2H, m, H2 x 2), 1.74-1.67 (2H, m, H3 x 2); 
13C NMR (125 MHz, CDCl3): δC 154.7, 138.1, 131.3, 128.0, 127.2 x 2, 118.5, 72.6, 69.2, 68.0, 67.6, 
25.7, 25.3; HRMS calculated for C15H21O4 [M+H]+ 264.1434, found 264.1438. 
Allyl (8-hydroxyoctyl) carbonate 
 
1,8-Octanediol (303 mg, 2.07 mmol) was added in small portions to a solution of allyl chloroformate (45 
µL, 0.423 mmol) in CH2Cl2/pyr (1:1, 3 mL) at 0 °C, then warmed to rt. After stirring for 2 h the reaction 
was quenched by addition of NaHCO3 solution (5 mL) and extracted with EtOAc (3 x 3 mL). Combined 
organic layers were dried (Na2SO4) and concentrated in vacuo. Crude product was purified by flash 
column chromatography (gradient elution: EtOAc/40-60 PE, 1:10 ® 1:4) to afford allyl (8-hydroxyoctyl) 
carbonate (59.0 mg, 0.256 mmol, 61%) as a colourless oil. 
Rf 0.35 (EtOAc/40-60 PE, 1:2); IR (thin film, νmax / cm−1): 3369, 2937, 2865, 1742, 1459, 1393, 1362, 
1249, 1056, 1025, 997, 955, 933, 789; 1H NMR (400 MHz, CDCl3): δH 5.97-5.89 (1H, m, CH=CH2), 
5.35 (1H, br d, J = 17.2 Hz, CH=CHaCHb), 5.26 (1H, br d, J = 10.4 Hz, CH=CHaHb), 4.61 (2H, ddd, J = 
5.9, 2.6, 1.5 Hz, OCH2), 4.13 (2H, t, J = 6.6 Hz, H1 x 2), 3.61 (2H, t, J = 6.6 Hz, H8 x 2), 1.82-1.69 (1H, 
m, OH), 1.66 (2H, quin, J = 7.0 Hz, H2 x 2), 1.55 (2H, quin, J = 6.9 Hz, H7 x 2), 1.39-1.28 (8H, m, H3 x 
2, H4 x 2, H5 x 2, H6 x 2); 13C NMR (125 MHz, CDCl3): δC 155.1, 131.7, 118.8, 68.3, 68.2, 62.9, 32.7, 
29.2, 29.1, 28.6, 25.6 x 2; HRMS calculated for C12H23O4 [M+H]+ 231.1591, found 231.1593. 
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Allyl (8-oxoxyoctyl) carbonate (264) 
 
Dess-Martin periodinane (157 mg, 0.371 mmol) was added to a suspension of allyl (8-hydroxyoctyl) 
carbonate (57.0 mg, 0.248 mmol) and NaHCO3 (104 mg, 1.24 mmol) in CH2Cl2 (5 mL) at 0 °C and 
stirred for 5 min. The mixture was then warmed to rt and stirred for a further 15 min until complete. The 
reaction was quenched with Na2S2O3 solution (10 mL) and the biphasic mixture stirred rapidly for 20 
min. Phases were separated and the aqueous layer extracted with EtOAc (3 x 5 mL). Combined organic 
layers were dried (MgSO4), concentrated in vacuo and the residue was purified by flash column 
chromatography (EtOAc/40-60 PE, gradient elution: 1:20 ® 1:10). Aldehyde 264 (45.1 mg, 0.197 mmol, 
80%) was obtained as a colourless oil. 
Rf 0.70 (EtOAc/40-60 PE, 1:3); IR (thin film, νmax / cm−1) 2929, 2857, 1742, 1722, 1461, 1397, 1362, 
1245, 993, 955, 937, 795; 1H NMR (400 MHz, CDCl3): δH 9.77 (1H, br t, J = 1.7 Hz, CHO), 5.94 (1H, 
ddt, J = 17.1 Hz, 10.8 Hz, 5.7 Hz, CH=CH2), 5.36 (1H, dd, J = 17.1, 1.3 Hz, CH=CHaHb), 5.27 (1H, dd, J 
= 10.8, 0.9 Hz, CH=CHaHb), 4.62 (2H, br d, J = 5.7 Hz, OCH2), 4.14 (2H, t, J = 6.6 Hz, H1 x 2), 2.43 (2H, 
td, J = 7.3, 1.6 Hz, H8 x 2), 1.71-1.60 (4H, m, H2 x 2, H7 x 2), 1.42-1.31 (8H, m, H3 x 2, H4 x 2, H5 x 2, 
H6 x 2); 13C NMR (125 MHz, CDCl3): δC 202.7, 155.1, 131.7, 118.8, 68.3, 68.1, 43.8, 29.0, 28.9, 28.6, 
25.5, 21.9; HRMS calculated for C12H21O4 [M+H]+ 229.1434, found 229.1435. 
Enone 264a 
 
A solution of phosphonate 123 (80.0 mg, 0.385 mmol) in THF (2 mL) was added via cannula to a flask 
containing of Ba(OH)2 (83.0 mg, 0.482 mmol) in THF (2 mL). The resulting suspension was stirred at rt 
for 45 min before adding a solution of aldehyde 264 (44.0 mg, 0.193 mmol) in THF/H2O (40:1, 2 mL). 
The reaction was stirred for 16 h during which a pale yellow colour developed. The mixture was 
quenched by addition of NH4Cl solution (5 mL) and extracted with EtOAc (3 x 5 mL). Combined organic 
phases were dried (MgSO4), concentrated in vacuo and purified by flash column chromatography 
(gradient elution: EtOAc/40-60 PE, 1:15 ® 1:10) to yield enone 264a (29.0 mg, 0.103 mmol, 53%, 
>20:1 E/Z) as a colourless oil. 
Rf 0.71 (EtOAc/40-60 PE, 1:3); IR (thin film, νmax / cm−1) 2925, 2853, 1746, 1667, 1637, 1459, 1393, 
1366, 1249, 1082, 957, 935, 789; 1H NMR (400 MHz, CDCl3): δH 6.60 (1H, t, J = 7.3 Hz, H8), 5.92 (1H 
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ddt, J = 17.1, 10.4, 5.9 Hz, CH=CH2), 5.34 (1H, br d, J = 17.1 Hz, CH=CHaHb), 5.25 (1H, br d, J = 10.4, 
CH=CHaHb), 4.61 (2H, d, J = 5.8 Hz, OCH2), 4.13 (2H, t, J = 6.7 Hz, H1 x 2), 2.29 (3H, s, Me11), 2.22 
(2H, dt, J = 7.4, 7.0 Hz, H7 x 2), 1.74 (3H, s, Me9), 1.70-1.63 (2H, m, H2 x 2), 1.49-1.42 (2H, m, H6 x 2), 
1.45-1.31 (6H, m, H3 x 2, H4 x 2, H5 x 2); 13C NMR (100 MHz, CDCl3): δC 199.6, 154.8, 143.4, 137.3, 
131.4, 118.6, 68.0, 67.7, 28.9, 28.7, 28.6, 28.2 x 2, 25.2, 25.0, 10.8; HRMS calculated for C16H27O4 
[M+Na]+ 283.1904, found 283.1906. 
Allylic alcohol 265 
 
(R)-Me-CBS catalyst (149 µL, 0.149 mmol) and BH3×SMe2 (11 µL, 0.119 mmol) were added sequentially 
to a solution of enone 264a (28.4 mg, 0.100 mmol) in THF (2 mL) at -10 °C. The reaction was stirred at 
this temperature for 1 h, then quenched by dropwise addition of MeOH. The mixture was warmed to rt 
and stirred for 15 minutes before being concentrated in vacuo. The residue was redissolved in MeOH (2 
mL), followed by concentration in vacuo, which was repeated twice. Crude product was purified by flash 
column chromatography (gradient elution: EtOAc/40-60 PE, 1:15 ® 1:10) to give allylic alcohol 265 
(26.0 mg, 91.4 µmol, 92%) as a colourless oil. 
Rf 0.38 (EtOAc/40-60 PE, 1:3); IR (thin film, νmax / cm−1); 3424, 2924, 2849, 1742, 1460, 1395, 1361, 
1252, 1078, 1034, 963, 935, 889, 796; 1H NMR (500 MHz, CDCl3): δH 5.95 (1H, ddt, J = 17.2, 10.5 Hz, 
CH=CH2), 5.42-5.39 (1H, m, H8), 5.37 (1H, dq, J = 17.2, 1.5 Hz, CH=CHaHb), 5.82 (1H, dq, J = 10.5, 
1.2 Hz, CH=HaHb), 4.64 (2H, dt, J = 5.8, 1.3 Hz, OCH2), 4.22 (1H, q, J = 6.4 Hz, H10), 4.15 (2H, t, J = 
6.8 Hz, H1 x 2), 2.03-1.99 (2H, m, H7 x 2), 1.71-1.65 (2H, m, H2 x 2), 1.63 (3H, s, Me9), 1.41-1.31 (8H, 
m, H3 x 2, H4 x 2, H5 x 2, H6 x 2), 1.26 (3H, d, J = 6.4 Hz, Me11); 13C NMR (125 MHz, CDCl3): δC 155.1, 
138.4, 131.7, 125.2, 118.8, 73.4, 68.3, 68.2, 29.4, 29.1 x 2, 28.6, 27.4, 25.6, 21.6, 11.4; HRMS calculated 
for C16H28O4Na [M+Na]+ 307.1880, found 307.1883. 
Enone 251 
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A suspension of Ba(OH)2 (47.0 mg, 0.275 mmol) in THF (2 mL) was sonicated for 5 min before a 
solution of 253 and 254 (3:1, 336 mg, 0.324 mmol) in THF (2 mL) was added. The mixture was stirred at 
rt for 1.5 h before a solution of aldehyde 161 (166 mg, 0.262 mmol) in THF/H2O (40:1, 2 mL) was added 
via cannula. The reaction mixture was stirred for 20 h before being quenched with NH4Cl solution (5 mL) 
and diluted with H2O (2 mL). The layers were separated and the aqueous phase was extracted with EtOAc 
(3 x 10 mL). Combined organic extracts were dried (MgSO4), concentrated in vacuo and the crude 
material purified by flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:30 ® 1:5). 
Enone 251 (315 mg, 0.250 mmol, 96%) was obtained as a colourless oil. 
Rf 0.53 (EtOAc/40-60 PE, 1:5); [α] !"# = +1.1 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2953, 2876, 1746, 
1670, 1514, 1459, 1377, 1292, 1247, 1169, 1092, 1038, 1006, 969, 835, 776, 736, 735, 723; 1H NMR 
(500 MHz, CDCl3): δH 7.26 (2H, d, J = 8.4 Hz, ArH), 6.89 (2H, d, J = 8.4 Hz, ArH), 6.64 (1H, t, J = 6.9 
Hz, H15), 6.21 (1H, dd, J = 15.0, 10.5 Hz, H3), 6.07 (1H, dd, J = 15.0, 10.5 Hz, H4), 6.00-5.92 (1H, m, 
CH=CH2), 5.71 (1H, dt, J = 15.2, 7.5 Hz, H2), 5.66 (1H, dt, J = 15.2, 5.5 Hz, H5), 5.64-5.58 (1H, m, H21), 
5.38 (1H, dd, J = 17.2, 1.4 Hz, CH=CHaHb), 5.33 (1H, dd, J = 15.5, 8.5 Hz, H20), 5.28 (1H, dd, J = 10.4, 
1.3 Hz, CH=CHaHb), 4.64 (2H, d, J = 5.7 Hz, OCH2), 4.59 (1H, d, J = 11.1 Hz, ArCHaHbO), 4.40 (1H, d, 
J = 11.1 Hz, ArCHaHbO), 4.32 (1H, dd, J = 10.8, 4.3 Hz, H27a), 4.22 (2H, d, J = 5.6 Hz, H1 x 2), 3.96 (1H, 
dd, J = 10.5, 9.0 Hz, H27b), 3.82 (3H, s, ArOCH3), 3.74 (1H, dd, J = 7.5, 2.8 Hz, H25), 3.71-3.63 (2H, m, 
H7, H23), 3.61-3.56 (2H, m, H9, H19), 3.26 (3H, s, OCH3), 2.76 (1H, ddd, J = 15.3, 9.8, 5.3 Hz, H12a), 
2.62-2.50 (2H, m, H12b, H22a), 2.35-2.28 (2H, m, H16a, H22b), 2.20-2.05 (4H, m, H6 x 2, H16b, H26), 
1.84-1.73 (4H, m, H8, H11a, H17, H24), 1.79 (3H, s, Me14), 1.60-1.53 (2H, m, H10, H18a), 1.46-1.39 (2H, m, 
H11b, H18b), 1.06 (3H, d, J = 6.9 Hz, Me26), 1.00-0.92 (36H, m, Me8, Me17, Me24, SiCH2CH3 x 9), 0.93 
(9H, s, SiC(CH3)3), 0.88 (3H, d, J = 6.9 Hz, Me10), 0.66-0.57 (18H, m, SiCH2CH3 x 9), 0.09 (6H, s, 
SiCH3 x 2); 13C NMR (125 MHz, CDCl3): δC 201.9, 159.0, 155.2, 140.4, 138.1, 133.0, 131.7, 131.4, 
131.2, 130.6, 130.4, 130.3, 128.6 x 2, 118.8, 113.7, 80.5, 78.3, 77.5, 74.5, 70.8, 69.8, 68.3, 63.7, 55.8, 
55.3, 42.9, 41.8, 41.3, 38.1, 36.1 x 2, 35.6, 35.4, 34.9, 29.6, 26.8, 26.0 x 2, 20.0, 18.4, 16.2, 16.0, 11.6, 
10.5, 10.2, 7.2, 7.1, 7.0, 5.6 x 2, 5.3, -5.2; HRMS calculated for C70H132NO11Si4 [M+NH4]+ 1274.8872, 
found 1274.8855.  
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Allylic alcohol 256 
 
(R)-Me-CBS catalyst (1.62 mL, 1.0 M in PhMe, 1.61 mmol) was added to a solution of enone 251 (1.56 
g, 1.24 mmol) in THF (50 mL) at -20 °C, followed by dropwise addition of BH3×SMe2 (141 µL, 1.48 
mmol). The mixture was warmed to -10 °C and stirred for 3 h before being slowly quenched with 
NaHCO3 solution (10 mL), warmed to rt and stirred for a further 20 min until bubbling had ceased. The 
mixture was diluted with H2O (20 mL), extracted with EtOAc (3 x 40 mL), dried (Na2SO4) and 
concentrated in vacuo. Purification by flash column chromatography (gradient elution: EtOAc/40-60 PE, 
1:15 ® 1:8) yielded allylic alcohol 256 (1.45 g, 1.15 mmol, 93%, 20:1 dr) as a colourless oil. 
Rf 0.44 (EtOAc/40-60 PE, 1:5); [α] !"# = +6.3 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2952, 2873, 1748, 
1516, 1460, 1415, 1379, 1299, 1248, 1100, 1042, 1006, 969, 834, 778, 741; 1H NMR (500 MHz, CDCl3): 
δH 7.26 (2H, d, J = 8.5 Hz, ArH), 6.89 (2H, d, J = 8.5 Hz, ArH), 6.21 (1H, dd, J = 15.0, 10.5 Hz, H3), 6.06 
(1H, dd, J = 15.0, 10.4 Hz, H4), 5.96 (1H, ddt, J = 17.1, 10.4, 5.8 Hz, CH=CH2), 5.70 (1H, dt, J = 15.1, 
7.5 Hz, H2), 5.66 (1H, dt, J = 15.1, 5.3 Hz, H5), 5.63-5.57 (1H, m, H21), 5.40-5.36 (2H, m, H15, 
CH=CHaHb), 5.32-5.27 (2H, m, H20, CH=CHaHb), 4.65-4.63 (2H, m, OCH2), 4.60 (1H, d, J = 11.2 Hz, 
ArCHaHbO), 4.40 (1H, d, J = 11.2 Hz, ArCHaHbO), 4.32 (1H, dd, J = 10.6, 4.2 Hz, H27a), 4.23 (2H, d, J = 
5.1 Hz, H1 x 2), 3.98-3.94 (2H, m, H13, H27b), 3.82 (3H, s, ArOCH3), 3.74 (1H, dd, J = 7.7, 2.7 Hz, H25), 
3.69 (1H, ddd, J = 7.7, 5.3, 2.7 Hz, H23), 3.64-3.61 (1H, m, H7), 3.58-3.53 (1H, m, H19), 3.52 (1H, dd, J 
= 5.0, 3.4 Hz, H9), 3.25 (3H, s, OCH3), 2.52 (1H, dd, J = 14.1, 5.4 Hz, H22a), 2.32 (1H, dd, J = 14.1, 7.9 
Hz, H22b), 2.22 (4H, m, H6 x 2, H16a, H26), 1.87-1.74 (3H, m, H8, H16b, H24), 1.68-1.60 (2H, m, H12a, H18a), 
1.61 (3H, s, Me14), 1.57-1.39 (6H, m, H10, H11 x 2, H12b, H17, H18b), 1.06 (3H, d, J = 6.9 Hz, Me26), 
0.99-0.95 (33H, m, Me10, Me24, SiCH2CH3 x 9), 0.94 (9H, s, SiC(CH3)3), 0.91 (3H, d, J = 6.8 Hz, Me17), 
0.88 (6H, d, J = 6.8 Hz, Me8), 0.67-0.57 (18H, m, SiCH2CH3 x 9), 0.10 (6H, s, SiCH3 x 2); 13C NMR 
(125 MHz, CDCl3): δC 158.9, 155.2, 138.0, 133.3, 131.7, 131.6, 131.4, 131.2, 130.3 x 2, 128.6, 125.8, 
118.8, 113.7, 80.8, 79.0, 78.3, 77.7, 77.2, 74.6, 70.8, 69.8, 68.3, 63.7, 55.8, 55.2, 42.9, 41.9, 41.3, 38.5, 
35.9, 35.6, 35.0, 34.9, 33.1, 29.9, 27.8, 26.0 x 2, 19.8, 18.5, 16.5, 16.1, 11.0, 10.4, 10.2, 7.2, 7.1, 7.0, 5.7, 
5.6, 5.2, -5.1; HRMS calculated for C70H134NO11Si4 [M+NH4]+ 1276.9028, found 1276.9018. 
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DCC (80 µL, 1.0 M in CH2Cl2, 80 µmol) was added to a solution of allylic alcohol 256 (10.9 mg, 8.6 
µmol), (R)-(-)-a-methoxy-a-(trifluoromethyl)-phenylacetic acid (19.0 mg, 81.1 µmol) and DMAP (10.0 
mg, 81.9 µmol) in CH2Cl2 (1 mL). The cloudy reaction mixture was stirred at rt for 3 h until complete. 
Solvent was removed in vacuo,  the residue dissolved in Et2O and filtered through cotton wool. The 
solution was concentrated in vacuo and the crude mixture purified by flash column chromatography 
(gradient elution: EtOAc/40-60 PE, 1:25 ® 1:20) to yield (R)-Mosher ester 257 (9.8 mg, 6.6 µmol, 54%) 
as a colourless oil. 
Rf 0.51 (EtOAc/40-60 PE, 1:10); 1H NMR (500 MHz, CDCl3): δH 7.52-7.50 (2H, m, PhH), 7.41-7.38 
(3H, m, PhH), 7.26 (2H, d, J = 8.5 Hz, ArH), 6.89 (2H, d, J = 8.5 Hz, ArH), 6.21 (1H, dd, J = 14.9, 10.1 
Hz, H3), 6.06 (1H, dd, J = 14.9, 10.4 Hz, H4), 5.96 (1H, ddt, J = 17.1, 10.4, 5.8 Hz, CH=CH2), 5.69-5.67 
(2H, m, H2, H5), 5.62-5.54 (2H, m, H13, H21), 5.40-5.31 (3H, m, H15, H20, CH=CHaHb), 5.29 (1H, br d, J  
= 10.4 Hz, CH=CHaHb), 4.64 (1H, d, J = 5.6 Hz, OCH2), 4.60 (1H, d, J = 11.1 Hz, ArCHaCHbO), 4.40 
(1H, d, J = 11.1 Hz, ArCHaHbO), 4.32 (1H, dd, J = 10.6, 4.0 Hz, H27a), 4.23 (2H, d, J = 5.3 Hz, H1 x 2), 
3.97 (1H, dd, J = 10.5, 9.3 Hz, H27b), 3.82 (3H, s, ArOCH3), 3.75 (1H, dd, J = 7.6, 2.4 Hz, H25), 3.70-3.65 
(1H, m H23), 3.62-3.55 (2H, m, H7, H19), 3.58 (3H, s, OCH3), 3.51 (1H, dd, J = 4.9, 3.2 Hz, H9), 3.25 
(3H, s, OMe19), 2.52 (1H, dt, J = 14.0, 5.3 Hz, H22a), 2.31 (1H, dt, J = 14.0, 8.2 Hz, H22b), 2.22-2.09 (4H, 
m, H6 x 2, H12a, H26), 1.84-1.75 (3H, m, H12b, H16a, H24), 1.73-1.69 (1H, m, H8), 1.67-1.60 (2H, m, H16b, 
H17), 1.55-1.47 (2H, m, H10, H18a), 1.43 (3H, s, Me14), 1.43-1.37 (2H, m, H11a, H18b), 1.06 (3H, d, J = 6.8 
Hz, Me26), 0.99-0.91 (34H, m, H11b, Me10, Me24, SiCH2CH3 x 9), 0.93 (9H, s, SiC(CH3)3), 0.87 (3H, d, J 
= 6.8 Hz, Me8), 0.87 (3H, d, J = 6.8 Hz, Me17), 0.67-0.56 (18H, m, SiCH2CH3 x 9), 0.10 (6H, s, SiCH3 x 
2); HRMS calculated for C80H141F3O13NSi4 [M+NH4] + 1492.9427, found 1492.9418. 
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(S)-Mosher ester 258 
 
DCC (80 µL, 1.0 M in CH2Cl2, 80 µmol) was added to a solution of allylic alcohol 256 (10.6 mg, 8.4 
µmol), (S)-(+)-a-methoxy-a-(trifluoromethyl)-phenylacetic acid (19.0 mg, 81.1 µmol) and DMAP (10.0 
mg, 81.9 µmol) in CH2Cl2 (1 mL). The cloudy reaction mixture was stirred at rt for 3 h until complete. 
Solvent was removed in vacuo,  the residue dissolved in Et2O and filtered through cotton wool. The 
solution was concentrated in vacuo and the crude mixture purified by flash column chromatography 
(gradient elution: EtOAc/40-60 PE, 1:25 ® 1:20) to yield (S)-Mosher ester 258 (11.0 mg, 7.5 µmol, 
89%) as a colourless oil. 
Rf 0.47 (EtOAc/40-60 PE, 1:10); 1H NMR (500 MHz, CDCl3): δH 7.53-7.49 (2H, m, PhH), 7.41-7.38 
(3H, m, PhH), 7.26 (2H, d, J = 8.4 Hz, ArH), 6.89 (2H, d, J = 8.4 Hz, ArH), 6.20 (1H, dd, J = 14.9, 10.3 
Hz, H3), 6.06 (1H, dd, J = 14.9, 10.9 Hz, H4), 5.96 (1H, ddt, J = 17.1, 10.6, 5.7 Hz, CH=CH2), 5.72-5.65 
(2H, m, H2, H5), 5.63-5.56 (2H, m, H13, H21), 5.41-5.28 (4H, m, H15, H20, CH=CHaHb, CH=CHaHb), 4.64 
(2H, d, J = 5.7 Hz, OCH2), 4.59 (1H, d, J = 10.8 Hz, ArCHaCHbO), 4.40 (1H, d, J = 10.8 Hz, 
ArCHaHbO), 4.32 (1H, dd, J = 10.6, 4.2 Hz, H27a), 4.23 (2H, d, J = 5.4 Hz, H1 x 2), 3.97 (1H, dd, J = 10.4, 
9.3 Hz, H27b), 3.82 (3H, s, ArOCH3), 3.74 (1H, dd, J = 7.5, 2.5 Hz, H25), 3.69-3.64 (1H, m, H23), 
3.62-3.56 (2H, m, H7, H19), 3.54 (3H, s, OCH3), 3.49 (1H, dd, J = 4.7, 3.4 Hz, H9), 3.24 (3H, s, OMe19), 
2.51 (1H, dt, J = 14.0, 5.5 Hz, H22a), 2.33-2.27 (1H, m, H22b), 2.20-2.10 (4H, m, H6 x 2, H12a, H26), 
1.86-1.76 (3H, m, H12b, H16a, H24), 1.75-1.65 (2H, m, H8, H10), 1.61 (3H, s, Me14), 1.62-1.48 (3H, m, 
H16b, H17, H18a), 1.43-1.19 (2H, m, H11a, H18b), 1.05 (3H, d, J = 6.7 Hz, Me26), 0.99-0.92 (31H, m, H11b, 
Me24, SiCH2CH3 x 9), 0.93 (9H, s, SiC(CH3)3), 0.90-0.85 (9H, m, Me8, Me10, Me17), 0.67-0.56 (18H, m, 
SiCH2CH3 x 9), 0.09 (6H, s, SiCH3 x 2); HRMS calculated for C80H141F3O13NSi4 [M+NH4]+ 1492.9427, 
found 1492.9413. 
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Methyl ether 162 
 
A solution of allylic alcohol 256 (1.66 g, 1.32 mmol) in CH2Cl2 (20 mL) was added via cannula to a flask 
containing trimethyloxonium tetrafluoroborate (1.36 g, 9.25 mmol) and Proton-SpongeÒ (1.98 g, 9.25 
mmol). The resulting mixture was stirred for 4 h during which a colour change from pale yellow to 
orange was observed, then quenched by addition of NH4Cl solution (50 mL). Phases were separated and 
the aqueous layer extracted with CH2Cl2 (3 x 50 mL). Combined organic extracts were dried (Na2SO4) 
and concentrated in vacuo to give a yellow solid. Crude product was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:40 ® 1:5) to give methyl ether 162 (1.28 g, 0.278 
mmol, 76%) as a pale yellow oil. 
Rf 0.64 (EtOAc/40-60 PE, 1:5); [α] !"# = +5.6 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2960, 2933, 2873, 
1746, 1514, 1461, 1380, 1296, 1251, 1098, 1041, 1011, 989, 973, 843, 776, 739, 725; 1H NMR (500 
MHz, CDCl3): δH 7.25 (2H, d, J = 8.5 Hz, ArH), 6.89 (2H, d, J = 8.5 Hz, ArH), 6.20 (1H, dd, J = 15.1, 
10.5 Hz, H3), 6.06 (1H, dd, J = 15.1, 10.5 Hz, H4), 5.96 (1H, ddt, J = 17.1, 10.5, 5.8 Hz, CH=CH2), 5.70 
(1H, dt, J = 15.1, 7.5 Hz, H2), 5.66 (1H, dt, J = 15.1, 5.4 Hz, H5), 5.59 (1H, ddd, J = 14.8, 7.9, 6.3 Hz, 
H21), 5.37-5.31 (1H, m, CH=CHaHb), 5.37-5.31 (2H, m, H15, H20), 5.30-5.27 (1H, m, CH=CHaHb), 4.64 
(2H, d, J = 5.9 Hz, OCH2), 4.60 (1H, d, J = 11.0 Hz, ArCHaHbO), 4.40 (1H, d, J = 11.0 Hz, ArCHaHbO), 
4.32 (1H, dd, J = 10.6, 4.3 Hz, H27a), 4.23 (2H, d, J = 5.2 Hz, H1 x 2), 3.96 (1H, dd, J = 10.6, 9.0 Hz, 
H27b), 3.83 (3H, s, ArOCH3), 3.75 (1H, dd, J = 7.5, 2.6 Hz, H25), 3.71-3.67 (1H, m, H23), 3.64-3.57 (2H, 
m, H7, H19), 3.51 (1H, dd, J = 4.3, 3.4 Hz, H9), 3.38 (1H, dd, J = 7.0, 6.9 Hz, H13), 3.26 (3H, s, OMe19), 
3.17 (3H, s, OMe13), 2.52 (1H, ddd, J = 14.1, 5.5, 5.3 Hz, H22a), 2.31 (1H, ddd, J = 14.1, 8.0, 7.3 Hz, 
H22b), 2.20-2.12 (4H, m, H6 x 2, H16a, H26), 1.89-1.74 (3H, m, H8, H16b, H24), 1.68-1.63 (1H, m, H17), 
1.58-1.48 (4H, m, H10, H11a, H12 x 2), 1.52 (3H, s, Me14), 1.46-1.40 (2H, m, H11b, H18b), 1.06 (3H, d, J = 
6.9 Hz, Me26), 0.99-0.96 (30H, m, Me24, SiCH2CH3 x 9), 0.94 (9H, s, SiC(CH3)3), 0.91-0.87 (9H, m, 
Me8, Me10, Me17), 0.67-0.58 (18H, m, SiCH2CH3 x 9), 0.10 (6H, s, SiCH3 x 2); 13C NMR (125 MHz, 
CDCl3): δC 159.0, 155.2, 135.1, 133.4, 131.8 x 2, 131.4, 131.2, 130.3 x 2, 130.2, 128.7, 127.8, 118.8, 
113.7, 88.5, 80.9, 78.4, 77.7, 77.1, 74.7, 70.8, 69.8, 68.2, 63.8, 55.9, 55.6, 55.3, 42.9, 41.7, 41.3, 38.6, 
35.8, 35.6, 35.0, 34.8, 32.0, 29.9, 27.9, 26.0, 19.8, 18.4, 16.3, 15.9, 10.3, 10.2, 10.1, 7.2, 7.1, 7.0, 5.7, 5.6, 
5.2, -5.2; HRMS calculated for C71H136NO11Si4 [M+NH4]+ 1290.9185, found 1290.9173.  
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Aldehyde 163 
 
DDQ (107 mg, 0.471 mmol) was added to a stirred solution of TBS ether 162 (201 mg, 0.158 mmol) in 
CH2Cl2/pH 7 buffer solution (3:1, 10 mL) at 0 °C and a colour change to dark blue was observed. The 
mixture was warmed to rt and stirred for 30 min during which a gradual colour change to red was seen. 
An additional portion of DDQ (18.0 mg, 79.0 µmol) was added and the mixture stirred for an additional 
30 min until complete. The reaction was quenched with NaHCO3 solution (10 mL), warmed to rt and 
stirred for 30 min. Phases were separated and the aqueous layer extracted with CH2Cl2 (3 x 10 mL). 
Combined organic extracts were dried (Na2SO4), concentrated in vacuo and purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:15 ® 1:8). Aldehyde 163 (133 mg, 0.128 mmol, 
82%) was obtained as a pale yellow oil.  
Rf 0.33 (EtOAc/40-60 PE, 1:5); [α] !"# = +3.0 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2948, 2873, 1752, 
1683, 1637, 1461, 1376, 1251, 1156, 1094, 1006, 967, 801, 795, 737, 723; 1H NMR (500 MHz, CDCl3): 
δH 9.57 (1H, d, J = 7.9 Hz, CHO), 7.10 (1H, dd, J = 15.3, 10.0 Hz, H3), 6.38-6.30 (2H, m, H4 H5), 6.10 
(1H, dd, J = 15.2, 7.9 Hz, H2), 5.95 (1H, ddt, J = 17.1, 10.4, 5.8 Hz, CH=CH2), 5.62 (1H, ddd, J = 15.1, 
8.3, 5.9 Hz, H21), 5.38 (1H, ddt, J = 17.1, 1.3, 1.3 Hz, CH=CHaHb), 5.36-5.31 (2H, m, H15, H20), 5.29 
(1H, ddt, J = 10.4, 1.2, 1.2 Hz, CH=CHaHb), 4.67 (1H, dddd, J = 13.0, 5.9, 1.2, 1.2 Hz, OCHaHb), 4.62 
(1H, dddd, J = 13.0, 5.9, 1.2, 1.2 Hz, OCHaHb), 4.28 (1H, dd, J = 10.5, 3.9 Hz, H27a), 4.09-4.05 (2H, m, 
H23, H27b), 3.74 (1H, dd, J = 7.7, 2.9 Hz, H25), 3.70-3.67 (1H, m, H7), 3.58-3.53 (1H, m, H19), 3.51 (1H, 
dd, J = 4.0, 3.9 Hz, H9), 3.37 (1H, dd, J = 6.9, 6.8 Hz, H13), 3.24 (3H, s, OMe19), 3.16 (3H, s, OMe13), 
2.37-2.27 (3H, m, H6 x 2, H22a), 2.19-2.12 (3H, m, H16a, H22b, H26), 1.89-1.83 (1H, m, H16b), 1.79-1.70 
(2H, m, H8, H24), 1.66-1.60 (1H, m, H17), 1.57-1.39 (7H, m, H10, H11 x 2, H12 x 2, H18 x 2), 1.51 (3H, s, 
Me14), 1.04 (3H, d, J = 7.1 Hz, Me24), 1.01-0.95 (30H, m, Me26, SiCH2CH3 x 9), 0.90-0.88 (9H, m, Me8, 
Me10, Me17), 0.69 (6H, q, J = 7.9 Hz, SiCH2CH3 x 3), 0.64-0.58 (12H, m, SiCH2CH3 x 6); 13C NMR (125 
MHz, CDCl3): δC 194.0, 155.1, 152.4, 144.8, 135.1, 133.2, 131.6, 130.3 x 2, 130.2, 127.7, 119.0, 88.4, 
80.8, 79.9, 77.4, 74.3, 70.3, 70.2, 68.4, 55.8, 55.7, 42.7, 41.6, 38.9, 37.9, 36.9 x 2, 36.4, 34.9, 32.0, 29.9, 
29.7, 28.3, 19.9, 16.0, 14.4, 11.2, 10.4, 10.0, 7.1, 7.0, 5.6, 5.2 x 2; HRMS calculated for C57H112NO10Si3 
[M+NH4]+ 1054.7589, found 1054.7586.  
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Seco acid 164 
 
A solution of NaClO2 (367 mg, 4.06 mmol) and NaH2PO4×H2O (845 mg, 5.42 mmol) in H2O (8.3 mL) 
was added dropwise to a solution of aldehyde 163 (281 mg, 0.271 mmol) in tBuOH/2-methyl-but-2-ene 
(10:1, 16.7 mL) at rt and stirred for 21 h. The mixture was diluted with H2O (30 mL) and EtOAc (30 mL) 
and the phases were separated. The organic layer was washed with H2O (3 x 20 mL) and back-extracted 
with EtOAc (2 x 10 mL). Combined organic phases were dried (Na2SO4) and concentrated in vacuo. 
Crude seco-acid 164 (274 mg, 0.260 mmol, 96% yield) was used in the next step without additional 
purification. 
Rf 0.37 (EtOAc/40-60 PE, 1:2); [α] !"# = -1.3 (c 1.0, CHCl3); IR (thin film, νmax / cm−1): 2952, 2916, 2880, 
1746, 1722, 1692, 1639, 1460, 1417, 1395, 1377, 1252, 1092, 1034, 1004, 965, 743, 727; 1H NMR (500 
MHz, CDCl3): δH 7.35-7.29 (1H, m, H3), 6.27-6.16 (2H, m, H4, H5), 5.94 (1H, ddt, J = 17.1, 10.4, 5.8 
Hz, CH=CH2), 5.80 (1H, d, J = 15.3 Hz, H2), 5.61 (1H, ddd, J = 14.9, 8.0, 6.4 Hz, H21), 5.37 (1H, ddt, J = 
17.2, 1.4, 1.4 Hz, CH=CHaHb), 5.36-5.29 (2H, m, H15, H20), 5.28 (1H, ddt, J = 10.4, 1.2, 1.2 Hz, 
CH=CHaHb), 4.69-4.59 (2H, m, OCH2), 4.27 (1H, dd, J = 10.4, 3.7 Hz, H27a), 4.12-4.04 (2H, m, H23, 
H27b), 3.74 (1H, dd, J = 7.8, 2.7 Hz, H25), 3.67-3.63 (1H, m, H7), 3.60-3.53 (2H, m, H9, H19), 3.36 (1H, 
dd, J = 6.9, 6.8 Hz, H13), 3.23 (3H, s, OMe19), 3.15 (3H, s, OMe13), 2.38-2.27 (3H, m, H6 x 2, H22a), 
2.19-2.09 (3H, m, H16a, H22b, H26), 1.89-1.79 (1H, m, H16b), 1.77-1.66 (2H, m, H8, H24), 1.65-1.58 (1H, 
m, H17), 1.50 (3H, s, Me14), 1.56-1.32 (7H, m, H10, H11 x 2, H12 x 2, H18 x 2), 1.04 (3H, d, J = 7.2 Hz, 
Me24), 1.00-0.93 (30H, m, Me26, SiCH2CH3 x 9), 0.89-0.84 (9H, m, Me8, Me10, Me17), 0.68 (6H, q, J = 
7.8 Hz, SiCH2CH3 x 3), 0.60 (6H, q, J = 7.8 Hz, SiCH2CH3 x 3), 0.58 (6H, q, J = 7.8 Hz, SiCH2CH3 x 3); 
13C NMR (125 MHz, CDCl3): δC 171.6, 155.1, 146.8, 143.1, 135.0, 133.2, 131.6, 130.3, 130.0, 127.8, 
118.9, 118.7,  88.4, 80.9, 79.8, 77.2, 74.3, 70.4, 70.1, 68.4, 55.8, 55.6, 42.6, 41.4, 39.0, 37.8, 36.9, 36.8, 
36.4, 34.9, 31.9, 29.9, 28.3, 19.9, 15.8, 14.4, 11.2, 10.3, 10.2, 7.1, 7.0, 6.9, 5.6, 5.2 x 2; HRMS calculated 
for C57H112NO11Si3 [M+NH4]+ 1070.7538, found 1070.7544. 
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Macrolactone 165 
 
Et3N (59 µL, 0.759 mmol) was added to a solution of seco-acid 164 (20.0 mg, 19.0 µmol) in THF (0.55 
mL), followed by dropwise addition of TCBC (103 µL, 0.38 mmol). The mixture was stirred at rt for 1 h, 
then diluted with PhMe (2.2 mL) and the resulting cloudy orange solution added via syringe pump at a 
rate of 0.2 mL/h to a mixture of DMAP (139 mg, 1.14 mmol) and PhMe (3.4 mL). Upon completion, the 
reaction mixture was stirred for a further 3 h before being quenched with NH4Cl solution (5 mL) and 
diluted with H2O (3 mL). The organic layer was washed with NH4Cl solution (3 x 5 mL), the combined 
organic phases dried (Na2SO4) and concentrated in vacuo. Crude residue was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:15 ® 1:8) to give macrolactone 165 (14.0 mg, 
13.5 mmol, 70%) as a colourless oil. 
Rf 0.50 (EtOAc/40-60 PE, 1:5); [α] !"# = +46.8 (c 0.5, CHCl3); IR (thin film, νmax / cm−1): 2948, 2885, 
1748, 1713, 1641, 1459, 1300, 1259, 1235, 1084, 1054, 1039, 1003, 967, 791, 753; 1H NMR (500 MHz, 
CDCl3): δH 7.23 (1H, dd, J = 15.4, 10.8 Hz, H3), 6.25 (1H, ddd, J = 14.5, 9.6, 4.4 Hz, H5), 6.16 (1H, dd, J 
= 15.3, 10.8 Hz, H4), 5.96 (1H, ddt, J = 16.5, 10.7, 5.8 Hz, CH=CH2), 5.85 (1H, d, J = 15.3 Hz, H2), 5.57 
(1H, ddd, J = 14.9, 9.1, 6.1 Hz, H21), 5.38 (1H, ddt, J = 17.2, 2.8, 1.6 Hz, CH=CHaHb), 5.31-5.27 (2H, m, 
CH=CHaHb, H23), 5.06 (1H, dd, J = 15.5, 9.1 Hz, H20), 5.05-5.02 (1H, m, H15), 4.67-4.61 (2H, m, 
OCH2), 4.30 (1H, dd, J = 10.6, 3.9 Hz, H27a), 4.02 (1H, dd, J = 10.6, 7.5 Hz, H27b), 3.65-3.62 (1H, m, H7), 
3.59 (1H, dd, J = 5.1, 5.1 Hz, H25), 3.52 (1H, dt, J = 10.2, 4.2 Hz, H19), 3.42-3.38 (2H, m, H9, H13), 3.22 
(3H, s, OMe19), 3.19 (3H, s, OMe13), 2.40-2.33 (2H, m, H22 x 2), 2.31-2.25 (1H, m, H6a), 2.19-2.12 (1H, 
m, H26), 2.00-1.93 (2H, m, H6b, H16a), 1.86-1.80 (1H, m, H24), 1.75-1.46 (6H, m, H8, H10, H12 x 2, H16b, 
H18a), 1.45 (3H, s, Me14), 1.28-1.21 (2H, m, H17, H18b), 1.13-1.07 (2H, m, H11 x 2), 1.04 (3H, d, J = 7.1 
Hz, Me24), 1.03 (3H, d, J = 6.9 Hz, Me26), 0.99-0.95 (30H, m, Me10, SiCH2CH3 x 9), 0.92 (3H, d, J = 7.0 
Hz, Me8), 0.82 (3H, d, J = 5.6 Hz, Me17), 0.68-0.56 (18H, m, SiCH2CH3 x 9); 13C NMR (125 MHz, 
CDCl3): δC 166.0, 155.1, 144.3, 142.1, 134.0, 132.9, 131.6, 131.2, 129.6, 129.4, 120.2, 118.7, 87.4, 81.5, 
79.0, 77.1, 72.4, 71.4, 70.1, 68.2, 55.5 x 2, 42.5, 42.2, 40.2, 39.0, 38.2, 36.7, 36.2, 35.9, 30.8, 29.5, 27.7, 
19.9, 15.4, 14.2, 11.9, 11.4, 9.5, 6.9 x 3, 5.2 x 2, 5.1; HRMS calculated for C57H110NO10Si3 [M+NH4]+ 
1052.7432, found 1052.7430. 
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Macrocyclic alcohol 159 
 
A solution of macrolactone 165 (18.0 mg, 17.4 µmol) in THF (2 mL) was added via cannula to a flask 
containing tetrakis(triphenylphosphine)palladium(0) (2.0 mg, 1.7 µmol) and dimedone (24.0 mg, 0.174 
mmol) at rt. The mixture was stirred for 1 h until completion, then quenched with NaHCO3 solution (10 
mL) and extracted with EtOAc (2 x 20 mL). Combined organic extracts were dried (Na2SO4), 
concentrated in vacuo and the yellow residue was purified by flash column chromatography (gradient 
elution: EtOAc/40-60 PE, 1:15 ® 1:5). Macrocyclic alcohol 159 (16.4 mg, 0.124 mmol, 99%) was 
obtained as a pale yellow oil. 
Rf 0.20 (EtOAc/40-60 PE, 1:5); 1H NMR (500 MHz, CDCl3): δH 7.25 (1H, dd, J = 15.2, 10.7 Hz, H3), 
6.27 (1H, ddd, J = 15.0, 10.2, 4.8 Hz, H5), 6.17 (1H, dd, J = 14.9, 10.9 Hz, H4), 5.85 (1H, d, J = 15.3 Hz, 
H2), 5.58 (1H, ddd, J = 14.7, 10.2, 4.0 Hz, H21), 5.26 (1H, ddd, J = 10.7, 4.9, 1.7 Hz, H23), 5.08 (1H, dd, J 
= 15.2, 9.0 Hz, H20), 5.04 (1H, dd, J = 10.5, 3.2 Hz, H15), 3.72 (1H, ddd, J = 11.0, 5.5, 4.1 Hz, H27a), 3.69 
(1H, dd, J = 4.8, 4.8 Hz, H25), 3.65-3.60 (2H, m, H7, H27b), 3.52 (1H, dt, J = 9.8, 4.1 Hz, H19), 3.44-3.38 
(2H, m, H9, H13), 3.22 (3H, s, OMe19), 3.19 (3H, s, OMe13), 2.53 (1H, t, J = 5.7 Hz, OH), 2.45-2.41 (1H, 
m, H22a), 2.35 (1H, t, J = 10.7 Hz, H22b), 2.33-2.26 (1H, m, H6a), 2.02-1.92 (3H, m, H6b, H16a, H26), 
1.91-1.87 (1H, m, H24), 1.76-1.46 (6H, m, H8, H10, H12 x 2, H16b, H18a), 1.45 (3H, s, Me14), 1.26-1.21 
(2H, m, H17, H18b), 1.14-1.07 (2H, obs m, H11 x 2), 1.05 (3H, d, J = 6.2 Hz, Me24), 1.04 (3H, d, J = 6.2 
Hz, Me26), 0.99-0.95 (30H, m, Me10, SiCH2CH3 x 9), 0.92 (3H, d, J = 6.4 Hz, Me8), 0.82 (3H, d, J = 5.8 
Hz, Me17), 0.73-0.67 (6H, m, SiCH2CH3 x 3), 0.62 (6H, q, J = 7.8 Hz, SiCH2CH3 x 3), 0.59 (6H, q, J = 
7.8 Hz, SiCH2CH3 x 3).  
Data in agreement with that presented by Paterson.108 
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6.6. Experimental Procedures for Chapter 5 
Alcohol 275 
 
DDQ (4.81 g, 21.2 mmol) was added portionwise to a rapidly stirring biphasic mixture of PMB ether 274 
(4.20 g, 9.28 mmol) in CH2Cl2/pH 7 buffer (4:1, 125 mL) at 0 °C. The resulting dark blue mixture was 
stirred at this temperature for 75 min, during which a colour change to murky red occurred. The reaction 
was quenched by addition of NaHCO3 solution (100 mL), warmed to rt and diluted with H2O (500 mL). 
The aqueous phase was extracted with CH2Cl2 (5 x 200 mL), the combined organic extracts dried 
(Na2SO4) and concentrated in vacuo. The crude product was purified by flash column chromatography 
(gradient elution: EtOAc/PhMe, 1:20 ® 1:10) to yield alcohol 275 (2.84 g, 8.54 mmol, 92%) as a 
colourless oil.  
Rf 0.39 (EtOAc/40-60 PE, 1:4); 1H NMR (500 MHz, CDCl3): δH 5.03 (1H, qd, J = 6.2, 3.9 Hz, H29), 3.81 
(1H, ddd, J = 11.1, 4.3, 4.2 Hz, H33a), 3.68 (1H, dd, J = 7.0, 3.5 Hz, H31), 3.60 (1H, ddd, J = 11.5, 6.8, 4.9 
Hz, H33b), 2.67 (1H, dd, J = 6.8, 4.4 Hz, OH), 2.32 (1H, q, J = 7.6 Hz, H2' x 2), 1.92-1.85 (1H, m, H30), 
1.81 (1H, app dqd, J = 7.0, 7.0, 4.1 Hz, H32), 1.28 (3H, d, J = 6.4 Hz, Me28), 1.15 (3H, t, J = 7.6 Hz, 
Me3'), 1.08 (3H, d, J = 7.0 Hz, Me32), 1.00 (9H, t, J = 8.0 Hz, SiCH2CH3 x 3), 0.99 (3H, d, J = 7.1 Hz, 
Me30), 0.68 (6H, q, J = 7.9 Hz, SiCH2CH3 x 3). 
Data in agreement with that presented by Paterson.108 
Diol 151 
 
DIBALH (25.6 mL, 1.0 M in hexane, 25.6 mmol) was added dropwise to a solution of ester 275 (2.84 g, 
8.54 mmol) in CH2Cl2 (150 mL) at -78 °C and the mixture stirred at this temperature for 2.5 h. The 
reaction was quenched by addition of Na+/K+ tartrate solution (250 mL), warmed to rt and stirred for 16 h. 
The phases were separated, the organic layer extracted with EtOAc (3 x 150 mL). Combined organic 
phases were dried (Na2SO4) and concentrated in vacuo. The crude was purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:10 ® 1:7) to give diol 151 (2.21 g, 7.99 mmol, 
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94%) as a colourless oil. 
Rf 0.16 (EtOAc/40-60 PE, 1:4); 1H NMR (400 MHz, CDCl3): δH 4.25 (1H, br q, J = 6.3 Hz, H29), 3.74 
(1H, dd, J = 7.0, 3.4 Hz, H31), 3.67 (1H, app t, J = 3.9 Hz, H33), 2.91 (1H, br s, OH29), 2.02-1.93 (1H, m, 
H32), 1.83 (1H, app t, J = 5.4 Hz, OH33), 1.65-1.58 (1H, m, H30), 1.15 (3H, d, J = 6.5 Hz, Me28), 1.02 (3H, 
d, J = 7.0 Hz, Me30), 1.00 (9H, t, J = 8.0 Hz, SiCH2CH3 x 3), 0.98 (3H, d, J = 7.0 Hz, Me32), 0.71 (6H, q, 
J = 7.8 Hz, SiCH2CH3 x 3).  
Data in agreement with that presented by Paterson.108 
Aldehyde 277 
 
DMSO (2.59 mL, 36.5 mmol) was added dropwise to a solution of oxalyl chloride (1.54 mL, 18.3 mmol) 
in CH2Cl2 (100 mL) at -78 °C and stirred for 15 min. A solution of diol 151 (1.68 g, 6.08 mmol) in 
CH2Cl2 (25 mL) was added via cannula and the mixture stirred for further 15 min before dropwise 
addition of Et3N (10.1 mL, 73.0 mmol). The reaction was kept at this temperature for an additional 1 h 
before removing the cooling bath and stirring for 10 min until completion. The mixture was quenched 
with NH4Cl solution (100 mL), the layers separated and the aqueous phase extracted with CH2Cl2 (50 
mL). Combined organic extracts were sequentially washed with 0.5 M HCl (100 mL), H2O (100 mL) and 
NaHCO3 solution (100 mL), dried (Na2SO4) and concentrated in vacuo. Due to risk of epimerisation, 
crude aldehyde 277 was used in the subsequent step without further purification. 
(Z)-vinylformamide 152 
 
Freshly prepared LiHDMS (8.51 mL, 1.0 M in THF, 8.51 mmol) was added dropwise to a suspension of 
phosphonium salt 150 (3.37 g, 9.12 mmol) in THF (30 mL) at -78 °C. The mixture was warmed to 0 °C 
and stirred for 45 min before the resulting yellow suspension was cooled back to -78 °C. A solution of 
crude aldehyde 277 (1.63 g, ca. 5.98 mmol, dried over CaH2 in THF for 20 min before use) in THF (15 
mL) was then added slowly via cannula and the reaction was stirred for 1.5 h until completion. The 
mixture was quenched with NH4Cl solution (50 mL), warmed to rt and extracted with EtOAc (3 x 30 
mL). Combined organic phases were dried (MgSO4), concentrated in vacuo and purified by flash column 
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chromatography (gradient elution: EtOAc/CH2Cl2, 1:30 ® 1:20) to yield (Z)-vinylformamide 152 (1.38 g, 
4.21 mmol, 70% over 2 steps, 4.3:1 Z/E) as a colourless oil. 
Data for the (Z)-isomer: 
Rf 0.46 (EtOAc/ 40-60 PE, 1:1); 1H NMR (400 MHz, CDCl3): δH 8.18 (0.83H, s, NCHO), [8.06] (0.17H, 
s, NCHO*), [6.26] (0.17H, s, NCHO*), 5.96 (1H, d, J = 8.8 Hz, H34), 5.35 (0.83H, dd, J = 10.7, 8.8 Hz, 
H33), [5.12] (0.17H, dd, J = 10.7, 8.8 Hz, H33*), 3.86 (1H, dd, J = 8.0, 2.9 Hz, H31), [3.16] (0.51H, s, 
NMe*), 3.02 (2.49H, s, NMe), 2.75-2.59 (2H, m, H30, H32), 2.16 (3H, s, Me28), [1.07] (0.51H, d, J = 6.9 
Hz, Me30*), 1.07 (2.49H, d, J = 6.9 Hz, Me30), 0.96 (9H, t, J = 8.1 Hz, SiCH2CH3 x 3), 0.92 (3H, d, J = 
7.1 Hz, Me32), 0.61 (6H, q, J = 7.9 Hz, SiCH2CH3 x 3). 
Distinguishable resonances of the minor rotamer (4.7:1 ratio) are given in brackets and marked with an 
asterisk. Data in agreement with that presented by Paterson.108 
Alcohol 278 
 
Distilled acetic acid (1.01 mL) was added to a solution of TBAF (22.3 mL, 1.0 M in THF, 22.3 mmol) at 
0 °C and stirred for 30 min. The mixture was added via cannula to a flask containing TES ether 152 (1.05 
g, 3.21 mmol) at 0 °C and stirred for 4 h until completion. The reaction mixture was poured into a 
solution of NaHCO3 (100 mL) at 0 °C, stirred for 30 min then extracted with EtOAc (5 x 50 mL). 
Combined organic phases were dried (Na2SO4), concentrated in vacuo and purified by flash column 
chromatography (gradient elution: EtOAc/40-60 PE, 1:5 ® 1:0). Alcohol 278 (684 mg, 3.20 mmol, 99%) 
was obtained as a colourless oil. 
Data for the (Z)-isomer: 
Rf 0.12 (EtOAc/40-60 PE, 3:2); 1H NMR (400 MHz, CDCl3): δH 8.18 (0.83H, s, NCHO), [8.04] (0.17H, 
s, NCHO*), 6.00 (1H, d, J = 8.8 Hz, H34), 5.32 (1H, dd, J = 10.7, 9.1 Hz, H33), 3.62 (0.83H, dd, J = 7.2, 
3.5 Hz, H31), [3.56-3.52] (0.17H, m, H31*), [3.13] (0.51H, s, NMe*), 3.04 (2.49H, s, NMe), 2.84 (1H, br 
s, OH), 2.72-2.65 (1H, m, H32), 2.60 (1H, dq, J = 7.4, 7.4 Hz, H30), [2.21] (0.51H, s, Me28*), 2.20 (2.49H, 
s, Me28), [1.18] (0.51H, obs, Me32*), 1.16 (2.49H, d, J = 6.8 Hz, Me32), [1.08] (0.51H, obs, Me30*), 1.06 
(2.49H, d, J = 7.4 Hz, Me30). 
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Distinguishable resonances of the minor rotamer (4.7:1 ratio) are given in brackets and marked with an 
asterisk. Data in agreement with that presented by Paterson.108 
Acetate 279 
 
Et3N (1.20 mL, 16.3 mmol), Ac2O (1.40 mL, 14.9 mmol) and DMAP (1 crystal) were added sequentially 
to a stirring mixture of alcohol 278 (634 mg, 2.97 mmol) in CH2Cl2 (15 mL) at 0 °C and the reaction was 
stirred at this temperature for 1 h. Upon completion, the mixture was quenched by addition of NaHCO3 
solution (20 mL), warmed to room temperature and the aqueous phase extracted with CH2Cl2 (3 x 10 
mL). Combined organic layers were dried (MgSO4), concentrated in vacuo and filtered through a short 
silica plug, eluting with EtOAc/40-60 PE (3:2). The filtrate was concentrated in vacuo and submitted 
directly to the subsequent isomerisation reaction. 
Data for the (Z)-isomer: 
Rf 0.31 (EtOAc/CH2Cl2, 1:1); 1H NMR (400 MHz, CDCl3): δH 8.19 (0.83H, s, NCHO), [8.09] (0.17H, s, 
NCHO*), [6.29] (0.17H, d, J = 8.8 Hz, H34*), 6.03 (0.83H, d, J = 8.9 Hz, H34), 5.18 (1H, dd, J = 9.3 Hz, 
H33), 5.13 (1H, dd, J = 10.8 Hz, H31), [3.19] (0.51H, s, NMe*), 3.06 (2.49H, s, NMe), 2.92-2.83 (1H, m, 
H32), 2.75 (1H, dq, J = 7.6, 7.1 Hz, H30), 2.16 (3H, s, Me28), 2.06 (3H, s, OC(O)Me), 1.07 (3H, d, J = 7.1 
Hz, Me32), 1.07 (3H, d, J = 6.8 Hz, Me30). 
Distinguishable resonances of the minor rotamer (4.7:1 ratio) are given in brackets and marked with an 
asterisk. Data in agreement with that presented by Paterson.108 
(E)-enamide 118 
 
Iodine (1.13 g, 4.46 mmol) was added in one portion to a solution of (Z)-enamide 279 (ca. 759 mg, 2.97 
mmol, 4.3:1 Z/E) in CH2Cl2 (200 mL) in the dark and stirred at rt for 22 h before quenching with Na2S2O3 
solution (100 mL). The biphasic mixture was rapidly stirred for 30 min during which a colour change 
from dark red to pale yellow was observed. The phases were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 100 mL). Combined organic phases were dried (MgSO4), concentrated in 
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vacuo and the crude product was purified by flash column chromatography (gradient elution: 
EtOAc/40-60 PE, 1:2 ® 3:2) to give the (E)-enamide 118 (724 mg, 2.84 mmol, 95% over 2 steps) as a 
pale yellow oil. 
Rf 0.31 (EtOAc/CH2Cl2, 1:1); 1H NMR (500 MHz, CDCl3): δH 1H NMR (500 MHz, CDCl3): δH 8.31 
(0.65H, s, NCHO), [8.10] (0.35H, s, NCHO*), [7.19] (0.35H, d, J = 14.5 Hz, H34*), 6.52 (0.65H, d, J = 
14.2 Hz, H34), 5.14 (1H, dd, J = 8.8, 4.2 Hz, H31), [5.02] (0.35H, obs, H33*), 4.99 (0.65H, dd, J = 14.1, 9.4 
Hz, H33), [3.09] (1.05H, s, NMe*), 3.05 (1.95H, s, NMe), 2.79 (0.65H, dq, J = 8.0, 7.0 Hz, H30), [2.74] 
(0.35H, dq, J = 8.2, 7.0 Hz, H30*) 2.58-2.49 (1H, m, H32, H32*), 2.17 (1.95H, s, Me28*), [2.16] (1.05H, s, 
Me28*), 2.06 (1.95H, s, OC(O)Me), [2.05] (1.05H, s, OC(O)Me*), 1.13 (1.95H, d, J = 7.2 Hz, Me30), 
[1.12] (1.05H, d, J = 7.2 Hz, Me30*), 1.08 (1.95H, d, J = 7.0 Hz, Me32), [1.07] (1.05H, d, J = 6.8 Hz, 
Me32*). 
Distinguishable resonances of the minor rotamer (1.8:1 ratio) are given in brackets and marked with an 
asterisk. Data in agreement with that presented by Paterson.108 
Aldehyde 120 
 
Oxalyl chloride (8 µL, 94.6 mol) was added to a solution of DMSO (13 µL, 189 µmol) in CH2Cl2 (2 mL) 
at -78 °C and stirred for 30 min before a solution of alcohol 159 (30.0 mg, 31.5 µmol) in CH2Cl2 (1.5 
mL) was added via cannula. The resulting mixture was stirred for 30 min, followed by the addition of 
Et3N (38 µL, 284 µmol). The reaction was stirred at this temperature for 30 min, then warmed up to 0 °C 
for a further 15 min. Upon completion, the mixture was quenched with NH4Cl solution (2 mL), warmed 
to rt and the phases separated. The aqueous phase was extracted with Et2O (3 x 5 mL), the combined 
organic layers dried (MgSO4) and concentrated in vacuo to give aldehyde 120 (29.3 mg, 30.9 µmol, 98%) 
as a pale yellow oil, which was used immediately in the subsequent aldol reaction. 
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Rf 0.50 (EtOAc/40-60 PE, 1:5); 1H NMR (500 MHz, CDCl3): δH 9.81 (1H, d, J = 2.1 Hz, CHO), 7.26 
(1H, dd, J = 15.2, 10.7 Hz, H3), 6.28 (1H, ddd, J = 15.2, 9.5, 4.7 Hz, H5), 6.18 (1H, dd, J = 15.6, 11.0 Hz, 
H4), 5.86 (1H, d, J = 15.2 Hz, H2), 5.59 (1H, ddd, J = 14.9, 8.9, 5.1 Hz, H21), 5.32 (1H, dt, J = 9.4, 3.7 Hz, 
H23), 5.08 (1H, dd, J = 15.0, 9.0 Hz, H20), 5.07-5.04 (1H, m, H15), 3.95 (1H, dd, J = 5.4, 4.0 Hz, H25), 3.64 
(1H, dd, J = 7.8, 4.1 Hz, H7), 3.54 (1H, app td, J = 10.0, 4.0, H19), 3.45-3.39 (1H, obs, H19), 3.39 (1H, dd, 
J = 10.9, 4.4 Hz, H13), 3.22 (3H, s, OMe19), 3.16 (3H, s, OMe13), 2.69-2.64 (1H, m, H26), 2.43-2.33 (2H, 
m, H22 x 2), 2.32-2.26 (1H, m, H6a), 2.02-1.95 (2H, m, H6b, H16a), 1.88 (1H, qdd, J = 7.0, 3.9, 1.7 Hz, 
H24), 1.77-1.64 (3H, m, H8, H12a, H16b), 1.62-1.46 (2H, m, H10, H12b), 1.45 (3H, s, Me14), 1.28-1.19 (2H, 
m, H17, H18b), 1.14 (3H, d, J = 7.1 Hz, Me26), 1.13-1.08 (2H, obs, H11 x 2), 0.99-0.95 (33H, SiCH2CH3 x 
9, Me10, Me24), 0.93 (3H, d, J = 6.9 Hz, Me8), 0.82 (3H, d, J = 5.7 Hz, Me17), 0.68-0.57 (18H, m, 
SiCH2CH3 x 9). 
Data in agreement with that presented by Paterson.108 
Enone 282 via aldol adduct 281 
 
Ketone 118 (38.0 mg, 0.149 mmol) and aldehyde 120 (29.3 mg, 30.8 µmol) were dried azeotropically 
with PhH and placed under vacuum for 18 h. Ketone 118 was dissolved in Et2O (0.5 mL), followed by 
sequential addition of Et3N (28 µL, 0.201 mmol) and Cy2BCl (31 µL, 0.150 mmol) at 0 °C. The resulting 
cloudy yellow solution was stirred for 1 h at this temperature before being cooled to –78 °C and a 
solution of aldehyde 120 in Et2O (1.5 mL) was added. The reaction mixture was stirred at –78 °C for 1 h, 
warmed to –40 °C for an additional 1 h and gradually warmed to –10 °C over 1 h before quenching with 
pH 7 buffer (2 mL) and MeOH (2 mL). The mixture was stirred for 30 min before being extracted with 
EtOAc (3 × 10 mL), dried over (MgSO4) and concentrated in vacuo. The crude material was purified by 
flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:5 → 3:1) and all fractions containing 
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product along with recovered ketone 118 were collected and combined. The resulting mixture was used 
directly in the subsequent elimination. 
Burgess reagent (27.0 mg, 95.0 µmol) was added to a flask containing the mixture of aldol adduct 281 
and ketone 118 dissolved in THF (0.5 mL). The reaction mixture was stirred at rt for 16 h before 
quenching with NH4Cl solution (3 mL) and the mixture being extracted with EtOAc (5 × 3 mL). The 
combined organic extracts were dried (MgSO4), concentrated in vacuo and the crude product purified by 
flash column chromatography (gradient elution: EtOAc/40-60 PE, 1:4 → 2:5) to afford enone 282 (22.8 
mg, 19.2 µmol, 63% over 2 steps) as a colourless oil. 
Rf 0.87 (EtOAc/40-60 PE, 3:2); 1H NMR (500 MHz, CDCl3) δH 8.32 (0.67H, s, CHO), [8.11] (0.33H, s, 
CHO*), 7.24 (1H, dd, J = 15.2, 10.5 Hz, H3), [7.20] (0.33H, d, J = 15.0 Hz, H34*), 7.02 (0.67H, dd, J = 
15.6, 8.0 Hz, H27), [7.00] (0.33H, dd, J = 15.8, 7.8 Hz, H27*), 6.52 (0.67H, d, J = 14.0 Hz, H34), 6.27 (1H, 
ddd, J = 15.2, 9.2, 4.1 Hz, H5), 6.20 (0.67H, d, J = 15.7 Hz, H28), [6.19] (0.33H, d, J = 15.6 Hz, H28*), 
6.15 (1H, dd, J = 15.6, 10.6 Hz, H4), 5.85 (1H, d, J = 15.3 Hz, H2), 5.62-5.56 (1H, m, H21), 5.31-5.27 
(1H, m, H23), 5.21 (0.67H, dd, J = 8.8, 3.7 Hz, H31), [5.20] (0.33H, dd, J = 8.5, 3.6 Hz, H31*), 5.10-5.02 
(2H, m, H33, H20), 5.02 (1H, dd, J = 13.9, 9.3 Hz, H15), 3.66-3.61 (2H, m, H7, H25), 3.53 (1H, ddd, J = 
13.0, 9.9, 4.0 Hz, H19), 3.40 (1H, obs, H9), 3.40 (1H, dd, J = 11.0, 4.3 Hz, H13), 3.22 (3H, s, OMe19), 3.19 
(3H, s, OMe13), [3.10] (1H, s, NMe*), 3.06 (2H, s, NMe), 3.01 (0.67H, dq, J = 8.5, 7.2 Hz, H32), [2.97] 
(0.33H, dq, J = 8.8, 7.0 Hz, H32*), 2.67-2.51 (2H, m, H26, H30), 2.38-2.27 (3H, m, H6a, H22 x 2), 2.01 
(2H, s, COCH3), [2.00] (1H, s, COCH3*), 2.02-1.95 (2H, m, H6b, H16a), 1.80-1.63 (4H, m, H8, H12a, H16b, 
H24), 1.63-1.43 (3H, m, H10, H12b, H18a), 1.45 (3H, s, Me14), 1.26-1.19 (2H, m, H18b, H17), 1.11-1.07 (8H, 
m, H11 x 2, Me26, Me32), 1.00 (3H, d, J = 7.1 Hz, Me30), 0.99-0.95 (30H, m, Me10, SiCH2CH3 x 9), 0.94 
(3H, d, J = 6.7 Hz, Me24), 0.93 (3H, d, J = 6.7 Hz, Me8), 0.82 (3H, d, J = 5.5 Hz, Me17), 0.68-0.57 (18H, 
m, SiCH2CH3 x 9).  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and marked with an 
asterisk. 
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Appendix 
Selected 1H and 13C NMR spectra 
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